

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 17:32:40 ; Search time 183.78 Seconds
(without alignments)
134.791 Million cell updates/sec

Title: US-09-540-843-5
Perfect score: 11
Sequence: 1 gtagggttag 11

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 2063506

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: N.GeneSeq_101002.*
2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
25: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001C.DAT:*
26: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result.	No.	Score	Query Match	Length	DB	ID	Description
	1	11	100.0	11	18	AAV07769	N3 to P5 oligonucleotide
	2	11	100.0	11	18	AAAT89250	DNA oligonucleotide
	3	11	100.0	11	18	AAAT89237	Peptide nucleic acid
	4	11	100.0	11	18	AAAT90060	Telomerase primer
	5	11	100.0	11	21	AAA37556	PNA sequence #13 u
	6	11	100.0	11	21	AAA37561	PNA sequence #18 u
	7	11	100.0	11	21	AAA37562	PNA sequence #19 u
	8	11	100.0	11	21	AAA37573	PNA sequence #31 u
	9	11	100.0	11	21	AAA37566	Antisense sequence

10	11	100.0	11	22	AAAT81185	Oligonucleotide th
11	11	100.0	11	22	AAAT26728	Phosphoramidate-11
12	11	100.0	11	22	AAAT26732	Phosphoramidate-11
13	11	100.0	11	23	AAAT14909	Melanogenesis asso
14	11	100.0	11	23	AAAT14913	PNA 7/IV inhibitin
15	11	100.0	11	23	AAAT15434	Oligonucleotide #6
16	11	100.0	11	23	AAAT15450	Phosphorothioate (
17	11	100.0	11	23	AAAT15457	Modified peptide n
18	11	100.0	11	24	AAAT98619	Peptide nucleic ac
19	11	100.0	11	24	AAAT97513	Peptide nucleic ac
20	11	100.0	12	18	AAAT99232	Peptide nucleic ac
21	11	100.0	12	21	AAAT37551	PNA sequence #8 us
22	11	100.0	12	23	AAAT15429	PNA V inhibiting n
23	11	100.0	12	23	AAAT15428	Oligonucleotide pr
24	11	100.0	12	23	AAAT15427	Oligonucleotide pr
25	11	100.0	13	18	AAAT89225	Peptide nucleic ac
26	11	100.0	13	18	AAAT89236	Peptide nucleic ac
27	11	100.0	13	21	AAAT37544	PNA sequence #1 us
28	11	100.0	13	21	AAAT37555	PNA sequence #12 u
29	11	100.0	13	22	AAAT81195	Thiophosphoramidat
30	11	100.0	13	23	AAAT15423	PNA 8/VI inhibitin
31	11	100.0	13	23	AAAT15433	PNA 6/X inhibiting
32	11	100.0	13	23	AAAT19881	Oligonucleotide SE
33	11	100.0	13	23	AAAT19882	Oligonucleotide SE
34	11	100.0	13	23	AAAT19883	Oligonucleotide SE
35	11	100.0	13	23	AAAT19884	Oligonucleotide SE
36	11	100.0	15	18	AAAT89226	Peptide nucleic ac
37	11	100.0	15	18	AAAT89229	Telomerase primer
38	11	100.0	15	18	AAAT90068	PNA sequence #2 us
39	11	100.0	15	21	AAAT37545	PNA sequence #5 us
40	11	100.0	15	21	AAAT37548	Antisense sequence
41	11	100.0	15	21	AAAT37587	PNA VII inhibiting
42	11	100.0	15	23	AAAT15424	PNA XIII inhibitin
43	11	100.0	15	23	AAAT15427	Phosphorothioate (
44	11	100.0	15	23	AAAT15458	Telomeric repeat-b
45	11	100.0	16	16	AAAT01177	

ALIGNMENTS

RESULT 1	AAV07769	standard; DNA; 11 BP.
XX	AAV07769;	
XX	07-DEC-1998	(first entry)
DT	N3 to P5 oligonucleotide phosphoramidate useful as telomerase inhibitor.	
DE	telomerase inhibitor; phosphoramidate; telomerase-binding region; TBR;	
KW	cell proliferation; tumour; leukaemia; duplex; ss.	
KM	Synthetic.	
XX		
OS		
XX		
FH	Key	Location/Qualifiers
FT	misc_feature	1..11
FT		/*tag= a
FT		/note= "each linkage is a phosphoramidate linkage"
XX		
PN	WO9737691-A1.	
PD	16-OCT-1997.	
XX		
PF	08-APR-1997;	97WO-US05773.
XX		
PR	10-APR-1996;	96US-0630242.
XX		
PA	(LYNX-) LYNX THERAPEUTICS INC.	
XX		
PI	Lloyd DH;	
XX		

```
DR      WPI; 1997-512422/47.
```

```
PT      Treating elevated telomerase levels with N3 to p5 oligonucleotide
```

```
PR      phosphoramidates - that bind to the RNA component of telomerase,
```

```
PT      specifically for preventing growth of cancer cells, fungi and
```

```
PT      protozoa
```

```
XX
```

```
XX      Claim 5; Page 25; 38pp; English.
```

The invention relates to treatment of conditions associated with high
levels of telomerase activity in a cell. The treatment comprises
administering an oligonucleotide N3' => p5' phosphoramidate having a
sequence complementary to part of the telomere-binding region (TBR) of
the RNA component of telomerase, so as to inhibit its activity. The
N3' => p5' oligonucleotide phosphoramidates are used therapeutically to
inhibit cell proliferation, e.g. against a wide range of solid tumours
or leukaemia, and also against fungal and protozoal pathogens. They are
soluble and resistant to nuclease, and they bind strongly to RNA forming
short but stable duplexes under physiological conditions. Thus they are
very effective and selective inhibitors of telomerase. The present
sequence represents a specific example of an oligonucleotide N3' => p5'
phosphoramidate disclosed in the specification.

```
SQ      Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;
```

```
OY      Query Match          100.0%; Score 11; DB 18; Length 11;
```

```
DG      Best Local Similarity   100.0%; Pred. No. 1.7e+03;
```

```
MATCHES 11; Conservative    0; Mismatches    0; Indels     0; Gaps     0;
```

```
OY      1 GTTAGGGCTAG 11
```

```
DG      1 |||||
```

```
DG      1 GTTAGGGTTAG 11
```

```
RESULT 2
```

```
ID      AAT89250/c
```

```
AC      AAT89250 standard; DNA; 11 BP.
```

```
XX
```

```
AA      AAT89250;
```

```
DT      12-MAY-1998 (first entry)
```

```
XX
```

DNA oligonucleotide 6, used in the measurement of Tm values.

Peptide nucleic acid; PNA; cancer; telomerase; probe; hybridisation;
inhibitor; human telomerase RNA; hTR; PCR; oligonucleotide; ss.
Synthetic.

```
OS      XX
```

```
SN      WO9738013-A1.
```

```
PN      XX
```

```
PD      16-OCT-1997.
```

```
KX      XX
```

```
PF      09-APR-1997; 97WO-USO5931.
```

```
XX      XX
```

```
PR      09-APR-1996; 96US-0630019.
```

```
XX      XX
```

```
PA      (GERO-) GERON CORP.
```

```
FI      Corey D, Norton JC, Piatyszek MA, Shay JW, Wright WE;
```

```
DR      WPI; 1997-512647/47.
```

```
PT
```

```
PT      New peptide nucleic acids hybridising to mammalian telomerase RNA -
```

```
PS      used to inhibit telomerase, for treating tumours and other
```

```
XX      proliferative diseases, also for diagnosis
```

```
XX
```

```
XX      Example 2; Page 49; 76pp; English.
```

This is an oligonucleotide used in the measurement of Tm values and
their complimentary peptide nucleic acids (PNAs), (e.g.
AAT89231-T89240). PNAs hybridise specifically to an RNA component of
mammalian telomerase, and include the sequence GGG for specific

	CC	hybridisation to the template region of this component.	PNA's can be used as probes to detect the RNA component of mammalian telomerase and as inhibitors of telomerase activity, especially in the treatment of cancer.	XX XX
SQ	Sequence 11 BP; 4 A; 5 C; 0 G; 2 T; 0 other;			XX
OY	Query Match	100.0%; Score 11; DB 18; Length 11; Best Local Similarity 100.0%; Pred. No. 1./e+03; Matches 11; Conservative 0; Mismatches 0; Indels 0; Caps 0		YY
DB	1 GTTAGGGTTAG 11 11 GTTAA GGCTTG 1			DD
RESULT 3	AAT89237			AC
ID	AAT89237 standard; DNA; 11 BP.			XX
AC	AAT89237;			XX
D7	12-MAY-1998 (first entry)			DE
PE	Peptide nucleic acid 12, targeted to mammalian telomerase.			KW
RN	Peptide nucleic acid; PNA; cancer; telomerase; probe; hybridisation; inhibitor; ss.			OS
SY	Synthetic.			FH
FT	Key Location/Qualifiers			FT
FT	modified_base 1..13 /tag= a			FT
FT	/note= "Sugar-phosphate backbone has been replaced by a peptide backbone"			FN
FT	modified_base 1 /tag= b			XX
FT	/note= "Optionally conjugated to peptide AAU31919"			PD
FT	modified_base 13 /tag= c			PF
FT	/note= "Optionally conjugated to peptide AAU31919"			PR
PN	WC9738013-AI.			PS
PP	16-OCT-1997.			XX
PT	09-APR-1997; 97WO-US05931.			PA
PT	09-APR-1996; 96US-0630019.			XI
TX	(GERO-) GERON CORP.			I1
XX	Corey D, Norton JC, Platyszek MA, Shay JW, Wright WE;			DR
XX	WPL; 1997-512647/A7.			XX
XX	New peptide nucleic acids hybridising to mammalian telomerase RNA - used to inhibit telomerase, for treating tumours and other proliferative diseases, also for diagnosis			XX
XX	Claim 9; Page 59; 76pp; English.			XX
XX	This sequence is a novel peptide nucleic acid (PNA), which acts as an inhibitor of mammalian, preferably human, telomerase. The PNAs hybridise specifically to an RNA component of mammalian telomerase, CC include the sequence CGG for specific hybridisation to the template region of this component. PNAs can be used as probes to detect the RNA component of mammalian telomerase and as inhibitors of telomerase activity, especially in the treatment of cancer.			XX
XX	Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;			XX

Query Match 100.0%; Score 11; DB 18; Length 11;
 Best Local Similarity 100.0%; Pred. NO. 1.7e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GTTAGGCTTAG 11
 11
 DB 1 GTTAGGCTTAG 11

RESULT 4

AAT90060
 ID AAT90060 standard; DNA; 11 BP.

AC AAT90060;

DT 24-NOV-1997 (first entry)

DE Telomerase primer.

XX Detection; telomerase; amplification; polymerase chain reaction;

KW PCR; primer; cancer; carcinoma; sarcoma; leukemia; leukemia;

KW myeloma; lymphoma; neuroblastoma; astrocytoma; glioma;

KW glioblastoma; retinoblastoma; melanoma; screen; drug;

KW determination; telomere length; ss.

OS Synthetic.

PN WO9711198-A1.

PD 27-MAR-1997.

PF 20-SEP-1996; 96WO-US15162.

PR 20-SEP-1995; 95US-0531743.

PA (CTRC-) CTRC RES FOUNDED.

PI Chen S, Fletcher TM, Maine I, Qiu M, Windle BF;

DR WPI; 1997-202904/18.

PT Detecting telomerase activity by ligation sequential reaction -

PT useful for diagnosis of cancer or to screen for telomerase

PT inhibitors

PS Claim 40; Page 27; 71pp; English.

XX A novel method of detecting telomerase activity in a sample,

CC comprising amplifying a sample with a telomerase primer, e.g. the

CC present sequence, and contacting the product with 1st and 2nd

CC oligonucleotides, which hybridise to the product so that no single

CC stranded region intervenes between them. The hybridised product and

CC oligonucleotides are then contacted with ligase and the ligated

CC form of the oligonucleotides detected.

CC The method can be used to detect cancer, e.g. carcinomas of the

CC breast, colon, oesophagus, kidney, liver, lung, ovaries, prostate,

CC stomach, uterus, pancreas and head and neck, sarcomas of bone and

CC muscle, leukaemias, myelomas, lymphomas, neuroblastomas, and

CC astrocytomas, gliomas, glioblastomas, retinoblastomas and

CC melanomas. The method can also be used to screen for

CC anti-telomerase activity in candidate drugs and to determine

CC telomere length.

SO Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;

Query Match 100.0%; Score 11; DB 18; Length 11;

Best Local Similarity 100.0%; Pred. NO. 1.7e+03;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGCTTAG 11
 11
 DB 1 GTTAGGCTTAG 11

RESULT 5

AAA37556
 ID AAA37556 standard; DNA; 11 BP.

AC AAA37556;

DT 15-AUG-2000 (first entry)

DE PNA sequence #13 used to inhibit telomerase activity.

XX Peptide nucleic acid; PNA; telomerase; ribonucleoprotein enzyme; cancer;

KW inhibitor; neoplasia; neurodegenerative disease; aging; hyperplasia;

KW AIDS; HIV; fungal infection; forensic identification; detect; tumour;

XX paternity testing; ss.

OS Synthetic.

PN US6046307-A.

PD 04-APR-2000.

PF 09-APR-1997; 97US-0838545.

PR 09-APR-1996; 96US-0630019.

PA (TEXA) UNIV TEXAS SYSTEM.

PI Wright WE, Piatyszek MA, Shay JW, Norton JC, Corey DR;

DR WPI; 2000-292432/25.

PT New peptide nucleic acid (PNA) compounds that inhibit telomerase

PT activity in mammalian cells. Is useful as probes to detect the RNA

PT component of a mammalian telomerase

XX Claim 6; Column 71; 45pp; English.

XX The present sequence represents a peptide nucleic acid molecule which

CC hybridises to the mRNA component of mammalian telomerase, and inhibits

CC telomerase activity. Telomerase is a ribonucleoprotein enzyme that

CC synthesizes one strand of the telomeric DNA, using as a template an 11

CC nucleotide sequence contained within the RNA component of the enzyme. The

CC invention relates to PNA molecules having a sequence of no more than 25

CC bases, which include the sequence GTTAGG. The uncharged nature of the PNA

CC backbone increases the melting temperature of associating strands,

CC and increases the rate of association with targeted nucleic acids, and

CC affords greater resistance of degradation by proteases or nucleases. The

CC therapeutic PNAs may be used for treating disease conditions such as

CC cancers, neoplasia, hyperplasia, neurodegenerative diseases, aging, human

CC immunodeficiency virus (HIV) infection/AIDS (acquired immunodeficiency

CC syndrome) and associated pathologies, fungal infections, and other

CC diseases characterized by abnormal telomere metabolism or telomerase

CC activity, in combination with antineoplastic and other cytotoxic or

CC cytostatic agents, antifungal agents, and other nucleotides. PNAs may be

CC used for molecular diagnostics, labelled PNAs are used as hybridization

CC probes to detect or quantitate polynucleotides having a human telomerase

CC RNA (hTR) sequence. PNA probes are also used for forensic identification

CC of individuals, e.g. paternity testing, based on hTR gene restriction

CC fragment length polymorphism (RFLP) pattern. PNAs are also useful as

CC inhibitors of telomerase activity. The method of the present invention and

CC allows cancerous conditions to be detected with increased confidence and

CC possibly at an earlier stage, before cells are detected as cancerous

CC based on pathological characteristics. The diagnostic and prognostic

CC methods if the present invention can be used to detect an immortal or
CC neoplastic cell or tumour tissue or cancer of any origin, provided the
CC cell expresses telomerase activity and its RNA component.

XQ Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;

Query Match	100.0%;	Score 11;	DB 21;	Length 11;
Best Local Similarity	100.0%;	Pred. No. 1.7e+03;		
Matches	11;	Conservative	0;	Mismatches 0;
			Indels	0;
			Gaps	0;

QY	1	GTTAGGGTTAG	11
Db	1	GTTAGGGTTAG	11

RESULT 6
AAA37561
ID AAA37561 standard; DNA; 11 BP.

15-AUG-2000 (first entry)

PNA sequence #18 used to inhibit telomerase activity.

KM Peptidase/uncleic acid; PM: telomerase; ribonucleoprotein enzyme; cancer;
KM Inhibitor; neoplasia; neurodegenerative disease; aging; hyperplasia;
KM AIDS; HIV; fungal infection; forensic identification; detect; tumour;
KM paternity testing; ss.

OS Synthetic.

FH	Key	Location/Qualifiers
----	-----	---------------------

ET

FT="Peptide nucleic acid molecule, where
FT N-(2-aminoethyl)glycine units are linked to
FT nucleotide bases via glycine amino N through a
FT methylenecarbonyl linker"

	/note=	"G residue is linked to the carboxy end of the peptide GGRQIKIWQNMMKWK"
FT		
FT		

PN US6046307-A.

PD 04-APR-2000.

PF 09-APR-1997; 97US-0838545.

PR 09-APR-1996; 96US-0630019.

PA (TEXA) UNIV TEXAS SYSTEM.

PI Wright WE, Platyszek MA, Shay JW, Norton JC, Corey DR;

DR WPI: 2000-292432/25.

PT New peptide nucleic acid (PNA) compounds that inhibit telomerase
PT activity in mammalian cells is useful as probes to detect the RNA
PT component of a mammalian telomerase ⁷
XX
SS Claim 9; Column 71-72; 45pp; English.

PS Claim 9; Column 71-72; 45pp; English.

The present sequence represents peptide nucleic acid molecule which hybridizes to the mRNA component of mammalian telomerase, and inhibits telomerase activity. Telomerase is a ribonucleoprotein enzyme that synthesizes one strand of the telomeric DNA, using as a template an 11 nucleotide sequence contained within the RNA component of the enzyme. The invention relates to PNA molecules having a sequence of no more than 25 bases, which include the sequence GTTAGG. The uncharged nature of the PNA backbone increases the melting temperature of associating strands, and increases the rate of association with targeted nucleic acids, and

affords greater resistance of degradation by proteases or nucleases. The therapeutic PNAs may be used for treating disease conditions such as cancers, neoplasia, hyperplasia, neurodegenerative diseases, ageing, human immunodeficiency virus (HIV) infection/AIDS (acquired immunodeficiency syndrome) and associated pathologies, fungal infections, and other diseases characterized by abnormal telomere metabolism or telomerase activity. In combination with antineoplastic and other cytotoxic or cytostatic agents, antifungal agents, and other nucleotides, PNAs may be used for molecular diagnostics. Labelled PNAs are used as hybridization probes to detect or quantitate polynucleotides having a human telomerase RNA (hTR) sequence. PNA probes are also used for forensic identification of individuals, e.g. paternally testing, based on hTR gene restriction fragment length polymorphism (RFLP) pattern. PNAs are also useful as probes to detect the RNA component of a mammalian telomerase and as inhibitors of telomerase activity. The method of the present invention allows cancerous conditions to be detected with increased confidence and possibly at an earlier stage, before cells are detected as cancerous based on pathological characteristics. The diagnostic and prognostic methods of the present invention can be used to detect an immortal or neoplastic cell or tumour tissue or cancer of any origin, provided the cell expresses telomerase activity and its RNA component.

Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;

Query Match	100.0%	Score 11;	DB 21;	Length 11;
Best Local Similarity	100.0%	Pred. No. 1.7e+03;		
Matches	11;	Conservative	0;	Mismatches 0;
			Indels	0;
			Gaps	0

QY	1	GTTAGGCTAG	11
Db	1	GTTAGGCTAG	11

```

RESULT 7
AAA37562
ID      AAA37562 standard; DNA; 11 BP.

```

AAA 37562;

DT 15-AUG-2000 (first entry)

DE PNA sequence #19 used to inhibit telomerase activity.

KW Peptide nucleic acid; PNA; telomerase; ribonucleoprotein enzyme; cancer
KW Inhibitor; neoplasia; neurodegenerative disease; aging; hyperplasia;
KW AIDS; HIV; fungal infection; forensic identification; detect; tumour;
KW paternity testing; ss.

Synthetic.

FH	Key	Location/Qualifiers
2000		
2001		
2002		
2003		
2004		
2005		
2006		
2007		
2008		
2009		
2010		
2011		
2012		
2013		
2014		
2015		
2016		
2017		
2018		
2019		
2020		
2021		
2022		
2023		
2024		
2025		
2026		
2027		
2028		
2029		
2030		
2031		
2032		
2033		
2034		
2035		
2036		
2037		
2038		
2039		
2040		
2041		
2042		
2043		
2044		
2045		
2046		
2047		
2048		
2049		
2050		
2051		
2052		
2053		
2054		
2055		
2056		
2057		
2058		
2059		
2060		
2061		
2062		
2063		
2064		
2065		
2066		
2067		
2068		
2069		
2070		
2071		
2072		
2073		
2074		
2075		
2076		
2077		
2078		
2079		
2080		
2081		
2082		
2083		
2084		
2085		
2086		
2087		
2088		
2089		
2090		
2091		
2092		
2093		
2094		
2095		
2096		
2097		
2098		
2099		
2100		
2101		
2102		
2103		
2104		
2105		
2106		
2107		
2108		
2109		
2110		
2111		
2112		
2113		
2114		
2115		
2116		
2117		
2118		
2119		
2120		
2121		
2122		
2123		
2124		
2125		
2126		
2127		
2128		
2129		
2130		
2131		
2132		
2133		
2134		
2135		
2136		
2137		
2138		
2139		
2140		
2141		
2142		
2143		
2144		
2145		
2146		
2147		
2148		
2149		

FT	/*tag=	a	"Peptide nucleic acid molecule, where
FT	/note=		

FT nucleotide bases via a glycine amino N through a methylenecarbonyl linker"

```

FT      /*tag= b
FT      /note= "g residue is linked to the amino end of the
FT      peptide GGRQIKINFQNMMKKK"
XX
NN      US6046307-A.

```

PN US6046307-A.

PD 04-APR-2000.

PF 09-APR-1997; 97US-0838545.

PR 09-APR-1996; 96US-0630019.

PA (TEXA) UNIV TEXAS SYSTEM.

PI Wright WE, Piatyszek MA, Shay JW, Norton JC, Corey DR;

XX
DR WPI; 2000-292432/25.

PT	New peptide nucleic acid (PNA) compounds that inhibit telomerase
PT	activity in mammalian cells is useful as probes to detect the RNA
PT	component of a mammalian telomerase

PS Claim 9; Column 71-72; 45pp; English.

The present sequence represents a peptide nucleic acid molecule which hybridises to the mRNA component of mammalian telomerase, and inhibits telomerase activity. Telomerase is a ribonucleoprotein enzyme that synthesises one strand of the telomeric DNA, using as a template an 11 nucleotide sequence contained within the RNA component of the enzyme. The invention relates to PNA molecules having a sequence of no more than 25 bases, which include the sequence CTTAGC. The uncharged nature of the PNAs backbone increases the melting temperature of associating strands, and increases the rate of association with targeted nucleic acids, and affords greater resistance of degradation by proteases or nucleases. The therapeutic PNAs may be used for treating disease conditions such as cancers, neoplasia, hyperplasia, neurodegenerative diseases, aging, human immunodeficiency virus (HIV) infection/AIDS (acquired immunodeficiency syndrome) and associated pathologies, fungal infections, and other diseases characterized by abnormal telomere metabolism or telomerase activity, in combination with antineoplastic and other cytotoxic or cytostatic agents, antifungal agents, and other nucleotides. PNAs may be used for molecular diagnostics, labelled PNAs are used as hybridization probes to detect or quantitate polynucleotides having a human telomerase RNA (hTR) sequence. PNA probes are also used for forensic identification of individuals, e.g. paternity testing, based on hTR gene restriction fragment length polymorphism (RFLP) pattern. PNAs are also useful as probes to detect the RNA component of a mammalian telomerase and as inhibitors of telomerase activity. The method of the present invention allows cancerous conditions to be detected with increased confidence and possibly at an earlier stage, before cells are detected as cancerous based on pathological characteristics. The diagnostic and prognostic methods of the present invention can be used to detect an immortal or neoplastic cell or tumour tissue or cancer of any origin, provided the cell expresses telomerase activity and its RNA component.

Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;

Query match	100.0%;	Score 11;	DB 21;	Length 11;
-------------	---------	-----------	--------	------------

Best Local Similarity 100.0%; Pred. No. 1.7e+03,

```
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1 GTTAGGGTTAG 11

Db 1 GTTAGGGTTAG 11

RESULT 8
AAA37573/C

AC AAA37573;

DT 15-AUG-2000 (first entry)

DE PNA sequence #31 used to inhibit telomerase activity.

peptide nucleic acid; PNA; telomerase; ribonucleoprotein enzyme; cancer
inhibitor; neoplasia; neurodegenerative disease; aging; hyperplasia;
AIDS; HIV; fungal infection; forensic identification; detect; tumour;
paternity testing; ss.

OS Synthetic.

FH	key	Location/Qualifiers
1	1	1
2	2	2
3	3	3
4	4	4
5	5	5
6	6	6
7	7	7
8	8	8
9	9	9
10	10	10
11	11	11
12	12	12
13	13	13
14	14	14
15	15	15
16	16	16
17	17	17
18	18	18
19	19	19
20	20	20
21	21	21
22	22	22
23	23	23
24	24	24
25	25	25
26	26	26
27	27	27
28	28	28
29	29	29
30	30	30
31	31	31
32	32	32
33	33	33
34	34	34
35	35	35
36	36	36
37	37	37
38	38	38
39	39	39
40	40	40
41	41	41
42	42	42
43	43	43
44	44	44
45	45	45
46	46	46
47	47	47
48	48	48
49	49	49
50	50	50
51	51	51
52	52	52
53	53	53
54	54	54
55	55	55
56	56	56
57	57	57
58	58	58
59	59	59
60	60	60
61	61	61
62	62	62
63	63	63
64	64	64
65	65	65
66	66	66
67	67	67
68	68	68
69	69	69
70	70	70
71	71	71
72	72	72
73	73	73
74	74	74
75	75	75
76	76	76
77	77	77
78	78	78
79	79	79
80	80	80
81	81	81
82	82	82
83	83	83
84	84	84
85	85	85
86	86	86
87	87	87
88	88	88
89	89	89
90	90	90
91	91	91
92	92	92
93	93	93
94	94	94
95	95	95
96	96	96
97	97	97
98	98	98
99	99	99
100	100	100

misc_feature

/*tag

FT peptide nucleic acid molecule, where
FT N-(2-aminoethyl)glycine units are linked to

FT nucleotide bases via glycine amino N through a
FT methylenecarbonyl linker^a

PN US6046307-A

PD 04-APR-2000

PF 09-APR-1997; 97US-0838545.

PR 09-APR-1996; 96US-0630019.

PA (TEXA) UNIV TEXAS SYSTEM.

PI Wright WE, Piatyszek MA, Shay JW, Norton JC, Corey DR,

DR WPI; 2000-292432/25.

PT New peptide nucleic acid (PNA) compounds that inhibit telomerase activity in mammalian cells is useful as probes to detect the RNA component of a mammalian telomerase

PS Example 2; Column 33; 45pp; English.

The present sequence represents a peptide nucleic acid molecule which hybridises to the mRNA component of mammalian telomerase, and inhibits telomerase activity. Telomerase is a ribonucleoprotein enzyme that synthesizes one strand of the telomeric DNA, using as a template an RNA nucleotide sequence contained within the RNA component of the enzyme. The invention relates to PNA molecules having a sequence of no more than 25 bases, which include the sequence GTTAAAG. The uncharged nature of the PNAs, which include the sequence GTTAAAG, increases the rate of association with targeted nucleic acids, and affords greater resistance of degradation by proteases or nucleases. The therapeutic PNAs may be used for treating disease conditions such as cancers, neoplasia, hyperplasia, neurodegenerative diseases, aging, human immunodeficiency virus (HIV) infection/AIDS (acquired immunodeficiency syndrome) and associated pathologies, fungal infections, and other diseases characterized by abnormal telomere metabolism or telomerase activity, in combination with antineoplastic and other cytotoxic or cytostatic agents, antifungal agents, and other nucleotides. PNAs may be used for molecular diagnostics, labelled PNAs are used as hybridization probes to detect or quantitate polynucleotides having a human telomerase RNA (hTR) sequence. PNA probes are also used for forensic identification of individuals, e.g. paternity testing, based on hTR gene restriction fragment length polymorphism (RFLP) pattern. PNAs are also useful as probes to detect the RNA component of a mammalian telomerase and as inhibitors of telomerase activity. The method of the present invention allows cancerous conditions to be detected with increased confidence and possibly at an earlier stage, before cells are detected as cancerous based on pathological characteristics. The diagnostic and prognostic methods of the present invention can be used to detect an immortal or neoplastic cell or tumour tissue or cancer of any origin, provided the cell expresses telomerase activity and its RNA component.

Sequence 11 BP; 4 A; 5 C; 0 G; 2 T; 0 other;

Query Match	Score 11;	DB 21;	Length 11;
100.0%			

Best Local Similarity 100.0%; Pred. No. 1.7e+03;

Matches	11;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
---------	-----	--------------	----	------------	----	--------	----	------	----

QY 1 GTTAGGGTTAG 11

D_b 11 GTTACGGGTTAG 1

RESULT 9
AAA37586

XX

XX
 1E-115-2000 4450 + 03 + 377

XX

DE Antisense sequence #44 used to inhibit telomerase activity.

XX Peptide nucleic acid; PNA; telomerase; ribonucleoprotein enzyme; cancer;

KW inhibitor; neoplasia; neurodegenerative disease; aging; hyperplasia;

KW AIDS; HIV; fungal infection; forensic identification; detect; tumour;

KW paternity testing; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT misc_feature 1..11

FT /**tag= a

FT /note= "Phosphorothioate internucleotide linkages"

XX US6046307-A.

XX 04-APR-2000.

XX 09-APR-1997; 9705-0838545.

XX 09-APR-1996; 9605-0630019.

XX (TEXA) UNIV TEXAS SYSTEM.

XX Wright WE, Piatyszek MA, Shay JW, Norton JC, Corey DR;

XX WPI; 2000-292432/25.

XX New peptide nucleic acid (PNA) compounds that inhibit telomerase

PT activity in mammalian cells is useful as probes to detect the RNA

PT component of a mammalian telomerase

XX Example 1; Column 27-28; 45pp; English.

XX The present sequence represents an antisense oligonucleotide used as a

CC control sequence alongside a peptide nucleic acid molecule which

CC hybridises to the mRNA component of mammalian telomerase, and inhibits

CC telomerase activity. Telomerase is a ribonucleoprotein enzyme that

CC synthesises one strand of the telomeric DNA, using as a template an 11

CC nucleotide sequence contained within the RNA component of the enzyme. The

CC invention relates to PNA molecules having a sequence of no more than 25

CC bases, which include the sequence GTTAGG. The uncharged nature of the PNA

CC backbone increases the melting temperature of associating strands,

CC affords greater resistance of degradation by proteases or nucleases. The

CC therapeutic PNAs may be used for treating disease conditions such as

CC cancers, neoplasia, hyperplasia, neurodegenerative diseases, aging, human

CC immunodeficiency virus (HIV) infection/AIDS (acquired immunodeficiency

CC syndrome) and associated pathologies, fungal infections, and other

CC diseases characterized by abnormal telomere metabolism or telomerase

CC activity. In combination with antineoplastic and other cytotoxic or

CC cytostatic agents, antifungal agents, and other nucleotides, PNAs may be

CC used for molecular diagnostics, labelled PNAs are used as hybridization

CC probes to detect or quantitate polynucleotides having a human telomerase

CC RNA (hTR) sequence. PNA probes are also used for forensic identification

CC of individuals, e.g. paternity testing, based on hTR gene restriction

CC fragment length polymorphism (RFLP) pattern. PNAs are also useful as

CC probes to detect the RNA component of a mammalian telomerase and as

CC inhibitors of telomerase activity. The method of the present invention

CC allows cancerous conditions to be detected with increased confidence and

CC possibly at an earlier stage, before cells are detected as cancerous

CC based on pathological characteristics. The diagnostic and prognostic

CC methods of the present invention can be used to detect an immortal or

CC neoplastic cell or tumour tissue or cancer of any origin, provided the

CC cell expresses telomerase activity and its RNA component.

XX Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;

XX

Query Match 100.0%; Score 11; DB 21; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.7e+03;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGGTTAG 11

DB 1 |||||

1 GTTAGGGTTAG 11

RESULT 10

AAE81185

ID AAE81185 standard; DNA; 11 BP.

XX

XX AAE81185;

XX

XX 30-MAY-2001 (first entry)

XX

XX Oligonucleotide thiophosphoramidate, SEQ ID NO: 1.

XX

XX Thiophosphoramidate oligonucleotide; vitruclide; cytosstatic;

XX immunosuppressive; contraceptive; RNA inhibitor; telomerase inhibitor;

XX antisense therapy; viral infection; cancer; hyperproliferative disorder;

XX autoimmune disorder; ss.

XX

XX Synthetic.

XX WO200118015-A1.

XX

XX 15-MAR-2001.

XX

XX 08-SEP-2000; 2000WO-US24688.

XX

XX 10-SEP-1999; 99US-0153201.

XX 19-OCT-1999; 99US-0160444.

XX

XX (GERO-) GERON CORP.

XX

XX Gryaznov S, Pongracz K, Matray T;

XX WPI; 2001-265967/27.

XX

XX Novel thiophosphoramidate polynucleotide useful for detection of RNA or

PT DNA having a given target sequence, for inhibiting RNA function in a

PT cell, and for treating cancer and viral infection

XX

XX Example 3; Page 39; 68pp; English.

XX The present sequence was synthesised in an example 11 illustrating an

CC invention relating to polynucleotides comprising a non-homopolymeric

CC sequence of nucleoside subunits joined by at least one inter-subunit

CC linkage that is a N3'-5' thiophosphoramidate. The thiophosphoramidate

CC oligonucleotides retain a high RNA binding affinity and exhibit a much

CC higher acid stability. They are useful for detecting a specific sequence

CC in a sample, by forming a hybridisation complex with the sequence. They

CC are useful for inhibiting function of an RNA in a cell (for inhibiting

CC translation of a mRNA or for inhibiting telomerase enzyme in a cell).

CC They are also useful in the preparation of a medicament for treatment of

CC viral infection or cancer. The oligonucleotides are useful for anti-sense

CC and anti-gene diagnostic or therapeutic applications and may be used for

CC treating telomerase-mediated conditions or diseases, such as

CC hyperproliferative and autoimmune disorders, and for contraceptive

CC purposes.

XX

XX Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;

XX

Query Match 100.0%; Score 11; DB 22; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.7e+03;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGGTTAG 11

DB 1 GTTAGGGTTAG 11

RESULT 11

AAH26728

ID AAH26728 standard; DNA; 11 BP.

AC	AAH26728;
XX	
DT	26-NOV-2001 (first entry)
XX	
DE	Phosphoramidate-linked 2'-arabino-fluorooligonucleotide.
KW	2'-arabino-fluorooligonucleotide; phosphoramidate; telomerase;
KW	inhibitor; infection; cancer; diagnosis; therapy; cytostatic;
KW	virucide; antisense; antigenic; ss.
OS	Synthetic.
XX	
FH	Key
FT	modified_base
FT	Location/Qualifiers
FT	2..11
FT	/tag= a
FT	/mod_base= "OTHER"
FT	/note= "2'-arabino-fluoronucleosides"
FT	2..11
FT	/tag= b
FT	/mod_base= "OTHER"
PN	/note= "phosphoramidate linkage"
XX	
PX	WO200153307-A1.
XX	
PD	26-JUL-2001.
XX	
PF	19-JAN-2001; 2001WO-US01918.
XX	
PR	21-JAN-2000; 2000US-178248P.
PA	(GERO-) GERON CORP.
PI	Gryaznov S, Schultz RG;
XX	
DR	WPI: 2001-589652/66.
XX	
PT	Polynucleotides, used to detect and isolate nucleic acids, inhibit
PT	function of RNA and telomerase enzymes and to treat e.g. viral
PT	infections, contain 2'-arabino-fluoronucleoside(s) linked to
PT	nucleoside(s) -
PS	
XX	
XX	Example 6; Page 46; 61pp; English.
CC	The present sequence is that of a N3'-P5' 2'-arabino-fluoro
CC	phosphoramidate oligonucleotide that is complementary to
CC	telomerase RNA. The oligonucleotide was used to assess the
CC	relative efficacy of novel 2'-arabino-fluoro phosphoramidate
CC	oligonucleotides and their 2',-ribo fluorooligonucleotide
CC	counterparts (see AAH26728-35) for the inhibition of telomerase
CC	activity. Novel phosphoramidate 2'-arabino-fluorooligonucleotides
CC	are generally more acid stable, more resistant to cellular
CC	proteases, and also show greater telomerase inhibition activity
CC	than 2'-ribose-fluoro phosphoramidates. They are therefore useful
CC	for treating cancer (claimed) and other diseases in which telomerase
CC	activity is present at abnormal levels, such as hyperproliferative
CC	or autoimmune diseases e.g. psoriasis, rheumatoid arthritis,
CC	immune system disorders requiring immunosuppression, and in the
CC	treatment of viral infection (claimed).
SO	
Sequence	11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;
Query Match	100.0%; Score 11; DB 22; Length 11;
Best Local Similarity	100.0%; Pred. No. 1.7e+03;
Matches	11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	1 GTTAGGGTTAG 11 1 GTTAGGGTTAG 11
Db	1 GTTAGGGTTAG 11
RESULT 12	
AAH26732	
ID	AAH26732 standard; DNA; 11 BP.

XX	AAH26732;	
AC	26-NOV-2001 (first entry)	
XX		
DT		
XX	Phosphoramidate-linked 2'-ribose-fluorooligonucleotide.	
DE		
XX		
XX	2'-ribose-fluorooligonucleotide; phosphoramidate; telomerase;	
KW	inhibitor; infection; cancer; diagnosis; therapy; cytostatic;	
KW	virucide; antisense; antigenic; ss.	
XX		
OS	Synthetic.	
XX		
XX		
FT	Key	Location/Qualifiers
FT	modified_base	2..11
FT		/tag= a
FT		/mod_base= "OTHER"
FT	modified_base	/note= "2'-ribose-fluoronucleosides"
FT		2..11
FT		/tag= b
FT		/mod_base= "OTHER"
FT		/note= "phosphoramidate linkage"
PN	WO200153307-A1.	
XX		
XX	26-JUL-2001.	
PD		
XX		
PF	19-JAN-2001; 2001WO-US01918.	
XX		
PR	21-JAN-2000; 2000US-178248P.	
XX		
PA	(GERO-) GERON CORP.	
XX		
PI	Gryaznov S, Schultz RG;	
XX		
DR	WPI; 2001-589652/66.	
XX		
PT	Polynucleotides, used to detect and isolate nucleic acids, inhibit	
PT	function of RNA and telomerase enzymes and to treat e.g. viral	
PT	infections, contain 2'-arabino-fluoronucleoside(s) linked to	
PT	nucleoside(s) -	
XX		
XX		
PS	Example 6; Page 46; 61pp; English.	
XX		
CC	The present sequence is that of a 2'-ribose-fluoro	
CC	phosphoramidate oligonucleotide that is complementary to	
CC	telomerase RNA. The oligonucleotide was used to assess the	
CC	relative efficacy of novel 2'-arabino-fluoro phosphoramidate	
CC	oligonucleotides and their 2'-ribose fluorooligonucleotide	
CC	counterparts (see AAH26728-35) for the inhibition of telomerase	
CC	activity. Novel phosphoramidate 2'-arabino-fluorooligonucleotides	
CC	are generally more acid stable, more resistant to cellular	
CC	proteases, and also show greater telomerase inhibition activity	
CC	than 2'-ribose-fluoro phosphoramidates. They are therefore useful	
CC	for treating cancer (claimed) and other diseases in which telomerase	
CC	activity is present at abnormal levels, such as hyperproliferative	
CC	or autoimmune diseases e.g. psoriasis, rheumatoid arthritis,	
CC	immune system disorders requiring immunosuppression, and in the	
CC	treatment of viral infection (claimed).	
XX		
SQ	Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;	
	Query Match	100.0%; Score 11; DB 22; Length 11;
	Best Local Similarity	100.0%; Pred. No. 1.7e+03;
	Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
OY	1 GTTAGCGTTAG 11	
DB	1 GTTAGCGTTAG 11	

ID AAS14909 standard; DNA; 11 BP.
 XX AAS14909;
 AC
 XX 14-FEB-2002 (first entry)
 DT
 XX Melanogenesis associated oligonucleotide #5.
 DE
 XX Melanin; melanogenic; oligomer; cytosolic; anti-allergic; p53;
 KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KW conjunctivitis; allergic rhinitis; vitiligo; ss.
 XX
 OS Synthetic.
 FH
 FH Key Location/Qualifiers
 FT modified_base 1
 FT /tag= a
 FT /mod_base= g
 FT /note= "Optionally phosphorylated"
 FT modified_base 1..11
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= optionally phosphorothiolate linkages"
 XX
 PN WO200174342-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-US10162.
 XX
 PR 31-MAR-2000; 2000US-0540843.
 XX
 PA (UYBO-) UNIV BOSTON.
 XX
 PI Gilchrist BA, Yaar M, Eller M;
 XX
 DR WPI; 2001-626338/72.
 XX
 XX Inhibiting proliferation of epithelial cells, useful e.g. for treating
 PT carcinoma, using specific oligonucleotides that mimic the effects of
 PT ultra-violet light
 XX
 PS Claim 1; Page 37; 74pp; English.
 CC
 CC The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytosolic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergic rhinitis and conjunctivitis; prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #5, representative
 CC of the telomere overhang sequence and one of the oligonucleotides used
 CC to inhibit mammalian epithelial cell proliferation, described in the
 CC method of the invention.

SQ Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;
 Query Match 100.0%; Score 11; DB 23; Length 11;
 Best Local Similarity 100.0%; Pred. No. 1.7e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTTAGGTTAG 11
 Db 1 GTTAGGTTAG 11
 RESULT 14
 AAS14913/c
 ID AAS14913 standard; DNA; 11 BP.
 XX
 AC AAS14913;
 XX
 DT 14-FEB-2002 (first entry)
 XX
 DE Melanogenesis associated oligonucleotide #9.
 XX
 KW Melanin; melanogenic; oligomer; cytosolic; anti-allergic; p53;
 KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KW conjunctivitis; allergic rhinitis; vitiligo; ss.
 XX
 OS Synthetic.
 FH
 FH Key Location/Qualifiers
 FT modified_base 1
 FT /tag= a
 FT /mod_base= c
 FT /note= "Phosphorylated"
 XX
 PN WO200174342-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-US10162.
 XX
 PR 31-MAR-2000; 2000US-0540843.
 XX
 PA (UYBO-) UNIV BOSTON.
 XX
 PI Gilchrist BA, Yaar M, Eller M;
 XX
 DR WPI; 2001-626338/72.
 XX
 XX Inhibiting proliferation of epithelial cells, useful e.g. for treating
 PT carcinoma, using specific oligonucleotides that mimic the effects of
 PT ultra-violet light
 XX
 PS Example 12; Page 37; 74pp; English.
 CC
 CC The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytosolic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergic rhinitis and conjunctivitis; prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production

CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #9, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell proliferation,
 CC described in the method of the invention.
 CC
 SQ Sequence 11 BP; 4 A; 5 C; 0 G; 2 T; 0 other;
 Query Match 100.0%; Score 11; DB 23; Length 11;
 Best Local Similarity 100.0%; Pred. NO. 1.7e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTTAGGGTTAG 11
 Db 11 GTTAGGGTTAG 1

RESULT 15
 AAS15434 standard; DNA; 11 BP.
 ID AAS15434
 AC AAS15434;
 XX
 XX 14-FEB-2002 (first entry)
 DE PNA 7/IV inhibiting human and mammalian telomerase activity.
 XX
 XX Mammalian; peptide nucleic acid; probe; forensic; paternity testing;
 KM human telomerase RNA component; htr gene RFLP pattern; cancer;
 KM inflammation; lymphoproliferative disease; autoimmune disease;
 KM neurodegenerative disease; neoplasia; hyperplasia; HIV; AIDS;
 KM human immunodeficiency virus; acquired immunodeficiency syndrome;
 KM telomere metabolism; mutant; cytostatic; anti-inflammatory;
 KM immunosuppressive; polyamide backbone; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT 1.11
 FT modified_base
 FT /*tag- a
 FT /note= "This sequence is a peptide nucleic acid, i.e. it
 FT contains a polyamide backbone instead of a
 FT deoxyribose backbone"
 XX
 PN US6294650-B1.
 XX
 XX 25-SEP-2001.
 PD
 XX 08-JUL-1999; 99US-0349532.
 PF
 XX 09-APR-1997; 97US-0838545.
 PR 09-APR-1996; 96US-0630019.
 XX
 XX (TEXA) UNIV TEXAS SYSTEM.
 PA
 XX Shay JW, Wright WE, Piatyszek MA, Corey DR, Norton JC;
 PI WPI; 2001-638024/73.
 DR
 XX New peptide nucleic acids that hybridizes to the RNA component of
 PT mammalian telomerase, useful for treating or preventing cancer,
 PT inflammation, lymphoproliferative diseases, autoimmune disease, or
 PT neurodegenerative diseases -
 XX
 PS Claim 7; Column 73; 46pp; English.
 XX
 CC The present invention relates to peptide nucleic acids (PNAs), comprising
 CC a sequence of 6-25 nucleobases, that inhibit telomerase activity in
 CC mammalian cells by hybridising to the RNA component of mammalian
 CC telomerase. The PNAs are useful as probes to detect the RNA component

CC of mammalian telomerase and as inhibitors of telomerase activity, or to
 CC detect and/or quantitate polynucleotide having the human telomerase
 CC RNA component (htr) sequence, as well as in forensic identification of
 CC individuals, such as paternity testing or identification of criminal
 CC suspects or unknown descendants based on the htr gene RFLP pattern. The
 CC PNA can be further used for treating or preventing cancer, inflammation,
 CC diseases. The PNAs in combination with other pharmaceuticals (such as
 CC antineoplastic or cytostatic agents) can be used for treating neoplasia,
 CC hyperplasia, human immunodeficiency virus (HIV) infections, acquired
 CC immunodeficiency syndrome (AIDS) and associated pathologies, and other
 CC diseases characterised by abnormal telomere metabolism or telomerase
 CC activity. The present sequence represents one of the PNA sequences
 CC of the invention.
 CC
 SQ Sequence 11 BP; 2 A; 0 C; 5 G; 4 T; 0 other;
 Query Match 100.0%; Score 11; DB 23; Length 11;
 Best Local Similarity 100.0%; Pred. NO. 1.7e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTTAGGGTTAG 11
 Db 1 GTTAGGGTTAG 11

Search completed: June 2, 2003, 18:45:12
 Job time : 183.98 secs

Plate: 0443 row: A column: 17
 Seq primer: CACACAGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 19.

FEATURES

Location/Qualifiers

1..19
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="U06C1M043A17"
 /clone_1lb="Mouse 10kb plasmid U06C1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD42ny; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT

3 a 0 c 10 g 6 t

ORIGIN

Query Match 100.0%; Score 11; DB 17; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.1e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTAGGGTTAG 11
 |||||
 Db 3 GTTAGGGTTAG 13

RESULT 2

TA158A03P/c

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

TA158A03P 20 bp DNA linear GSS 13-DEC-2000
 T. brucei sheared genomic DNA clone 158a03, forward sequence,
 genomic survey sequence.
 AL472050
 AL472050.1 GI:11837404
 GSS.
 Trypanosoma brucei.
 Trypanosoma brucei.
 Eukaryota; Euzlenozoa; Kinetoplastida; Trypanosomatidae;
 Trypanosoma.
 1 (bases 1 to 20)
 Hall, N., Bowman, S., Lennard, N.J., Doggett, J., Atkin, R.,
 Chillingworth, C., Ormond, D., Harris, B., El-Sayed, N., Hou, L.,
 Melville, S.E., Rajandream, M.A. and Barrell, B.G.
 Direct Submission
 Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
 project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,
 Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and
 nh@sanger.ac.uk
 Constructed at the Institute for Genomic Research (TIGR),
 Rockville, MD. Genomic DNA isolated from a cloned population of
 Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
 to give a tight size distribution (4 kb). The v + i method used for the library construction is
 described in detail in Smith, H. and Venter, J.C. (Making small
 insert libraries for whole genome shotgun sequencing projects. In
 Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.

Barrell, Oxford University Press, 1999).
 Email: nelsayed@tigr.org
 Details of T. brucei sequencing at the Sanger Centre are available
 at http://www.sanger.ac.uk/Projects/T_brucei/.

FEATURES

Location/Qualifiers

1..20
 /organism="Trypanosoma brucei"
 /strain="TREU927"
 /db_xref="taxon:5691"
 /clone="158a03"
 /clone_1lb="Mouse 10kb plasmid U06C1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD42ny; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT

6 a 11 c 0 g 3 t

ORIGIN

Query Match 100.0%; Score 11; DB 17; Length 20;
 Best Local Similarity 100.0%; Pred. No. 7.2e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTAGGGTTAG 11
 |||||
 Db 20 GTTAGGGTTAG 10

RESULT 3

TA84A06P

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

TA84A06P 25 bp DNA linear GSS 13-DEC-2000
 T. brucei sheared genomic DNA clone 84a06, forward sequence,
 genomic survey sequence.
 AL462065
 AL462065.1 GI:11860923
 GSS.
 Trypanosoma brucei.
 Trypanosoma brucei.
 Eukaryota; Euzlenozoa; Kinetoplastida; Trypanosomatidae;
 Trypanosoma.
 1 (bases 1 to 25)
 Hall, N., Bowman, S., Lennard, N.J., Doggett, J., Atkin, R.,
 Chillingworth, C., Ormond, D., Harris, B., El-Sayed, N., Hou, L.,
 Melville, S.E., Rajandream, M.A. and Barrell, B.G.
 Direct Submission
 Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
 project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,
 Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and
 nh@sanger.ac.uk
 Constructed at the Institute for Genomic Research (TIGR),
 Rockville, MD. Genomic DNA isolated from a cloned population of
 Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
 to give a tight size distribution (4 kb). The v + i method used for the library construction is
 described in detail in Smith, H. and Venter, J.C. (Making small
 insert libraries for whole genome shotgun sequencing projects. In
 Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.
 Barrell, Oxford University Press, 1999).
 Email: nelsayed@tigr.org
 Details of T. brucei sequencing at the Sanger Centre are available
 at http://www.sanger.ac.uk/Projects/T_brucei/.

FEATURES

Location/Qualifiers

1..25
 /organism="Trypanosoma brucei"
 /strain="TREU927"
 /db_xref="taxon:5691"
 /clone="84a06"

BASE COUNT 4 a 0 c 12 g 9 t

ORIGIN

Query Match 100.0%; Score 11; DB 17; Length 25;
 Best Local Similarity 100.0%; Pred. No. 7.8e+03;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTTAGGGTTAG 11
 |||||
 Db 6 GTTAGGGTTAG 16

RESULT 4
A2803795/c

LOCUS 27 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M064D22F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0064D22 F, DNA sequence.

ACCESSION A2803795
VERSION A2803795.1 GI:12956118
KEYWORDS GSS.

SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 27)

AUTHORS

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly,
M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausern, A.
and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

JOURNAL Unpublished (2000)

COMMENT

Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0064 row: D column: 22
Seq primer: CCTTGTAAACGACGCGCCGCT
Class: plasmid ends
High quality sequence stop: 27.
Location/Qualifiers

FEATURES

source

1. 27
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0064D22"
/clone_1lb="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (g114732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

BASE COUNT
ORIGIN

Query Match 100.0%; Score 11; DB 17; Length 27;
Best Local Similarity 100.0%; Pred. No. 7.9e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGCTTAG 11
|||||
DB 26 GTTAGGCTTAG 16

RESULT 5
A2380089/c

LOCUS 40 bp DNA linear GSS 02-OCT-2000
DEFINITION 1M0135K14R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0135K14 R, DNA sequence.

ACCESSION A2380089
VERSION A2380089.1 GI:10493789
KEYWORDS GSS.

SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 40)

AUTHORS

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly,
M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausern, A.
and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

JOURNAL Unpublished (2000)

COMMENT

Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0135 row: K column: 14
Seq primer: CACACGAGAAACGCTATGAC
Class: plasmid ends
High quality sequence stop: 40.
Location/Qualifiers

FEATURES

source

1. 40
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0135K14"
/clone_1lb="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (g114732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

BASE COUNT
ORIGIN

Query Match 100.0%; Score 11; DB 17; Length 40;
Best Local Similarity 100.0%; Pred. No. 8.9e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGCTTAG 11
|||||
DB 12 GTTAGGCTTAG 2

RESULT 6
A2666649
LOCUS
DEFINITION 22 bp DNA linear GSS 14-DEC-2000
1M0548M19R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0548M19 R, DNA sequence.

ACCESSION
A2666649
VERSION
A2666649.1 GI:11803795
KEYWORDS
GSS.
SOURCE
house mouse.
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 22)
REFERENCE
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
JOURNAL
Unpublished (2000)
COMMENT
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert length: 10000 Std Error: 0.00
Plate: 0548 row: M column: 19
Seq primer: CACACGAGAAACAGCTATGAC
Class: plasmid ends
High quality sequence stop: 22.
Location/Qualifiers
1..22
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0548M19"
/clone_1lb="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (g114732114[gb]AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance.

BASE COUNT
ORIGIN
3 a 0 c 14 g 5 t

Query Match 85.5%; Score 9.4; DB 17; Length 22;
Best Local Similarity 90.9%; Pred. No. 6.9e+04;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||
Db 4 GTTAGGGGTAG 14

RESULT 7
A2514597/c
LOCUS
DEFINITION 29 bp DNA linear GSS 05-OCT-2000
1M0361E14F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0361E14 F, DNA sequence.

ACCESSION
A2514597
VERSION
A2514597.1 GI:10695829
KEYWORDS
GSS.
SOURCE
house mouse.
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 29)
REFERENCE
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
JOURNAL
Unpublished (2000)
COMMENT
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert length: 10000 Std Error: 0.00
Plate: 0361 row: E column: 14
Seq primer: CGTTGTAAACGACGCGCAT
Class: plasmid ends
High quality sequence stop: 29.
Location/Qualifiers
1..29
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0361E14"
/clone_1lb="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (g114732114[gb]AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance.

BASE COUNT
ORIGIN
6 a 9 c 6 g 8 t

Query Match 85.5%; Score 9.4; DB 17; Length 29;
Best Local Similarity 90.9%; Pred. No. 7.5e+04;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||
Db 12 GTTAGGGTTAG 2

RESULT 8
BG419809 33 bp mRNA linear EST 14-MAR-2001
LOCUS 602453261F1 NIH_MGC_14 Homo sapiens cDNA clone IMAGE:4591599 5',
DEFINITION mRNA sequence.
ACCESSION BG419809
VERSION BG419809.1 GI:13326315
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 33)
AUTHORS NIH-MGC <http://mhc.nci.nih.gov/>.
TITLES National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: DCTD/DPF
CDNA Library Preparation: Ling Hong/Rubin Laboratory
DNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
<http://image.llnl.gov>
Plate: LNCMI328 row: j column: 16
High quality sequence stop: 33.
Location/Qualifiers
1. 33
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:4591599"
/clone_lib="NIH-MGC_14"
/tissue_type="renal cell adenocarcinoma"
/lab_host="PH10B (phage-resistant)"
/note="Organ: kidney; Vector: pOT7; Site_1: XhoI; Site_2:
EcoRI; cDNA made by oligo-dT priming. Directionally
cloned into EcoRI/XhoI sites using the following 5'
adaptor: GGCACGAG(G). Size-selected >500bp for average
insert size 1.8kb. Library constructed by Ling Hong in
the laboratory of Gerald M. Rubin (University of
California, Berkeley) using ZAP-cDNA synthesis kit
(Stratagene) and Superscript II RT (Life Technologies)."
BASE COUNT 9 a 3 c 12 g 9 t
ORIGIN
Query Match 85.5%; Score 9.4; DB 12; Length 33;
Best Local Similarity 90.9%; Pred. No. 7.8e+04;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 GTTAGGGTTAG 11
|||||
Db 7 GTTAGGGTTAG 17
RESULT 9
AZ334282 33 bp DNA linear GSS 29-SEP-2000
LOCUS 1M0063808R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0063808 R, DNA sequence.
ACCESSION AZ334282
VERSION AZ334282.1 GI:10401456
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 33)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.
and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb

JOURNAL
COMMENT Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0063 row: B column: 08
Seq primer: CACACAGCAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 33.
Location/Qualifiers
1. 33
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0063808"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Fl-resistant, F-"
/note="Vector: pMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(<http://www.jax.org/resources/documents/dnares/>). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD42 (g114732114[gb|AF129072.1]), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
BASE COUNT 11 a 13 c 2 g 7 t
ORIGIN
Query Match 85.5%; Score 9.4; DB 17; Length 33;
Best Local Similarity 90.9%; Pred. No. 7.8e+04;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 GTTAGGGTTAG 11
|||||
Db 22 GTTAGGGTTAG 12
RESULT 10
AZ776073 34 bp DNA linear GSS 16-FEB-2001
LOCUS 2M0009M20F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC2M0009M20 F, DNA sequence.
ACCESSION AZ776073
VERSION AZ776073.1 GI:12903271
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 34)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.
and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb

JOURNAL COMMENT

Plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: rdunn@genetics.utah.edu
Insert length: 10000 Std Error: 0.00
Plate: 0009 row: M column: 20
Seq primer: CGTGTGTAACGACGCGCCAGT
Class: Plasmid ends
High quality sequence stop: 34.
Location/Qualifiers

FEATURES

source

1. .34
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCG2M009M20"
/clone_1lb="Mouse 10kb plasmid UUCG1M library"
/sex="Male"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42ny; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g1473214[gblAF129072.1]), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT

19 a 9 c 2 g 4 t

ORIGIN

Query Match 85.5%; Score 9.4; DB 17; Length 34;

Best Local Similarity 90.9%; Pred. No. 7.9e+04; Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GTTAGGGCTTAG 11
||||| |||||

Db 20 GTTAGGACTTAG 10

RESULT 11
AL767851 36 bp DNA linear GSS 18-JUN-2002
LOCUS AL767851
DEFINITION Arabidopsis thaliana T-DNA flanking sequence GK-222E01-014236,
genomic survey sequence.
ACCESSION AL767851
VERSION AL767851.1 GI:21520970
KEYWORDS GSS.
SOURCE
ORGANISM Arabidopsis thaliana
thale cress.
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
Rosidae; eurosoids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE

1 Strizhov,N., Li,Y., Rosso,M., Viehoveer,P., Dekker,K., Saedler,H.
and Weisshaar,B.
A pipeline for automated high-throughput generation of FSTs
(flanking sequence tags) from Arabidopsis thaliana T-DNA

TITLE

JOURNAL REFERENCE

transformed lines
Unpublished
2 Rosso,M., Strizhov,N., Li,Y., Reiss,B., Dekker,K. and Weisshaar,B.
A new Arabidopsis thaliana T-DNA mutagenised population (GABI-Kat)
for flanking sequence tag based reverse genetics
Unpublished
3 (bases 1 to 36)

COMMENT

Rosso,M., Strizhov,N., Li,Y. and Weisshaar,B.
Direct Submission
Submitted (17-JUN-2002) Weissshaar B., Max-Planck-Institut fuer
Zuechtungsforchung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany
This sequence is recovered from the left border of the T-DNA. It
indicates an insertion within the locus defined by clone F28H19.
The sequences are generated at the MPI for Plant Breeding Research
in the context of the GABI-Kat project. GABI-Kat is part of the
German Plant Genomics program designated 'GABI'. Information on
line availability can be found at:
<http://www.mpiz-koeln.mpg.de/GABI-Kat/>.
Location/Qualifiers

FEATURES

source

1. .36
/organism="Arabidopsis thaliana"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="GK-222E01-014236"
/clone_1lb="Arabidopsis thaliana T-DNA insertion lines"
/note="PCR was performed on DNA from Arabidopsis thaliana
plants (T1) which were transformed with the T-DNA from
vector PAC161. The lines contain one or more T-DNA
insertions. The DNA fragment(s) resulting from the PCR
were directly sequenced to determine the genomic sequence
flanking the insertion. Sequences displaying significant
similarity to the A. thaliana nuclear genome sequence were
processed for submission. T-DNA derived sequences were
removed"

BASE COUNT

14 a 10 c 4 g 8 t

ORIGIN

Query Match 85.5%; Score 9.4; DB 17; Length 36;

Best Local Similarity 90.9%; Pred. No. 8e+04; Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 GTTAGGGCTTAG 11
||||| |||||

Db 24 GATAGGGCTTAG 14

RESULT 12

AU008671 39 bp mRNA linear EST 31-JUL-1998

LOCUS

AU008671 Schizosaccharomyces pombe late log phase cDNA

DEFINITION

Schizosaccharomyces pombe cDNA clone spc03845, mRNA sequence.

ACCESSION

AU008671

VERSION

AU008671.1 GI:3345129

KEYWORDS

EST.

SOURCE

fission yeast.
Schizosaccharomyces pombe

ORGANISM

Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
Schizosaccharomycetales; Schizosaccharomycetaceae;
Schizosaccharomyces.

REFERENCE

1 (bases 1 to 39)

AUTHORS

Moriyomo,M. and Mita,K.

TITLE

Identification of expressed sequence tags of Schizosaccharomyces
pombe

JOURNAL

Unpublished (1998)

COMMENT

Contact: Mitsunori Moriyomo
Genome Research Group
National Institute of Radiological Sciences
9-1, Anagawa-4-chome, Inage-ku, Chiba, Chiba 263-8555, Japan
Email: moriyomo@nirs.go.jp.
Location/Qualifiers

FEATURES

source

1. .39
/organism="Schizosaccharomyces pombe"

RESULT 15	
LOCUS	AU255689/c
DEFINITION	32 bp mRNA linear EST 25-APR-2002
ACCESSION	AU255689 3'-directed mouse cDNA library Mus musculus cDNA clone
VERSION	BEP0006171 3 , mRNA sequence.
KEYWORDS	AU255689 AU255689.1 GI:20318670
SOURCE	EST.
ORGANISM	house mouse. Mus musculus Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE	1 (bases 1 to 32)
TITLE	Kato,K. and Matoba,R.
JOURNAL	Generation of expressed sequence tags from mouse brain unpublished (2002)

COMMENT

Contact: Kikuya Kato
Graduate School of Biological Sciences
Nara Institute of Science and Technology
8916-5 Takayama, Ikoma, Nara 630-0101, Japan
Tel: 81-743-72-5581
Fax: 81-743-72-5589
Email: kkatoids.aist-nara.ac.jp,
URL: <http://love2.aist-nara.ac.jp/BD/index.html>.

FEATURES

source

1..32
Location/Qualifiers
/organism="Mus musculus"
/db_xref="taxon:10090"
/clone="BED0006171"
/clone_lib="3'-directed mouse cDNA library"
/tissue_type="brain"
/note="Vector: pGEM-T-easy"
8 c 6 g 8 t

BASE COUNT
ORIGIN

10 a

8 c

6 g

8 t

Query Match

81.8%; Score 9; DB 9; Length 32;

Best Local Similarity 100.0%; Pred. No. 1.4e+05; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0;

QY 2 TTAGGGTTA 10
|||||

DB 31 TTAGGGTTA 23

Search completed: June 2, 2003, 20:35:47
Job time : 1384.37 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:31:20 ; Search time 45.0732 Seconds
(without alignments)
74.844 Million cell updates/sec

Title: US-09-540-843-5
Perfect score: 11
Sequence: 1 gttagagtttag 11

Scoring table: IDENTITY_MNC
Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 15338381 residues
Total number of hits satisfying chosen parameters: 558892

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_MA:*
1: /cgn2_6/ptodata/1/ina/5A.COMB.seq:*
2: /cgn2_6/ptodata/1/ina/5B.COMB.seq:*
3: /cgn2_6/ptodata/1/ina/6A.COMB.seq:*
4: /cgn2_6/ptodata/1/ina/6B.COMB.seq:*
5: /cgn2_6/ptodata/1/ina/PCOTUS.COMB.seq:*
6: /cgn2_6/ptodata/1/ina/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	11	100.0	11	1	US-08-330-123A-2	Sequence 2, Appl1
2	11	100.0	11	1	US-08-482-115B-2	Sequence 2, Appl1
3	11	100.0	11	2	US-08-660-678A-2	Sequence 2, Appl1
4	11	100.0	11	2	US-08-531-743-11	Sequence 11, Appl1
5	11	100.0	11	2	US-08-531-743-12	Sequence 12, Appl1
6	11	100.0	11	2	US-08-485-778-36	Sequence 36, Appl1
7	11	100.0	11	2	US-08-472-802C-3	Sequence 3, Appl1
8	11	100.0	11	2	US-08-520-550A-36	Sequence 36, Appl1
9	11	100.0	11	3	US-08-630-019A-9	Sequence 9, Appl1
10	11	100.0	11	3	US-08-630-019A-30	Sequence 30, Appl1
11	11	100.0	11	3	US-08-630-019A-39	Sequence 39, Appl1
12	11	100.0	11	3	US-08-838-545-13	Sequence 13, Appl1
13	11	100.0	11	3	US-08-838-545-41	Sequence 31, Appl1
14	11	100.0	11	3	US-08-838-545-44	Sequence 44, Appl1
15	11	100.0	11	3	US-08-998-443-2	Sequence 2, Appl1
16	11	100.0	11	4	US-09-060-523-2	Sequence 2, Appl1
17	11	100.0	11	4	US-09-349-532-13	Sequence 13, Appl1
18	11	100.0	11	4	US-09-349-532-31	Sequence 31, Appl1
19	11	100.0	11	4	US-09-349-532-44	Sequence 44, Appl1
20	11	100.0	11	4	US-09-580-517-2	Sequence 2, Appl1
21	11	100.0	11	3	US-08-630-019A-10	Sequence 10, Appl1
22	11	100.0	11	3	US-08-838-545-8	Sequence 8, Appl1
23	11	100.0	11	4	US-09-349-532-8	Sequence 8, Appl1
24	11	100.0	11	4	US-08-630-019A-11	Sequence 11, Appl1
25	11	100.0	11	3	US-08-630-019A-15	Sequence 15, Appl1
26	11	100.0	11	3	US-08-838-545-1	Sequence 1, Appl1
27	11	100.0	11	3	US-08-838-545-12	Sequence 12, Appl1

28	11	100.0	13	4	US-09-349-532-1	Sequence 1, Appl1
29	11	100.0	13	4	US-09-349-532-12	Sequence 12, Appl1
30	11	100.0	15	2	US-08-531-743-4	Sequence 4, Appl1
31	11	100.0	15	3	US-08-630-019A-12	Sequence 12, Appl1
32	11	100.0	15	3	US-08-630-019A-18	Sequence 18, Appl1
33	11	100.0	15	3	US-08-630-019A-40	Sequence 40, Appl1
34	11	100.0	15	3	US-08-838-545-2	Sequence 2, Appl1
35	11	100.0	15	3	US-08-838-545-5	Sequence 5, Appl1
36	11	100.0	15	3	US-08-838-545-45	Sequence 45, Appl1
37	11	100.0	15	4	US-09-349-532-2	Sequence 2, Appl1
38	11	100.0	15	4	US-09-349-532-5	Sequence 5, Appl1
39	11	100.0	15	4	US-09-349-532-45	Sequence 45, Appl1
40	11	100.0	16	1	US-08-153-051B-11	Sequence 11, Appl1
41	11	100.0	16	2	US-08-151-477A-11	Sequence 11, Appl1
42	11	100.0	16	3	US-08-819-867-20	Sequence 20, Appl1
43	11	100.0	16	4	US-08-464-011B-60	Sequence 60, Appl1
44	11	100.0	17	2	US-08-531-743-13	Sequence 13, Appl1
45	11	100.0	17	4	US-08-857-721-12	Sequence 12, Appl1

ALIGNMENTS

RESULT 1
US-08-330-123A-2/c
Sequence 2, Application US/08330123A
Patent No. 5583016
GENERAL INFORMATION:
APPLICANT: VILLEPONTIEU, Bryant
APPLICANT: FENG, Junli
APPLICANT: FUNK, Walter
APPLICANT: ANDREWS, William H.
TITLE OF INVENTION: HUMAN TELOMERASE
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourile and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/330,123A
FILING DATE: 27-OCT-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M.
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 15389-000810
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA
US-08-330-123A-2

Query Match 100.0%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.le+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGGTTAG 11
|||||
Db 11 GTTAGGGTTAG 1

RESULT 2

US-08-482-115B-2/c
; Sequence 2, Application US/08482115B
; Patent No. 5776679
; GENERAL INFORMATION:
; APPLICANT: Villeponteau, Bryant
; APPLICANT: Feng, Junli
; APPLICANT: Funk, Walter
; APPLICANT: Andrews, William H.
; TITLE OF INVENTION: Assays for the RNA Component of Human
; NUMBER OF SEQUENCES: 40
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/482,115B
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/272,102
; FILING DATE: 07-JUL-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/330,123
; FILING DATE: 27-OCT-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Storella, John R.
; REGISTRATION NUMBER: 32,944
; REFERENCE/DOCKET NUMBER: 015389-000830US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA
US-08-482-115B-2

Query Match 100.0%; Score 11; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGGTTAG 11
|||||
Db 11 GTTAGGGTTAG 1

RESULT 3
US-08-660-678A-2/c
; Sequence 2, Application US/08660678A
; Patent No. 5837857
; GENERAL INFORMATION:
; APPLICANT: Villeponteau, Bryant
; APPLICANT: Feng, Junli
; APPLICANT: Funk, Walter
; APPLICANT: Andrews, William H.

;; TITLE OF INVENTION: Mammalian Telomerase
;; NUMBER OF SEQUENCES: 30
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Townsend and Crew LLP
;; STREET: Two Embarcadero Center, Eighth Floor
;; CITY: San Francisco
;; STATE: California
;; COUNTRY: USA
;; ZIP: 94111-3834
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patentin Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/660,678A
;; FILING DATE: 05-JUN-1996
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/330,123
;; FILING DATE: 27-OCT-1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/272,102
;; FILING DATE: 07-JUL-1994
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Storella, John R.
;; REGISTRATION NUMBER: 32,944
;; REFERENCE/DOCKET NUMBER: 015389-000811US
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (415) 576-0200
;; TELEFAX: (415) 576-0300
;; INFORMATION FOR SEQ ID NO: 2:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 11 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: RNA
US-08-660-678A-2

Query Match 100.0%; Score 11; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGGTTAG 11
|||||
Db 11 GTTAGGGTTAG 1

RESULT 4

US-08-531-743-11
; Sequence 11, Application US/08531743
; Patent No. 5856096
; GENERAL INFORMATION:
; APPLICANT: Windle, Bradford E.
; APPLICANT: Qiu, Ming
; APPLICANT: Chen, Shi-fong
; APPLICANT: Fletcher, Terrace M.
; APPLICANT: Maine, Ira
; TITLE OF INVENTION: Rapid and Sensitive Assays for Detecting and
; TITLE OF INVENTION: Distinguishing Between Processive and
; TITLE OF INVENTION: No. 5856096-Processive Telomerase Activities
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: United States of America
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible


```

1 OPERATING SYSTEM: PC-DOS/MS-DOS
2 SOFTWARE: PatentIn Release #1.0, Version #1.30
3 CURRENT APPLICATION DATA:
4 APPLICATION NUMBER: US/08/531,743
5 FILING DATE: 20-SEP-1995
6 CLASSIFICATION: 435
7
8 AUTOREY/AGENT INFORMATION:
9 NAME: Highlander, Steven L.
10 REGISTRATION NUMBER: 37,642
11 REFERENCE/DOCKET NUMBER: CTCR:026/HYL
12 TELECOMMUNICATION INFORMATION:
13 TELEPHONE: (512) 418-3000
14 TELEFAX: (512) 474-7577
15 INFORMATION FOR SEQ ID NO: 11:
16
17 SEQUENCE CHARACTERISTICS:
18 LENGTH: 11 base pairs
19 TYPE: nucleic acid
20 STRANDEDNESS: single
21
22 TOPOLOGY: Linear
23
24 US-08-531-743-11

```

Query Match	100.0%;	Score 11;	DB 2;	Length 11;
Best Local Similarity	100.0%;	Pred. No. 1.1e+02;		
Matches 11;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

QY	1	GTTAGGGTTAG	11
Db	1	GTTAGGGTTAG	11

RESULT 5
 US-08-531-743-12/C
 : Sequence 12, Application US/08531743
 : Patent No. 5856096
 :
 : GENERAL INFORMATION:
 : APPLICANT: Windle, Bradford E.
 : APPLICANT: Qiu, Ming
 : APPLICANT: Chen, Shi-Tong
 : APPLICANT: Fletcher, Terace M.
 : APPLICANT: Maine, Ira
 : TITLE OF INVENTION: Rapid and Sensitive Assays for Detecting and
 : TITLE OF INVENTION: Distinguishing Between Processive and
 : TITLE OF INVENTION: No. 5856096-Processive Telomerase Activities
 : NUMBER OF SEQUENCES: 17
 : CORRESPONDENCE ADDRESS:
 : ADDRESSEE: Arnold, White & Durkee
 : STREET: P.O. Box 4433
 : CITY: Houston
 : STATE: Texas
 : COUNTRY: United States of America
 : ZIP: 77210
 :
 : COMPUTER READABLE FORM:
 : MEDIUM TYPE: Floppy disk
 : COMPUTER: IBM PC compatible
 : OPERATING SYSTEM: PC-DOS/MS-DOS
 : SOFTWARE: PatentIn Release #1.0, Version #1.30
 : CURRENT APPLICATION DATA:
 : APPLICATION NUMBER: US/08/531,743
 : FILING DATE: 20-SEP-1995
 : CLASSIFICATION: 435
 : ATTORNEY/AGENT INFORMATION:
 : NAME: Highlander, Steven L.
 : REGISTRATION NUMBER: 37,642
 : REFERENCE/DOCKET NUMBER: CTCR:026/HYL
 : TELECOMMUNICATION INFORMATION:
 : TELEPHONE: (512) 474-7577
 : TELEFAX: (512) 474-7577
 : INFORMATION FOR SEQ ID NO: 12:
 : SEQUENCE CHARACTERISTICS:
 : LENGTH: 11 base pairs
 : TYPE: nucleic acid
 : STRANDEDNESS: single
 : TOPOLOGY: linear

US-08-531-743-12

```
Query Match      100.0%; Score 11; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0
```

QY	1	GTTAGGGTTAG	11
Db	11	GTTAGGGTTAG	1

```

      RESULT 6
US-08-485-778-36/c
; Sequence 36, Application US/08485778
; Patent No. 5876979
; GENERAL INFORMATION:
; APPLICANT: Andrews, William H.
; APPLICANT: Avillion, Ariel Athena
; APPLICANT: Feng, Junli
; APPLICANT: Funk, Walter
; APPLICANT: Greider, Carol
; APPLICANT: Marhuenda, Maria Antonia Biasco
; APPLICANT: Villeponteau, Bryant
; TITLE OF INVENTION: RNA COMPONENT OF TELOMERASE
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: MA
; COUNTRY: US
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,778
; FILING DATE: 07-JE-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/387,524
; FILING DATE: 13-FEB-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/330,123
; FILING DATE: 27-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/272,102
; FILING DATE: 07-JUL-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: CSHL94-05A4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-861-6240
; TELEFAX: 617-861-9540
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; type: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; US-08-485-778-36

Query Match          100.0%; Score 11; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.le+02;
Matches    11; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

QY      1 GTTAGCGTTAG 11
        |||||||||
Db       11 GTTAGCGTTAG 1

```

RESULT 7

US-08-472-802C-3/C
Sequence 3, Application US/08472802C
Patent No. 5958680
GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/472,802C
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M.
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 15389-000820
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA
US-08-472-802C-3

Query Match 100.0%; Score 11; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||
Db 11 GTTAGGGTTAG 1

RESULT 8
US-08-520-550A-36/C
Sequence 36, Application US/08520550A
Patent No. 6013468
GENERAL INFORMATION:
APPLICANT: Andrews, William H.
APPLICANT: Avillion, Ariel A.
APPLICANT: Feng, Junli
APPLICANT: Greider, Carol
APPLICANT: Funk, Walter
APPLICANT: Marhuenda, Maria A. B.
APPLICANT: Villeponteau, Bryant
TITLE OF INVENTION: RNA Component of Telomerase
NUMBER OF SEQUENCES: 47
CORRESPONDENCE ADDRESS:

ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.

STREET: Two Millitia Drive
CITY: LexingtonSTATE: MA
COUNTRY: US

ZIP: 02173

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/520,550A

FILING DATE: 29-AUG-1995

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/387,524

FILING DATE: 13-FEB-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/330,123

FILING DATE: 27-OCT-1994

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/272,102

FILING DATE: 07-JUL-1994

ATTORNEY/AGENT INFORMATION:

NAME: Granahan, Patricia

REGISTRATION NUMBER: 32,227

REFERENCE/DOCKET NUMBER: CSHL94-05A3B

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617-861-6240

TELEFAX: 617-861-9540

INFORMATION FOR SEQ ID NO: 36:

SEQUENCE CHARACTERISTICS:

LENGTH: 11 base pairs

TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

US-08-520-550A-36

Query Match 100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||
Db 11 GTTAGGGTTAG 1

RESULT 9
US-08-630-019A-9
Sequence 9, Application US/08630019A
Patent No. 6015710
GENERAL INFORMATION:
APPLICANT: Shay, Jerry W.
APPLICANT: Wright, Woodring E.
APPLICANT: Piatyszek, Mieczyslaw A.
APPLICANT: Corey, David
APPLICANT: No. 6015710ton, James C.
TITLE OF INVENTION: Modulation of Mammalian Telomerase by
TITLE OF INVENTION: Peptide Nucleic Acids
NUMBER OF SEQUENCES: 46
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/630,019A
FILING DATE: 09-JUN-1996
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-001600US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "peptide nucleic acid (PNA),
DESCRIPTION: where (deoxy)ribose-phosphate linkages are replaced by
DESCRIPTION: N-(2-aminoethyl)glycine units linked to nucleotide bases via
DESCRIPTION: glycine amino nitrogen through a methylenecarbonyl linker"
US-08-630-019A-9

Query Match
Best Local Similarity 100.0%; Score 11; DB 3; Length 11;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGTTAG 11
DB 1 GTTAGGTTAG 11

RESULT 10
US-08-630-019A-30/C
Sequence 30, Application US/08630019A
Patent No. 6015710
GENERAL INFORMATION:
APPLICANT: Shay, Jerry W.
APPLICANT: Wright, Woodring E.
APPLICANT: Piatyszek, Mieczyslaw A.
APPLICANT: Corey, David
APPLICANT: No. 6015710ton, James C.
TITLE OF INVENTION: Modulation of Mammalian Telomerase by
TITLE OF INVENTION: Peptide Nucleic Acids
NUMBER OF SEQUENCES: 46
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/630,019A
FILING DATE: 09-JUN-1996
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-001600US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA
US-08-630-019A-30

Query Match
Best Local Similarity 100.0%; Score 11; DB 3; Length 11;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGTTAG 11
DB 1 GTTAGGTTAG 11

RESULT 11
US-08-630-019A-39
Sequence 39, Application US/08630019A
Patent No. 6015710
GENERAL INFORMATION:
APPLICANT: Shay, Jerry W.
APPLICANT: Wright, Woodring E.
APPLICANT: Piatyszek, Mieczyslaw A.
APPLICANT: Corey, David
APPLICANT: No. 6015710ton, James C.
TITLE OF INVENTION: Modulation of Mammalian Telomerase by
TITLE OF INVENTION: Peptide Nucleic Acids
NUMBER OF SEQUENCES: 46
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/630,019A
FILING DATE: 09-JUN-1996
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-001600US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "phosphorothioate (PS) nucleic acid"
US-08-630-019A-39

Query Match
Best Local Similarity 100.0%; Score 11; DB 3; Length 11;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGTTAG 11
DB 1 GTTAGGTTAG 11

RESULT 12
US-08-838-545-13
Sequence 13, Application US/08838545
Patent No. 6046307

```

GENERAL INFORMATION:
APPLICANT: Shay, Jerry W.
APPLICANT: Wright, Woodring E.
APPLICANT: Platyszek, Mieczyslaw A.
APPLICANT: Corey, David R.
APPLICANT: No. 6046307ton, James C.
TITLE OF INVENTION: Modulation of Mammalian Telomerase by
TITLE OF INVENTION: Peptide Nucleic Acids
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/838,545
FILING DATE: 09-APR-1997
CLASSIFICATION: 536
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 08/630,019
FILING DATE: 09-APR-1996
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-00161005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "peptide nucleic acid (PNA),
DESCRIPTION: where (deoxy/ribose-phosphate linkages are replaced by
DESCRIPTION: N-(2-aminoethyl)glycine units linked to nucleotide bases via
DESCRIPTION: glycine amino N through a methylencarbonyl linker"
US-08-838-545-13

Query Match 100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGCTTAG 11
DB 1 GTTAGGCTTAG 11

RESULT 13
US-08-838-545-31/C
Sequence 31, Application US/08838545
GENERAL INFORMATION:
APPLICANT: Shay, Jerry W.
APPLICANT: Wright, Woodring E.
APPLICANT: Platyszek, Mieczyslaw A.
APPLICANT: Corey, David R.
APPLICANT: No. 6046307ton, James C.
TITLE OF INVENTION: Modulation of Mammalian Telomerase by
TITLE OF INVENTION: Peptide Nucleic Acids
NUMBER OF SEQUENCES: 60
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/838,545
FILING DATE: 09-APR-1997
STREET: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
```

```

CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/838,545
FILING DATE: 09-APR-1997
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 08/630,019
FILING DATE: 09-APR-1996
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-00161005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "peptide nucleic acid (PNA),
DESCRIPTION: where (deoxy/ribose-phosphate linkages are replaced by
DESCRIPTION: N-(2-aminoethyl)glycine units linked to nucleotide bases via
DESCRIPTION: glycine amino N through a methylencarbonyl linker"
US-08-838-545-31

Query Match 100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGCTTAG 11
DB 11 GTTAGGCTTAG 11

RESULT 14
US-08-838-545-44
Sequence 44, Application US/08838545
GENERAL INFORMATION:
APPLICANT: Shay, Jerry W.
APPLICANT: Wright, Woodring E.
APPLICANT: Platyszek, Mieczyslaw A.
APPLICANT: Corey, David R.
APPLICANT: No. 6046307ton, James C.
TITLE OF INVENTION: Modulation of Mammalian Telomerase by
TITLE OF INVENTION: Peptide Nucleic Acids
NUMBER OF SEQUENCES: 60
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/838,545
FILING DATE: 09-APR-1997
```

```
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/630,019
FILING DATE: 09-APR-1996
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-001610US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 44:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "phosphorothioate (PS)
US-08-838-545-44
nucleic acid"
```

```
Query Match          100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 GTTAGGGTTAG 11
        |||
Db       1 GTTAGGGTTAG 11
```

```
RESULT 15
US-08-998-443-2/c
Sequence 2, Application US/08998443
Patent No. 6054575
GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/998,443
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/660,678
FILING DATE: 05-JUN-1996
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000811US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
```

```
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA
US-08-998-443-2
```

```
Query Match          100.0%; Score 11; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 GTTAGGGTTAG 11
        |||
Db       1 GTTAGGGTTAG 1
```

```
Search completed: June 2, 2003, 20:38:35
Job time : 46.0732 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 19:09:45 ; Search time 78.0732 Seconds
(without alignments)
189.976 Million cell updates/sec

Title: US-09-540-843-5
Perfect score: 11
Sequence: 1 gttagggttag 11

Scoring table:
IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 845702 seqs, 674182571 residues

Total number of hits satisfying chosen parameters: 477662

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_NA:*

- 1: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
- 2: /cgn2_6/ptodata/2/pubpna/PCR_NEM_PUB.seq:*
- 3: /cgn2_6/ptodata/2/pubpna/US06_NEM_PUB.seq:*
- 4: /cgn2_6/ptodata/2/pubpna/US06_PUBCOMB.seq:*
- 5: /cgn2_6/ptodata/2/pubpna/US07_NEM_PUB.seq:*
- 6: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
- 7: /cgn2_6/ptodata/2/pubpna/US08_PUB.seq:*
- 8: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
- 9: /cgn2_6/ptodata/2/pubpna/US09_NEM_PUB.seq:*
- 10: /cgn2_6/ptodata/2/pubpna/US09_PUBCOMB.seq:*
- 11: /cgn2_6/ptodata/2/pubpna/US10_NEM_PUB.seq:*
- 12: /cgn2_6/ptodata/2/pubpna/US10_PUBCOMB.seq:*
- 13: /cgn2_6/ptodata/2/pubpna/US60_NEM_PUB.seq:*
- 14: /cgn2_6/ptodata/2/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	11	100.0	11	9	US-09-835-370-63
2	11	100.0	11	9	US-10-122-630-5
3	11	100.0	11	9	US-10-122-630-9
4	11	100.0	11	9	US-10-122-633-5
5	11	100.0	11	9	US-10-122-633-9
6	11	100.0	11	10	US-09-057-351-2
7	11	100.0	13	9	US-09-893-252-4
8	11	100.0	13	9	US-10-038-335-1
9	11	100.0	13	9	US-10-038-335-2
10	11	100.0	18	8	US-08-463-404-5
11	11	100.0	18	8	US-08-463-404-5
12	11	100.0	18	9	US-09-893-252-1
13	11	100.0	18	9	US-10-132-002-2
14	11	100.0	18	9	US-10-132-002-4
15	11	100.0	18	9	US-10-238-732-2
16	11	100.0	18	9	US-10-044-692-295
17	11	100.0	18	10	US-10-044-692-296
18	11	100.0	18	10	US-09-057-351-26
19	11	100.0	18	10	US-09-947-659-1

20	11	100.0	18	10	US-09-947-659-2	Sequence 2, Appli
21	11	100.0	18	10	US-09-947-659-7	Sequence 7, Appli
22	11	100.0	19	10	US-09-817-387-19	Sequence 19, Appli
23	11	100.0	20	9	US-09-888-326-808	Sequence 808, App
24	11	100.0	20	9	US-10-112-653-824	Sequence 824, App
25	11	100.0	20	9	US-10-017-993-853	Sequence 853, App
26	11	100.0	20	9	US-09-776-479-853	Sequence 853, App
27	11	100.0	20	9	US-09-057-351-40	Sequence 40, Appli
28	11	100.0	20	10	US-09-816-248-36	Sequence 36, Appli
29	11	100.0	20	10	US-09-816-248-37	Sequence 37, Appli
30	11	100.0	21	9	US-10-079-5008-1	Sequence 1, Appli
31	11	100.0	21	9	US-10-040-370A-1	Sequence 1, Appli
32	11	100.0	21	10	US-09-817-387-23	Sequence 23, Appli
33	11	100.0	21	10	US-09-817-387-28	Sequence 28, Appli
34	11	100.0	21	10	US-09-801-346-2	Sequence 2, Appli
35	11	100.0	21	10	US-09-923-541-1	Sequence 1, Appli
36	11	100.0	22	9	US-09-940-173A-2	Sequence 2, Appli
37	11	100.0	22	9	US-09-940-173A-8	Sequence 8, Appli
38	11	100.0	22	10	US-09-057-351-41	Sequence 41, Appli
39	11	100.0	22	10	US-09-730-893-2	Sequence 2, Appli
40	11	100.0	22	10	US-09-730-893-8	Sequence 8, Appli
41	11	100.0	23	10	US-09-817-387-14	Sequence 14, Appli
42	11	100.0	23	10	US-09-817-387-16	Sequence 16, Appli
43	11	100.0	23	10	US-09-817-387-18	Sequence 18, Appli
44	11	100.0	24	8	US-08-463-404-6	Sequence 6, Appli
45	11	100.0	24	8	US-08-463-404-29	Sequence 29, Appli

ALIGNMENTS

RESULT 1
US-09-835-370-63
Sequence 63, Application US/09835370
Publication No. US20030022172A1
GENERAL INFORMATION:
APPLICANT: UHLMANN, EDGEN
BREIPOHL, GERHARD
APPLICANT: WILL, DAVID W
TITLE OF INVENTION: POLYMERASE NUCLEIC ACID DERIVATIVES AND AGENTS AND
TITLE OF INVENTION: POLYMERASE NUCLEIC ACID DERIVATIVES AND AGENTS AND
FILE REFERENCE: 02481.1742 SEQUENCE LISTING
CURRENT FILING DATE: 2001-04-17
NUMBER OF SEQ ID NOS: 64
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO 63
LENGTH: 11
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: nucleotide
OTHER INFORMATION: base sequence of PNA derivatives that bind to
OTHER INFORMATION: viral and cellular targets
US-09-835-370-63
Query Match 100.0%; Score 11; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTTAGGGTTAG 11
Db 1 GTTAGGGTTAG 11
RESULT 2
US-10-122-630-5
Sequence 5, Application US/10122630
Publication No. US20030032610A1
GENERAL INFORMATION:
APPLICANT: Gilchrist, Barbara A.
APPLICANT: Eller, Mark S.
APPLICANT: Yaar, Mina

```

; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE OF INVENTION: Oligonucleotides
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-5
```

```
Query Match          100.0%; Score 11; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 GTTAGGCTTAG 11
        |||||||
DB      1 GTTAGGCTTAG 11
```

```

RESULT 3
US-10-122-630-9/c
; Sequence 9, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-9
```

```
Query Match          100.0%; Score 11; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 GTTAGGCTTAG 11
        |||||||
DB      1 GTTAGGCTTAG 11
```

```

DB      11 GTTAGGCTTAG 1

RESULT 4
US-10-122-633-5
; Sequence 5, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-5
```

```
Query Match          100.0%; Score 11; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 GTTAGGCTTAG 11
        |||||||
DB      1 GTTAGGCTTAG 11
```

```

RESULT 5
US-10-122-633-9/c
; Sequence 9, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-9
```

```
Query Match          100.0%; Score 11; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 GTTAGGCTTAG 11
        |||||||
DB      11 GTTAGGCTTAG 1
```


RESULT 6
US-09-057-351-2/c
; Sequence 2, Application US/09057351
; Patent No. US20010034439A1
; GENERAL INFORMATION:
; APPLICANT: Villeponteau, Bryant
; APPLICANT: Feng, Junli
; APPLICANT: Funk, Walter
; APPLICANT: Andrews, William H.
; TITLE OF INVENTION: Mammalian Telomerase
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/057,351
; FILING DATE: 08-APR-1994
; CLASSIFICATION: 435
; ERROR APPLICATION DATA:
; APPLICATION NUMBER: US 08/272,102
; FILING DATE: 07-JUL-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/330,123
; FILING DATE: 27-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/472,802
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Storella, John R.
; REGISTRATION NUMBER: 32,944
; REFERENCE/DOCKET NUMBER: 015389-000821US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA
US-09-057-351-2

Query Match 100.0%; Score 11; DB 10; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGTTAG 11
DB 11 GTTAGGTTAG 1

RESULT 7
US-09-893-252-4
; Sequence 4, Application US/09893252
; Publication No. US20030012755A1
; GENERAL INFORMATION:
; APPLICANT: Styczynski, Peter
; APPLICANT: Ahluwalia, Gurpreet S.
; TITLE OF INVENTION: REDUCTION OF HAIR GROWTH
; FILE REFERENCE: 00216-552001
; CURRENT APPLICATION NUMBER: US/09/893,252

; CURRENT FILING DATE: 2001-10-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 13
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-893-252-4

Query Match 100.0%; Score 11; DB 9; Length 13;
Best Local Similarity 63.6%; Pred. No. 2.2e+03;
Matches 7; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGTTAG 11
DB 3 GUTAGGGUUG 13

RESULT 8
US-10-038-335-1
; Sequence 1, Application US/10038335
; Publication No. US20030096776A1
; GENERAL INFORMATION:
; APPLICANT: Eckert, David J.
; APPLICANT: Wyatt, Jacqueline
; APPLICANT: Bennett, C. Frank
; APPLICANT: Hanecak, Ronnie
; APPLICANT: Brown-Driver, Vickie
; APPLICANT: Vickers, Timothy
; APPLICANT: Chiang, Ming-yi
; APPLICANT: Anderson, Kevin
; TITLE OF INVENTION: Modulation of Telomere Length By Oligonucleotides Having A G-C
; FILE REFERENCE: ISIS-4976
; CURRENT APPLICATION NUMBER: US/10/038,335
; CURRENT FILING DATE: 2001-01-02
; PRIOR APPLICATION NUMBER: 09/299,058
; PRIOR FILING DATE: 1999-04-23
; PRIOR APPLICATION NUMBER: 08/403,888
; PRIOR FILING DATE: 1995-06-12
; PRIOR APPLICATION NUMBER: PCT/US93/09297
; PRIOR FILING DATE: 1993-09-29
; PRIOR APPLICATION NUMBER: 07/954,185
; PRIOR FILING DATE: 1992-09-29
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 1
; LENGTH: 13
; TYPE: DNA
; ORGANISM: No. US20030096776A1el sequence
; FEATURE:
; OTHER INFORMATION: Antisense sequence
US-10-038-335-1

Query Match 100.0%; Score 11; DB 9; Length 13;
Best Local Similarity 63.6%; Pred. No. 2.2e+03;
Matches 7; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGTTAG 11
DB 3 GUTAGGGUUG 13

RESULT 9
US-10-038-335-2
; Sequence 2, Application US/10038335
; Publication No. US20030096776A1
; GENERAL INFORMATION:
; APPLICANT: Eckert, David J.
; APPLICANT: Wyatt, Jacqueline
; APPLICANT: Bennett, C. Frank
; APPLICANT: Hanecak, Ronnie
; APPLICANT: Brown-Driver, Vickie

APPLICANT: Vickers, Timothy
APPLICANT: Chiang, Ming-Yi
APPLICANT: Anderson, Kevin
TITLE OF INVENTION: Modulation of Telomere Length By Oligonucleotides Having A G-Core
TITLE OF INVENTION: Sequence
FILE REFERENCE: ISIS-4976
CURRENT APPLICATION NUMBER: US/10/038,335
CURRENT FILING DATE: 2001-01-02
PRIOR APPLICATION NUMBER: 09/299,058
PRIOR FILING DATE: 1999-04-23
PRIOR APPLICATION NUMBER: 08/403,888
PRIOR FILING DATE: 1995-06-12
PRIOR APPLICATION NUMBER: PCT/US93/09297
PRIOR FILING DATE: 1993-09-29
PRIOR APPLICATION NUMBER: 07/954,185
PRIOR FILING DATE: 1992-09-29
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn version 3.1
SEQ ID NO 2
LENGTH: 13
TYPE: DNA
ORGANISM: No. US20030096776A1el sequence
FEATURE:
OTHER INFORMATION: Antisense sequence
US-10-038-335-2

Query Match 100.0%; Score 11; DB 9; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.2e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGTTAG 11
DB 3 GTTAGGTTAG 13

RESULT 10
US-08-463-404-4/C
Sequence 4, Application US/08463404
Patent No. US20020127634A1
GENERAL INFORMATION:
APPLICANT: Michael D. West
APPLICANT: Jerry W. Shay
APPLICANT: Woodring E. Wright
APPLICANT: Elizabeth Blackburn
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF CONDITIONS
RELATED TO TETRAOXY LENGTH AND/OR
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/463,404
FILING DATE: 05-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,952
FILING DATE: May 13, 1993
APPLICATION NUMBER: 07/882,438
FILING DATE: May 13, 1992
APPLICATION NUMBER: 08/038,766
FILING DATE: March 24, 1993

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 202/045
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-463-404-4

Query Match 100.0%; Score 11; DB 8; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGTTAG 11
DB 13 GTTAGGTTAG 3

RESULT 11
US-08-463-404-5
Sequence 5, Application US/08463404
Patent No. US20020127634A1
GENERAL INFORMATION:
APPLICANT: Michael D. West
APPLICANT: Jerry W. Shay
APPLICANT: Woodring E. Wright
APPLICANT: Elizabeth Blackburn
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF CONDITIONS
RELATED TO TETRAOXY LENGTH AND/OR
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/463,404
FILING DATE: 05-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/060,952
FILING DATE: May 13, 1993
APPLICATION NUMBER: 07/882,438
FILING DATE: May 13, 1992
APPLICATION NUMBER: 08/038,766
FILING DATE: March 24, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 202/045
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:

LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-463-404-5

Query Match 100.0%; Score 11; DB 8; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGGTTAG 11
DB 6 GTTAGGGTTAG 16

RESULT 12
US-09-893-252-1
Sequence 1, Application US/09893252
Publication No. US20030012755A1
GENERAL INFORMATION:
APPLICANT: Styczynski, Peter
APPLICANT: Ahluwalia, Gurpreet S.
TITLE OF INVENTION: REDUCTION OF HAIR GROWTH
FILE REFERENCE: 00216-552001
CURRENT APPLICATION NUMBER: US/09/893,252
CURRENT FILING DATE: 2001-10-12
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 1
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens
US-09-893-252-1

Query Match 100.0%; Score 11; DB 9; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGGTTAG 11
DB 6 GTTAGGGTTAG 16

RESULT 13
US-10-132-002-2/c
Sequence 2, Application US/10132002
Publication No. US20030022204A1
GENERAL INFORMATION:
APPLICANT: Lansdorp, Peter
TITLE OF INVENTION: Method for Detecting Multiple Copies of
a Repeat Sequence in a Nucleic Acid Molecule
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: HOWSON & HOWSON
STREET: 321 NO. US20030022204A1ristown Road
CITY: Spring House
STATE: PA
COUNTRY: U.S.A.
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/132,002
FILING DATE: 25-Apr-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/730,635
FILING DATE: 11-OCT-1996
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.

REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: B&P7USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 540-9200
TELEFAX: (215) 540-5818
TELEX: N/A
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-132-002-2

Query Match 100.0%; Score 11; DB 9; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGGTTAG 11
DB 13 GTTAGGGTTAG 3

RESULT 14
US-10-132-002-4
Sequence 4, Application US/10132002
Publication No. US20030022204A1
GENERAL INFORMATION:
APPLICANT: Lansdorp, Peter
TITLE OF INVENTION: Method for Detecting Multiple Copies of
a Repeat Sequence in a Nucleic Acid Molecule
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: HOWSON & HOWSON
STREET: 321 NO. US20030022204A1ristown Road
CITY: Spring House
STATE: PA
COUNTRY: U.S.A.
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/132,002
FILING DATE: 25-Apr-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/730,635
FILING DATE: 11-OCT-1996
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: B&P7USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 540-9200
TELEFAX: (215) 540-5818
TELEX: N/A
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-10-132-002-4

Query Match 100.0%; Score 11; DB 9; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGTTAG 11
|||||

Db 6 GTTAGGTTAG 16

RESULT 15

US-10-238-732-2/C

; Sequence 2, Application US/10238732

; Publication No. US2003007635A1

; GENERAL INFORMATION:

; APPLICANT: DAKO A/S

; TITLE OF INVENTION: DENDRIMERS AND METHODS FOR THEIR PREPARATION AND USE

; FILE REFERENCE: P65587US1

; CURRENT APPLICATION NUMBER: US/10/238,732

; PRIOR FILING DATE: 2002-09-11

; PRIOR APPLICATION NUMBER: 09/606,315

; PRIOR FILING DATE: 2000-06-29

; PRIOR APPLICATION NUMBER: PA 1999 00934

; PRIOR FILING DATE: 1999-06-29

; NUMBER OF SEQ ID NOS: 11

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 2

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: Linker sequence.

US-10-238-732-2

Query Match 100.0%; Score 11; DB 9; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.1e+03;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTTAGGTTAG 11
|||||

Db 16 GTTAGGTTAG 6

Search completed: June 2, 2003, 23:43:14
Job time : 79.0732 secs

score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result	Query	Match	Length	DB	ID	Description
No.	Score					
1	7	100.0	7	6	AX268755	AX268755 SE
2	7	100.0	7	6	AX268759	AX268759 SE

3	100.0	9	6	AX268753	AX268753	\$6
4	100.0	10	6	AX377258	AX377258	\$6

Case	Age	Sex	Occupation	Education	Religion	Marital Status	Family Size	Income	Health	Life Expectancy
1	25	M	Teacher	High School	Catholic	Married	3	\$40,000	Good	75
2	35	F	Nurse	College	Protestant	Single	1	\$50,000	Excellent	80
3	45	M	Engineer	University	Jewish	Married	2	\$60,000	Very Good	85
4	55	F	Homemaker	High School	Muslim	Married	4	\$30,000	Fair	70
5	65	M	Retired	College	Buddhist	Widowed	1	\$45,000	Good	78
6	75	F	Teacher	University	Catholic	Married	2	\$55,000	Excellent	82
7	85	M	Engineer	High School	Protestant	Widowed	1	\$65,000	Very Good	88
8	95	F	Homemaker	High School	Muslim	Married	3	\$35,000	Fair	72
9	105	M	Retired	College	Buddhist	Widowed	1	\$48,000	Good	76
10	115	F	Teacher	University	Catholic	Married	2	\$58,000	Excellent	84

Case	Year	Age	Sex	Occupation	Education	Marital Status	Religion	Political Party	Income	Assets	Liabilities	Net Worth	Spouse's Net Worth	Children's Net Worth	Other Assets	Other Liabilities	Other Net Worth	Other Spouse's Net Worth	Other Children's Net Worth	Other Assets	Other Liabilities	Other Net Worth	Other Spouse's Net Worth	Other Children's Net Worth
1	1990	12	6	A91497																				
2	1990	13	6	A91497																				
3	1990	13	6	A91497																				
4	1990	13	6	A91497																				
5	1990	13	6	A91497																				
6	1990	13	6	A91497																				
7	1990	13	6	A91497																				
8	1990	13	6	A91497																				
9	1990	13	6	A91497																				
10	1990	13	6	A91497																				
11	1990	13	6	A91497																				
12	1990	13	6	A91497																				
13	1990	13	6	A91497																				
14	1990	13	6	A91497																				
15	1990	13	6	A91497																				
16	1990	13	6	A91497																				
17	1990	13	6	A91497																				
18	1990	13	6	A91497																				
19	1990	13	6	A91497																				
20	1990	13	6	A91497																				
21	1990	13	6	A91497																				
22	1990	13	6	A91497																				
23	1990	13	6	A91497																				
24	1990	13	6	A91497																				
25	1990	13	6	A91497																				
26	1990	13	6	A91497																				
27	1990	13	6	A91497					</															

C	10	100.0	14	8	AR082813	Se
	11	100.0	14	6	AR088823	Se

13	7	100.0	14	6	AX343036	AX343036 Se
12	7	100.0	14	6	AX018/48	AX018/48 Se
9	7	100.0	14	6	AX343036	AX343036 Se

14	7	100.0	A33153
15	7	100.0	A33153 Synt
16	7	100.0	AR041154
17	7	100.0	AR082814
18	7	100.0	AR082814
19	7	100.0	AR082814
20	7	100.0	AR082814
21	7	100.0	AR082814
22	7	100.0	AR082814
23	7	100.0	AR082814
24	7	100.0	AR082814
25	7	100.0	AR082814
26	7	100.0	AR082814
27	7	100.0	AR082814
28	7	100.0	AR082814
29	7	100.0	AR082814
30	7	100.0	AR082814
31	7	100.0	AR082814
32	7	100.0	AR082814
33	7	100.0	AR082814
34	7	100.0	AR082814
35	7	100.0	AR082814
36	7	100.0	AR082814
37	7	100.0	AR082814
38	7	100.0	AR082814
39	7	100.0	AR082814
40	7	100.0	AR082814
41	7	100.0	AR082814
42	7	100.0	AR082814
43	7	100.0	AR082814
44	7	100.0	AR082814
45	7	100.0	AR082814
46	7	100.0	AR082814
47	7	100.0	AR082814
48	7	100.0	AR082814
49	7	100.0	AR082814
50	7	100.0	AR082814
51	7	100.0	AR082814
52	7	100.0	AR082814
53	7	100.0	AR082814
54	7	100.0	AR082814
55	7	100.0	AR082814
56	7	100.0	AR082814
57	7	100.0	AR082814
58	7	100.0	AR082814
59	7	100.0	AR082814
60	7	100.0	AR082814
61	7	100.0	AR082814
62	7	100.0	AR082814
63	7	100.0	AR082814
64	7	100.0	AR082814
65	7	100.0	AR082814
66	7	100.0	AR082814
67	7	100.0	AR082814
68	7	100.0	AR082814
69	7	100.0	AR082814
70	7	100.0	AR082814
71	7	100.0	AR082814
72	7	100.0	AR082814
73	7	100.0	AR082814
74	7	100.0	AR082814
75	7	100.0	AR082814
76	7	100.0	AR082814
77	7	100.0	AR082814
78	7	100.0	AR082814
79	7	100.0	AR082814
80	7	100.0	AR082814
81	7	100.0	AR082814
82	7	100.0	AR082814
83	7	100.0	AR082814
84	7	100.0	AR082814
85	7	100.0	AR082814
86	7	100.0	AR082814
87	7	100.0	AR082814
88	7	100.0	AR082814
89	7	100.0	AR082814
90	7	100.0	AR082814
91	7	100.0	AR082814
92	7	100.0	AR082814
93	7	100.0	AR082814
94	7	100.0	AR082814
95	7	100.0	AR082814
96	7	100.0	AR082814
97	7	100.0	AR082814
98	7	100.0	AR082814
99	7	100.0	AR082814
100	7	100.0	AR082814

Case	Year	Age	Sex	Location	Outcome
1	1971	13	M	ARI30719	Se
2	1971	15	F	ARI30720	Se
3	1971	15	F	ARI30720	Se
4	1971	15	F	ARI30720	Se
5	1971	15	F	ARI30720	Se
6	1971	15	F	ARI30720	Se
7	1971	15	F	ARI30720	Se
8	1971	15	F	ARI30720	Se
9	1971	15	F	ARI30720	Se
10	1971	15	F	ARI30720	Se
11	1971	15	F	ARI30720	Se
12	1971	15	F	ARI30720	Se
13	1971	15	F	ARI30720	Se
14	1971	15	F	ARI30720	Se
15	1971	15	F	ARI30720	Se
16	1971	15	F	ARI30720	Se
17	1971	15	F	ARI30720	Se
18	1971	15	F	ARI30720	Se
19	1971	15	F	ARI30720	Se
20	1971	15	F	ARI30720	Se
21	1971	15	F	ARI30720	Se
22	1971	15	F	ARI30720	Se
23	1971	15	F	ARI30720	Se
24	1971	15	F	ARI30720	Se
25	1971	15	F	ARI30720	Se
26	1971	15	F	ARI30720	Se
27	1971	15	F	ARI30720	Se
28	1971	15	F	ARI30720	Se
29	1971	15	F	ARI30720	Se
30	1971	15	F	ARI30720	Se
31	1971	15	F	ARI30720	Se
32	1971	15	F	ARI30720	Se
33	1971	15	F	ARI30720	Se
34	1971	15	F	ARI30720	Se
35	1971	15	F	ARI30720	Se
36	1971	15	F	ARI30720	Se
37	1971	15	F	ARI30720	Se
38	1971	15	F	ARI30720	Se
39	1971	15	F	ARI30720	Se
40	1971	15	F	ARI30720	Se
41	1971	15	F	ARI30720	Se
42	1971	15	F	ARI30720	Se
43	1971	15	F	ARI30720	Se
44	1971	15	F	ARI30720	Se
45	1971	15	F	ARI30720	Se
46	1971	15	F	ARI30720	Se
47	1971	15	F	ARI30720	Se
48	1971	15	F	ARI30720	Se
49	1971	15	F	ARI30720	Se
50	1971	15	F	ARI30720	Se
51	1971	15	F	ARI30720	Se
52	1971	15	F	ARI30720	Se
53	1971	15	F	ARI30720	Se
54	1971	15	F	ARI30720	Se
55	1971	15	F	ARI30720	Se
56	1971	15	F	ARI30720	Se
57	1971	15	F	ARI30720	Se
58	1971	15	F	ARI30720	Se
59	1971	15	F	ARI30720	Se
60	1971	15	F	ARI30720	Se
61	1971	15	F	ARI30720	Se
62	1971	15	F	ARI30720	Se
63	1971	15	F	ARI30720	Se
64	1971	15	F	ARI30720	Se
65	1971	15	F	ARI30720	Se
66	1971	15	F	ARI30720	Se
67	1971	15	F	ARI30720	Se
68	1971	15	F	ARI30720	Se
69	1971	15	F	ARI30720	Se
70	1971	15	F	ARI	

15	/	100:0	AR131705	Se
20	7	100.0	AR132890	Se

22	100.0	15	6	AX377250	AX018/50	Se
7	100.0	15	6	AX377250	AX018/50	Se

RESULT 1						
LOCUS	AX268755					
DEFINITION	Sequence 3 from Patent WO01/4342.	7 bp	DNA	linear	PAT'29-OCT-2001	
ACCESSION	AX268755					
VERSION	AX268755.1	GI:16541827				
KEYWORDS	.					
SOURCE	synthetic construct.					
ORGANISM	synthetic construct					
REFERENCE	artificial sequences.					
AUTHORS	Gilchrist,B.A., Yaar,M. and Eller,M.					
TITLE	Use of locally amplified DNA fragments					

JOURNAL
Patent: WO 01/4342-A 3 11-OCT-2001
TRUSTEES OF BOSTON UNIVERSITY (US)

```

FEATURES
  source
    Location/Qualifiers
      1..7
        /organism="synthetic construct"
        /db_xref="taxon:32630"
        /note="Synthetic DNA Fragment"
BASE COUNT
  3 a 0 c 2 g
  ORIGIN

Query Match
  Best Local Similarity 100.0%; Score 7; DB 6; Length 7;
  Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
  1 AGTATGA 7
  |||||
  1 AGTATGA 7

RESULT 2
AX268759
LOCUS
  Sequence 7 from Patent WO0174342.
  7 bp DNA linear PAT 29-OCT-2001
ACCESSION
  AX268759.1 GI:16541831
VERSION
  AX268759.1
KEYWORDS
  synthetic construct.
  artificial sequences.
SOURCE
  ORGANISM
    synthetic construct.
    artificial sequences.
REFERENCE
  1
  AUTHORS
    Gilchrist, B.A., Yaar, M. and Eller, M.
  TITLE
    Use of locally applied dna fragments
  JOURNAL
    Patent: WO 0174342-A 7 11-OCT-2001;
    TRUSTEES OF BOSTON UNIVERSITY (US)
FEATURES
  source
    1..7
      /organism="synthetic construct"
      /db_xref="taxon:32630"
      /note="Synthetic DNA Fragment"
BASE COUNT
  3 a 0 c 2 g
  ORIGIN

Query Match
  Best Local Similarity 100.0%; Score 7; DB 6; Length 7;
  Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
  1 AGTATGA 7
  |||||
  1 AGTATGA 7

RESULT 3
AX268753
LOCUS
  Sequence 1 from Patent WO0174342.
  9 bp DNA linear PAT 29-OCT-2001
ACCESSION
  AX268753
VERSION
  AX268753.1 GI:16541825
KEYWORDS
  synthetic construct.
  synthetic construct.
  artificial sequences.
SOURCE
  ORGANISM
    synthetic construct.
    artificial sequences.
REFERENCE
  1
  AUTHORS
    Gilchrist, B.A., Yaar, M. and Eller, M.
  TITLE
    Use of locally applied dna fragments
  JOURNAL
    Patent: WO 0174342-A 1 11-OCT-2001;
    TRUSTEES OF BOSTON UNIVERSITY (US)
FEATURES
  source
    1..9
      /organism="synthetic construct"
      /db_xref="taxon:32630"
      /note="Synthetic DNA Fragment"
BASE COUNT
  3 a 0 c 4 g
  ORIGIN

Query Match
  Best Local Similarity 100.0%; Score 7; DB 6; Length 9;

```

```

  Best Local Similarity 100.0%; Pred. No. 3.2e+09;
  Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
  1 AGTATGA 7
  |||||
  2 AGTATGA 8

RESULT 4
AX377258/c
LOCUS
  Sequence 20 from Patent WO0212562.
  10 bp DNA linear PAT 18-MAR-2002
ACCESSION
  AX377258
VERSION
  AX377258.1 GI:19573546
KEYWORDS
  human.
SOURCE
  ORGANISM
    Homo sapiens
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
  1
  AUTHORS
    Kazem, A., Kilem, S.E. and Koshy, B.
  TITLE
    Haplotypes of the plazgib gene
  JOURNAL
    Patent: WO 0212562-A 20 14-FEB-2002;
    Genaisance Pharmaceuticals, Inc. (US)
FEATURES
  source
    1..10
      /organism="Homo sapiens"
      /db_xref="taxon:9606"
BASE COUNT
  3 a 3 c 0 g 4 t

Query Match
  Best Local Similarity 100.0%; Score 7; DB 6; Length 10;
  Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
  1 AGTATGA 7
  |||||
  9 AGTATGA 3

RESULT 5
BD007857
LOCUS
  LPS activated human monocyte expressing genes.
  10 bp DNA linear PAT 31-JAN-2002
ACCESSION
  BD007857
VERSION
  BD007857.1 GI:18636230
KEYWORDS
  JP 2001069993-A/133.
  Homo sapiens.
SOURCE
  ORGANISM
    Homo sapiens
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
  1
  AUTHORS
    Matsushima, K., Hashimoto, S. and Suzuki, T.
  TITLE
    LPS activated human monocyte expressing genes
  JOURNAL
    Patent: JP 2001069993-A 133 21-MAR-2001;
    JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT
  OS Homo sapiens (human)
  PN JP 2001069993-A/133
  PD 21-MAR-2001
  PF 28-APR-2000 JP 2000131079
  PR KOJI MATSUSHIMA, SHINICHI HASHIMOTO, TAKUJI SUZUKI PC
  PI C12N15/09, C07K14/47, C07K16/18, G01N33/50, G01N33/53//A61K45/00, PC
  A61P29/00,
  PC A61P31/00, C12P21/08, C12N15/00

FEATURES
  source
    1..10
      /organism="Homo sapiens"
      /db_xref="taxon:9606"

```

BASE COUNT 4 a 0 c 4 g 2 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 7.1e+05; Indels 0; Gaps 0;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||
DB 1 AGTATGA 7

RESULT 6
AX470905 11 bp DNA linear PAT 09-AUG-2002
LOCUS Sequence 482 from Patent WO02053773.
DEFINITION AX470905
ACCESSION AX470905
VERSION AX470905.1 GI:22206030
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 482 11-JUL-2002;
HENKEL KGAA (DE)

FEATURES
source Location/Qualifiers
1..11
/organism="Homo sapiens"
/db_xref="taxon:9606"

BASE COUNT 4 a 2 c 2 g 3 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 7e+05; Indels 0; Gaps 0;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||
DB 1 AGTATGA 7

RESULT 7
A91497 12 bp DNA linear PAT 22-JAN-2000
LOCUS Sequence 24 from Patent WO9824928.
DEFINITION A91497
ACCESSION A91497
VERSION A91497.1 GI:6740452
KEYWORDS
SOURCE unidentified.
ORGANISM unidentified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Pallsgaard,N. and Hokland,P.
TITLE DETECTION OF CHROMOSOMAL ABNORMALITIES
JOURNAL Patent: WO 9824928-A 24 11-JUN-1998;
PALLSGAARD NIELS (DK); HOKLAND PETER (DK)

FEATURES
source Location/Qualifiers
1..12
/organism="unidentified"
/db_xref="taxon:32644"

BASE COUNT 2 a 4 c 2 g 4 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.9e+05; Indels 0; Gaps 0;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||
DB 11 AGTATGA 5

RESULT 8
AX018746/c 13 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 4 from Patent WO943848.
DEFINITION AX018746
ACCESSION AX018746
VERSION AX018746.1 GI:10042869
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 13)
AUTHORS Ong,C.J. and Jirik,F.R.
TITLE Protein interaction and transcription factor trap
JOURNAL Patent: WO 943848-A 4 02-SEP-1999;
ONG CHRISTOPHER J (CA); UNIV BRITISH COLUMBIA (CA); JIRIK FRANK R (CA)

FEATURES
source Location/Qualifiers
1..13
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligomer for adjusting a reading frame for ligation"

BASE COUNT 3 a 4 c 1 g 5 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 13;
Best Local Similarity 100.0%; Pred. No. 6.8e+05; Indels 0; Gaps 0;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||
DB 7 AGTATGA 1

RESULT 9
A33152 14 bp DNA linear PAT 07-MAY-1996
LOCUS Synthetic HLA DR typing probe.
DEFINITION A33152
ACCESSION A33152
VERSION A33152.1 GI:1567736
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 14)
AUTHORS
TITLE
JOURNAL

FEATURES
source Location/Qualifiers
1..14
/organism="synthetic construct"
/db_xref="taxon:32630"

BASE COUNT 6 a 1 c 4 g 3 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+05; Indels 0; Gaps 0;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||
DB 8 AGTATGA 14

RESULT 10
AR082813 14 bp DNA linear PAT 01-SEP-2000
LOCUS Sequence 27 from patent US 5976789.
DEFINITION AR082813
ACCESSION AR082813
VERSION AR082813.1 GI:10009603
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 14)

AUTHORS Allibert, P., Andre., Cros, P., Mach, B., Francois., Mandrand, B., Fabien, and Tiercy, J.-M.
TITLE System of probes enabling HLA-DR typing to be performed, and typing method using said probes
JOURNAL Patent: US 5976789-A 27 02-NOV-1999;
FEATURES Location/Qualifiers
source 1..14
BASE COUNT 6 a 1 c 4 g 3 t

Query Match 100.0%; Score 7; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 8 AGTATGA 14

RESULT 11
AR088823/c AR088823 14 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 4 from patent US 5990294.
ACCESSION AR088823
VERSION AR088823.1 GI:10015586
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 14)
AUTHORS Murphy, G.P., Boynton, A.L. and Sehgal, A.
TITLE Nucleotide and amino acid sequences of C4-2, a tumor suppressor gene, and methods of use thereof
JOURNAL Patent: US 5990294-A 4 23-NOV-1999;
FEATURES Location/Qualifiers
source 1..14
BASE COUNT 2 a 4 c 2 g 5 t 1 others

Query Match 100.0%; Score 7; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 14 AGTATGA 8

RESULT 12
AX018748/c AX018748 14 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 6 from Patent WO943848.
ACCESSION AX018748
VERSION AX018748.1 GI:10042871
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
REFERENCE artificial sequences.
1 (bases 1 to 14)
AUTHORS Ong, C.J. and Jirik, F.R.
TITLE Protein interaction and transcription factor trap
JOURNAL Patent: WO 943848-A 6 02-SEP-1999;
ONG CHRISTOPHER J (CA); UNIV BRITISH COLUMBIA (CA); JIRIK FRANK R (CA)
FEATURES Location/Qualifiers
source 1..14
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligomer for adjusting a reading frame for ligation"
BASE COUNT 3 a 4 c 2 g 5 t

ORIGIN
Query Match 100.0%; Score 7; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 7 AGTATGA 1

RESULT 13
AX343036/c AX343036 14 bp DNA linear PAT 12-JAN-2002
LOCUS Sequence 22 from Patent WO0198350.
ACCESSION AX343036
VERSION AX343036.1 GI:18152236
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
REFERENCE artificial sequences.
1
AUTHORS Reinhard, C., Jefferson, A.B., Winter, J.A. and Randazzo, F.
TITLE Compositions and methods for treating neoplastic disease using net-4 modulators
JOURNAL Patent: WO 0198350-A 22 27-DEC-2001;
CHIRON CORPORATION (US)
FEATURES Location/Qualifiers
source 1..14
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligonucleotide NET-4 oligo 868 used for in-situ hybridization"
BASE COUNT 3 a 4 c 2 g 5 t

Query Match 100.0%; Score 7; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 13 AGTATGA 7

RESULT 14
A33153 A33153 15 bp DNA linear PAT 07-MAY-1996
LOCUS Synthetic HLA DR typing probe.
ACCESSION A33153
VERSION A33153.1 GI:1567737
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
REFERENCE artificial sequences.
1
FEATURES Location/Qualifiers
source 1..15
/organism="synthetic construct"
/db_xref="taxon:32630"
BASE COUNT 6 a 1 c 5 g 3 t

Query Match 100.0%; Score 7; DB 6; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 9 AGTATGA 15

RESULT 15
AR041154/c

LOCUS AR041154 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2 from patent US 5811270.
ACCESSION AR041154
VERSION AR041154.1 GI:5961650
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grandgenett,D.P.
TITLE In vitro method for concerted integration of donor DNA molecules
JOURNAL using retroviral integrase proteins
FEATURES Patent: US 5811270-A 2 22-SEP-1998;
source Location/Qualifiers
1..15
/organism="unknown"
BASE COUNT 2 a 4 c 4 g 5 t
ORIGIN

Query Match 100.0%; Score 7; DB 6; Length 15;
Best Local Similarity 100.0%; Pred. No. 6,7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||
Db 9 AGTATGA 3

Search completed: June 2, 2003, 19:09:36
Job time : 249.39 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:06:10 ; Search time 318.073 Seconds

(without alignments)
823.475 Million cell updates/sec

Title: US-09-540-843-1

Perfect score: 9

Sequence: 1 gagatagag 9

Scoring table: IDENTITY_NDC

Gapop 10.0 , Gapext 1.0

Searched: 2054640 segs, 14551402878 residues

Total number of hits satisfying chosen parameters: 774614

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl:*
1: gb_ba:*
2: gb_htg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vl:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vl:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htg_mus:*
34: em_htg_pln:*
35: em_htg_rtd:*
36: em_htg_mam:*
37: em_htg_vrt:*
38: em_sy:*
39: em_htgo_hum:*
40: em_htgo_mus:*
41: em_htgo_other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	9	100.0	9	AX268753	AX268753 Sequence
2	9	100.0	15	AR130719	AR130719 Sequence
3	9	100.0	15	AR130720	AR130720 Sequence
4	9	100.0	17	AR039517	AR039517 Sequence
5	9	100.0	17	AR039519	AR039519 Sequence
6	9	100.0	17	AR039521	AR039521 Sequence
7	9	100.0	17	AR039523	AR039523 Sequence
8	9	100.0	18	AX306555	AX306555 Sequence
9	9	100.0	20	AR116520	AR116520 Sequence
10	9	100.0	20	AR116521	AR116521 Sequence
11	9	100.0	22	AX338664	AX338664 Sequence
12	9	100.0	23	AX404121	AX404121 Sequence
13	9	100.0	25	AX454970	AX454970 Sequence
14	9	100.0	25	E13462	E13462 PCR primer
15	9	100.0	26	AX112180	AX112180 Sequence
16	9	100.0	26	AX327686	AX327686 Sequence
17	9	100.0	27	AX115612	AX115612 Sequence
18	9	100.0	30	I08713	I08713 Sequence 1
19	9	100.0	31	A87084	A87084 Sequence 12
20	9	100.0	31	A87152	A87152 Sequence 12
21	9	100.0	31	AX229078	AX229078 Sequence
22	9	100.0	31	AX249534	AX249534 Sequence
23	9	100.0	32	AX339727	AX339727 Sequence
24	9	100.0	33	AX281025	AX281025 Sequence
25	9	100.0	33	AX281060	AX281060 Sequence
26	9	100.0	33	AX463705	AX463705 Sequence
27	9	100.0	34	AR080618	AR080618 Sequence
28	9	100.0	34	AX416939	AX416939 Sequence
29	9	100.0	36	A87098	A87098 Sequence 8
30	9	100.0	36	A87126	A87126 Sequence 36
31	9	100.0	36	AR206352	AR206352 Sequence
32	9	100.0	36	AR206380	AR206380 Sequence
33	9	100.0	36	AX300708	AX300708 Sequence
34	9	100.0	37	A87090	A87090 Sequence 18
35	9	100.0	37	A87160	A87160 Sequence 20
36	9	100.0	38	A87076	A87076 Sequence 4
37	9	100.0	38	A87120	A87120 Sequence 30
38	9	100.0	38	A87144	A87144 Sequence 4
39	9	100.0	38	A87171	A87171 Sequence 6
40	9	100.0	38	AR159979	AR159979 Sequence
41	9	100.0	38	AR206374	AR206374 Sequence
42	9	100.0	38	AX028965	AX028965 Sequence
43	9	100.0	39	A87099	A87099 Sequence 9
44	9	100.0	39	AR183718	AR183718 Sequence
45	9	100.0	39	AR206353	AR206353 Sequence

ALIGNMENTS

RESULT 1
LOCUS AX268753 9 bp DNA
DEFINITION Sequence 1 from Patent WO0174342. Linear PAT 29-OCT-2001
ACCESSION AX268753
VERSION AX268753.1 GI:16541825
KEYWORDS
SOURCE
ORGANISM
synthetic construct.
artificial sequences.
REFERENCE
AUTHORS
TITLE
JOURNAL
1
Glitchrest,B.A., Yaar,M. and Elier,M.
Use of locally applied dna fragments
Patent: WO 0174342-A 1 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)

FEATURES Location/Qualifiers
 source 1..9
 /organism="Synthetic construct"
 /db_xref="taxon:32630"
 /note="Synthetic DNA Fragment"

BASE COUNT 3 a 0 c 4 g 2 t

Query Match 100.0%; Score 9; DB 6; Length 9;
 Best Local Similarity 100.0%; Pred. No. 3.2e+09;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
 |||||
 1 GAGTATGAG 9

RESULT 2
 LOCUS AR130719 15 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 6 from patent US 6190866.
 ACCESSION AR130719
 VERSION AR130719.1 GI:14119044
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Nielsen,P.E. and Good,L.
 TITLE Methods of bacterial gene function determination using peptide
 nucleic acids
 JOURNAL Patent: US 6190866-A 6 20-FEB-2001;
 FEATURES Location/Qualifiers
 source 1..15
 /organism="unknown"

BASE COUNT 3 a 6 c 0 g 6 t

Query Match 100.0%; Score 9; DB 6; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
 |||||
 11 GAGTATGAG 3

RESULT 3
 LOCUS AR130720 15 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 7 from patent US 6190866.
 ACCESSION AR130720
 VERSION AR130720.1 GI:14119045
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Nielsen,P.E. and Good,L.
 TITLE Methods of bacterial gene function determination using peptide
 nucleic acids
 JOURNAL Patent: US 6190866-A 7 20-FEB-2001;
 FEATURES Location/Qualifiers
 source 1..15
 /organism="unknown"

BASE COUNT 5 a 4 c 1 g 5 t

Query Match 100.0%; Score 9; DB 6; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9

DB 14 GAGTATGAG 6
 |||||

RESULT 4
 LOCUS AR039517 17 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 365 from patent US 5807743.
 ACCESSION AR039517
 VERSION AR039517.1 GI:5958880
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
 TITLE Interleukin-2 receptor gamma-chain ribozymes
 JOURNAL Patent: US 5807743-A 365 15-SEP-1998;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"

BASE COUNT 3 a 7 c 2 g 5 t

Query Match 100.0%; Score 9; DB 6; Length 17;
 Best Local Similarity 100.0%; Pred. No. 5.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
 |||||
 17 GAGTATGAG 9

RESULT 5
 LOCUS AR039519 17 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 367 from patent US 5807743.
 ACCESSION AR039519
 VERSION AR039519.1 GI:5958882
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
 TITLE Interleukin-2 receptor gamma-chain ribozymes
 JOURNAL Patent: US 5807743-A 367 15-SEP-1998;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"

BASE COUNT 3 a 7 c 2 g 5 t

Query Match 100.0%; Score 9; DB 6; Length 17;
 Best Local Similarity 100.0%; Pred. No. 5.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
 |||||
 15 GAGTATGAG 7

RESULT 6
 LOCUS AR039521 17 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 369 from patent US 5807743.
 ACCESSION AR039521
 VERSION AR039521.1 GI:5958884
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)

AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
TITLE Interleukin-2 receptor gamma-chain ribozymes
JOURNAL Patent: US 5807743-A 369 15-SEP-1998;
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unknown"
BASE COUNT 3 a 8 c 1 g 5 t
ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
12 GAGTATGAG 4

RESULT 7
AR039523/c AR039523 17 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 371 from patent US 5807743.
DEFINITION AR039523
ACCESSION AR039523
VERSION AR039523.1 GI:5958886
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.
TITLE Interleukin-2 receptor gamma-chain ribozymes
JOURNAL Patent: US 5807743-A 371 15-SEP-1998;
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unknown"
BASE COUNT 4 a 9 c 0 g 4 t
ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 17;
Best Local Similarity 100.0%; Pred. No. 5.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
9 GAGTATGAG 1

RESULT 8
AX306555/c AX306555 18 bp DNA linear PAT 11-DEC-2001
LOCUS Sequence 1 from Patent W00187285.
DEFINITION AX306555
ACCESSION AX306555
VERSION AX306555.1 GI:17645773
KEYWORDS
SOURCE black rat.
ORGANISM Rattus rattus
REFERENCE 1
AUTHORS Johns,R.A. and Tao,Y.C.
TITLE Inhibition of the interaction of psd93 and psd95 with the nnos and
JOURNAL nmda receptors
Patent: WO 0187285-A 1 22-NOV-2001;
The Johns Hopkins University (US) ; Johns, Roger A. (US) ; Tao,
Yuanxiang (US)
FEATURES Location/Qualifiers
SOURCE 1..18
/organism="Rattus rattus"
BASE COUNT 3 a 6 c 2 g 7 t
ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
18 GAGTATGAG 10

RESULT 9
AR116520 AR116520 20 bp DNA linear PAT 16-MAY-2001
LOCUS Sequence 101 from patent US 6133246.
DEFINITION AR116520
ACCESSION AR116520
VERSION AR116520.1 GI:14096842
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS McKay,R., Dean,N., Monia,B.P., Nero,P.S. and Gaarde,W.A.
TITLE Antisense oligonucleotide compositions and methods for the
JOURNAL modulation of JNK proteins
Patent: US 6133246-A 101 17-OCT-2000;
FEATURES Location/Qualifiers
SOURCE 1..20
/organism="unknown"
BASE COUNT 4 a 3 c 7 g 6 t
ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.3e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
9 GAGTATGAG 17

RESULT 10
AR116521 AR116521 20 bp DNA linear PAT 16-MAY-2001
LOCUS Sequence 102 from patent US 6133246.
DEFINITION AR116521
ACCESSION AR116521
VERSION AR116521.1 GI:14096843
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS McKay,R., Dean,N., Monia,B.P., Nero,P.S. and Gaarde,W.A.
TITLE Antisense oligonucleotide compositions and methods for the
JOURNAL modulation of JNK proteins
Patent: US 6133246-A 102 17-OCT-2000;
FEATURES Location/Qualifiers
SOURCE 1..20
/organism="unknown"
BASE COUNT 5 a 3 c 7 g 5 t
ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.3e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
9 GAGTATGAG 17

RESULT 11
AX338664/c AX338664 22 bp DNA linear PAT 09-JAN-2002
LOCUS Sequence 29 from Patent W00164713.
DEFINITION

ACCESSION AX338664
VERSION AX338664.1 GI:18129026
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Gasche, C., Zakeri, S.M. and Reinisch, W.
JOURNAL Mammalian Interleukin-10 (11-10) receptor variants
Patent: WO 0164713-A 29 07-SEP-2001;
Gasche, Christoph (AT) ; Zakeri, Schaker M. (AT)
LOCATION/Qualifiers
FEATURES
source 1..22
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="primer"
BASE COUNT 6 a 6 c 5 g 5 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 22;
Best Local Similarity 100.0%; Pred. No. 5.3e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
|||||
Db 15 GAGTATGAG 7
RESULT 12
AX404121/c 23 bp DNA linear PAT 14-JUN-2002
LOCUS Sequence 17 from Patent W00222819.
DEFINITION AX404121
ACCESSION AX404121
VERSION AX404121.1 GI:21437421
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Sonderogger, P., Hintsch, G., Kinter, J., Meskenalte, V., Schirmpf, S.,
Vogl, L. and Zurlinden, A.
JOURNAL Calcium binding proteins
Patent: WO 0222819-A 17 21-MAR-2002;
Universitaet Zuerich (CH)
LOCATION/Qualifiers
FEATURES
source 1..23
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="primer"
BASE COUNT 6 a 8 c 3 g 5 t 1 others
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 5.3e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
|||||
Db 20 GAGTATGAG 12
RESULT 13
AX454970 25 bp DNA linear PAT 06-JUL-2002
LOCUS Sequence 37 from Patent W00208453.
DEFINITION AX454970
ACCESSION AX454970
VERSION AX454970.1 GI:21714155
KEYWORDS
SOURCE dog.
ORGANISM Canis familiaris
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE 1

AUTHORS Farr, S.B., Pickett, G.C., Neft, R.E. and Dunn, R.T.
TITLE Canine toxicity genes
JOURNAL Patent: WO 0208453-A 37 31-JAN-2002;
Phase-1 Molecular Toxicology (US)
LOCATION/Qualifiers
FEATURES
source 1..25
/organism="Canis familiaris"
/db_xref="taxon:9615"
BASE COUNT 8 a 2 c 10 g 5 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 25;
Best Local Similarity 100.0%; Pred. No. 5.2e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
|||||
Db 9 GAGTATGAG 17
RESULT 14
E13462 25 bp DNA linear PAT 27-APR-1998
LOCUS PCR primer for detecting mRNA which encode human cholecystokinin/
pancreozymin.
DEFINITION E13462
ACCESSION E13462
VERSION E13462.1 GI:3252267
KEYWORDS JP 1997187299-A/24.
SOURCE unidentified.
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 25)
AUTHORS Kimoto, Y.
TITLE PRIMER FOR PCR
JOURNAL Patent: JP 1997187299-A 24 22-JUL-1997;
NIPPON BIO SERAPII KK
COMMENT OS None
OC Artificial sequences.
PN JP 1997187299-A/24
PD 22-JUL-1997
PF 05-JAN-1996 JP 1996027222
PI KIMOTO YASUHIKO
PC C1201/68, C07H21/04, C12N15/09;
CC strandedness: Single;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: Yes;
FH Key
FH Location/Qualifiers
FT source 1..25
/organism="Artificial sequences" FT
FT misc-feature 1..25
/note="PCR primer, CCK-4".
FEATURES
source 1..25
Location/Qualifiers
/organism="unidentified"
/db_xref="taxon:32644"
BASE COUNT 5 a 8 c 6 g 6 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 25;
Best Local Similarity 100.0%; Pred. No. 5.2e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
|||||
Db 24 GAGTATGAG 16
RESULT 15
AX112180 26 bp DNA linear PAT 01-MAY-2001
LOCUS Sequence 32 from Patent W00127287.
DEFINITION AX112180

ACCESSION AX112180
VERSION AX112180.1 GI:13939031
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 26)
AUTHORS Long,D.M., Metz,A.M. and Love,R.
TITLE Telomerase reverse transcriptase (tert) genes
JOURNAL Patent: WO 0127287-A 32 19-APR-2001;
Research & Development Institute Inc. (US)
FEATURES
source 1..26
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="RT-PCR primer used with P. falciparum sequences"
BASE COUNT 9 a 3 c 7 g 7 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 26;
Best Local Similarity 100.0%; Pred. No. 5.2e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 GAGTATGAG 9
|||||
Db 16 GAGTATGAG 24

Search completed: June 2, 2003, 19:09:32
Job time : 320.073 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 17:32:40 ; Search time 150.366 Seconds
(Without alignments)
134.791 Million cell updates/sec

Title: US-09-540-843-1

Perfect score: 9

Sequence: 1 gagatagag 9

Scoring table:

IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 2063506

Minimum DB seq length: 0

Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

N_Geneseq_101002:.*
1: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:.*
2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:.*
3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:.*
4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:.*
5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:.*
6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:.*
7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:.*
8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:.*
9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:.*
10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:.*
11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:.*
12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:.*
13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:.*
14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:.*
15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:.*
16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:.*
17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:.*
18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:.*
19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:.*
20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:.*
21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:.*
22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:.*
23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:.*
24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	9	100.0	9	AAZ10692	Oligonucleotide se
2	9	100.0	9	AAZ10692	Oligonucleotide se
3	9	100.0	9	AAZ10692	Oligonucleotide se
4	9	100.0	9	AAZ10692	Oligonucleotide se
5	9	100.0	9	AAZ10692	Oligonucleotide se
6	9	100.0	9	AAZ10692	Oligonucleotide se
7	9	100.0	9	AAZ10692	Oligonucleotide se
8	9	100.0	9	AAZ10692	Oligonucleotide se
9	9	100.0	9	AAZ10692	Oligonucleotide se

C	10	9	100.0	13	23	ABC29989	Oligonucleotide SE
C	11	9	100.0	13	23	ABC37140	Oligonucleotide SE
C	12	9	100.0	13	23	ABC37141	Oligonucleotide SE
C	13	9	100.0	13	23	ABC41298	Oligonucleotide SE
C	14	9	100.0	13	23	ABC41299	Oligonucleotide SE
C	15	9	100.0	13	23	ABC48092	Oligonucleotide SE
C	16	9	100.0	13	23	ABC48093	Oligonucleotide SE
C	17	9	100.0	13	23	ABC48093	Oligonucleotide SE
C	18	9	100.0	13	23	ABC51860	Oligonucleotide SE
C	19	9	100.0	13	23	ABC51861	Oligonucleotide SE
C	20	9	100.0	13	23	ABC51864	Oligonucleotide SE
C	21	9	100.0	13	23	ABC51865	Oligonucleotide SE
C	22	9	100.0	13	23	ABC78830	Oligonucleotide SE
C	23	9	100.0	13	23	ABC78831	Oligonucleotide SE
C	24	9	100.0	13	23	ABC99290	Oligonucleotide SE
C	25	9	100.0	13	23	ABC99291	Oligonucleotide SE
C	26	9	100.0	13	23	ABF09008	Oligonucleotide SE
C	27	9	100.0	13	23	ABF09009	Oligonucleotide SE
C	28	9	100.0	13	23	ABF15710	Oligonucleotide SE
C	29	9	100.0	13	23	ABF15711	Oligonucleotide SE
C	30	9	100.0	13	23	ABF17600	Oligonucleotide SE
C	31	9	100.0	13	23	ABF17601	Oligonucleotide SE
C	32	9	100.0	13	23	ABF20572	Oligonucleotide SE
C	33	9	100.0	13	23	ABF20573	Oligonucleotide SE
C	34	9	100.0	13	23	ABF20576	Oligonucleotide SE
C	35	9	100.0	13	23	ABF20577	Oligonucleotide SE
C	36	9	100.0	13	23	ABF48816	Oligonucleotide SE
C	37	9	100.0	13	23	ABF48817	Oligonucleotide SE
C	38	9	100.0	13	23	ABF56046	Oligonucleotide SE
C	39	9	100.0	13	23	ABF56047	Oligonucleotide SE
C	40	9	100.0	13	23	ABF64312	Oligonucleotide SE
C	41	9	100.0	13	23	ABF64313	Oligonucleotide SE
C	42	9	100.0	13	23	ABF64318	Oligonucleotide SE
C	43	9	100.0	13	23	ABF64319	Oligonucleotide SE
C	44	9	100.0	13	23	ABF95900	Oligonucleotide SE
C	45	9	100.0	13	23	ABF95901	Oligonucleotide SE
						ABH11442	Oligonucleotide SE

ALIGNMENTS

RESULT 1
AAZ10692
ID AAZ10692 standard; DNA; 9 BP.
XX
AC AAZ10692;
XX
DT 23-NOV-1999 (first entry)
XX
DE Oligonucleotide sequence that increases p53 activity in a cell.
XX
KW p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;
KW UV-induced hyperproliferative disease; psoriasis; vitiligo;
KW atopic dermatitis; allergic rhinitis; conjunctivitis; photoaging;
KW skin cancer; ss.
XX
OS Synthetic.
XX
PN GB2336157-A.
XX
PD 13-OCT-1999.
XX
PF 24-MAR-1999; 99GB-0006758.
XX
PR 26-MAR-1998; 98US-0048927.
XX
PA (UYBO-) UNITV BOSTON.
XX
PI Glioblastoma, Yaar M, Eller M;
XX WPI; 1999-543520/46.
XX
PT DNA fragments useful for increasing p53 activity in a cell and reducing

PT susceptibility to UV-induced hyperproliferative diseases -
 XX
 PS Claim 11, Page 29; 44pp; English.
 XX
 CC AA210692-97 represent DNA fragments that are used for increasing p53
 CC activity in a cell. The oligonucleotides are are UV mimetics and
 CC protect cells against subsequent exposure to UV-irradiation or
 CC chemicals. The oligonucleotides are useful for increasing p53 activity
 CC in a cell, reducing the susceptibility to UV-induced hyperproliferative
 CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic
 CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging
 CC and reducing susceptibility to skin cancer.
 XX
 SQ Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;
 XX
 Query Match 100.0%; Score 9; DB 20; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAGTATGAG 9
 Db 1 GAGTATGAG 9
 XX
 RESULT 2
 AAS14905
 ID AAS14905 standard; DNA; 9 BP.
 XX
 AC AAS14905;
 XX
 DT 14-FEB-2002 (first entry)
 XX
 DE Melanogenesis associated oligonucleotide #1.
 XX
 DE Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;
 KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KW conjunctivitis; allergic rhinitis; vitiligo; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1
 FT *tag= a
 FT /mod_base= g
 FT /note="Optionally phosphorylated"
 XX
 PN WO200174342-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-US10162.
 XX
 PR 31-MAR-2000; 2000US-0540843.
 XX
 PA (UYBO-) UNIV BOSTON.
 XX
 PI Gilchrist BA, Yaar M, Eller M;
 XX
 DR WPI; 2001-626338/72.
 XX
 PT Inhibiting proliferation of epithelial cells, useful e.g. for treating
 PT carcinoma, using specific oligonucleotides that mimic the effects of
 PT ultra-violet light -
 XX
 PS Claim 1; Page 36; 74pp; English.
 XX
 CC The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and

CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing more time
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergically mediated inflammation (atopic or contact dermatitis;
 CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #1, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell
 CC proliferation, described in the method of the invention.
 XX
 SQ Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;
 XX
 Query Match 100.0%; Score 9; DB 23; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAGTATGAG 9
 Db 1 GAGTATGAG 9
 XX
 RESULT 3
 AB105192
 ID AB105192 standard; DNA; 12 BP.
 XX
 AC AB105192;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 305165 for detecting SNP TSC0021329.
 XX
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB00713.
 XX
 PR 07-APR-2000; 2000DE-1019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX
 PS Claim 1; SEQ ID 305165; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 9e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 1 GAGTATGAG 9

RESULT 4
AB106838
ID AB106838 standard; DNA; 12 BP.
XX
AC AB106838;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 306811 for detecting SNP TSC0022179.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EP1G-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
XX
PS Claim 1; SEQ ID 306811; 29pp + Sequence Listing; German.
XX
SQ This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system and metabolic disorders. The
CC central nervous system, cardiovascular and gastrointestinal, respiratory,
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 0 C; 4 G; 5 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 9e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 3 GAGTATGAG 11

RESULT 5
AB106839
ID AB106839 standard; DNA; 12 BP.
XX
AC AB106839;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 306812 for detecting SNP TSC0022179.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EP1G-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
XX
PS Claim 1; SEQ ID 306812; 29pp + Sequence Listing; German.
XX
SQ This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system and metabolic disorders. The
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 1 C; 4 G; 4 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 9e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 3 GAGTATGAG 11

RESULT 6
AB121133
ID AB121133 standard; DNA; 12 BP.
XX
AC AB121133;
XX
DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 321106 for detecting SNP TSC0030074.
 DE SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB00713.
 XX 07-APR-2000; 2000DE-1019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX Claim 1; SEQ ID 321106; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989 and
 CC ABH00010-ABH82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX Sequence 12 BP; 3 A; 0 C; 5 G; 4 T; 0 other;
 SQ
 Query Match 100.0%; Score 9; DB 23; Length 12;
 Best Local Similarity 100.0%; Pred. No. 9e+03;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GAGTATGAG 9
 DB 2 GAGTATGAG 10
 RESULT 7
 AB126099
 ID AB126099 standard; DNA; 12 BP.
 AC AB126099;
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 326072 for detecting SNP TSC0032886.
 DE SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD

PF 06-APR-2001; 2001WO-IB00713.
 XX 07-APR-2000; 2000DE-1019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX Claim 1; SEQ ID 326072; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989 and
 CC ABH00010-ABH82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX Sequence 12 BP; 3 A; 0 C; 6 G; 3 T; 0 other;
 SQ
 Query Match 100.0%; Score 9; DB 23; Length 12;
 Best Local Similarity 100.0%; Pred. No. 9e+03;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GAGTATGAG 9
 DB 4 GAGTATGAG 12
 RESULT 8
 AB148017/c
 ID AB148017 standard; DNA; 12 BP.
 AC AB148017;
 XX 22-FEB-2002 (first entry)
 DT
 XX Oligonucleotide primer SEQ ID NO 347990 for detecting SNP TSC0045390.
 DE SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB00713.
 XX 07-APR-2000; 2000DE-1019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX

XX Claim 1; SEQ ID 347990; 29pp + Sequence Listing; German.
PS
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed CC specification, but was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 9e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
Db 10 GAGTATGAG 2
|||||
|
RESULT 9
ABC29988 ID ABC29988 standard; DNA; 13 BP.
XX
AC ABC29988;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 30005 for detecting SNP TSC0009039.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is PT designed to detect single nucleotide polymorphisms and cytosine PT methylation status
XX
PS Claim 1; SEQ ID 30005; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed CC

CC specification, but was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
Db 4 GAGTATGAG 12
|||||
|
RESULT 10
ABC29989/C ID ABC29989 standard; DNA; 13 BP.
XX
AC ABC29989;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 30006 for detecting SNP TSC0009039.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is PT designed to detect single nucleotide polymorphisms and cytosine PT methylation status
XX
PS Claim 1; SEQ ID 30006; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed CC specification, but was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
Db 10 GAGTATGAG 2
|||||
|

```

RESULT 11
ABC37140
ID ABC37140 standard; DNA; 13 BP.
XX
AC ABC37140;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 37157 for detecting SNP TSC0011603.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 37157; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 other;
XX
Query Match 100.0%; Score 9; DB 23; Length 13;
Best Local Similarity 100.0%; Pred. No. 9, 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
DB 3 GAGTATGAG 11
XX
RESULT 12
ABC37141/C
ID ABC37141 standard; DNA; 13 BP.
XX
AC ABC37141;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 37158 for detecting SNP TSC0011603.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX
PA (EPIG-) EPIGENOMICS AG.

```

```

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 37158; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 other;
XX
Query Match 100.0%; Score 9; DB 23; Length 13;
Best Local Similarity 100.0%; Pred. No. 9, 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
DB 11 GAGTATGAG 3
XX
RESULT 13
ABC41298
ID ABC41298 standard; DNA; 13 BP.
XX
AC ABC41298;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 41315 for detecting SNP TSC0012414.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173;
XX
PA (EPIG-) EPIGENOMICS AG.

```

XX Olek A, Piepenbrock C, Berlin K;
XX WPI, 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
PS
XX Claim 1; SEQ ID 41315; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABR00010-ABF99989, ABR00010-ABH99989 and
CC ABR00010-ABH82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 GAGTATGAG 9
DB 5 GAGTATGAG 13
RESULT 14
ID ABC41299/c
XX ABC41299 standard; DNA; 13 BP.
AC ABC41299;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 41316 for detecting SNP TSC0012414.
DE
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI, 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
PS
XX Claim 1; SEQ ID 41316; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABR00010-ABF99989, ABR00010-ABH99989 and
CC ABR00010-ABH82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 GAGTATGAG 9
DB 9 GAGTATGAG 1
RESULT 15
ID ABC48092
XX ABC48092 standard; DNA; 13 BP.
AC ABC48092;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 48109 for detecting SNP TSC0013750.
DE
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI, 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
PS
XX Claim 1; SEQ ID 48109; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABR00010-ABF99989, ABR00010-ABH99989 and
CC ABR00010-ABH82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 6 A; 0 C; 5 G; 2 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 13;
Best Local Similarity 100.0%; Pred. No. 9.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
|||||||
Db 5 GAGTATGAG 13

Search completed: June 2, 2003, 18:45:09
Job time : 151.566 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:29:55 ; Search time 1129.39 Seconds
(without alignments)
129.060 Million cell updates/sec

Title: US-09-540-843-1

Perfect score: 9

Sequence: 1 gagtatgag 9

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 60474

Minimum DB seq length: 0

Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

EST: *
1: em_estba: *
2: em_esthum: *
3: em_estlin: *
4: em_estnu: *
5: em_estov: *
6: em_estpl: *
7: em_estro: *
8: em_hnc: *
9: gb_estl: *
10: gb_est2: *
11: gb_hnc: *
12: gb_est3: *
13: gb_est4: *
14: gb_est5: *
15: em_estfun: *
16: em_estom: *
17: gb_gss: *
18: em_gss_hum: *
19: em_gss_inv: *
20: em_gss_pln: *
21: em_gss_vrt: *
22: em_gss_fun: *
23: em_gss_nam: *
24: em_gss_mus: *
25: em_gss_other: *
26: em_gss_pro: *
27: em_gss_rod: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	100.0	22	17	AZ658158	
2	100.0	29	17	BH856420	
3	100.0	36	17	AL771699	
4	100.0	40	9	AI613042	
5	88.9	24	10	AM059679	
6	88.9	24	17	AZ478673	

C 7	8	88.9	25	17	AZ65844	AZ65844 1M0427322
C 8	8	88.9	27	14	DA5824	DA5824 HMG503044
C 9	8	88.9	30	17	AL766985	AL766985 Arabidops
C 10	8	88.9	33	17	AZ778279	AZ778279 2M013N15
C 11	8	88.9	33	17	TA307A09Q	TA307A09Q T. brucei
C 12	8	88.9	34	17	AZ333219	AZ333219 1M062009
C 13	8	88.9	36	17	AZ76722	AZ76722 2M0010A12
C 14	8	88.9	36	17	BH789482	BH789482 SALK_0297
C 15	8	88.9	37	9	AA088913	AA088913 z169b11.s
C 16	8	88.9	37	17	AZ429862	AZ429862 1M0214105
C 17	8	88.9	37	17	BH847696	BH847696 SALK_0558
C 18	8	88.9	38	17	BH130009	BH130009 G-6f16.f
C 19	8	88.9	38	17	TA131D03P	TA131D03P T. brucei
C 20	8	88.9	39	17	AZ659283	AZ659283 1M0536M03
C 21	8	88.9	39	17	BH846916	BH846916 SALK_0110
C 22	8	88.9	40	17	AZ311244	AZ311244 1M0026M06
C 23	7.4	82.2	17	13	BG926068	BG926068 HNC23-1-E
C 24	7.4	82.2	19	9	AI747751	AI747751 u121h05.x
C 25	7.4	82.2	19	17	AZ358656	AZ358656 1M010K12
C 26	7.4	82.2	19	17	AZ457990	AZ457990 1M0261R11
C 27	7.4	82.2	19	17	AZ991531	AZ991531 2M0275K15
C 28	7.4	82.2	20	17	AZ646291	AZ646291 1M0512D07
C 29	7.4	82.2	21	17	AZ806440	AZ806440 2M0068B05
C 30	7.4	82.2	22	9	AI052232	AI052232 oz21a12.x
C 31	7.4	82.2	22	9	AI630912	AI630912 tz31g03.x
C 32	7.4	82.2	22	17	AZ591103	AZ591103 1M0401K07
C 33	7.4	82.2	22	17	BH811671	BH811671 SALK_0595
C 34	7.4	82.2	22	17	TA119E04Q	TA119E04Q T. brucei
C 35	7.4	82.2	23	17	AZ484572	AZ484572 1M0531D10
C 36	7.4	82.2	23	17	AZ660131	AZ660131 1M0538R03
C 37	7.4	82.2	23	17	AZ830077	AZ830077 2M0109O06
C 38	7.4	82.2	24	17	AZ370614	AZ370614 1M0121O10
C 39	7.4	82.2	24	17	AZ772496	AZ772496 1M0583123
C 40	7.4	82.2	24	17	AZ847502	AZ847502 2M0148C08
C 41	7.4	82.2	24	17	BH86517	BH86517 SALK_0987
C 42	7.4	82.2	25	9	AA871952	AA871952 vq43b09.r
C 43	7.4	82.2	25	17	AZ810630	AZ810630 2M0076114
C 44	7.4	82.2	25	17	AZ831709	AZ831709 2M0110O06
C 45	7.4	82.2	25	17	BH856297	BH856297 SALK_0810

ALIGNMENTS

RESULT 1
LOCUS AZ658158 22 bp DNA linear GSS 14-DEC-2000
DEFINITION 1M0534H17R Mouse 10kb plasmid UGCCIM library Mus musculus genomic
clone UGCCIM0534H17 R, DNA sequence.
ACCESSION AZ658158
VERSION
KEYWORDS
SOURCE
ORGANISM
house mouse.
Mus musculus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.

REFERENCE
AUTHORS
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,
M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)

TITLE
JOURNAL
COMMENT
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: dduun@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

Plate: 0534 row: H column: 17
 Seq primer: CACACAGGAAACACCTATGACC
 Class: plasmid ends
 High quality sequence stop: 22.
 Location/Qualifiers

1..22
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UDGCM0534H17"
 /clone_1lb="Mouse 10kb plasmid UDGCM library"
 /sex="Male"
 /lab_host="E. coli strain XL10-Gold, TI-resistant, F-"
 /note="Vector: PMD42nv, Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g147321149b|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
 ORIGIN
 6 a 0 c 9 g 7 t

Query Match
 Best Local Similarity 100.0%; Score 9; DB 17; Length 22;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
 |||||
 DB 12 GAGTATGAG 20

RESULT 2
 BH856420/c 29 bp DNA linear GSS 08-JUL-2002
 LOCUS SALK_079762.18.10.x Arabidopsis thaliana T-DNA insertion lines
 DEFINITION Arabidopsis thaliana genomic clone SALK_079762.18.10.x, DNA sequence.

ACCESSION
 VERSION BH856420
 KEYWORDS
 SOURCE GSS
 ORGANISM

thale cress.
 Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
 1 (bases 1 to 29)

REFERENCE
 AUTHORS Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrihab
 'C., Jeske,A., Kanes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P.
 ' Zimmerman,J. and Ecker,J.R.
 ' A Sequence-indexed library of Insertion Mutations in the
 Arabidopsis Genome
 Unpublished (2001)

JOURNAL
 COMMENT Contact: Joseph R. Ecker
 Salk Institute Genomic Analysis Laboratory (SIGAL)
 The Salk Institute for Biological Studies
 10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
 Tel: 858 453 4100 x1752
 Fax: 858 558 6379
 Email: ecker@salk.edu
 This is single pass sequence recovered from the left border of

TDNA. This sequence lies within an annotated exon of At5g63570.
 Class: TDNA tagged.
 Location/Qualifiers

1..29
 /organism="Arabidopsis thaliana"
 /strain="Columbia 0"
 /db_xref="taxon:3702"
 /clone="SALK_079762.18.10.x"
 /clone_1lb="Arabidopsis thaliana T-DNA insertion lines"
 /note="PCR was performed on Arabidopsis thaliana lines each of which contains one or more TDNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at http://signal.salk.edu/tdna_protocols.html"

BASE COUNT
 ORIGIN
 6 a 10 c 4 g 9 t

Query Match
 Best Local Similarity 100.0%; Score 9; DB 17; Length 29;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
 |||||
 DB 22 GAGTATGAG 14

RESULT 3
 AL771699 36 bp DNA linear GSS 19-JUN-2002
 LOCUS Arabidopsis thaliana T-DNA flanking sequence GK-182E01-013594,
 DEFINITION genomic survey sequence.

ACCESSION
 VERSION AL771699
 KEYWORDS
 SOURCE GSS
 ORGANISM

thale cress.
 Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
 1

REFERENCE
 AUTHORS Strizhov,N., Li,Y., Rosso,M., Viehoveer,P., Dekker,K., Saeedler,H.
 and Weishaar,B.
 TITLE A pipeline for automated high-throughput generation of ESTs
 (flanking sequence tags) from Arabidopsis thaliana T-DNA transformed lines
 Unpublished

JOURNAL
 REFERENCE
 AUTHORS Rosso,M., Strizhov,N., Li,Y., Reiss,B., Dekker,K. and Weishaar,B.
 TITLE A new Arabidopsis thaliana T-DNA mutagenised population (GABI-Kat)
 for flanking sequence tag based reverse genetics
 Unpublished

JOURNAL
 REFERENCE
 AUTHORS Rosso,M., Li,Y., Strizhov,N. and Weishaar,B.
 TITLE Direct Submission
 3 (bases 1 to 36)

Submitted (17-JUN-2002) Weishaar B., Max-Planck-Institut fuer
 Zuechtungsforshung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany
 This sequence is recovered from the left border of the T-DNA. It
 indicates an insertion within the locus defined by clone fls24.
 The sequences are generated at the MPI for Plant Breeding Research
 in the context of the GABI-Kat project. GABI-Kat is part of the
 German Plant Genomics program designated 'GABI'. Information on
 line availability can be found at:
<http://www.mpiz-koeln.mpg.de/GABI-Kat/>.

FEATURES
 SOURCE Location/Qualifiers

1..36
 /organism="Arabidopsis thaliana"
 /strain="Columbia 0"
 /db_xref="taxon:3702"
 /clone="GK-182E01-013594"
 /clone_1lb="Arabidopsis thaliana T-DNA insertion lines"
 /note="PCR was performed on DNA from Arabidopsis thaliana plants (T1) which were transformed with the T-DNA from

vector pAC161. The lines contain one or more T-DNA insertions. The DNA fragment(s) resulting from the PCR were directly sequenced to determine the genomic sequence flanking the insertion. Sequences displaying significant similarity to the A. thaliana nuclear genome sequence were processed for submission. T-DNA derived sequences were removed

BASE COUNT 9 a 8 c 6 g 13 t

Query Match 100.0%; Score 9; DB 17; Length 36;
Best Local Similarity 100.0%; Pred. No. 4.3e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
|||||||
DB 2 GAGTATGAG 10

RESULT 4 40 bp mRNA linear EST 16-DEC-1999
A1613042
LOCUS ty06h09.x1 NCI_CGAP_Ut3 Homo sapiens cDNA IMAGE:2278337 3'
DEFINITION similar to SW:RL11_FIG Q29205 60S RIBOSOMAL PROTEIN L11; mRNA sequence.

ACCESSION A1613042.1 GI:4622209
VERSION A1613042.1
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 40)
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapb-remail.nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/ILIN at: www.bio.lnl.gov/dbirp/image/image.html
Insert length: 705 Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 1
POLYA-No.

FEATURES Location/Qualifiers
source 1..40

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2278337"
/clone_lib="NCI_CGAP_Ut3"
/tissue_type="poorly-differentiated endometrial adenocarcinoma; 2 pooled tumors"
/lab_host="DH10B"
/note="Organ: uterus; Vector: pCMV-SPORT6; Site.1: Salt; Site.2: NotI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 1.45 kb. Life Technologies catalog #: 11541-018"

BASE COUNT 9 a 15 c 3 g 13 t

Query Match 100.0%; Score 9; DB 9; Length 40;
Best Local Similarity 100.0%; Pred. No. 4.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
|||||||

DB 16 GAGTATGAG 8

RESULT 5 24 bp mRNA linear EST 23-APR-2000
AM059679/c
LOCUS Ahutr.bst.dnc15.aa.A050g08 DNC15 Homo sapiens cDNA, mRNA sequence.
DEFINITION AM059679
ACCESSION AM059679
VERSION AM059679.1 GI:6652001
KEYWORDS EST.
SOURCE human.

ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 24)
AUTHORS Brenner, S., Williams, S.R., Vernass, E.H., Storck, T., Moon, K., McCoilum, C., Mao, D.I., Kirchner, J.J., Elert, S., Dubridge, R.B., Burcham, T., and Albrecht, G.
TITLE In vitro cloning of complex mixtures of DNA on microbeads: physical separation of differentially expressed cDNAs
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (4), 1665-1670 (2000)

COMMENT Contact: Burcham TS
LYNX Therapeutics, Inc.
25861 Industrial Blvd., Hayward, CA 94545, USA
Tel: 510 670 9338
Fax: 510 670 9302
Email: tlmbelynxgen.com

Sequence obtained from LYNX Therapeutics Megasort technology.
Collected from the down-regulated gate.
High quality sequence stop: 24.

FEATURES Location/Qualifiers
source 1..24

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="DNC15"
/cell_type="monocytic leukemia"
/note="Vector: pCR2.1; Cloning of PCR products from microbeads carrying 3' end of down-regulated cDNA. TBP-1 cells non-induced (treated with DMSO only)."

BASE COUNT 9 a 6 c 1 g 8 t

Query Match 88.9%; Score 8; DB 10; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGA 8
|||||||
DB 24 GAGTATGA 17

RESULT 6 24 bp DNA linear GSS 04-OCT-2000
A2478673/c
LOCUS 1K0298120R Mouse 10kb plasmid UUCG1M library Mus musculus genomic
DEFINITION clone UUCG1M0298120 R, DNA sequence.
ACCESSION A2478673
VERSION A2478673.1 GI:10637794
KEYWORDS GSS.

SOURCE house mouse.

ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 24)
AUTHORS Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamli, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A., and Wright, D., Weiss, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)

COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0298 row: J column: 20
Seq primer: CACACGAGAAACAGCATATAC
Class: plasmid ends
High quality sequence stop: 24.

FEATURES
source
1. 24
Location/Qualifiers
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone_lib="UUCG1M0298J20"
/clone_lib="Mouse 10kb plasmid UUCG1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN
6 a
8 c
3 g
7 t

Query Match
Best Local Similarity 100.0%; Score 8; DB 17; Length 24;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGTATGAG 9
|||||||

Db 8 AGTATGAG 1

RESULT 7
A2605844/c 25 bp DNA linear GSS 13-DEC-2000
LOCUS 1M0427J22F Mouse 10kb plasmid UUCG1M library Mus musculus genomic
DEFINITION clone UUCG1M0427J22 F, DNA sequence.
ACCESSION A2605844
VERSION A2605844.1 GI:11728034
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 25)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Rellily, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)

COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0427 row: J column: 22
Seq primer: CGTGTAAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 25.

FEATURES
source
1. 25
Location/Qualifiers
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone_lib="UUCG1M0427J22"
/clone_lib="Mouse 10kb plasmid UUCG1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN
7 a
6 c
5 g
7 t

Query Match
Best Local Similarity 100.0%; Score 8; DB 17; Length 25;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGTATGAG 9
|||||||

Db 17 AGTATGAG 10

RESULT 8
D45824/c 27 bp mRNA linear EST 21-FEB-1995
LOCUS HUMG503044 Human adult lung 3' directed MboI cDNA Homo sapiens cDNA
DEFINITION 3', mRNA sequence.
ACCESSION D45824
VERSION D45824.1 GI:662778
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 27)
Itoh, K., Okubo, K., Yosi, J., Yokouchi, H. and Matsubara, K.
TITLE An expression profile of active genes in human lung
JOURNAL DNA Res. 1, 279-287 (1994)
MEDLINE 95236275
COMMENT Contact: Kohichi Itoh
Institute for Molecular and Cellular Biology
Osaka University

3-1, Yamadaoka, Suita, Osaka, 565, Japan
 Tel: 06-877-5111 x3910
 Fax: 06-877-1922.

Location/Qualifiers
 1. .27
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_lib="Human adult lung 3' directed MboI cDNA"
 /note="Adult human lung, 3' directed MboI"

BASE COUNT
 ORIGIN
 12 a 6 c 1 g 8 t

Query Match
 Best Local Similarity 88.9%; Score 8; DB 14; Length 27;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY
 1 GAGTATGA 8
 |||||
 24 GAGTATGA 17

RESULT 9
 AL766985 30 bp DNA linear GSS 18-JUN-2002
 LOCUS
 Arabidopsis thaliana T-DNA flanking sequence GK-215C11-014144,
 genomic survey sequence.
 ACCESSION
 AL766985
 VERSION
 AL766985.1 GI:21520104
 KEYWORDS
 GSS.
 SOURCE
 thale cress.
 ORGANISM
 Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
 AUTHORS
 1 Strizhov,N., Li,Y., Rosso,M., Viehoveer,P., Dekker,K., Saedler,H.
 and Weissshaar,B.
 A pipeline for automated high-throughput generation of FSTS
 (flanking sequence tags) from Arabidopsis thaliana T-DNA
 transformed lines
 Unpublished
 2

JOURNAL
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 Rosso,M., Strizhov,N., Li,Y., Reiss,B., Dekker,K. and Weissshaar,B.
 A new Arabidopsis thaliana T-DNA mutagenised population (GABI-Kat)
 for flanking sequence tag based reverse genetics
 Unpublished
 3 (bases 1 to 30)
 Li,Y., Rosso,M., Strizhov,N. and Weissshaar,B.
 Submitted (17-JUN-2002) Weissshaar B., Max-Planck-Institut fuer
 Zuechtungsforschung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany
 This sequence is recovered from the left border of the T-DNA. It
 indicates an insertion within the locus defined by clone F9L1. The
 sequences are generated at the MPI for Plant Breeding Research in
 Plant Genomics program designated 'GABI-Kat'. Information on line
 availability can be found at:
 http://www.mpiz-koeln.mpg.de/GABI-Kat/.

FEATURES
 SOURCE
 Location/Qualifiers
 1. .30
 /organism="Arabidopsis thaliana"
 /strain="Columbia 0"
 /db_xref="taxon:3702"
 /clone="GK-215C11-014144"
 /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
 /note="PCR was performed on DNA from Arabidopsis thaliana
 vector PAC161. The lines contain one or more T-DNA
 insertions. The DNA fragment(s) resulting from the PCR
 were directly sequenced to determine the genomic sequence
 flanking the insertion. Sequences displaying significant
 similarity to the A. thaliana nuclear genome sequence were
 processed for submission. T-DNA derived sequences were

BASE COUNT
 ORIGIN
 11 a 5 c 4 g 10 t removed"

Query Match
 Best Local Similarity 88.9%; Score 8; DB 17; Length 30;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY
 1 GAGTATGA 8
 |||||
 19 GAGTATGA 26

RESULT 10
 A2778279/c 33 bp DNA linear GSS 16-FEB-2001
 LOCUS
 2M0013N15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 clone UUGC2M0013N15 F, DNA sequence.
 ACCESSION
 A2778279
 VERSION
 A2778279.1 GI:12907753
 KEYWORDS
 GSS.
 SOURCE
 house mouse.
 ORGANISM
 Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 33)
 Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
 M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.
 and Wright,D., Weiss,R.
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts
 Unpublished (2000)
 JOURNAL
 REFERENCE
 AUTHORS
 CONTACT
 COMMENT
 University of Utah Genome Center
 Contact: Robert B. Weiss
 Km. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0013 row: N column: 15
 Seq primer: CGTTGTAAACGACGCCACT
 Class: plasmid ends
 High quality sequence stop: 33.

FEATURES
 SOURCE
 Location/Qualifiers
 1. .33
 /organism="Mus musculus"
 /strain="C57Bl/6J"
 /db_xref="taxon:10090"
 /clone="UUGC2M0013N15"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD42ny; Purified genomic DNA from M.
 musculus C57Bl/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 adaptor DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of PMD42 (g14732114|gb|AF19072.1), a copy-number
 inducible derivative of plasmid RI. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells

BASE COUNT 14 a 9 c 3 g 7 t and selected for ampicillin resistance."

ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 33;
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 AGTATGAG 9
|||||||

DB 23 AGTATGAG 16

RESULT 11
TA307A090 33 bp DNA linear GSS 13-DEC-2000
LOCUS
DEFINITION T. brucei sheared genomic DNA clone 307a09, reverse sequence,
ACCESSION AL488827
VERSION AL488827.1 GI:11864397
KEYWORDS
SOURCE
ORGANISM Trypanosoma brucei.
Eukaryota; Euklenozoa; Kinetoplastida; Trypanosomatidae;
Trypanosoma.
1 (bases 1 to 33)
Hall, N., Bowman, S., Lennard, N.J., Doggett, J., Atkin, R.,
Chillingworth, C., Ormond, D., Harris, B., El-Sayed, N., Hou, L.,
Melville, S.E., Rajandream, M.A. and Barrell, B.G.
Direct Submission
Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,
Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and
nh@sanger.ac.uk
Constructed at the Institute for Genomic Research (TIGR),
Rockville, MD. Genomic DNA isolated from a cloned population of
Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
to give a tight size distribution (4 kb). The v + 1 method used for the library construction is
described in detail in Smith, H. and Venter, J.C. (Making small
insert libraries for whole genome shotgun sequencing projects. In
Genome Sequencing: A Practical Approach, eds. M. Vaubin and B.
Barrell, Oxford University Press, 1999).
Email: nelsayed@tigr.org
Details of T. brucei sequencing at the Sanger Centre are available
at http://www.sanger.ac.uk/Projects/T_brucei/.
Location/Qualifiers
1..33
/organism="Trypanosoma brucei"
/strain="TREU927"
/db_xref="taxon:5691"
/clone="307a09"

BASE COUNT 7 a 6 c 10 g 10 t

ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 33;
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGA 8
|||||||

DB 8 GAGTATGA 15

RESULT 12
AZ333219/c 34 bp DNA linear GSS 29-SEP-2000
LOCUS
DEFINITION 1M0062009F Mouse 10kb plasmid UGCG1M library Mus musculus genomic
clone UGCG1M0062009 F, DNA sequence.
ACCESSION AZ333219
VERSION AZ333219.1 GI:10397621
KEYWORDS
SOURCE house mouse.

ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murine; Mus.
1 (bases 1 to 34)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamll, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly,
M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A.,
and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0062 row: 0 column: 09
Seq primer: CCTGTAAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 34.
Location/Qualifiers
1..34
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UGCG1M0062009"
/clone_lib="Mouse 10kb plasmid UGCG1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42ny; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(<http://www.jax.org/resources/documents/dnares/>). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (g1147321149d|A129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

BASE COUNT 13 a 6 c 4 g 11 t

ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 34;
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 AGTATGAG 9
|||||||

DB 22 AGTATGAG 15

RESULT 13
AZ776722 36 bp DNA linear GSS 16-FEB-2001
LOCUS
DEFINITION 2M0010A12R Mouse 10kb plasmid UGCG1M library Mus musculus genomic
clone UGCG2M0010A12 R, DNA sequence.
ACCESSION AZ776722
VERSION AZ776722.1 GI:12904580
KEYWORDS
SOURCE house mouse.

ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 36)

REFERENCE
AUTHORS Dunn, D., Aoyagi, A., Barber, M., Becorn, T., Duval, B., Hamill, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausern, A. and Wright, D., Weiss, R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 1000 Std Error: 0.00
Plate: 0010 row: A column: 12
Seq primer: CACACGAGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 36.

FEATURES
source
Location/Qualifiers
1. 36
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="U08C2M0010A12"
/clone_1lb="Mouse 10kb plasmid U08C1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/note="Vector: PWD42my; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g114732114[9b]AR129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN
13 a 4 c 8 g 11 t

Query Match 88.9%; Score 8; DB 17; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGTATGAG 9
Db 10 AGTATGAG 17
|||||

RESULT 14
BH789482/c 36 bp DNA linear GSS 02-APR-2002
LOCUS SALK_029703.49.45.x Arabidopsis thaliana TDNA insertion lines
DEFINITION Arabidopsis thaliana genomic clone SALK_029703.49.45.x, DNA sequence.
ACCESSION BH789482
VERSION BH789482
KEYWORDS GSS.

SOURCE
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eustosids II; Brassicales; Brassicaceae; Arabidopsids. 1 (bases 1 to 36)

REFERENCE
AUTHORS Alonso, J.M., Leisse, T.J., Barajas, P., Chen, H., Cheuk, R., Gadrinab, C., Jeske, A., Karnes, M., Kim, C.J., Parker, H., Prednis, L., Shinn, P., Zimmerman, J., and Ecker, J.R.
TITLE A Sequence-Indexed Library of Insertion Mutations in the Arabidopsis Genome
JOURNAL Unpublished (2001)
COMMENT Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of TDNA.
Class: TDNA tagged

FEATURES
source
Location/Qualifiers
1. 36
/organism="Arabidopsis thaliana"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="SALK_029703.49.45.x"
/clone_1lb="Arabidopsis thaliana TDNA insertion lines"
/note="PCR was performed on Arabidopsis thaliana lines each of which contains one or more TDNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at http://signal.salk.edu/Tdna_protocols.html.

BASE COUNT
ORIGIN
10 a 6 c 7 g 13 t

Query Match 88.9%; Score 8; DB 17; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGA 8
Db 28 GAGTATGA 21
|||||

RESULT 15
AA088913/c 37 bp mRNA linear EST 19-MAY-1997
LOCUS 216911.1,1 Stratagene colon (#337204) Homo sapiens cDNA clone
DEFINITION IMAGE:509853 3' similar to TR:G189397 G189397 HYPOTHETICAL 33.4 KD
PROTEIN: mRNA sequence.
ACCESSION AA088913
VERSION AA088913
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo. 1 (bases 1 to 37)

Chissos, S., Dietrich, N., Dubuque, T., Favellio, A., Gish, W., Hawkins, M., Hultman, M., Kucaba, T., Lacy, M., Le, M., Le, N., Mardis, E., Moore, B., Morris, M., Parsons, J., Prange, C., Rifkin, L., Rohlfing, T., Schellenberg, K., Soares, M.B., Tan, F., Thiermy-Meg, J., Trevas, E., Underwood, K., Wohlmann, P., Waterston, R., Wilson, R. and Marra, M.
Generation and analysis of 280,000 human expressed sequence tags
Genome Res. 6 (9), 807-828 (1996)

97044478
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800
 Fax: 314 286 1810
 Email: estewatson.wustl.edu
 This clone is available royalty-free through LLNL; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.
 Insert Length: 1260 Std Error: 0.00
 Seq primer: -40M13 fwd. from AmerSham
 High quality sequence stop: 1.
 Location/Qualifiers
 1. .37

/organism="Homo sapiens"
 /db_xref="GDB:3813185"
 /db_xref="taxon:9606"
 /clone="IMAGE:509853"
 /clone_id="Stratagene colon (#937204)"
 /tissue_type="tumor"
 /cell_line="T84 carcinoma cell line"
 /lab_host="SOBR cells (kanamycin resistant)"
 /note="Organ: colon; Vector: pBluescript SK-; Site_1:
 EcoRI; Site_2: XhoI; Cloned unidirectionally. Primer:
 Oligo dt. T-84 colonic epithelial cell line. Average
 insert size: 1.0 kb; Uni-ZAP XR Vector; ~5' adaptor
 sequence: 5' GAATTCGCGACGAG 3' ~3' adaptor sequence: 5'
 CTCGAGTTTTTTTTTTTTTTT 3'"

BASE COUNT 7 a 10 c 10 g 9 t 1 others
 ORIGIN

Query Match 88.9%; Score 8; DB 9; Length 37;
 Best Local Similarity 100.0%; Pred. No. 2e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GAGTATGA 8
 |||||
 DB 22 GAGTATGA 15

Search completed: June 2, 2003, 20:35:33
 Job time : 1133.39 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:31:20 ; Search time 36.878 Seconds
(without alignments)
74.844 Million cell updates/sec

Title: US-09-540-843-1

Perfect score: 9

Sequence: 1 gagtatgag 9

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 441362 segs, 153338381 residues

Total number of hits satisfying chosen parameters: 558892

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents, NA: *
1: /cgn2_6/ptodata/1/ina/5A.COMB.seq: *
2: /cgn2_6/ptodata/1/ina/5B.COMB.seq: *
3: /cgn2_6/ptodata/1/ina/6A.COMB.seq: *
4: /cgn2_6/ptodata/1/ina/6B.COMB.seq: *
5: /cgn2_6/ptodata/1/ina/PCITUS.COMB.seq: *
6: /cgn2_6/ptodata/1/ina/backfile1.seq: *

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	9	100.0	9	US-09-048-927-1	Sequence 1, Appl
2	9	100.0	15	US-09-049-190-6	Sequence 6, Appl
3	9	100.0	15	US-09-049-190-7	Sequence 7, Appl
4	9	100.0	15	US-08-932-140C-6	Sequence 6, Appl
5	9	100.0	15	US-08-932-140C-7	Sequence 7, Appl
6	9	100.0	17	US-08-758-306-365	Sequence 365, App
7	9	100.0	17	US-08-758-306-367	Sequence 367, App
8	9	100.0	17	US-08-758-306-369	Sequence 369, App
9	9	100.0	17	US-08-758-306-371	Sequence 371, App
10	9	100.0	20	US-09-287-796-101	Sequence 101, App
11	9	100.0	20	US-09-287-796-102	Sequence 102, App
12	9	100.0	20	US-09-130-616-101	Sequence 101, App
13	9	100.0	20	US-09-130-616-102	Sequence 102, App
14	9	100.0	20	US-09-105-058C-15	Sequence 15, App
15	9	100.0	20	US-09-851-062-29	Sequence 29, Appl
16	9	100.0	20	US-09-517-467B-84	Sequence 84, Appl
17	9	100.0	21	US-09-088-274-8	Sequence 8, Appl
18	9	100.0	24	US-09-245-248B-23	Sequence 23, Appl
19	9	100.0	27	US-08-932-140C-21	Sequence 21, Appl
20	9	100.0	28	US-09-031-006-4	Sequence 4, Appl
21	9	100.0	34	US-08-211-718-14	Sequence 14, Appl
22	9	100.0	34	US-09-383-143-8	Sequence 8, Appl
23	9	100.0	36	US-09-383-143-36	Sequence 36, Appl
24	9	100.0	37	US-08-029-030-1	Sequence 1, Appl
25	9	100.0	37	US-08-029-030-1	Sequence 1, Appl
26	9	100.0	37	US-08-029-030-1	Sequence 1, Appl
27	9	100.0	38	US-09-194-613-18	Sequence 18, Appl

28	9	100.0	38	4	US-09-383-143-30	Sequence 30, Appl
29	9	100.0	39	3	US-08-980-032-4	Sequence 4, Appl
30	9	100.0	39	4	US-09-477-871-4	Sequence 4, Appl
31	9	100.0	39	4	US-09-383-143-9	Sequence 9, Appl
32	9	100.0	40	2	US-08-425-684-27	Sequence 27, Appl
33	9	100.0	40	2	US-08-425-684-34	Sequence 34, Appl
34	9	100.0	40	2	US-08-675-502-27	Sequence 27, Appl
35	9	100.0	40	2	US-08-675-502-34	Sequence 34, Appl
36	8	88.9	14	2	US-08-744-905A-4	Sequence 4, Appl
37	8	88.9	15	2	US-08-747-121-4	Sequence 24, Appl
38	8	88.9	15	2	US-08-585-684B-1315	Sequence 1315, Appl
39	8	88.9	15	2	US-09-038-073-1315	Sequence 1315, Appl
40	8	88.9	16	1	US-07-977-284A-59	Sequence 59, Appl
41	8	88.9	16	1	US-07-977-284A-59	Sequence 59, Appl
42	8	88.9	17	2	US-08-255-426B-59	Sequence 59, Appl
43	8	88.9	17	3	US-08-985-162-443	Sequence 443, Appl
44	8	88.9	17	3	US-08-985-162-444	Sequence 444, Appl
45	8	88.9	18	1	US-07-688-352C-8	Sequence 8, Appl

ALIGNMENTS

```
RESULT 1
US-09-048-927-1
; Sequence 1, Application US/09048927
; Patent No. 6147056
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Yaar, Mina
; APPLICANT: Eller, Mark
; TITLE OF INVENTION: Use of Locally Applied DNA Fragments
; FILE REFERENCE: B094-68A2
; CURRENT APPLICATION NUMBER: US/09/048,927
; CURRENT FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 08/952,697
; EARLIER FILING DATE: 1996-06-03
; EARLIER APPLICATION NUMBER: 08/467,012
; EARLIER FILING DATE: 1995-06-06
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA Fragment
US-09-048-927-1
Query Match 100.0%; Score 9; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 3 2e+07;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGTATGAG 9
Db 1 GAGTATGAG 9
RESULT 2
US-09-049-190-6/c
; Sequence 6, Application US/09049190
; Patent No. 6190866
; GENERAL INFORMATION:
; APPLICANT: Nielsen et al.
; TITLE OF INVENTION: Peptide Nucleic Acids Having
; TITLE OF INVENTION: Antibacterial Activity
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
6 No. 6190866r1s LLP
```

```

ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 MB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/049,190
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-2560
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
NAME/KEY: Modified-site
LOCATION: 3
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
NAME/KEY: Modified-site
LOCATION: 7
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
NAME/KEY: Modified-site
LOCATION: 8
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
NAME/KEY: Modified-site
LOCATION: 9
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
NAME/KEY: Modified-site

```

```

LOCATION: 10
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 11
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 12
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 13
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 14
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 15
OTHER INFORMATION: N-[acetyl(2-aminoethyl)]-C-lysine-glycine
OTHER INFORMATION: backbone
US-09-049-190-6

```

```

Query Match      100.0%; Score 9; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 GAGTATGAG 9
DB      11 GAGTATGAG 3

```

```

RESULT 3
US-09-049-190-7/c
Sequence 7, Application US/09049190
Patent No. 6190866
GENERAL INFORMATION:
APPLICANT: Nielsen et al.
TITLE OF INVENTION: Peptide Nucleic Acids Having
TITLE OF INVENTION: Antibacterial Activity
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESS: Woodcock Washburn Kurtz MacKiewicz
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 MB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/049,190
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-2560
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100

```

TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 3
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 7
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 8
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 9
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 10
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 11
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 12
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 13
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone

NAME/KEY: Modified-site
LOCATION: 14
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
NAME/KEY: Modified-site
LOCATION: 15
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
FEATURE:
OTHER INFORMATION: backbone
US-09-049-190-7

Query Match 100.0%; Score 9; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
DB 14 GAGTATGAG 6

RESULT 4
US-08-932-140C-6/C
Sequence 6, Application US/08932140C
Patent No. 6300318
GENERAL INFORMATION:
APPLICANT: Nielsen et al.
TITLE OF INVENTION: Peptide Nucleic Acids Having
TITLE OF INVENTION: Antibacterial Activity
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz &
ADDRESSEE: No. 6300318ris LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Microsoft Word
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/932,140C
FILING DATE: September 16, 1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-2560
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 3

OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 7
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 8
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 9
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 10
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 11
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 12
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 13
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 14
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 15
OTHER INFORMATION: N-[acetyl(2-aminoethyl)]-C-lysine-glycine backbone
US-08-932-140C-6
Query Match 100.0%; Score 9; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
Db 11 GAGTATGAG 3

RESULT 5
US-08-932-140C-7/C
Sequence 7, Application US/08932140C
Patent No. 6300318
GENERAL INFORMATION:
APPLICANT: Nielsen et al.
TITLE OF INVENTION: Peptide Nucleic Acids Having
Antibacterial Activity
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz &

ADDRESSEE: No. 6300318ris LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Microsoft Word
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/932,140C
FILING DATE: September 16, 1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-2560
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEO ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 3
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 7
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 8
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site

LOCATION: 9
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 10
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 11
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 12
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 13
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 14
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 15
OTHER INFORMATION: N-[acetyl(2-aminoethyl)]-C-
OTHER INFORMATION: lysine-glycine backbone
US-08-932-140C-7

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 15;
Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
DB 14 GAGTATGAG 6

RESULT 6
US-08-758-306-365/C
Sequence 365, Application US/08758306
Patent No. 5807743
GENERAL INFORMATION:
APPLICANT: Sclinchomb, Dan T.
APPLICANT: McSwiggen, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
NUMBER OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306

FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 365:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-758-306-365

Query Match
Best Local Similarity 100.0%; Score 9; DB 1; Length 17;
Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
DB 17 GAGTATGAG 9

RESULT 7
US-08-758-306-367/C
Sequence 367, Application US/08758306
Patent No. 5807743
GENERAL INFORMATION:
APPLICANT: Sclinchomb, Dan T.
APPLICANT: McSwiggen, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
NUMBER OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306
FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 367:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-758-306-367

Query Match 100.0%; Score 9; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
DB 15 GAGTATGAG 7

RESULT 8
US-08-758-306-369/c
Sequence 369, Application US/08758306
Patent No. 5807743

GENERAL INFORMATION:
APPLICANT: Sclincocomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
INTERLEUKIN-2 RECEPTOR
TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Fastseq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306
FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ. ID NO: 369:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-758-306-369

Query Match 100.0%; Score 9; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
DB 12 GAGTATGAG 4

RESULT 9
US-08-758-306-371/c
Sequence 371, Application US/08758306
Patent No. 5807743

GENERAL INFORMATION:
APPLICANT: Sclincocomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
INTERLEUKIN-2 RECEPTOR
TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Fastseq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306
FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ. ID NO: 371:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

Query Match 100.0%; Score 9; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
DB 9 GAGTATGAG 1

RESULT 10
US-09-287-796-101
Sequence 101, Application US/09287796A
Patent No. 6133246

GENERAL INFORMATION:
APPLICANT: McKay, Robert A.
APPLICANT: Dean, Nicholas M.
APPLICANT: Monia, Brett
APPLICANT: Nero, Pam
APPLICANT: Gaarde, William A.
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
FOR THE MODULATION OF JNK PROTEINS

```
FILE REFERENCE: ISPH-0350
CURRENT APPLICATION NUMBER: US/09/287,796A
CURRENT FILING DATE: 1999-04-07
EARLIER APPLICATION NUMBER: 09/130,616
EARLIER FILING DATE: 1998-08-07
EARLIER APPLICATION NUMBER: 08/910,629
EARLIER FILING DATE: 1997-08-03
NUMBER OF SEQ ID NOS: 165
SEQ ID NO 101
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Sequence
US-09-287-796-101

Query Match
Best Local Similarity 100.0%; Score 9; DB 3; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
DB 9 GAGTATGAG 17

RESULT 11
US-09-287-796-102
Sequence 102, Application US/09287796A
Patent No. 6133246
GENERAL INFORMATION:
APPLICANT: McKay, Robert A.
APPLICANT: Dean, Nicholas M.
APPLICANT: Monia, Brett
APPLICANT: Nero, Pam
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
FILE REFERENCE: ISPH-0350
CURRENT APPLICATION NUMBER: US/09/287,796A
CURRENT FILING DATE: 1999-04-07
EARLIER APPLICATION NUMBER: 09/130,616
EARLIER FILING DATE: 1998-08-07
EARLIER APPLICATION NUMBER: 08/910,629
EARLIER FILING DATE: 1997-08-03
NUMBER OF SEQ ID NOS: 165
SEQ ID NO 102
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Sequence
US-09-287-796-102

Query Match
Best Local Similarity 100.0%; Score 9; DB 3; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
DB 9 GAGTATGAG 17

RESULT 12
US-09-130-616-101
Sequence 101, Application US/09130616C
Patent No. 6221850
GENERAL INFORMATION:
APPLICANT: McKay, Robert A.
APPLICANT: Dean, Nicholas M.
APPLICANT: Monia, Brett
APPLICANT: Nero, Pam
APPLICANT: Gaarde, William A.
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
```

```
FILE REFERENCE: ISPH-0318
CURRENT APPLICATION NUMBER: US/09/130,616C
CURRENT FILING DATE: 1998-08-07
EARLIER APPLICATION NUMBER: 08/910,629
EARLIER FILING DATE: 1997-08-03
NUMBER OF SEQ ID NOS: 178
SEQ ID NO 101
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic sequence
US-09-130-616-101

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
DB 9 GAGTATGAG 17

RESULT 13
US-09-130-616-102
Sequence 102, Application US/09130616C
Patent No. 6221850
GENERAL INFORMATION:
APPLICANT: McKay, Robert A.
APPLICANT: Dean, Nicholas M.
APPLICANT: Monia, Brett
APPLICANT: Nero, Pam
APPLICANT: Gaarde, William A.
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
FILE REFERENCE: ISPH-0318
CURRENT APPLICATION NUMBER: US/09/130,616C
CURRENT FILING DATE: 1998-08-07
EARLIER APPLICATION NUMBER: 08/910,629
EARLIER FILING DATE: 1997-08-03
NUMBER OF SEQ ID NOS: 178
SEQ ID NO 102
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic sequence
US-09-130-616-102

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
DB 9 GAGTATGAG 17

RESULT 14
US-09-105-058C-15
Sequence 15, Application US/09105058C
Patent No. 6403360
GENERAL INFORMATION:
APPLICANT: Blonar, Michael A.
APPLICANT: Dworetzky, Steven
APPLICANT: Gridkov, Valentin K.
APPLICANT: Levesque, Paul C.
APPLICANT: Little, Wayne A.
APPLICANT: Neubaer, Michael G.
APPLICANT: Yang, Wen-pin
TITLE OF INVENTION: KONO POTASSIUM CHANNELS AND METHODS OF MODULATING SAME
FILE REFERENCE: 3053-4052
```

```

; CURRENT APPLICATION NUMBER: US/09/105,058C
; CURRENT FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: US 60/055,599
; PRIOR FILING DATE: 1997-08-12
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Forward primer
; OTHER INFORMATION: from EST sequence similar to the KVLQT gene
US-09-105-058C-15

```

```

Query Match          100.0%; Score 9; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 GAGTATGAG 9
        |||||
Db      1 GAGTATGAG 9

```

```

RESULT 15
US-09-851-062-29/c
; Sequence 29, Application US/09851062
; Patent No. 6448081
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; TITLE OF INVENTION: ANTISENSE MODULATION OF INTERLEUKIN 12 P40 SUBUNIT EXPRESSION
; FILE REFERENCE: RFS-0247
; CURRENT APPLICATION NUMBER: US/09/851,062
; CURRENT FILING DATE: 2001-05-07
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-09-851-062-29

```

```

Query Match          100.0%; Score 9; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 GAGTATGAG 9
        |||||
Db      19 GAGTATGAG 11

```

```

Search completed: June 2, 2003, 20:38:31
Job time : 37.878 secs

```


GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 19:09:45 ; Search time 63.878 Seconds
(without alignments)
189.976 Million cell updates/sec

Title: US-09-540-843-1
Perfect score: 9
Sequence: 1 gagatagag 9

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 845702 seqs, 674182571 residues

Total number of hits satisfying chosen parameters: 477662

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_NA:*

- 1: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
- 2: /cgn2_6/ptodata/2/pubpna/PCT_NEW_PUB.seq:*
- 3: /cgn2_6/ptodata/2/pubpna/US06_NEW_PUB.seq:*
- 4: /cgn2_6/ptodata/2/pubpna/US06_PUBCOMB.seq:*
- 5: /cgn2_6/ptodata/2/pubpna/US07_NEW_PUB.seq:*
- 6: /cgn2_6/ptodata/2/pubpna/PCTUS_PUBCOMB.seq:*
- 7: /cgn2_6/ptodata/2/pubpna/US08_NEW_PUB.seq:*
- 8: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
- 9: /cgn2_6/ptodata/2/pubpna/US09_NEW_PUB.seq:*
- 10: /cgn2_6/ptodata/2/pubpna/US09_PUBCOMB.seq:*
- 11: /cgn2_6/ptodata/2/pubpna/US10_NEW_PUB.seq:*
- 12: /cgn2_6/ptodata/2/pubpna/US10_PUBCOMB.seq:*
- 13: /cgn2_6/ptodata/2/pubpna/US60_NEW_PUB.seq:*
- 14: /cgn2_6/ptodata/2/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	9	100.0	9	US-10-122-630-1	Sequence 1, Appl1
2	9	100.0	9	US-10-122-633-1	Sequence 1, Appl1
3	9	100.0	17	US-09-866-108-2750	Sequence 2750, Ap
4	9	100.0	17	US-09-866-108-2751	Sequence 2751, Ap
5	9	100.0	17	US-09-866-108-2752	Sequence 2752, Ap
6	9	100.0	17	US-09-866-108-2753	Sequence 2753, Ap
7	9	100.0	17	US-09-866-108-2754	Sequence 2754, Ap
8	9	100.0	17	US-09-866-108-2755	Sequence 2755, Ap
9	9	100.0	17	US-09-866-108-2756	Sequence 2756, Ap
10	9	100.0	17	US-09-866-108-2757	Sequence 2757, Ap
11	9	100.0	17	US-09-866-108-2758	Sequence 2758, Ap
12	9	100.0	18	US-09-853-895-1	Sequence 1, Appl1
13	9	100.0	20	US-10-128-870-15	Sequence 15, Appl1
14	9	100.0	20	US-09-774-809-101	Sequence 101, Appl
15	9	100.0	20	US-09-774-809-102	Sequence 102, Appl
16	9	100.0	20	US-10-131-685-15	Sequence 15, Appl
17	9	100.0	20	US-10-067-514-32	Sequence 32, Appl
18	9	100.0	24	US-09-815-656-23	Sequence 23, Appl
19	9	100.0	25	US-10-215-112-4205	Sequence 4205, Ap

20	9	100.0	25	US-10-215-112-4329	Sequence 4329, Ap
21	9	100.0	25	US-10-215-112-10765	Sequence 10765, A
22	9	100.0	25	US-10-215-112-10891	Sequence 10891, A
23	9	100.0	25	US-09-911-904-37	Sequence 37, Appl
24	9	100.0	25	US-09-866-108-5679	Sequence 5679, Ap
25	9	100.0	25	US-09-866-108-5680	Sequence 5680, Ap
26	9	100.0	25	US-09-866-108-5681	Sequence 5681, Ap
27	9	100.0	25	US-09-866-108-5682	Sequence 5682, Ap
28	9	100.0	25	US-09-866-108-5683	Sequence 5683, Ap
29	9	100.0	25	US-09-866-108-5684	Sequence 5684, Ap
30	9	100.0	25	US-09-866-108-5685	Sequence 5685, Ap
31	9	100.0	25	US-09-866-108-5686	Sequence 5686, Ap
32	9	100.0	25	US-09-866-108-5687	Sequence 5687, Ap
33	9	100.0	25	US-09-866-108-5688	Sequence 5688, Ap
34	9	100.0	25	US-09-866-108-5689	Sequence 5689, Ap
35	9	100.0	25	US-09-866-108-5690	Sequence 5690, Ap
36	9	100.0	25	US-09-866-108-5691	Sequence 5691, Ap
37	9	100.0	25	US-09-866-108-5692	Sequence 5692, Ap
38	9	100.0	25	US-09-866-108-5693	Sequence 5693, Ap
39	9	100.0	25	US-09-866-108-5694	Sequence 5694, Ap
40	9	100.0	25	US-09-866-108-5695	Sequence 5695, Ap
41	9	100.0	31	US-09-776-474-2450	Sequence 2450, Ap
42	9	100.0	31	US-09-801-274-1613	Sequence 1613, Ap
43	9	100.0	32	US-10-014-101-24	Sequence 24, Appl
44	9	100.0	33	US-09-828-313-59	Sequence 59, Appl
45	9	100.0	33	US-09-828-313-94	Sequence 94, Appl

ALIGNMENTS

RESULT 1
US-10-122-630-1
; Sequence 1, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Glitchest, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yeater, Mina
; TITLE OF INVENTION: Method to inhibit cell growth using
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
; US-10-122-630-1

Query Match 100.0%; Score 9; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 9; Conservative 0; Mismatches 0; Indels 0;

QY 1 GAGTATGAG 9
|||||||
DB 1 GAGTATGAG 9

```
RESULT 2
US-10-122-633-1
; Sequence 1, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eiler, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054,1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-1

Query Match      100.0%; Score 9; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GAGTATGAG 9
Db      1 GAGTATGAG 9

RESULT 3
US-09-866-108-2750
; Sequence 2750, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2750
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2750

Query Match      100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GAGTATGAG 9
Db      9 GAGTATGAG 17

RESULT 4
US-09-866-108-2751
; Sequence 2751, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
```

```
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2751
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2751
```

```
Query Match          100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 GAGTATGAG 9
        |||||||
DB      8 GAGTATGAG 16
```

```
RESULT 5
US-09-866-108-2752
; Sequence 2752, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: HANZEL, David G.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2752
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2752
```

```
Query Match          100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 GAGTATGAG 9
        |||||||
DB      7 GAGTATGAG 15
```

```
RESULT 6
US-09-866-108-2753
; Sequence 2753, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David G.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2753
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2753
```

```
Query Match          100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 GAGTATGAG 9
        |||||||
DB      6 GAGTATGAG 14
```

```
RESULT 7
US-09-866-108-2754
; Sequence 2754, Application US/09866108
; Patent No. US20020048800A1
```

```
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 2754
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-2754

Query Match          100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GAGTATGAG 9
        |||||||
DB      5 GAGTATGAG 13

RESULT 8
US-09-866-108-2755
; Sequence 2755, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
```

```
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 2755
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-2755

Query Match          100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GAGTATGAG 9
        |||||||
DB      4 GAGTATGAG 12

RESULT 9
US-09-866-108-2756
; Sequence 2756, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
```

;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO 2756
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-2756

Query Match 100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
Db 3 GAGTATGAG 11

RESULT 10
US-09-866-108-2757
;; Sequence 2757, Application US/09866108
;; Patent No. US20020048800A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AECOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30

;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO 2757
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-2757

Query Match 100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GAGTATGAG 9
|||||
Db 2 GAGTATGAG 10

RESULT 11
US-09-866-108-2758
;; Sequence 2758, Application US/09866108
;; Patent No. US20020048800A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AECOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; PRIOR FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 2758
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2758

Query Match 100.0%; Score 9; DB 10; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 1 GAGTATGAG 9

RESULT 12
US-09-853-895-1/c
; Sequence 1, Application US/09853895
; Patent No. US20020045590A1
; GENERAL INFORMATION:
; APPLICANT: Johns, Roger
; APPLICANT: Tao, Yuan-Xiang
; TITLE OF INVENTION: Inhibition of Interaction of PSD93 and
; TITLE OF INVENTION: PSD95 with nNOS and NMDA receptors
; FILE REFERENCE: 01107, 00130
; CURRENT APPLICATION NUMBER: US/09/853,895
; CURRENT FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: 60/242590
; PRIOR FILING DATE: 2000-10-23
; PRIOR APPLICATION NUMBER: 60/203894
; PRIOR FILING DATE: 2000-05-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Rattus rattus
US-09-853-895-1

Query Match 100.0%; Score 9; DB 10; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 18 GAGTATGAG 10

RESULT 13
US-10-128-870-15
; Sequence 15, Application US/10128870
; Patent No. US20020168724A1
; GENERAL INFORMATION:
; APPLICANT: Bhanar, Michael A.
; APPLICANT: Dworetzky, Steven
; APPLICANT: Gribkoff, Valentin K.
; APPLICANT: Levesque, Paul C.
; APPLICANT: Little, Wayne A.
; APPLICANT: Neubaumer, Michael G.
; APPLICANT: Yang, Wen-Pin
; TITLE OF INVENTION: KCNQ POTASSIUM CHANNELS AND METHODS OF MODULATING SAME
; FILE REFERENCE: DCS6adiV
; CURRENT APPLICATION NUMBER: US/10/128,870
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: 09/105,058
; PRIOR FILING DATE: June 26, 1998
; PRIOR APPLICATION NUMBER: 60/055,599
; PRIOR FILING DATE: August 12, 1997
; NUMBER OF SEQ ID NOS: 28

; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Forward
; OTHER INFORMATION: primer from EST sequence similar to the KvLOT gene
US-10-128-870-15

Query Match 100.0%; Score 9; DB 9; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 1 GAGTATGAG 9

RESULT 14
US-09-774-809-101
; Sequence 101, Application US/09774809
; Publication No. US20030004120A1
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS
; FILE REFERENCE: ISPH-0412
; CURRENT APPLICATION NUMBER: US/09/774,809
; CURRENT FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: 09/336,902
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 08/130,616
; PRIOR FILING DATE: 1998-08-07
; PRIOR APPLICATION NUMBER: 08/910,629
; PRIOR FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 101
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-774-809-101

Query Match 100.0%; Score 9; DB 9; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GAGTATGAG 9
Db 9 GAGTATGAG 17

RESULT 15
US-09-774-809-102
; Sequence 102, Application US/09774809
; Publication No. US20030004120A1
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS
; FILE REFERENCE: ISPH-0412
; CURRENT APPLICATION NUMBER: US/09/774,809
; CURRENT FILING DATE: 2001-01-31

; PRIOR APPLICATION NUMBER: 09/396,902
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 09/130,616
; PRIOR FILING DATE: 1998-08-07
; PRIOR APPLICATION NUMBER: 08/910,629
; PRIOR FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 102
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-774-809-102

Query Match 100.0%; Score 9; DB 9; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.1e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0;
QY 1 GAGTATGAG 9
|||
Db 9 GAGTATGAG 17

Search completed: June 2, 2003, 23:43:11
Job time : 64.8781 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 17:32:40 ; Search time 150.366 Seconds
(without alignments)
134.791 Million cell updates/sec

Title: US-09-540-843-2

Perfect score: 9

Sequence: 1 tagagagat 9

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 2063506

Minimum DB seq length: 0

Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

N_Geneseq_101002:*

1: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	9	100.0	9	20	AAZ10693	Oligonucleotide se
2	9	100.0	9	23	AAZ14906	Melanogenesis asso
3	9	100.0	9	23	ABH73149	Oligonucleotide pr
4	9	100.0	12	23	ABH79033	Oligonucleotide pr
5	9	100.0	12	23	ABH83668	Oligonucleotide pr
6	9	100.0	12	23	ABH86802	Oligonucleotide pr
7	9	100.0	12	23	ABH95571	Oligonucleotide pr
8	9	100.0	12	23	ABH99034	Oligonucleotide pr
9	9	100.0	12	23	ABH106447	Oligonucleotide pr

10	9	100.0	12	23	ABH14652	Oligonucleotide pr
11	9	100.0	12	23	ABH16049	Oligonucleotide pr
12	9	100.0	12	23	ABH13611	Oligonucleotide pr
13	9	100.0	12	23	ABH139203	Oligonucleotide pr
14	9	100.0	12	23	ABH140401	Oligonucleotide pr
15	9	100.0	12	23	ABH175163	Oligonucleotide pr
16	9	100.0	12	23	ABH176166	Oligonucleotide pr
17	9	100.0	12	23	ABH178087	Oligonucleotide pr
18	9	100.0	12	23	ABH180232	Oligonucleotide pr
19	9	100.0	12	23	ABH06168	Oligonucleotide pr
20	9	100.0	13	23	ABH06169	Oligonucleotide pr
21	9	100.0	13	23	ABH20906	Oligonucleotide pr
22	9	100.0	13	23	ABH20907	Oligonucleotide pr
23	9	100.0	13	23	ABH40316	Oligonucleotide pr
24	9	100.0	13	23	ABH40317	Oligonucleotide pr
25	9	100.0	13	23	ABH54924	Oligonucleotide pr
26	9	100.0	13	23	ABH54925	Oligonucleotide pr
27	9	100.0	13	23	ABH72172	Oligonucleotide pr
28	9	100.0	13	23	ABH72173	Oligonucleotide pr
29	9	100.0	13	23	ABH84890	Oligonucleotide pr
30	9	100.0	13	23	ABH84891	Oligonucleotide pr
31	9	100.0	13	23	ABH18052	Oligonucleotide pr
32	9	100.0	13	23	ABH18053	Oligonucleotide pr
33	9	100.0	13	23	ABH28786	Oligonucleotide pr
34	9	100.0	13	23	ABH28787	Oligonucleotide pr
35	9	100.0	13	23	ABH66366	Oligonucleotide pr
36	9	100.0	13	23	ABH66367	Oligonucleotide pr
37	9	100.0	13	23	ABH92852	Oligonucleotide pr
38	9	100.0	13	23	ABH92853	Oligonucleotide pr
39	9	100.0	13	23	ABH01812	Oligonucleotide pr
40	9	100.0	13	23	ABH01813	Oligonucleotide pr
41	9	100.0	13	23	ABH16364	Oligonucleotide pr
42	9	100.0	13	23	ABH16365	Oligonucleotide pr
43	9	100.0	13	23	ABH32012	Oligonucleotide pr
44	9	100.0	13	23	ABH32013	Oligonucleotide pr
45	9	100.0	13	23	ABH40490	Oligonucleotide pr

ALIGNMENTS

RESULT 1
AAZ10693
ID AAZ10693 standard; DNA; 9 BP.

AC AAZ10693;
XX
DT 23-NOV-1999 (first entry)
XX
DE Oligonucleotide sequence that increases p53 activity in a cell.
XX
XX p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;
KW UV-induced hyperproliferative disease; psoriasis; vitiligo;
KW atopic dermatitis; allergic rhinitis; conjunctivitis; photogingiv;
KW skin cancer; ss.
XX
OS Synthetic.
XX
PN GB2336157-A.
XX
PD 13-OCT-1999.
XX
PF 24-MAR-1999; 99GB-0006758.
XX
PR 26-MAR-1998; 98US-0048927.
XX (UYBO-) UNTV BOSTON.
XX
PI Gilchrist BA, Yaar M, Eller M;
XX WPI; 1999-543520/46.
DR
XX DNA fragments useful for increasing p53 activity in a cell and reducing

PT susceptibility to UV-induced hyperproliferative diseases -
 XX
 PS Claim 11, Page 29; 44pp; English.
 CC
 CC AA210692-97 represent DNA fragments that are used for increasing p53
 CC activity in a cell. The oligonucleotides are are UV mimetics and
 CC protect cells against subsequent exposure to UV-irradiation or
 CC chemicals. The oligonucleotides are useful for increasing p53 activity
 CC in a cell, reducing the susceptibility to UV-induced hyperproliferative
 CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic
 CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging
 CC and reducing susceptibility to skin cancer.
 XX
 SQ Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;
 Query Match 100.0%; Score 9; DB 20; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TAGGAGCAT 9
 Db 1 TAGGAGCAT 9
 RESULT 2
 AAS14906
 ID AAS14906 standard; DNA; 9 BP.
 XX
 AC AAS14906;
 XX
 DT 14-FEB-2002 (first entry)
 XX
 DE Melanogenesis associated oligonucleotide #2.
 XX
 KM Melanin; melanogenic; oligomer; cytosatic; anti-allergic; p53;
 KM anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KM immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KM tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KM carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KM conjunctivitis; allergic rhinitis; vitiligo; ss.
 XX
 OS Synthetic.
 OS
 PN WO200174342-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-US10162.
 XX
 PR 31-MAR-2000; 2000US-0540843.
 XX
 PA (UYBO-) UNIV BOSTON.
 XX
 PI Gilchrist BA, Yaar M, Eller M;
 XX
 DR WPI; 2001-626338/72.
 XX
 PT Inhibiting proliferation of epithelial cells, useful e.g. for treating
 PT carcinoma, using specific oligonucleotides that mimic the effects of
 PT ultra-violet light -
 XX
 PS Claim 1; Page 36; 74pp; English.
 XX
 CC The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytosatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time

CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergic rhinitis and inflammation (atopic or contact dermatitis,
 CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #2, a scrambled
 CC version of the oligonucleotide shown in AAS14905, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell proliferation,
 CC described in the method of the invention.
 XX
 SQ Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;
 Query Match 100.0%; Score 9; DB 23; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TAGGAGCAT 9
 Db 1 TAGGAGCAT 9
 RESULT 3
 ABH73149
 ID ABH73149 standard; DNA; 12 BP.
 XX
 AC ABH73149;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 273134 for detecting SNP TSC0003058.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB00713.
 XX
 PR 07-APR-2000; 2000DE-1019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX
 PS Claim 1; SEQ ID 273134; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABE00010-ABC99989, ABR00010-ABF99989, ABH00010-ABH99989 and
 CC ABI00010-ABI82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pcl_sequences.

SQ Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
| | | | | | | |
DB 3 TAGGAGGAT 11

RESULT 4

ABH79033/c
ID ABH79033 standard; DNA; 12 BP.

AC ABH79033;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 279026 for detecting SNP TSC0006799.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB00713.

PR 07-APR-2000; 2000DE-1019173.

XX (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -

PS Claim 1; SEQ ID 279026; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.

CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and

CC ABH00010-ABH82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pcl_sequences.

XX Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
| | | | | | | |
DB 12 TAGGAGGAT 4

RESULT 5

ABH83668
ID ABH83668 standard; DNA; 12 BP.

AC ABH83668;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 283661 for detecting SNP TSC0011446.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB00713.

PR 07-APR-2000; 2000DE-1019173.

XX (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -

PS Claim 1; SEQ ID 283661; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.

CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and

CC ABH00010-ABH82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pcl_sequences.

XX Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
| | | | | | | |
DB 3 TAGGAGGAT 11

RESULT 6

ABH86802/c
ID ABH86802 standard; DNA; 12 BP.

AC ABH86802;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 286795 for detecting SNP TSC0012825.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-1B00713.
 PF
 XX 07-APR-2000; 2000DE-1019173.
 PR
 XX (EPig-) EPiGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 PS
 PS Claim 1; SEQ ID 286795; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC AB100010-AB182073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 12 BP; 4 A; 5 G; 3 T; 0 other;
 XX
 Query Match 100.0%; Score 9; DB 23; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TAGGAGGAT 9
 Db 9 TAGGAGGAT 1
 DE
 XX
 AC ABH95571;
 XX
 XX 22-FEB-2002 (first entry)
 DE
 XX Oligonucleotide primer SEQ ID NO 295564 for detecting SNP TSC0016640.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-1B00713.
 PF
 XX 07-APR-2000; 2000DE-1019173.
 PR
 XX (EPig-) EPiGENOMICS AG.
 PA

XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 PS
 PS Claim 1; SEQ ID 295564; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC AB100010-AB182073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 CC
 SQ Sequence 12 BP; 4 A; 0 C; 5 G; 3 T; 0 other;
 XX
 Query Match 100.0%; Score 9; DB 23; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.4e+04;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TAGGAGGAT 9
 Db 4 TAGGAGGAT 12
 DE
 XX
 AC ABH99034;
 XX
 XX 22-FEB-2002 (first entry)
 DE
 XX Oligonucleotide primer SEQ ID NO 299027 for detecting SNP TSC0018404.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-1B00713.
 PF
 XX 07-APR-2000; 2000DE-1019173.
 PR
 XX (EPig-) EPiGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 PS
 PS Claim 1; SEQ ID 299027; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.

XX Sequence 12 BP; 3 A; 5 C; 0 G; 4 T; 0 other;

SO Query Match

Best Local Similarity 100.0%; Score 9; DB 23; Length 12;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGCAT 9
Dd 12 TAGGAGCAT 4

RESULT 9

AB106447 ID AB106447 standard; DNA; 12 BP.

XX AC AB106447;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 306420 for detecting SNP TSC0022000.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB00713.

XX PR 07-APR-2000; 2000DE-1019173.

XX PA (EP1G-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single nucleotide polymorphisms and cytosine
XX methylation status -

XX Claim 1; SEQ ID 306420; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.

XX Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGCAT 9
Dd 1 TAGGAGCAT 9

RESULT 10

AB114652 ID AB114652 standard; DNA; 12 BP.

XX AC AB114652;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 314625 for detecting SNP TSC0026468.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB00713.

XX PR 07-APR-2000; 2000DE-1019173.

XX PA (EP1G-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single nucleotide polymorphisms and cytosine
XX methylation status -

XX Claim 1; SEQ ID 314625; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.

XX Sequence 12 BP; 3 A; 0 C; 4 G; 5 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGCAT 9
Dd 4 TAGGAGCAT 12

RESULT 11

AB116049 ID AB116049 standard; DNA; 12 BP.

XX

AC AB116049;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 316022 for detecting SNP TSC0027234.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KV central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.
XX
PN WO200177384-A2.
XX

PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
DR WPI; 2001-657177/75.
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, its
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
PS Claim 1; SEQ ID 316022; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABCO0010-ABC99989, ABF00010-ABF99989, ASH00010-ASH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pcl_sequences.
XX
SQ Sequence 12 BP; 3 A; 0 G; 6 G; 3 T; 0 other;

Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2,4e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGCAT 9
 |||||
DB 2 TAGGAGCAT 10

RESULT 12
ABI38611/c
ID ABI38611 standard; DNA; 12 BP.
XX
AC ABI38611;
XX
DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 338584 for detecting; SNP TSC0040564.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KV central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX

```

XX      18-OCT-2001.
PD XX
XX      06-APR-2001; 2001WO-IB00713.
PF XX
XX      07-APR-2000; 2000DE-1019173.
PR XX
XX      (EPig-) EPIGENOMICS AG.
PA XX
XX      Olek A, Piepenbrock C, Berlin K;
PI XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
PS Claim 1; SEQ ID 338584; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC AB000010-ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABJ00010-ABJ82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 2 A; 5 C; 0 G; 5 T; 0 other;
XX
Query Match          100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2,4e+04;
Matches    9; Conservative    0; Mismatches    0; Indels    0; Gaps    0
YY      1 TAGCAGCAT 9
DB      |||||||||
        12 TAGCAGCAT 4
XX
RESULT 13
ID   ABI39203/C
XX   ABI39203 standard; DNA; 12 BP.
XX   ABI39203;
XX   DT 22-FEB-2002 (first entry)
XX   DE Oligonucleotide primer SEQ ID NO 339176 for detecting SNP TSC0040884.
XX   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX   peptide nucleic acid; cytosine methylation; cardiovascular; primer; sg;
XX   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX   Homo sapiens.
OS
XX   WO200177384-A2.
XX   PN 18-OCT-2001.
XX   PD 06-APR-2001; 2001WO-IB00713.
XX   PF 07-APR-2000; 2000DE-1019173.
XX   PR
XX   PA (EPig-) EPIGENOMICS AG.
XX   PI Olek A, Piepenbrock C, Berlin K;
XX   DR WPI; 2001-657177/75.
XX   PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX   PT designed to detect single nucleotide polymorphisms and cytosine
XX   PT methylation status -
XX   PS Claim 1; SEQ ID 338584; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC AB000010-ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABJ00010-ABJ82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 2 A; 5 C; 0 G; 5 T; 0 other;
XX
Query Match          100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2,4e+04;
Matches    9; Conservative    0; Mismatches    0; Indels    0; Gaps    0

```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
PS
XX Claim 1; SEQ ID 339176; 29pp + Sequence Listing; German.
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04; Mismatches 0; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TAGGAGGAT 9
DB 12 TAGGAGGAT 4
RESULT 14
ABI40401
ID ABI40401 standard; DNA; 12 BP.
XX
AC ABI40401;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 340374 for detecting SNP TSC0041493.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
PS
XX Claim 1; SEQ ID 340374; 29pp + Sequence Listing; German.
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.

CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 0 C; 6 G; 3 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04; Mismatches 0; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TAGGAGGAT 9
DB 1 TAGGAGGAT 9
RESULT 15
ABI75163/C
ID ABI75163 standard; DNA; 12 BP.
XX
AC ABI75163;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 375136 for detecting SNP TSC0061083.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status
PS
XX Claim 1; SEQ ID 375136; 29pp + Sequence Listing; German.
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC AB100010-AB182073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 12 BP; 3 A; 5 C; 0 G; 4 T; 0 other;
Query Match 100.0%; Score 9; DB 23; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.4e+04; Mismatches 0; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TAGGAGGAT 9

Wed Jun 4 11:08:12 2003

us-09-540-843-2.szlm40.rng

Page 8

|||||||
Db 11 TAGGAGAT 3

Search completed: June 2, 2003, 18:45:10
Job time : 151.566 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:29:55 ; Search time 1129.39 seconds
(without alignments)
129,060 Million cell updates/sec

Title: US-09-540-843-2

Perfect score: 9

Sequence: 1 tagaggagat 9

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 60474

Minimum DB seq length: 0

Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

ESR:*
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estinu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hic:*
9: gb_estl:*
10: gb_est2:*
11: gb_hic:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: gb_gss:*
18: em_gss_hum:*
19: em_gss_inv:*
20: em_gss_pln:*
21: em_gss_vrt:*
22: em_gss_fun:*
23: em_gss_mam:*
24: em_gss_mus:*
25: em_gss_other:*
26: em_gss_pro:*
27: em_gss_rtd:*

Pred. NO. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	100.0	35	17	AZ454138 IM0256A01
2	100.0	40	9	AA912717 01A1A03.S
3	88.9	19	17	AZ500675 IM0339J10
4	88.9	20	17	AZ393773 IM0157B04
5	88.9	21	17	AZ387199 IM0146P20
6	88.9	21	17	AZ645664 IM0511C13

7	88.9	22	9	AT631347
8	88.9	22	17	AZ411934
9	88.9	23	17	AZ822831
10	88.9	24	13	BG925475
11	88.9	24	17	AZ503909
12	88.9	24	17	BH789331
13	88.9	25	17	AZ491057
14	88.9	25	17	AZ496986
15	88.9	28	17	AZ480483
16	88.9	28	17	AZ799431
17	88.9	29	14	N22525
18	88.9	29	17	AZ759923
19	88.9	29	17	TAGH120
20	88.9	30	17	AZ312621
21	88.9	30	17	AZ658025
22	88.9	30	17	AZ817062
23	88.9	31	9	A1583630
24	88.9	31	9	AA209595
25	88.9	31	17	AZ500072
26	88.9	31	17	AZ663905
27	88.9	32	13	BJ059143
28	88.9	32	17	AZ325144
29	88.9	33	17	AZ435186
30	88.9	33	17	AZ486766
31	88.9	33	17	BH856998
32	88.9	34	17	BH814333
33	88.9	35	14	H38132
34	88.9	35	17	BH848385
35	88.9	36	13	BJ048452
36	88.9	36	14	T67214
37	88.9	37	9	A1629177
38	88.9	37	17	BH023763
39	88.9	37	17	BH850593
40	88.9	38	14	R37318
41	88.9	38	17	AZ802603
42	88.9	38	17	AZ818796
43	88.9	38	17	AL758045
44	88.9	40	9	AA743356
45	88.9	40	9	AT273000

ALIGNMENTS

AT631347 tz83c04.x
AA411934 IM0185M09
AZ822831 ZM0096J21
BG925475 HNC5-1-C6
AZ503909 IM0343E24
BH789331 SALK_0190
AZ491057 IM0324I24
AZ496986 IM0333J09
AZ480483 IM0302J04
AZ799431 ZM0056I22
N22525 YW45609.s1
AZ759923 IM0553I10
AL451765 T. brucei
AZ312621 IM028C18
AZ658025 IM0534N04
AZ817062 ZM0086A12
A1583630 t174b05.x
AA209595 mw75d07.r
AZ500072 IM0338A14
AZ663905 IM0543I17
BJ059143 BJ059143
AZ325144 IM0047J22
AZ435186 IM0222E03
AZ486766 IM0315H10
BH856998 SALK_0774
BH814333 SALK_0662
H38132 yp46e11.r1
BH848385 SALK_0680
BJ048452 BJ048452
T67214 ya53d11.r4
A1629177 f1c04e06.y
BH023763 BG02168-5
BH850593 SALK_0715
R37318 yf56b07.s1
AZ802603 ZM0061L06
AZ818796 ZM0089I06
AL758045 Arabidops
AA743356 ny18c01.s
AT273000 qv63e07.x

RESULT 1
AZ454138
LOCUS
DEFINITION
1M0256A01F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0256A01 F, DNA sequence.
AZ454138
ACCESSION
AZ454138.1 GI:10612263
VERSION
KEYWORDS
SOURCE
ORGANISM
house mouse.
Mus musculus
REFERENCE
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 35)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Rellly
M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A.
and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah
Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunne@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

JOURNAL
COMMENT

Plate: 0256 row: A column: 01
 Seq primer: CGTGTAAACGACGCCACT
 Class: plasmid ends
 High quality sequence stop: 35.
 Location/Qualifiers

FEATURES

source

1..35
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0256A01"
 /clone_1lb="Mouse 10kb plasmid UUGC1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMDA2 (g147321149b) (API29072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT

7 a 1 c 20 g 7 t

ORIGIN

Query Match 100.0%; Score 9; DB 17; Length 35;
 Best Local Similarity 100.0%; Pred. No. 1.2e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
 |||||
 Db 6 TAGGAGGAT 14

RESULT 2

AA912717 40 bp mRNA linear EST 26-AUG-1998
 LOCUS O141a03.s1 Soares_NFL_T_GBC-ST Homo sapiens cDNA clone
 DEFINITION IMAGE:1525996 3' similar to SW:BI3_MOUSE P28662 BRAIN PROTEIN I3 ;
 mRNA sequence.

ACCESSION

AA912717
 VERSION AA912717.1 GI:3052109
 EST.

KEYWORDS

human.

ORGANISM

Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE

1 (bases 1 to 40)
 NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 Unpublished (1997)
 Contact: Robert Strausberg, Ph.D.
 Email: cgapbs-remail.nih.gov

JOURNAL

Comment: This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.lnl.gov) for further information.
 Trace considered overall poor quality
 Insert Length: 449 Std Error: 0.00
 Seq primer: -40m13 fwd. ET from Amerham
 High quality sequence stop: 1.
 Location/Qualifiers

FEATURES

1..40
 /organism="Homo sapiens"

source

1..40
 /organism="Homo sapiens"

FEATURES

1..19
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0339J10"
 /clone_1lb="Mouse 10kb plasmid UUGC1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

BASE COUNT

8 a 10 c 10 g 12 t

ORIGIN

Query Match 100.0%; Score 9; DB 9; Length 40;
 Best Local Similarity 100.0%; Pred. No. 1.3e+05;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
 |||||
 Db 24 TAGGAGGAT 32

RESULT 3

AZ500675 19 bp DNA linear GSS 05-OCT-2000
 LOCUS IM0339J10F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 DEFINITION clone UUGC1M0339J10 F. DNA sequence.
 ACCESSION AZ500675
 VERSION AZ500675.1 GI:10680728
 KEYWORDS GSS.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

1 (bases 1 to 19)
 Dunn,D., Aoyagi,A., Barber,M., Beacom,T., Duval,B., Hamli,C.,
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Rellly
 'M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausen,A.
 and Wright,D., Weiss,R.
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts
 Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah
 University of Utah Genome Center
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0339 row: J column: 10
 Seq primer: CGTGTAAACGACGCCACT
 Class: plasmid ends
 High quality sequence stop: 19.
 Location/Qualifiers

FEATURES

1..19
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0339J10"
 /clone_1lb="Mouse 10kb plasmid UUGC1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

source

1..19
 /organism="Mus musculus"

(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g11473211419b1AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance.

BASE COUNT
ORIGIN
4 a 0 c 9 g 6 t

Query Match 88.9%; Score 8; DB 17; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGCA 8
Db 11 TAGGAGCA 18

RESULT 4
A2393773/c 20 bp DNA linear GSS 03-OCT-2000
LOCUS 1M0157B04F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0157B04 F, DNA sequence.
ACCESSION A2393773
VERSION A2393773.1 GI:10508845
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 20)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
'M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0157 row: B column: 04
Seq primer: CATTGTAAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 20.

FEATURES

source location/Qualifiers
1. 20
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0157B04"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pMD42ny; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g11473211419b1AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance.

BASE COUNT
ORIGIN
2 a 11 c 1 g 6 t

Query Match 88.9%; Score 8; DB 17; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.1e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 AGGAGGAT 9
Db 20 AGGAGGAT 13

RESULT 5
A2387199/c 21 bp DNA linear GSS 02-OCT-2000
LOCUS 1M0146P20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0146P20 R, DNA sequence.
ACCESSION A2387199
VERSION A2387199.1 GI:10500900
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 21)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
'M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0146 row: P column: 20
Seq primer: CACACAGAAACGCTATGACC
Class: plasmid ends
High quality sequence stop: 21.

FEATURES

source location/Qualifiers
1. 21
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0146P20"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pMD42ny; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g1147321149b1AF129072.1), a copy-number inducible derivative of plasmid RL. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance.

BASE COUNT
ORIGIN
3 a 13 c 0 g 5 t

Query Match
Best Local Similarity 100.0%; Score 8; DB 17; Length 21;
Pred. No. 4.2e+05; Mismatches 0; Indels 0; Gaps 0;
Matches 8; Conservative 0;

OY 1 TAGGAGGA 8
11111111
Db 15 TAGGAGGA 8

RESULT 6
A2645664 21 bp DNA linear GSS 14-DEC-2000
LOCUS A2645664
DEFINITION 1M0511C13F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0511C13 F, DNA sequence.

ACCESSION A2645664.1 GI:11775376
VERSION
KEYWORDS
SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE
AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamli, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausen, A. and Wright, D., Weiss, R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0511 row: C column: 13
Seq primer: CGTGTAAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 21.

FEATURES
source
Location/Qualifiers
1..21

/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0511C13"
/clone_1lb="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g1147321149b1AF129072.1), a copy-number inducible derivative of plasmid RL. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance.

BASE COUNT
ORIGIN
2 a 9 c 0 g 10 t

Query Match
Best Local Similarity 100.0%; Score 8; DB 17; Length 21;
Pred. No. 4.2e+05; Mismatches 0; Indels 0; Gaps 0;
Matches 8; Conservative 0;

OY 1 TAGGAGGA 8
11111111
Db 8 TAGGAGGA 1

RESULT 7
A1631347 22 bp mRNA linear EST 16-DEC-1999
LOCUS A1631347
DEFINITION t283c04.x1 NCI-CGAP_Pan1 Homo sapiens cDNA clone IMAGE:2295174 3'
similar to SW:PRP2.HUMAN P02812 SALIVARY PROLINE-RICH PROTEIN
PRECURSOR: contains element MER22 repetitive element ;, mRNA
sequence.

ACCESSION A1631347
VERSION A1631347.1 GI:4682677
KEYWORDS
SOURCE EST.
ORGANISM human.

REFERENCE
AUTHORS Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgaps-remail.nih.gov
Life Technologies catalog #: 11548-013
DNA Sequencing by: Washington University Genome Sequencing Center
clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/bdrp/image/image.html

Trace considered overall poor quality
Insert Length: 1010 Std Error: 0.00
Seq primer: -40UP from Glbco
High quality sequence stop: 1.
Location/Qualifiers
1..22

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2295174"
/clone_1lb="NCI-CGAP_Pan1"
/tissue_type="adenocarcinoma"
/lab_host="DH10B"
/note="Organ: pancreas; Vector: pCMV-Sport6; Site: 1; Salt; Site: 2; Note: Cloned unidirectionally. Primer: Oligo dT.
Average insert size 1.72 kb. Life Technologies catalog #: 11548-013"

BASE COUNT
ORIGIN
6 a 9 c 5 g 2 t

Query Match 88.9%; Score 8; DB 9; Length 22;
 Best Local Similarity 100.0%; Pred. No. 4.2e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGCA 8
 |||||
 12 TAGGAGCA 19

RESULT 8
 AZ411934/c 22 bp DNA linear GSS 03-OCT-2000
 LOCUS 1M0185M09F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 DEFINITION
 AZ411934
 accession clone UUGC1M0185M09 F, DNA sequence.
 VERSION
 AZ411934.1 GI:10535947
 KEYWORDS
 SOURCE GSS.
 ORGANISM house mouse.
 Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 22)
 Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
 Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly,
 M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A.
 and Wright, D., Weiss, R.
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts
 Unpublished (2000)
 JOURNAL
 COMMENT Contact: Robert B. Weiss
 University of Utah Genome Center
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0185 row: M column: 09
 Seq primer: CGTTGTAAACGACGCCACT
 Class: plasmid ends
 High quality sequence stop: 22.
 Location/Qualifiers
 1..22
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0185M09"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
 /note="Vector: PMD42nv; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 adaptor DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of PMD42 (g114732114[gb]/AF129072.1), a copy-number
 inducible derivative of plasmid R1. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells
 and selected for ampicillin resistance."

BASE COUNT
 ORIGIN

2 a 8 c 5 g 7 t

Query Match 88.9%; Score 8; DB 17; Length 22;
 Best Local Similarity 100.0%; Pred. No. 4.2e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGGAGCAT 9
 |||||
 9 AGGAGCAT 2

RESULT 9
 A2822831/c 23 bp DNA linear GSS 20-FEB-2001
 LOCUS 2M0096J21F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 DEFINITION
 clone UUGC2M0096J21 F, DNA sequence.
 accession A2822831
 version A2822831.1 GI:12992739
 keywords
 source GSS.
 organism house mouse.
 Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 23)
 Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
 Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly,
 M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A.
 and Wright, D., Weiss, R.
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts
 Unpublished (2000)
 JOURNAL
 COMMENT Contact: Robert B. Weiss
 University of Utah Genome Center
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0096 row: J column: 21
 Seq primer: CGTTGTAAACGACGCCACT
 Class: plasmid ends
 High quality sequence stop: 23.
 Location/Qualifiers
 1..23
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC2M0096J21"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
 /note="Vector: PMD42nv; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 adaptor DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of PMD42 (g114732114[gb]/AF129072.1), a copy-number
 inducible derivative of plasmid R1. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells
 and selected for ampicillin resistance."

BASE COUNT
 ORIGIN

7 a 5 c 6 g 5 t

Query Match 88.9%; Score 8; DB 17; Length 23;
 Best Local Similarity 100.0%; Pred. No. 4.3e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGA 8
 |||||
 14 TAGGAGGA 7

Db 14 TAGGAGGA 7

RESULT 10
 BG925475/c 24 bp mRNA linear EST 06-NOV-2001
 LOCUS HNC5-1-C6.R HNC (Human Normal Cartilage) Homo sapiens cDNA, mRNA
 DEFINITION
 BG925475
 ACCESSION
 VERSION BG925475.1 GI:14319998
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 24)
 Kumar, S., Connor, J.R., Dodds, R.A., Halsey, W., Van Horn, M., Mao, J.,
 Sathe, G., Mul, P., Agarwal, P., Badger, A.M., Lee, J.C., Gowen, M. and
 Latk, M.W.
 Identification and initial characterization of 5000 expressed
 sequenced tags (ESTs) each from adult human normal and
 osteoarthritic cartilage cDNA libraries
 Osteoarthr. Cartil. 9 (7), 641-653 (2001)
 21482651
 JOURNAL
 MEDLINE
 COMMENT Contact: Sanjay Kumar
 DM2109
 GlascoSmithKline
 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406, USA
 Tel: 610-270-7245
 Fax: 610-270-5598
 Email: sanjay_kumar-1@sk.com
 Seq primer: 17.

FEATURES
 source
 1..24
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_lib="HNC (Human Normal Cartilage)"
 /tissue_type="cartilage"
 /lab_host="E.coli DH10 B"
 /note="Vector: pSPORT 1; Site_1: SalI; Site_2: NotI;
 Directional"

BASE COUNT 4 a 9 c 1 g 10 t

ORIGIN

Query Match 88.9%; Score 8; DB 13; Length 24;
 Best Local Similarity 100.0%; Pred. No. 4.3e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2 AGGAGGAT 9
 |||||
 11 AGGAGGAT 4

Db 11 AGGAGGAT 4

RESULT 11
 AZ503909 24 bp DNA linear GSS 05-OCT-2000
 LOCUS 1M0343E24R Mouse 10kb plasmid UUC1M library Mus musculus genomic
 DEFINITION
 AZ503909
 ACCESSION
 VERSION AZ503909.1 GI:10685225
 KEYWORDS
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 24)

AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
 Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly,
 M., Rose, M., Rose, R., Stokes, R., Tinger, A., von Niederhausen, A.
 and Wright, D., Weiss, R.
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts
 Unpublished (2000)
 JOURNAL
 COMMENT Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunne@genetics.utah.edu
 Insert length: 10000 Std Error: 0.00
 Plate: 0343 row: E column: 24
 Seq primer: CACACAGGAACACGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 24.

FEATURES
 source
 1..24
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone_lib="UUC1M0343E24"
 /clone_lib="Mouse 10kb plasmid UUC1M library"
 /sex="Male"
 /lab_host="E. coli strain XL10-Gold, Ti-resistant, F-"
 /note="Vector: PMD42ny; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 ligated DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of pMD42 (g14732114[gb/AP129072.1]), a copy-number
 inducible derivative of plasmid R1. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells
 and selected for ampicillin resistance."

BASE COUNT 4 a 3 c 9 g 8 t

ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 24;
 Best Local Similarity 100.0%; Pred. No. 4.3e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGA 8
 |||||
 7 TAGGAGGA 14

Db 7 TAGGAGGA 14

RESULT 12
 BH789331/c 24 bp DNA linear GSS 02-APR-2002
 LOCUS BH789331
 DEFINITION SALK_019058.23.05.x Arabidopsis thaliana TDM insertion lines
 Arabidopsis thaliana genomic clone SALK_019058.23.05.x, DNA
 sequence.
 BH789331
 ACCESSION
 VERSION BH789331.1 GI:19882429
 KEYWORDS
 SOURCE thale cress.
 ORGANISM Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

REFERENCE Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1 (bases 1 to 24)
AUTHORS Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrinab
, C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P.
, Zimmerman,J. and Ecker,J.R.
TITLE A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis Genome
JOURNAL Unpublished (2001)
COMMENT Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGNAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of
TDNA.
Class: TDNA tagged.
FEATURES
Location/Qualifiers
1..24
/organism="Arabidopsis thaliana"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="SALK_019058.23.05.x"
/clone_lib="Arabidopsis thaliana TDNA insertion lines"
/note="PCR was performed on Arabidopsis thaliana lines
each of which contains one or more TDNA insertion
elements. The resultant fragment for each line was
directly sequenced to determine the genomic sequence at
the site of insertion. Details of the protocols used can
be found at http://signal.salk.edu/tdna_protocols.html"
BASE COUNT 2 a 14 c 0 g 8 t
ORIGIN
Query Match 88.9%; Score 8; DB 17; Length 24;
Best Local Similarity 100.0%; Pred. No. 4.3e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2 AGGAGGAT 9
|||||||
Db 8 AGGAGGAT 1
RESULT 13
AZ491057 25 bp DNA linear GSS 05-OCT-2000
LOCUS IM0324124F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0324124 F, DNA sequence.
ACCESSION AZ491057
VERSION AZ491057.1 GI:10662392
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 25)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
, M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0324 row: I column: 24

Seq primer: CGTTGTAACAGCGCCAGT
Class: plasmid ends
High quality sequence stop: 25.
Location/Qualifiers
1..25
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0324124"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Fl-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(<http://www.jax.org/resources/documents/dnares/>). The DNA
was hydridynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD42 (g114732114[gb|AF129072.1]), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
BASE COUNT 7 a 4 c 12 g 2 t
ORIGIN
Query Match 88.9%; Score 8; DB 17; Length 25;
Best Local Similarity 100.0%; Pred. No. 4.4e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2 AGGAGGAT 9
|||||||
Db 9 AGGAGGAT 16
RESULT 14
AZ496986 25 bp DNA linear GSS 05-OCT-2000
LOCUS AZ496986
DEFINITION IM03333H09R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M03333H09 R, DNA sequence.
ACCESSION AZ496986
VERSION AZ496986.1 GI:10673556
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 25)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
, M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0333 row: H column: 09

Seq primer: CACACAGGAAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 25.
 Location/Qualifiers
 1..25
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUCGIM033H09"
 /clone_1lb="Mouse 10kb plasmid UUCGIM library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g114732114[gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 12 a 1 c 10 g 2 t
 ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 25;
 Best Local Similarity 100.0%; Pred. No. 4.4e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGA 8
 |||||||
 DB 17 TAGGAGGA 24

RESULT 15 AZ480483 28 bp DNA linear GSS 04-OCT-2000
 LOCUS 1M030204F Mouse 10kb plasmid UUCGIM library Mus musculus genomic
 DEFINITION clone UUCGIM030204 F, DNA sequence.
 ACCESSION AZ480483
 VERSION AZ480483.1 GI:10641548
 KEYWORDS GSS.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 28)
 Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Stokes,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.
 Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std. Error: 0.00
 Plate: 0302 Row: J Column: 04

Seq primer: CCGTGTAAACGACGCCAGT
 Class: plasmid ends
 High quality sequence stop: 28.
 Location/Qualifiers
 1..28
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUCGIM0302J04"
 /clone_1lb="Mouse 10kb plasmid UUCGIM library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g114732114[gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 4 a 11 c 6 g 7 t
 ORIGIN

Query Match 88.9%; Score 8; DB 17; Length 28;
 Best Local Similarity 100.0%; Pred. No. 4.5e+05;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGA 8
 |||||||
 DB 13 TAGGAGGA 6

Search completed: June 2, 2003, 20:35:37
 Job time: 1133.39 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:31:20 ; Search time 36.878 Seconds
(Without alignments)
74.844 Million cell updates/sec

Title: US-09-540-843-2

Perfect score: 9

Sequence: 1 tagaggagat 9

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 15338381 residues

Total number of hits satisfying chosen parameters: 558892

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

Issued_Patents_MN:*
1: /cgn2_6/ptodata1/1na/5A_COMB.seq:*
2: /cgn2_6/ptodata1/1na/5B_COMB.seq:*
3: /cgn2_6/ptodata1/1na/6A_COMB.seq:*
4: /cgn2_6/ptodata1/1na/6B_COMB.seq:*
5: /cgn2_6/ptodata1/1na/PCTUS_COMB.seq:*
6: /cgn2_6/ptodata1/1na/Backfile1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	9	100.0	9	3	US-09-048-927-2	Sequence 2, Appl1
2	9	100.0	20	4	US-09-096-172-6	Sequence 6, Appl1
3	9	100.0	22	4	US-09-240-918-9	Sequence 9, Appl1
4	9	100.0	24	4	US-09-416-050A-15	Sequence 15, Appl1
5	9	100.0	24	4	US-09-664-800-15	Sequence 15, Appl1
6	9	100.0	24	4	US-09-665-309-15	Sequence 15, Appl1
7	9	100.0	24	4	US-09-661-569-15	Sequence 15, Appl1
8	9	100.0	28	4	US-09-661-768A-33	Sequence 33, Appl1
9	9	100.0	29	1	US-08-310-356-20	Sequence 20, Appl1
10	9	100.0	30	4	US-09-019-793A-105	Sequence 105, Appl1
11	9	100.0	33	2	US-08-189-256A-46	Sequence 46, Appl1
12	9	100.0	33	4	US-09-193-853-46	Sequence 46, Appl1
13	9	100.0	36	5	PCT-US95-00605-12	Sequence 12, Appl1
14	9	100.0	36	5	PCT-US95-00605-13	Sequence 13, Appl1
15	8	88.9	12	3	US-09-290-449-15	Sequence 15, Appl1
16	8	88.9	15	1	US-08-182-968A-168	Sequence 168, Appl1
17	8	88.9	15	1	US-08-182-968A-169	Sequence 169, Appl1
18	8	88.9	15	2	US-08-774-306A-168	Sequence 168, Appl1
19	8	88.9	15	2	US-08-774-306A-169	Sequence 169, Appl1
20	8	88.9	15	3	US-09-105-515-4	Sequence 4, Appl1
21	8	88.9	15	3	US-09-064-156A-168	Sequence 168, Appl1
22	8	88.9	15	3	US-09-064-156A-169	Sequence 169, Appl1
23	8	88.9	15	4	US-09-748-044-4	Sequence 4, Appl1
24	8	88.9	16	1	US-07-664-989B-100	Sequence 100, Appl1
25	8	88.9	16	1	US-07-664-989B-101	Sequence 101, Appl1
26	8	88.9	16	2	US-08-282-197C-20	Sequence 20, Appl1
27	8	88.9	17	1	US-08-184-422-4	Sequence 4, Appl1

c 28	8	88.9	17	1	US-08-758-306-1307	Sequence 1307, Ap
c 29	8	88.9	17	1	US-08-758-306-1309	Sequence 1309, Ap
c 30	8	88.9	17	1	US-08-758-306-1311	Sequence 1311, Ap
c 31	8	88.9	17	3	US-08-589-771B-4	Sequence 4, Appl1
c 32	8	88.9	17	3	US-08-606-505B-45	Sequence 45, Appl1
c 33	8	88.9	17	4	US-09-616-990-45	Sequence 45, Appl1
c 34	8	88.9	17	4	US-08-584-040-1958	Sequence 1958, Ap
c 35	8	88.9	18	1	US-08-135-511-12	Sequence 12, Appl1
c 36	8	88.9	18	1	US-08-319-492B-735	Sequence 735, App
c 37	8	88.9	18	1	US-08-320-558-9	Sequence 9, Appl1
c 38	8	88.9	18	1	US-08-327-392-9	Sequence 9, Appl1
c 39	8	88.9	18	1	US-08-187-453-12	Sequence 12, Appl1
c 40	8	88.9	18	1	US-08-758-306-1379	Sequence 1379, Ap
c 41	8	88.9	18	1	US-08-207-412B-7	Sequence 7, Appl1
c 42	8	88.9	18	3	US-08-545-860D-9	Sequence 9, Appl1
c 43	8	88.9	18	3	US-08-912-272-87	Sequence 87, Appl1
c 44	8	88.9	18	4	US-09-050-158-26	Sequence 26, Appl1
c 45	8	88.9	18	4	US-09-071-433-79	Sequence 79, Appl1

ALIGNMENTS

```

RESULT 1
US-09-048-927-2
; Sequence 2, Application US/09048927
; Patent No. 6147056
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Use of locally Applied DNA Fragments
; FILE REFERENCE: BU94-68A2
; CURRENT APPLICATION NUMBER: US/09/048, 927
; EARLIER FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 08/952, 697
; EARLIER FILING DATE: 1996-06-03
; EARLIER APPLICATION NUMBER: 08/467, 012
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA Fragment
US-09-048-927-2

Query Match          100.0%; Score 9; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 TAGGAGGAT 9
DB      1 TAGGAGGAT 9

RESULT 2
US-09-096-172-6
; Sequence 6, Application US/09096172
; Patent No. 6284252
; GENERAL INFORMATION:
; APPLICANT: MEHTALI, Majid
; APPLICANT: SORG, Tania
; TITLE OF INVENTION: NEW TRANSDOMINANT TAT VARIANTS OF THE
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Burns, Doane, Swecker & Mathis
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia

```

```
COUNTRY: United States
ZIP: 22313-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/096,172
FILING DATE:
CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/08/177,145
FILING DATE: 04-JAN-1994
APPLICATION NUMBER: FR 93 00004
FILING DATE: 04-JAN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Crane-Feury, Sharon E
REGISTRATION NUMBER: 36,113
REFERENCE/DOCKET NUMBER: 017753-040
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: YES
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: mutagenesis oligonucleotide (TAT
US-09-096-172-6

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
DB 5 TAGGAGGAT 13

RESULT 3
US-09-240-918-9
Sequence 9, Application US/09240918
Patent No. 6265165
GENERAL INFORMATION:
APPLICANT: Gruenert, Dieter C.
APPLICANT: Xu, Zhidong
TITLE OF INVENTION: METHODS FOR EST-SPECIFIC FULL LENGTH cDNA CLONING
FILE REFERENCE: 480.85.1(HV)
CURRENT APPLICATION NUMBER: US/09/240,918
CURRENT FILING DATE: 1999-01-29
PRIOR APPLICATION NUMBER: 60/108,183
PRIOR FILING DATE: 1998-11-12
NUMBER OF SEQ ID NOS: 96
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 9
LENGTH: 22
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-240-918-9

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 22;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 TAGGAGGAT 9
DB 9 TAGGAGGAT 17

RESULT 4
US-09-416-050A-15/c
Sequence 15, Application US/09416050A
Patent No. 6194559
GENERAL INFORMATION:
APPLICANT: Kim, Soo Young
TITLE OF INVENTION: Abscisic Acid Responsive Element -Binding Transcription Fac
FILE REFERENCE: 1942/42
CURRENT APPLICATION NUMBER: US/09/416,050A
CURRENT FILING DATE: 1999-10-12
NUMBER OF SEQ ID NOS: 83
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 15
LENGTH: 24
TYPE: DNA
ORGANISM: Arabidopsis thaliana
US-09-416-050A-15

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 24;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
DB 17 TAGGAGGAT 9

RESULT 5
US-09-664-800-15/c
Sequence 15, Application US/09664800
Patent No. 6218527
GENERAL INFORMATION:
APPLICANT: Kim, Soo Young
TITLE OF INVENTION: Abscisic Acid Responsive Element -Binding Transcription Fac
FILE REFERENCE: 1942/42
CURRENT APPLICATION NUMBER: US/09/664,800
CURRENT FILING DATE: 2000-09-19
PRIOR APPLICATION NUMBER: 09/416,050
PRIOR FILING DATE: 1999-10-12
NUMBER OF SEQ ID NOS: 83
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 15
LENGTH: 24
TYPE: DNA
ORGANISM: Arabidopsis thaliana
US-09-664-800-15

Query Match
Best Local Similarity 100.0%; Score 9; DB 4; Length 24;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
DB 17 TAGGAGGAT 9

RESULT 6
US-09-665-309-15/c
Sequence 15, Application US/09665309
Patent No. 6232461
GENERAL INFORMATION:
APPLICANT: Kim, Soo Young
TITLE OF INVENTION: Abscisic Acid Responsive Element -Binding Transcription Fac
FILE REFERENCE: 1942/42
CURRENT APPLICATION NUMBER: US/09/665,309
CURRENT FILING DATE: 2000-09-19
PRIOR APPLICATION NUMBER: 09/416,050
PRIOR FILING DATE: 1999-10-12
```

NUMBER OF SEQ ID NOS: 83
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Arabidopsis thaliana
US-09-665-309-15

Query Match 100.0%; Score 9; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
17 TAGGAGGAT 9

RESULT 7

US-09-661-569-15/c
; Sequence 15, Application US/09661569
; Patent No. 6245905
; GENERAL INFORMATION:
; APPLICANT: KIM, Soo Young
; TITLE OF INVENTION: Abscisic Acid Responsive Element -Binding Transcription Factor
; FILE REFERENCE: 1942/42
; CURRENT APPLICATION NUMBER: US/09/661,569
; PRIOR FILING DATE: 2000-09-14
; PRIOR APPLICATION NUMBER: 09/416,050
; PRIOR FILING DATE: 1999-10-12
; NUMBER OF SEQ ID NOS: 83
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Arabidopsis thaliana
US-09-661-569-15

Query Match 100.0%; Score 9; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.9e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
17 TAGGAGGAT 9

RESULT 8

US-09-061-768A-33
; Sequence 33, Application US/09061768A
; Patent No. 6204037
; GENERAL INFORMATION:
; APPLICANT: BRASH, ALAN R.
; APPLICANT: BOEGLIN, WILLIAM E.
; APPLICANT: JISAKA, MITSUO
; TITLE OF INVENTION: LIPOXYGENASE PROTEINS AND NUCLEIC ACIDS
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: ARLES A. TAYLOR, JR.
; STREET: SUITE 1400, UNIVERSITY TOWER, 3100 TOWER BOULEVARD
; CITY: DURHAM
; STATE: NORTH CAROLINA
; COUNTRY: USA
; ZIP: 27707
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 Inch, 1.4 MB storage
; OPERATING SYSTEM: IBM PC/XT/AT compatible
; SOFTWARE: WORD PERFECT 6.1 and ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/061,768A
; FILING DATE: APRIL 16, 1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: NONE

APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: ARLES A. TAYLOR, JR.
; REGISTRATION NUMBER: 39,395
; REFERENCE/DOCKET NUMBER: 1242/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919) 493-8000
; TELEFAX: (919) 419-0383
; TELEX:
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 28 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-061-768A-33

Query Match 100.0%; Score 9; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
7 TAGGAGGAT 15

RESULT 9

US-08-310-356-20/c
; Sequence 20, Application US/08310356
; Patent No. 5648243
; GENERAL INFORMATION:
; APPLICANT: Hurwitz, David R
; APPLICANT: Nathan, Margret
; APPLICANT: Shani, Moshe
; TITLE OF INVENTION: Transgenic Protein Production
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Rhone-Poulenc Rorer Legal Department
; STREET: 500 Arcola Road
; CITY: Collegeville
; STATE: PA
; COUNTRY: USA
; ZIP: 19426
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Macintosh
; OPERATING SYSTEM: Macintosh System 7.0
; SOFTWARE: Microsoft Word Version 5.0 (PatentIn)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/310,356
; FILING DATE:
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/737,853
; FILING DATE: 31-JUL-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Goodman, Rosanne
; REGISTRATION NUMBER: 32,534
; REFERENCE/DOCKET NUMBER: A0856
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 454-3817
; TELEFAX: (215) 454-3808
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 29 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-310-356-20

Query Match 100.0%; Score 9; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 2e+03;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TAGGAGGAT 9
 |||||||
 Db 23 TAGGAGGAT 15

RESULT 10
 US-09-019-793A-105/c
 ; Sequence 105, Application US/09019793A
 ; Patent No. 6380376
 ; GENERAL INFORMATION:
 ; APPLICANT: PAUL, Prem
 ; APPLICANT: MENG, Xiang-jin
 ; APPLICANT: MOROZOV, Igor
 ; APPLICANT: HALBUR, Patrick
 ; TITLE OF INVENTION: PROTEINS ENCODED BY POLYNUCLEIC ACIDS OF PORCINE
 ; TITLE OF INVENTION: REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV)
 ; FILE REFERENCE: 4625-0039-55X CIP
 ; CURRENT APPLICATION NUMBER: US/09/019,793A
 ; CURRENT FILING DATE: 1998-02-06
 ; PRIOR APPLICATION NUMBER: 08/478,316
 ; PRIOR FILING DATE: 1995-06-07
 ; PRIOR APPLICATION NUMBER: 08/301,435
 ; PRIOR FILING DATE: 1994-09-01
 ; PRIOR APPLICATION NUMBER: 08/131,625
 ; PRIOR FILING DATE: 1993-10-05
 ; PRIOR APPLICATION NUMBER: 07/969,071
 ; PRIOR FILING DATE: 1992-10-30
 ; NUMBER OF SEQ ID NOS: 108
 ; SOFTWARE: Patentln. Ver. 2.1
 ; SEQ ID NO: 105
 ; LENGTH: 30
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: synthetic DNA
 US-09-019-793A-105

Query Match 100.0%; Score 9; DB 4; Length 30;
 Best Local Similarity 100.0%; Pred. No. 2e+03; 0; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TAGGAGGAT 9
 |||||||
 Db 15 TAGGAGGAT 7

RESULT 11
 US-08-189-256A-46/c
 ; Sequence 46, Application US/08189256A
 ; Patent No. 5877402
 ; GENERAL INFORMATION:
 ; APPLICANT: Maliga, Pal
 ; APPLICANT: Svab, Zora
 ; APPLICANT: Staub, Jeffrey
 ; APPLICANT: Zoubenko, Oleg V.
 ; APPLICANT: Allison, Lori A.
 ; APPLICANT: Carter, Helaine
 ; APPLICANT: Kanevski, Ivan
 ; TITLE OF INVENTION: DNA Constructs and Methods for Stably
 ; TITLE OF INVENTION: Transforming Plasmids of Multicellular Plants and
 ; TITLE OF INVENTION: Expressing Recombinant Proteins Therein
 ; NUMBER OF SEQUENCES: 47
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Dann, Dorfman, Herrell and Skillman
 ; STREET: 1601 Market Street Suite 720
 ; CITY: Philadelphia
 ; STATE: PA
 ; COUNTRY: USA
 ; ZIP: 19103-2307
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patentln Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/189,256A
 ; FILING DATE: 31-JAN-1994
 ; CLASSIFICATION: 435
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/111,398
 ; FILING DATE: 25-AUG-1993
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 07/518,763
 ; FILING DATE: 01-MAY-1990
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Reed, Janet E.
 ; REGISTRATION NUMBER: 36,252
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (215) 563-4100
 ; TELEFAX: (215) 563-4044
 ; INFORMATION FOR SEQ ID NO: 46:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 33 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA (genomic)
 ; HYPOTHETICAL: NO
 ; ANTI-SENSE: NO
 ; US-08-189-256A-46

Query Match 100.0%; Score 9; DB 2; Length 33;
 Best Local Similarity 100.0%; Pred. No. 2e+03; 0; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TAGGAGGAT 9
 |||||||
 Db 27 TAGGAGGAT 19

RESULT 12
 US-09-193-853-46/c
 ; Sequence 46, Application US/09193853
 ; Patent No. 6386168
 ; GENERAL INFORMATION:
 ; APPLICANT: Maliga, Pal
 ; APPLICANT: Svab, Zora
 ; APPLICANT: Staub, Jeffrey
 ; APPLICANT: Zoubenko, Oleg V.
 ; APPLICANT: Allison, Lori A.
 ; APPLICANT: Carter, Helaine
 ; APPLICANT: Kanevski, Ivan
 ; TITLE OF INVENTION: DNA Constructs and Methods for Stably
 ; TITLE OF INVENTION: Transforming Plasmids of Multicellular Plants and
 ; TITLE OF INVENTION: Expressing Recombinant Proteins Therein
 ; NUMBER OF SEQUENCES: 47
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Dann, Dorfman, Herrell and Skillman
 ; STREET: 1601 Market Street Suite 720
 ; CITY: Philadelphia
 ; STATE: PA
 ; COUNTRY: USA
 ; ZIP: 19103-2307
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patentln Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/193,853
 ; FILING DATE:
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/189,256

;; FILING DATE:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/518,763
;; FILING DATE: 01-MAY-1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Reed, Janet E.
;; REGISTRATION NUMBER: 36,252
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (215) 563-4100
;; TELEFAX: (215) 563-4044
;; INFORMATION FOR SEQ ID NO: 46:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 33 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; HYPOTHEetical: NO
;; ANTI-SENSE: NO
US-09-193-853-46

Query Match 100.0%; Score 9; DB 4; Length 33;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 27 TAGGAGGAT 19

RESULT 13
PCT-US95-00605-12
Sequence 12, Application PC/TUS9500605
GENERAL INFORMATION:
APPLICANT: Lyle, Leon
APPLICANT: Thomas-Miller, Beth
TITLE OF INVENTION: THERAPEUTIC TREATMENT FOR INHIBITING
TITLE OF INVENTION: VASCULAR RESTENOSIS
NUMBER OF SEQUENCES: 23
CURRENT APPLICATION DATA:
CORRESPONDENCE ADDRESS:
ADDRESS: Mallinckrodt Medical, Inc.
STREET: 675 McDonnell Boulevard, P.O. Box 5840
CITY: St. Louis
STATE: Missouri
COUNTRY: USA
ZIP: 63134
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
APPLICATION NUMBER: PCT/US95/00605
FILING DATE: 13-JAN-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/182,917
FILING DATE: 14-JAN-1994
APPLICATION NUMBER: US 07/965,678
FILING DATE: 22-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: Vacca, Rita D.
REGISTRATION NUMBER: 33,624
REFERENCE/DOCKET NUMBER: 0783.2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 314-895-7215
TELEFAX: 314-895-2156
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

;; MOLECULE TYPE: RNA (genomic)
;; HYPOTHEtical: NO
;; ANTI-SENSE: YES
;; ORIGINAL SOURCE:
;; ORGANISM: Macrophage Inflammatory Protein-1 Beta
;; STRAIN: human
PCT-US95-00605-12

Query Match 100.0%; Score 9; DB 5; Length 36;
Best Local Similarity 77.8%; Pred. No. 2e+03;
Matches 7; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 2 UAGGAGGAT 10

RESULT 14
PCT-US95-00605-13
Sequence 13, Application PC/TUS9500605
GENERAL INFORMATION:
APPLICANT: Lyle, Leon
APPLICANT: Thomas-Miller, Beth
TITLE OF INVENTION: THERAPEUTIC TREATMENT FOR INHIBITING
TITLE OF INVENTION: VASCULAR RESTENOSIS
NUMBER OF SEQUENCES: 23
CURRENT APPLICATION DATA:
CORRESPONDENCE ADDRESS:
ADDRESS: Mallinckrodt Medical, Inc.
STREET: 675 McDonnell Boulevard, P.O. Box 5840
CITY: St. Louis
STATE: Missouri
COUNTRY: USA
ZIP: 63134
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
APPLICATION NUMBER: PCT/US95/00605
FILING DATE: 13-JAN-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/182,917
FILING DATE: 14-JAN-1994
APPLICATION NUMBER: US 07/965,678
FILING DATE: 22-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: Vacca, Rita D.
REGISTRATION NUMBER: 33,624
REFERENCE/DOCKET NUMBER: 0783.2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 314-895-7215
TELEFAX: 314-895-2156
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 36 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHEtical: NO
ANTI-SENSE: YES
ORIGINAL SOURCE:
ORGANISM: Macrophage Inflammatory Protein-1 Beta
STRAIN: human
PCT-US95-00605-13

Query Match 100.0%; Score 9; DB 5; Length 36;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9

Db 2 TAGGAGGAT 10

RESULT 15
US-09-290-449-15

; Sequence 15, Application US/09290449A

; Patent No. 6096505

; GENERAL INFORMATION:

; APPLICANT: SELBY, Mark

; APPLICANT: THHDIDM, Kent

; APPLICANT: DINH, Dino

; TITLE OF INVENTION: NONCLONING TECHNIQUE FOR EXPRESSING A GENE OF INTEREST

; FILE REFERENCE: 1448.002

; CURRENT APPLICATION NUMBER: US/09/290,449A

; CURRENT FILING DATE: 1999-04-13

; EARLIER APPLICATION NUMBER: US 60/081,777

; EARLIER FILING DATE: 1998-04-14

; NUMBER OF SEQ ID NOS: 20

; SOFTWARE: Patentln Ver. 2.0

; SEQ ID NO 15

; LENGTH: 12

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; NAME/KEY: CDS

; LOCATION: (1)..(12)

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Flexible Hinge

; OTHER INFORMATION: Sequence (Fig. 1)

; Patent No. 6096505

US-09-290-449-15

Query Match 88.9%; Score 8; DB 3; Length 12;
Best Local Similarity 100.0%; Pred. No. 8.5e+03;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGGAGGAT 9

Db 3 AGGAGGAT 10

Search completed: June 2, 2003, 20:38:32
Job time : 37.878 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 19:09:45 ; Search time 63.878 Seconds
(without alignments)
189.976 Million cell updates/sec

Title: US-09-540-843-2

Perfect score: 9

Sequence: 1 tagagagat 9

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 845702 seqs, 674182571 residues 477662

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 40

Post-processing:

Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	DB ID	Description
1	9	100.0	9	US-10-122-630-2
2	9	100.0	9	US-10-122-633-2
3	9	100.0	9	US-09-828-344-162
4	9	100.0	20	US-09-828-344-163
5	9	100.0	20	US-09-828-344-164
6	9	100.0	20	US-09-766-154-19
7	9	100.0	21	US-09-816-814-13
8	9	100.0	26	US-09-949-427-202
9	9	100.0	28	US-09-764-246-33
10	9	100.0	30	US-10-104-019-105
11	9	100.0	31	US-09-912-263-64
12	9	100.0	36	US-10-011-672-5
13	9	100.0	36	US-10-012-013-5
14	9	100.0	36	US-10-012-070A-5
15	9	88.9	10	US-10-055-713-67
16	9	88.9	10	US-09-990-186-1611
17	9	88.9	10	US-09-989-789-1611
18	8	88.9	15	US-10-287-919-1170
19	8	88.9	15	US-10-287-919-1205

c	20	8	88.9	15	10	US-09-504-231A-190	Sequence 190, App
c	21	8	88.9	15	10	US-09-504-231A-191	Sequence 191, App
c	22	8	88.9	15	10	US-09-274-553D-190	Sequence 190, App
c	23	8	88.9	15	10	US-09-274-553D-191	Sequence 191, App
c	24	8	88.9	16	9	US-10-287-919-1008	Sequence 1008, App
c	25	8	88.9	16	9	US-10-287-919-1009	Sequence 1009, App
c	26	8	88.9	16	10	US-09-781-988-100	Sequence 100, App
c	27	8	88.9	16	10	US-09-781-988-101	Sequence 101, App
c	28	8	88.9	17	9	US-10-060-830-246	Sequence 246, App
c	29	8	88.9	17	9	US-10-060-830-247	Sequence 247, App
c	30	8	88.9	17	9	US-10-060-830-248	Sequence 248, App
c	31	8	88.9	17	9	US-10-060-830-249	Sequence 249, App
c	32	8	88.9	17	9	US-10-060-830-250	Sequence 250, App
c	33	8	88.9	17	9	US-10-060-830-251	Sequence 251, App
c	34	8	88.9	17	9	US-10-060-830-252	Sequence 252, App
c	35	8	88.9	17	9	US-10-060-830-253	Sequence 253, App
c	36	8	88.9	17	9	US-10-060-830-254	Sequence 254, App
c	37	8	88.9	17	9	US-10-060-830-255	Sequence 255, App
c	38	8	88.9	17	9	US-09-780-164-394	Sequence 394, App
c	39	8	88.9	17	9	US-09-780-164-395	Sequence 395, App
c	40	8	88.9	17	9	US-09-780-164-396	Sequence 396, App
c	41	8	88.9	17	9	US-09-780-164-397	Sequence 397, App
c	42	8	88.9	17	9	US-09-780-164-398	Sequence 398, App
c	43	8	88.9	17	9	US-09-780-164-399	Sequence 399, App
c	44	8	88.9	17	9	US-09-780-164-400	Sequence 400, App
c	45	8	88.9	17	9	US-09-780-164-401	Sequence 401, App

ALIGNMENTS

RESULT 1
US-10-122-630-2
Sequence 2, Application US/10122630
Publication No. US20030032610A1
GENERAL INFORMATION:
APPLICANT: Gilchrist, Barbara A.
APPLICANT: Eller, Mark S.
TITLE OF INVENTION: Method to Inhibit Cell Growth Using
FILE REFERENCE: 0054, 1088-018
CURRENT FILING DATE: 2002-04-12
PRIOR APPLICATION NUMBER: US/10/122,630
PRIOR FILING DATE: 1995-06-06
PRIOR APPLICATION NUMBER: PCT/US96/08386
PRIOR FILING DATE: 1996-06-03
PRIOR APPLICATION NUMBER: US 09/048,927
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: US 09/540,843
PRIOR FILING DATE: 2000-03-31
PRIOR APPLICATION NUMBER: PCT/US01/10162
PRIOR FILING DATE: 2001-03-30
NUMBER OF SEQ ID NOS: 15
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-2

Query Match 100.0%; Score 9; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGAGAT 9
DB 1 TAGGAGAGAT 9

```
RESULT 2
US-10-122-633-2
; Sequence 2, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US/10/122,633
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-2

Query Match
Best Local Similarity 100.0%; Score 9; DB 9; Length 9;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 1 TAGGAGGAT 9

RESULT 3
US-09-828-344-162
; Sequence 162, Application US/09828344
; Publication No. US20030044979A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE I EXPRESSION
; FILE REFERENCE: RTS-0147
; CURRENT APPLICATION NUMBER: US/09/828,344
; CURRENT FILING DATE: 2001-04-06
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 162
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-828-344-162

Query Match
Best Local Similarity 100.0%; Score 9; DB 9; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 1 TAGGAGGAT 9

RESULT 4
US-09-828-344-163
; Sequence 163, Application US/09828344
; Publication No. US20030044979A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE I EXPRESSION
```

```
; FILE REFERENCE: RTS-0147
; CURRENT APPLICATION NUMBER: US/09/828,344
; CURRENT FILING DATE: 2001-04-06
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 163
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-828-344-163

Query Match
Best Local Similarity 100.0%; Score 9; DB 9; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 3 TAGGAGGAT 11

RESULT 5
US-09-828-344-164
; Sequence 164, Application US/09828344
; Publication No. US20030044979A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE I EXPRESSION
; FILE REFERENCE: RTS-0147
; CURRENT APPLICATION NUMBER: US/09/828,344
; CURRENT FILING DATE: 2001-04-06
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 164
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-828-344-164

Query Match
Best Local Similarity 100.0%; Score 9; DB 9; Length 20;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 4 TAGGAGGAT 12

RESULT 6
US-09-766-154-19
; Sequence 19, Application US/09766154
; Patent No. US20020010948A1
; GENERAL INFORMATION:
; APPLICANT: Patience, Clive
; TITLE OF INVENTION: Swine Defective for Transmission of Porcine Endogenous
; FILE REFERENCE: 61750-311
; CURRENT APPLICATION NUMBER: US/09/766,154
; CURRENT FILING DATE: 2001-01-19
; PRIOR APPLICATION NUMBER: U.S. 60/243695
; PRIOR FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: U.S. 60/182965
; PRIOR FILING DATE: 2000-02-16
; PRIOR APPLICATION NUMBER: U.S. 60/177003
; PRIOR FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```


FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
OTHER INFORMATION: sequence used in amplification of PERV-sequences.
US-09-766-154-19

Query Match 100.0%; Score 9; DB 10; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
|||||
DB 2 TAGGAGGAT 10

RESULT 7

US-09-816-814-13/C
Sequence 13, Application US/09816814
Publication No. US20030027136A1
GENERAL INFORMATION:
APPLICANT: Goronzy, Jorg J.
APPLICANT: Weyand, Cornelia M.
TITLE OF INVENTION: RHEUMATOID ARTHRITIS MARKERS
FILE REFERENCE: 07039-251001
CURRENT APPLICATION NUMBER: US/09/816, 814
CURRENT FILING DATE: 2001-03-23
NUMBER OF SEQ ID NOS: 23
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 13
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: primer for PCR
US-09-816-814-13

Query Match 100.0%; Score 9; DB 9; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.6e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
|||||
DB 15 TAGGAGGAT 7

RESULT 8

US-09-949-427-202
Sequence 202, Application US/09949427
Publication No. US20030054418A1
GENERAL INFORMATION:
APPLICANT: Bodnar, Jackie S.
APPLICANT: Castellani, Lawrence W.
APPLICANT: Chatterjee, Anubindo
APPLICANT: de Jong, Pieter
APPLICANT: Lusis, Aldons J.
APPLICANT: Ohmen, Jeff
APPLICANT: Ross, David
APPLICANT: Tafuri, Sherile
APPLICANT: Mu, Chenyan
TITLE OF INVENTION: Gene and Sequence Variation Associated with Cancer
FILE REFERENCE: 02810, 0014, NUS02
CURRENT APPLICATION NUMBER: US/09/949, 427
CURRENT FILING DATE: 2001-09-07
PRIOR APPLICATION NUMBER: 60/231,322
PRIOR FILING DATE: 2000-09-08
NUMBER OF SEQ ID NOS: 405
SOFTWARE: PatentIn version 3.1
SEQ ID NO 202
LENGTH: 26
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Primer
US-09-949-427-202

Query Match 100.0%; Score 9; DB 9; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
|||||
DB 6 TAGGAGGAT 14

RESULT 9

US-09-764-246-33
Sequence 33, Application US/09764246
Patent No. US20010046672A1
GENERAL INFORMATION:
APPLICANT: BRASH, ALAN R.
BOESLIN, WILLIAM E.
JISAKA, MITSUO
TITLE OF INVENTION: LIPOXYGENASE PROTEINS AND NUCLEIC ACIDS
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: ARLES A. TAYLOR, JR.
STREET: SUITE 1400, UNIVERSITY TOWER, 3100 TOWER BOULEVARD
CITY: DURHAM
STATE: NORTH CAROLINA
COUNTRY: USA
ZIP: 27707
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 Inch, 1.4 MB storage
COMPUTER: IBM PC/XT/AT compatible
OPERATING SYSTEM: Windows 3.1
SOFTWARE: WORD PERFECT 6.1 and ASCII
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/764, 246
FILING DATE: 17-Jan-2001
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: <Unknown>
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: ARLES A. TAYLOR, JR.
REGISTRATION NUMBER: 39,395
REFERENCE/DOCKET NUMBER: 1242/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (919) 493-8000
TELEFAX: (919) 419-0383
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 28 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-09-764-246-33

Query Match 100.0%; Score 9; DB 10; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
|||||
DB 7 TAGGAGGAT 15

RESULT 10

US-10-104-019-105/C
Sequence 105, Application US/10104019
Patent No. US20020168379A1
GENERAL INFORMATION:
APPLICANT: PAUL, Prem
APPLICANT: MENG, Xiang-jin
APPLICANT: MOROZOV, Igor

```
; APPLICANT: HALBOR, Patrick
; TITLE OF INVENTION: PROTEINS ENCODED BY POLYNUCLEIC ACIDS OF PORCINE
; FILE REFERENCE: 4625-0039-55X CIP
; CURRENT APPLICATION NUMBER: US/10/104,019
; CURRENT FILING DATE: 2002-03-25
; PRIOR APPLICATION NUMBER: 09/019,793
; PRIOR FILING DATE: 1998-02-06
; PRIOR APPLICATION NUMBER: 08/301,435
; PRIOR FILING DATE: 1994-09-01
; PRIOR APPLICATION NUMBER: 08/131,625
; PRIOR FILING DATE: 1993-10-05
; PRIOR APPLICATION NUMBER: 07/969,071
; PRIOR FILING DATE: 1992-10-30
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 105
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:synthetic DNA
US-10-104-019-105
```

```
Query Match          100.0%; Score 9; DB 9; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 TAGGAGGAT 9
        |||||||||
Db      15 TAGGAGGAT 7
```

```
RESULT 11
US-09-912-263-64/c
; Sequence 64, Application US/09912263
; Publication No. US20030039973A1
; GENERAL INFORMATION:
; APPLICANT: Gargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Lander, Eric S.
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: 2825.2017-001
; CURRENT APPLICATION NUMBER: US/09/912,263
; CURRENT FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: US 60/220,315
; PRIOR FILING DATE: 2000-07-24
; NUMBER OF SEQ ID NOS: 552
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 64
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-912-263-64
```

```
Query Match          100.0%; Score 9; DB 9; Length 31;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 TAGGAGGAT 9
        |||||||||
Db      31 TAGGAGGAT 23
```

```
RESULT 12
US-10-011-672-5/c
; Sequence 5, Application US/10011672
; Publication No. US20030049814A1
; GENERAL INFORMATION:
; APPLICANT: Hawkes, Timothy
; APPLICANT: Warner, Simon
; APPLICANT: Andrews, Christopher
; APPLICANT: Bachoo, Satvinder
```

```
; APPLICANT: Pickerill, Andrew
; TITLE OF INVENTION: HERBICIDE RESISTANT PLANTS
; FILE REFERENCE: 50489/UST
; CURRENT APPLICATION NUMBER: US/10/011,672
; CURRENT FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: PCT/GB00/01559
; PRIOR FILING DATE: 2000-04-20
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Primer
US-10-011-672-5
```

```
Query Match          100.0%; Score 9; DB 9; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 TAGGAGGAT 9
        |||||||||
Db      26 TAGGAGGAT 18
```

```
RESULT 13
US-10-012-013-5/c
; Sequence 5, Application US/10012013
; Publication No. US20030079246A1
; GENERAL INFORMATION:
; APPLICANT: Hawkes, Timothy
; APPLICANT: Warner, Simon
; APPLICANT: Andrews, Christopher
; APPLICANT: Bachoo, Satvinder
; APPLICANT: Pickerill, Andrew
; TITLE OF INVENTION: Herbicide Resistant Plants
; FILE REFERENCE: 50450/UST
; CURRENT APPLICATION NUMBER: US/10/012,013
; CURRENT FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: PCT/GB00/01572
; PRIOR FILING DATE: 2000-04-20
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer
US-10-012-013-5
```

```
Query Match          100.0%; Score 9; DB 9; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 TAGGAGGAT 9
        |||||||||
Db      26 TAGGAGGAT 18
```

```
RESULT 14
US-10-012-070A-5/c
; Sequence 5, Application US/10012070A
; Publication No. US20030077801A1
; GENERAL INFORMATION:
; APPLICANT: Hawkes, Timothy
; APPLICANT: Warner, Simon
; APPLICANT: Andrews, Christopher
; APPLICANT: Bachoo, Satvinder
; APPLICANT: Pickerill, Andrew
; TITLE OF INVENTION: Herbicide Resistant Plants
; FILE REFERENCE: 50490/UST
```

```

; CURRENT APPLICATION NUMBER: US/10/012,070A
; CURRENT FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: PCT/GB00/01573
; PRIOR FILING DATE: 2000-04-20
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer
US-10-012-070A-5

```

```

Query Match          100.0%; Score 9; DB 9; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.5e+04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 TAGGAGGAT 9
        |||||
Db      26 TAGGAGGAT 18

```

```

RESULT 15
US-10-055-713-67
; Sequence 67, Application US/10055713
; Publication No. US20030044957A1
; GENERAL INFORMATION:
; APPLICANT: JAMIESON, Andrew
; APPLICANT: LI, Guofu
; TITLE OF INVENTION: ZINC FINGER PROTEINS FOR DNA BINDING AND GENE
; TITLE OF INVENTION: REGULATION IN PLANTS
; FILE REFERENCE: 8325-0026 / S26-US1
; CURRENT APPLICATION NUMBER: US/10/055,713
; CURRENT FILING DATE: 2002-06-17
; PRIOR APPLICATION NUMBER: 60/263,445
; PRIOR FILING DATE: 2001-01-22
; PRIOR APPLICATION NUMBER: 60/290,716
; PRIOR FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 67
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: ZFP 9 target sequence
US-10-055-713-67

```

```

Query Match          88.9%; Score 8; DB 9; Length 10;
Best Local Similarity 100.0%; Pred. No. 7e+04;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      2 AGGAGGAT 9
        |||||
Db      2 AGGAGGAT 9

```

Search completed: June 2, 2003, 23:43:12
Job time : 64.8781 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:33:41 ; Search time 1862.56 Seconds
(without alignments)
121.490 Million cell updates/sec

Title: US-09-540-843-2
Perfect score: 9
Sequence: 1 taggagat 9

Scoring table: IDENTITY-NUC
Gapop 10.0 , Gapext 1.0

Searched: 24791104 seqs, 12571243825 residues
Total number of hits satisfying chosen parameters: 11746948

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

Pending-Patents_NA_Main:*

- 1: /cgn2_6/ptodata/1/pna/PCNUS.COMB.seq:*
- 2: /cgn2_6/ptodata/1/pna/US06.COMB.seq:*
- 3: /cgn2_6/ptodata/1/pna/US080.COMB.seq:*
- 4: /cgn2_6/ptodata/1/pna/US081.COMB.seq:*
- 5: /cgn2_6/ptodata/1/pna/US082.COMB.seq:*
- 6: /cgn2_6/ptodata/1/pna/US083.COMB.seq:*
- 7: /cgn2_6/ptodata/1/pna/US084.COMB.seq:*
- 8: /cgn2_6/ptodata/1/pna/US085.COMB.seq:*
- 9: /cgn2_6/ptodata/1/pna/US086.COMB.seq:*
- 10: /cgn2_6/ptodata/1/pna/US087.COMB.seq:*
- 11: /cgn2_6/ptodata/1/pna/US088.COMB.seq:*
- 12: /cgn2_6/ptodata/1/pna/US089.COMB.seq:*
- 13: /cgn2_6/ptodata/1/pna/US090.COMB.seq:*
- 14: /cgn2_6/ptodata/1/pna/US091.COMB.seq:*
- 15: /cgn2_6/ptodata/1/pna/US092.COMB.seq:*
- 16: /cgn2_6/ptodata/1/pna/US093.COMB.seq:*
- 17: /cgn2_6/ptodata/1/pna/US094.COMB.seq:*
- 18: /cgn2_6/ptodata/1/pna/US095.COMB.seq:*
- 19: /cgn2_6/ptodata/1/pna/US096.COMB.seq:*
- 20: /cgn2_6/ptodata/1/pna/US097.COMB.seq:*
- 21: /cgn2_6/ptodata/1/pna/US098.COMB.seq:*
- 22: /cgn2_6/ptodata/1/pna/US099.COMB.seq:*
- 23: /cgn2_6/ptodata/1/pna/US100.COMB.seq:*
- 24: /cgn2_6/ptodata/1/pna/US101.COMB.seq:*
- 25: /cgn2_6/ptodata/1/pna/US102.COMB.seq:*
- 26: /cgn2_6/ptodata/1/pna/US103.COMB.seq:*
- 27: /cgn2_6/ptodata/1/pna/US104.COMB.seq:*
- 28: /cgn2_6/ptodata/1/pna/US105.COMB.seq:*
- 29: /cgn2_6/ptodata/1/pna/US106.COMB.seq:*
- 30: /cgn2_6/ptodata/1/pna/US107.COMB.seq:*
- 31: /cgn2_6/ptodata/1/pna/US108.COMB.seq:*
- 32: /cgn2_6/ptodata/1/pna/US109.COMB.seq:*
- 33: /cgn2_6/ptodata/1/pna/US110.COMB.seq:*
- 34: /cgn2_6/ptodata/1/pna/US111.COMB.seq:*
- 35: /cgn2_6/ptodata/1/pna/US112.COMB.seq:*
- 36: /cgn2_6/ptodata/1/pna/US113.COMB.seq:*
- 37: /cgn2_6/ptodata/1/pna/US114.COMB.seq:*
- 38: /cgn2_6/ptodata/1/pna/US115.COMB.seq:*
- 39: /cgn2_6/ptodata/1/pna/US116.COMB.seq:*
- 40: /cgn2_6/ptodata/1/pna/US117.COMB.seq:*
- 41: /cgn2_6/ptodata/1/pna/US118.COMB.seq:*
- 42: /cgn2_6/ptodata/1/pna/US119.COMB.seq:*
- 43: /cgn2_6/ptodata/1/pna/US120.COMB.seq:*

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

```
22 9 100.0 20 30 US-09-766-154-19 Sequence 19, Appl
23 9 100.0 20 31 US-09-828-344-162 Sequence 162, App
24 9 100.0 20 31 US-09-828-344-163 Sequence 163, App
25 9 100.0 20 31 US-09-828-344-164 Sequence 164, App
26 9 100.0 20 38 US-10-006-191-104 Sequence 104, App
27 9 100.0 20 40 US-10-126-022-200 Sequence 200, App
28 9 100.0 21 18 US-09-422-978-9775 Sequence 9775, App
29 9 100.0 21 31 US-09-816-814-13 Sequence 13, Appl
30 9 100.0 22 3 US-07-598-420-16 Sequence 16, Appl
31 9 100.0 22 3 PCT-US97-02396-33 Sequence 33, Appl
32 9 100.0 23 8 US-08-472-801-1428 Sequence 1428, Ap
33 9 100.0 23 10 US-08-668-235-1428 Sequence 1428, Ap
34 9 100.0 23 24 US-09-634-306B-68219 Sequence 68219, A
35 9 100.0 23 38 US-10-027-632-68219 Sequence 68219, A
36 9 100.0 23 80 US-60-361-523-12 Sequence 12, Appl
37 9 100.0 23 80 US-60-361-523-13 Sequence 13, Appl
38 9 100.0 24 1 PCT-US00-20638-318 Sequence 318, App
39 9 100.0 25 17 US-09-396-196F-27660 Sequence 27660, A
40 9 100.0 25 17 US-09-396-196F-27631 Sequence 27631, A
41 9 100.0 25 17 US-09-396-196F-53922 Sequence 53922, A
42 9 100.0 25 17 US-09-396-196F-92449 Sequence 92449, A
43 9 100.0 25 17 US-09-396-196F-94038 Sequence 94038, A
44 9 100.0 25 17 US-09-396-196F-98060 Sequence 98060, A
45 9 100.0 25 17 US-09-396-196F-98061 Sequence 98061, A
```

ALIGNMENTS

```
RESULT 1
US-09-540-843-2
; Sequence 2, Application US/09540843
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Yaer, Mina
; TITLE OF INVENTION: USE OF LOCALLY APPLIED DNA FRAGMENTS
; FILE REFERENCE: 0054.1088-015
; CURRENT APPLICATION NUMBER: US/09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 08/952,697
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-09-540-843-2
```

```
Query Match 100.0%; Score 9; DB 21; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+09;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1 TAGGAGGAT 9
Db 1 TAGGAGGAT 9
```

```
RESULT 2
US-10-122-630-2
; Sequence 2, Application US/10122630
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaer, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
```

```
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-2
```

```
Query Match 100.0%; Score 9; DB 40; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+09;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1 TAGGAGGAT 9
Db 1 TAGGAGGAT 9
```

```
RESULT 3
US-10-122-633-2
; Sequence 2, Application US/10122633
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaer, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-2
```

```
Query Match 100.0%; Score 9; DB 40; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+09;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1 TAGGAGGAT 9
Db 1 TAGGAGGAT 9
```

```
RESULT 4
US-10-223-765-202
; Sequence 202, Application US/10223765
; GENERAL INFORMATION:
; APPLICANT: Kim, Jin-Soo
```

```
APPLICANT: Bae, Kwang-Hee
APPLICANT: Park, Kyung-Soon
APPLICANT: Kwon, Young Do
APPLICANT: Ryu, Eun-Hyun
APPLICANT: Hwang, Moon-Sun
TITLE OF INVENTION: ZINC FINGER DOMAIN LIBRARIES
FILE REFERENCE: 12279-005001
CURRENT APPLICATION NUMBER: US/10/223,765
CURRENT FILING DATE: 2002-08-19
PRIOR APPLICATION NUMBER: 60/374,355
PRIOR FILING DATE: 2002-04-22
PRIOR APPLICATION NUMBER: 60/313,402
PRIOR FILING DATE: 2001-08-17
NUMBER OF SEQ ID NOS: 305
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 202
LENGTH: 10
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: synthetically generated oligonucleotide
US-10-223-765-202
```

```
Query Match          100.0%; Score 9; DB 42; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 TAGGAGGAT 9
Db 2 TAGGAGGAT 10
```

```
RESULT 5
US-09-882-945A-169/c
; Sequence 169, Application US/09882945A
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neel, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/09/882,945A
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 169
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-882-945A-169
```

```
Query Match          100.0%; Score 9; DB 33; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 TAGGAGGAT 9
Db 12 TAGGAGGAT 4
```

```
RESULT 6
US-60-216-745-6947
; Sequence 6947, Application US/60216745
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Abderrahim, Hadi
; APPLICANT: Dufaire-Gare, Isabelle
```

```
;; TITLE OF INVENTION: BIALLELIC MARKER MAPS FOR USE IN CONSTRUCTING A HIGH DENSITY
;; FILE REFERENCE: 84.US1.PRO
;; CURRENT APPLICATION NUMBER: US/60/216,745
;; CURRENT FILING DATE: 2000-06-30
;; NUMBER OF SEQ ID NOS: 13665
;; SOFTWARE: Patent.pm
;; SEQ ID NO 6947
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Homo Sapiens
;; FEATURE:
;; NAME/KEY: primer_bind
;; LOCATION: 1..18
;; OTHER INFORMATION: upstream amplification primer 99-38923 for SEQ 2416,
US-60-216-745-6947
```

```
Query Match          100.0%; Score 9; DB 65; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 TAGGAGGAT 9
Db 1 TAGGAGGAT 9
```

```
RESULT 7
US-60-216-745-11899
; Sequence 11899, Application US/60216745
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Abderrahim, Hadi
; APPLICANT: Dufaire-Gare, Isabelle
; TITLE OF INVENTION: BIALLELIC MARKER MAPS FOR USE IN CONSTRUCTING A HIGH DENSITY
; FILE REFERENCE: 84.US1.PRO
; CURRENT APPLICATION NUMBER: US/60/216,745
; CURRENT FILING DATE: 2000-06-30
; NUMBER OF SEQ ID NOS: 13665
; SOFTWARE: Patent.pm
; SEQ ID NO 11899
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-43555 for SEQ 2837, in comp
US-60-216-745-11899
```

```
Query Match          100.0%; Score 9; DB 65; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 TAGGAGGAT 9
Db 4 TAGGAGGAT 12
```

```
RESULT 8
PCT-US00-25479-22/c
; Sequence 22, Application PC/TUS0025479
; GENERAL INFORMATION:
; APPLICANT: The Johns Hopkins University School of Medicine
; TITLE OF INVENTION: CACNAIG POLYNUCLEOTIDE POLYPEPTIDE AND
; TITLE OF INVENTION: METHODS OF USE THEREFOR
; FILE REFERENCE: JH01590WO
; CURRENT APPLICATION NUMBER: PCT/US00/25479
; CURRENT FILING DATE: 2000-09-14
; NUMBER OF SEQ ID NOS: 120
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 19
```

TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Bisulfite-PCR primer
NAME/KEY: misc_feature
LOCATION: (0)...(0)
OTHER INFORMATION: r = G or A
PCT-US00-25479-22

Query Match 100.0%; Score 9; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TAGGAGGAT 9
Db 17 TAGGAGGAT 9

RESULT 9
PCT-US00-25479-76
Sequence 76, Application PC/TUS0025479
GENERAL INFORMATION:
APPLICANT: The Johns Hopkins University School of Medicine
TITLE OF INVENTION: CACNAIG POLYNUCLEOTIDE POLYPEPTIDE AND
FILE REFERENCE: JHU1590M0
CURRENT APPLICATION NUMBER: PCT/US00/25479
CURRENT FILING DATE: 2000-09-14
NUMBER OF SEQ ID NOS: 120
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 76
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Target sequence for bisulfite-PCR primer
NAME/KEY: misc_feature
LOCATION: (0)...(0)
OTHER INFORMATION: y = C or T
PCT-US00-25479-76

Query Match 100.0%; Score 9; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TAGGAGGAT 9
Db 3 TAGGAGGAT 11

RESULT 10
US-09-398-522-22/C
Sequence 22, Application US/09398522
GENERAL INFORMATION:
APPLICANT: Issa, Jean-Pierre
TITLE OF INVENTION: CACNAIG POLYNUCLEOTIDE POLYPEPTIDE AND
FILE REFERENCE: JHU1590
CURRENT APPLICATION NUMBER: US/09/398,522
CURRENT FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 120
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Bisulfite-PCR primer
NAME/KEY: misc_feature
LOCATION: (0)...(0)
OTHER INFORMATION: r = G or A
US-09-398-522-22

Query Match 100.0%; Score 9; DB 17; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TAGGAGGAT 9
Db 17 TAGGAGGAT 9

RESULT 11
US-09-398-522-76
Sequence 76, Application US/09398522
GENERAL INFORMATION:
APPLICANT: Issa, Jean-Pierre
TITLE OF INVENTION: CACNAIG POLYNUCLEOTIDE POLYPEPTIDE AND
FILE REFERENCE: JHU1590
CURRENT APPLICATION NUMBER: US/09/398,522
CURRENT FILING DATE: 1999-09-15
NUMBER OF SEQ ID NOS: 120
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 76
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Target sequence for bisulfite-PCR primer
NAME/KEY: misc_feature
LOCATION: (0)...(0)
OTHER INFORMATION: y = C or T
US-09-398-522-76

Query Match 100.0%; Score 9; DB 17; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TAGGAGGAT 9
Db 3 TAGGAGGAT 11

RESULT 12
US-60-216-745-8613
Sequence 8613, Application US/60216745
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilya
APPLICANT: Abderrahim, Hadi
APPLICANT: Dufaire-Gare, Isabelle
TITLE OF INVENTION: BIALLELIC MARKER MAPS FOR USE IN CONSTRUCTING A HIGH DENSITY.
FILE REFERENCE: 84, US1, PRO
CURRENT APPLICATION NUMBER: US/60/216,745
CURRENT FILING DATE: 2000-06-30
NUMBER OF SEQ ID NOS: 13665
SOFTWARE: Patent.pm
SEQ ID NO 8613
LENGTH: 19
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: primer_bind
LOCATION: 1..19
OTHER INFORMATION: upstream amplification primer 99-27815 for SEQ 4082,
US-60-216-745-8613

Query Match 100.0%; Score 9; DB 65; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TAGGAGGAT 9

Db 7 TAGGAGGAT 15

RESULT 13

PCT-US01-01857-19
 ; Sequence 19, Application PC/TUS0101857
 ; GENERAL INFORMATION:
 ; APPLICANT: Patience, Clive
 ; TITLE OF INVENTION: Swine Defective for Transmission of Porcine Endogenous
 ; FILE REFERENCE: 61750-311
 ; CURRENT APPLICATION NUMBER: PCT/US01/01857
 ; PRIOR FILING DATE: 2001-01-19
 ; PRIOR APPLICATION NUMBER: U.S. 60/243695
 ; PRIOR FILING DATE: 2000-10-27
 ; PRIOR APPLICATION NUMBER: U.S. 60/182965
 ; PRIOR FILING DATE: 2000-02-16
 ; PRIOR APPLICATION NUMBER: U.S. 60/177003
 ; PRIOR FILING DATE: 2000-01-19
 ; NUMBER OF SEQ ID NOS: 33
 ; SOFTWARE: Patent In Ver. 2.1
 ; SEQ ID NO 19
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Primer
 ; OTHER INFORMATION: sequence used in amplification of PERV-sequences.
 PCT-US01-01857-19

Query Match

Best Local Similarity 100.0%; Score 9; DB 1; Length 20;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
 Db 2 TAGGAGGAT 10

RESULT 14

PCT-US02-10529-162
 ; Sequence 162, Application PC/TUS0210529
 ; GENERAL INFORMATION:
 ; APPLICANT: Isis Pharmaceuticals, Inc.
 ; APPLICANT: C. Frank Bennett
 ; APPLICANT: Jacqueline Wyatt
 ; TIME OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE I EXPRESSION
 ; FILE REFERENCE: RTSP-0291
 ; CURRENT APPLICATION NUMBER: PCT/US02/10529
 ; PRIOR FILING DATE: 2002-04-02
 ; PRIOR APPLICATION NUMBER: 09/828,344
 ; PRIOR FILING DATE: 2001-04-05
 ; NUMBER OF SEQ ID NOS: 176
 ; SEQ ID NO 162
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 PCT-US02-10529-162

Query Match

Best Local Similarity 100.0%; Score 9; DB 1; Length 20;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
 Db 1 TAGGAGGAT 9

RESULT 15
 PCT-US02-10529-163

; Sequence 163, Application PC/TUS0210529
 ; GENERAL INFORMATION:
 ; APPLICANT: Isis Pharmaceuticals, Inc.
 ; APPLICANT: C. Frank Bennett
 ; APPLICANT: Jacqueline Wyatt
 ; TIME OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE I EXPRESSION
 ; FILE REFERENCE: RTSP-0291
 ; CURRENT APPLICATION NUMBER: PCT/US02/10529
 ; PRIOR FILING DATE: 2002-04-02
 ; PRIOR APPLICATION NUMBER: 09/828,344
 ; PRIOR FILING DATE: 2001-04-05
 ; NUMBER OF SEQ ID NOS: 176
 ; SEQ ID NO 163
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Antisense Oligonucleotide
 PCT-US02-10529-163

Query Match

Best Local Similarity 100.0%; Score 9; DB 1; Length 20;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
 Db 3 TAGGAGGAT 11

Search completed: June 2, 2003, 23:00:11
 Job time : 1863.56 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:06:10 ; Search time 176.707 Seconds

(without alignments)
823.475 Million cell updates/sec

Title: US-09-540-843-4

Perfect score: 5

Sequence: 1 gtagt 5

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 774614

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl:*

- 1: gb_ba:*
- 2: gb_hgt:*
- 3: gb_in:*
- 4: gb_om:*
- 5: gb_ov:*
- 6: gb_pat:*
- 7: gb_ph:*
- 8: gb_pl:*
- 9: gb_pr:*
- 10: gb_ro:*
- 11: gb_sts:*
- 12: gb_sy:*
- 13: gb_un:*
- 14: gb_vl:*
- 15: em_ba:*
- 16: em_fun:*
- 17: em_hum:*
- 18: em_in:*
- 19: em_mu:*
- 20: em_om:*
- 21: em_or:*
- 22: em_ov:*
- 23: em_pat:*
- 24: em_ph:*
- 25: em_pl:*
- 26: em_ro:*
- 27: em_sts:*
- 28: em_un:*
- 29: em_vl:*
- 30: em_hgt_hum:*
- 31: em_hgt_inv:*
- 32: em_hgt_other:*
- 33: em_hgt_mus:*
- 34: em_hgt_pla:*
- 35: em_hgt_rtd:*
- 36: em_hgt_mam:*
- 37: em_hgt_vtl:*
- 38: em_sy:*
- 39: em_hgt_hum:*
- 40: em_hgt_mus:*
- 41: em_hgtg_other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	5	100.0	5	6	AX268756 Sequence
2	5	100.0	5	6	AX268758 Sequence
3	5	100.0	7	6	AX268755 Sequence
4	5	100.0	7	6	AX268759 Sequence
5	5	100.0	8	6	AX047565 Sequence
6	5	100.0	8	6	AX104946 Sequence
7	5	100.0	8	6	AX119567 Sequence
8	5	100.0	9	6	AX268753 Sequence
9	5	100.0	9	9	S50583
10	5	100.0	9	9	S50585
11	5	100.0	10	6	AX18263
12	5	100.0	10	6	AR065157 Sequence
13	5	100.0	10	6	AR079101 Sequence
14	5	100.0	10	6	AR079103 Sequence
15	5	100.0	10	6	AR098909 Sequence
16	5	100.0	10	6	AR107335 Sequence
17	5	100.0	10	6	AR107344 Sequence
18	5	100.0	10	6	AR123039 Sequence
19	5	100.0	10	6	AR136787 Sequence
20	5	100.0	10	6	AR160130 Sequence
21	5	100.0	10	6	AR202278 Sequence
22	5	100.0	10	6	AX080424 Sequence
23	5	100.0	10	6	AX104930 Sequence
24	5	100.0	10	6	AX112988 Sequence
25	5	100.0	10	6	AX112993 Sequence
26	5	100.0	10	6	AX113002 Sequence
27	5	100.0	10	6	AX152720 Sequence
28	5	100.0	10	6	AX152760 Sequence
29	5	100.0	10	6	AX152761 Sequence
30	5	100.0	10	6	AX153151 Sequence
31	5	100.0	10	6	AX153528 Sequence
32	5	100.0	10	6	AX153564 Sequence
33	5	100.0	10	6	AX153578 Sequence
34	5	100.0	10	6	AX153616 Sequence
35	5	100.0	10	6	AX252791 Sequence
36	5	100.0	10	6	AX252792 Sequence
37	5	100.0	10	6	AX252795 Sequence
38	5	100.0	10	6	AX252796 Sequence
39	5	100.0	10	6	AX252827 Sequence
40	5	100.0	10	6	AX252828 Sequence
41	5	100.0	10	6	AX252832 Sequence
42	5	100.0	10	6	AX252867 Sequence
43	5	100.0	10	6	AX252869 Sequence
44	5	100.0	10	6	AX252871 Sequence
45	5	100.0	10	6	AX252873 Sequence

ALIGNMENTS

RESULT 1	AX268756	5 bp	DNA	Linear	PAT 29-OCT-2001
LOCUS	AX268756				
DEFINITION	Sequence 4 from Patent WO01/4342.				
ACCESSION	AX268756				
VERSION	AX268756.1	GI:16541828			
KEYWORDS					
SOURCE					
ORGANISM					
REFERENCE	1				
AUTHORS	Gillchrest,B.A., Yaar,M. and Eller,M.				
TITLE	Use of locally applied dna fragments				
JOURNAL	Patent: WO 0174342-A 4 11-OCT-2001;				
	TRUSTEES OF BOSTON UNIVERSITY (US)				

FEATURES
source
Location/Qualifiers
1. .5
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT
1 a 0 c 2 g 2 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 5; DB 6; Length 5;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
1 GATG 5
|||||
1 GATG 5

RESULT 2
AX268758/c

LOCUS AX268758 5 bp DNA linear PAT 29-OCT-2001
DEFINITION Sequence 6 from Patent WO0174342.
ACCESSION AX268758
VERSION AX268758.1 GI:16541830
KEYWORDS
SOURCE
ORGANISM
synthetic construct.
synthetic construct.
artificial sequences.

REFERENCE
AUTHORS Gilchrist,B.A., Yaar,M. and Eller,M.
TITLE Use of locally applied dna fragments
JOURNAL Patent: WO 0174342-A 6 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)
LOCATION/Qualifiers

FEATURES
source

1. .5
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT
2 a 2 c 0 g 1 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 5; DB 6; Length 5;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
1 GATG 5
|||||
5 GATG 1

RESULT 3
AX268755

LOCUS AX268755 7 bp DNA linear PAT 29-OCT-2001
DEFINITION Sequence 3 from Patent WO0174342.
ACCESSION AX268755
VERSION AX268755.1 GI:16541827
KEYWORDS
SOURCE
ORGANISM
synthetic construct.
synthetic construct.
artificial sequences.

REFERENCE
AUTHORS Gilchrist,B.A., Yaar,M. and Eller,M.
TITLE Use of locally applied dna fragments
JOURNAL Patent: WO 0174342-A 3 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)
LOCATION/Qualifiers

FEATURES
source

1. .7
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT
3 a 0 c 2 g 2 t
ORIGIN

Query Match
100.0%; Score 5; DB 6; Length 7;

Best Local Similarity 100.0%; Pred. No. 4.2e+09;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
1 GATG 5
|||||
2 GATG 6

RESULT 4
AX268759

LOCUS AX268759 7 bp DNA linear PAT 29-OCT-2001
DEFINITION Sequence 7 from Patent WO0174342.
ACCESSION AX268759
VERSION AX268759.1 GI:16541831
KEYWORDS
SOURCE
ORGANISM
synthetic construct.
synthetic construct.
artificial sequences.

REFERENCE
AUTHORS Gilchrist,B.A., Yaar,M. and Eller,M.
TITLE Use of locally applied dna fragments
JOURNAL Patent: WO 0174342-A 7 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)
LOCATION/Qualifiers

FEATURES
source

1. .7
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT
3 a 0 c 2 g 2 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 5; DB 6; Length 7;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
1 GATG 5
|||||
2 GATG 6

DB
2 GATG 6

RESULT 5
AX047565/c
LOCUS AX047565 8 bp DNA linear PAT 15-DEC-2000
DEFINITION Sequence 6 from Patent WO0068399.
ACCESSION AX047565
VERSION AX047565.1 GI:11876556
KEYWORDS
SOURCE
ORGANISM
synthetic construct.
synthetic construct.
artificial sequences.

REFERENCE
AUTHORS McIvor,R.S., Hackett,P.B. and Aguilar-Cordova,E.
TITLE Vector-mediated delivery of integrating transposon sequences
JOURNAL Patent: WO 0068399-A 6 16-NOV-2000;
REGENTS OF THE UNIVERSITY OF MINNESOTA (US) ; BAYLOR COLLEGE OF
MEDICINE (US) ; McIVOR, R. Scott (US) ; HACKETT, Perry B. (US) ;
AGUILAR-CORDOVA, Estuardo (US)

FEATURES
source
Location/Qualifiers

1. .8
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Direct Repeat Sequence"
BASE COUNT
4 a 3 c 0 g 1 t
ORIGIN

Query Match
Best Local Similarity 100.0%; Score 5; DB 6; Length 8;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY
1 GATG 5
|||||
6 GATG 2

DB

RESULT 6
LOCUS AX104946 8 bp DNA linear PAT 30-APR-2001
DEFINITION Sequence 1138 from Patent WO0122972.
ACCESSION AX104946
VERSION AX104946.1 GI:13921143
KEYWORDS
SOURCE
ORGANISM synthetic construct.
REFERENCE
AUTHORS 1 (bases 1 to 8)
TITLE Kriegl, A.M., Schetter, C. and Vollmer, J.C.
JOURNAL Immunostimulatory nucleic acids
Patent: WO 0122972-A 1138 05-APR-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
GmbH (DE)
FEATURES
source Location/Qualifiers
1..8
/organism="synthetic construct"
/db_xref="taxon:32630"
BASE COUNT 2 a 1 c 2 g 3 t
ORIGIN

Query Match 100.0%; Score 5; DB 6; Length 8;
Best Local Similarity 100.0%; Pred. No. 3.6e+09;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 3 GTATG 7

RESULT 7
LOCUS AX119567 8 bp DNA linear PAT 11-MAY-2001
DEFINITION Sequence 224 from Patent WO0129251.
ACCESSION AX119567
VERSION AX119567.1 GI:14036486
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1 (bases 1 to 8)
TITLE Messiaen, L. and Callens, T.
JOURNAL Improved mutation analysis of the nfi gene
Patent: WO 0129251-A 224 26-APR-2001;
UNIVERSITEIT GENT (BE)
FEATURES
source Location/Qualifiers
1..8
/organism="Homo sapiens"
/db_xref="taxon:9606"
BASE COUNT 1 a 0 c 4 g 3 t
ORIGIN

Query Match 100.0%; Score 5; DB 6; Length 8;
Best Local Similarity 100.0%; Pred. No. 3.6e+09;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 3 GTATG 7

RESULT 8
LOCUS AX268753 9 bp DNA linear PAT 29-OCT-2001
DEFINITION Sequence 1 from Patent WO0174342.
ACCESSION AX268753
VERSION AX268753.1 GI:16541825
KEYWORDS
SOURCE synthetic construct.

ORGANISM synthetic construct
artificial sequences.
REFERENCE
AUTHORS 1
TITLE Gilchrist, B.A., Yaar, M. and Eller, M.
JOURNAL Use of locally applied dna fragments
Patent: WO 0174342-A 1 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)
FEATURES
source Location/Qualifiers
1..9
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic DNA Fragment"
BASE COUNT 3 a 0 c 4 g 2 t
ORIGIN

Query Match 100.0%; Score 5; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+09;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 3 GTATG 7

RESULT 9
LOCUS S50583 9 bp mRNA linear PRI 07-MAY-1993
DEFINITION type I procollagen [human, mRNA Mutant, 9 nt].
ACCESSION S50583
VERSION S50583.1 GI:233928
KEYWORDS
SOURCE Homo sapiens.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1 (bases 1 to 9)
TITLE Tsuneyoshi, T., Westerhausen, A., Constantinou, C.D. and Prockop, D.J.
JOURNAL Substitutions for glycine alpha 1-637 and glycine alpha 2-694 of
MEDLINE type I procollagen in lethal osteogenesis imperfecta. The
PUBMED conformational strain on the triple helix introduced by a glycine
91340689 substitution can be transmitted along the helix
1874719 J. Biol. Chem. 266 (24), 15608-15613 (1991)
REMARK Genbank staff at the National Library of Medicine created this
entry [NCBI gi233928 50583] from the original journal article.
This sequence comes from Fig 5A.
FEATURES
source Location/Qualifiers
1..9
/organism="Homo sapiens"
/db_xref="taxon:9606"
gene 1..9
/gene="type I procollagen"
BASE COUNT 1 a 3 c 2 g 3 t
ORIGIN

Query Match 100.0%; Score 5; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+09;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 5 GTATG 9

RESULT 10
LOCUS S50585 9 bp DNA linear PRI 07-MAY-1993
DEFINITION type I procollagen [human, Genomic Mutant, 9 nt].
ACCESSION S50585
VERSION S50585.1 GI:233929
KEYWORDS
SOURCE Homo sapiens.

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 9)
AUTHORS Tanueyoshi,T., Westerhausen,A., Constantinou,C.D. and Prockop,D.J.
TITLE Substitutions for glycine alpha 1-637 and glycine alpha 2-694 of
type I procollagen in lethal osteogenesis imperfecta. The
conformational strain on the triple helix introduced by a glycine
substitution can be transmitted along the helix
JOURNAL J. Biol. Chem. 266 (24), 15608-15613 (1991)
MEDLINE 91340689
PUBMED 1874719
REMARK GenBank staff at the National Library of Medicine created this
entry [NCBI 91bdsq 50585] from the original journal article.
This sequence comes from Fig 5B.
Location/Qualifiers
source 1..9
/organism="Homo sapiens"
/db_xref="taxon:9606"
gene 1..9
BASE COUNT 2 a 1 c 3 g 3 t
ORIGIN
Query Match 100.0%; Score 5; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+09;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
|||||
Db 5 GTATG 9

RESULT 11
A18263 10 bp DNA linear PAT 12-APR-1994
LOCUS oligonucleotide.
DEFINITION A18263
ACCESSION A18263
VERSION A18263.1 GI:512254
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 10)
AUTHORS Della Valle,F., Callegaro,L. and Negro,A.
TITLE Process for the preparation of genetic vectors for the nerve growth
factor expression in eukaryotic cells
JOURNAL Patent: EP 0432510-A 12 19-JUN-1991;
FIDIA S.p.A
Location/Qualifiers
source 1..10
/organism="synthetic construct"
/db_xref="taxon:32630"
BASE COUNT 3 a 1 c 3 g 3 t
ORIGIN
Query Match 100.0%; Score 5; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.8e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
|||||
Db 6 GTATG 10

RESULT 12
AR065157 10 bp DNA linear PAT 29-SEP-1999
LOCUS AR065157
DEFINITION Sequence 1 from patent US 5849489.
ACCESSION AR065157
VERSION AR065157.1 GI:5959373
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 10)
AUTHORS Heller,M.O.
TITLE Hybridization of polynucleotides conjugated with chromophores and
fluorophores to generate donor-to-donor energy transfer system
JOURNAL Patent: US 5849489-A 1 15-DEC-1998;
MEDLINE
PUBMED
REMARK Location/Qualifiers
source 1..10
/organism="unknown"
BASE COUNT 3 a 2 c 2 g 3 t
ORIGIN
Query Match 100.0%; Score 5; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.8e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
|||||
Db 8 GTATG 4

RESULT 13
AR079101 10 bp DNA linear PAT 31-AUG-2000
LOCUS AR079101
DEFINITION Sequence 23 from patent US 5965409.
ACCESSION AR079101
VERSION AR079101.1 GI:10005847
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 10)
AUTHORS Pardee,A.B. and Liang,P.
TITLE System for comparing levels or amounts of mRNAs
JOURNAL Patent: US 5965409-A 23 12-OCT-1999;
FIDIA S.p.A
Location/Qualifiers
source 1..10
/organism="unknown"
BASE COUNT 1 a 1 c 3 g 4 t 1 others
ORIGIN
Query Match 100.0%; Score 5; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.8e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
|||||
Db 1 GTATG 5

RESULT 14
AR079103 10 bp DNA linear PAT 31-AUG-2000
LOCUS AR079103
DEFINITION Sequence 25 from patent US 5965409.
ACCESSION AR079103
VERSION AR079103.1 GI:10005849
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 10)
AUTHORS Pardee,A.B. and Liang,P.
TITLE System for comparing levels or amounts of mRNAs
JOURNAL Patent: US 5965409-A 25 12-OCT-1999;
FIDIA S.p.A
Location/Qualifiers
source 1..10
/organism="unknown"
BASE COUNT 1 a 2 c 3 g 3 t 1 others
ORIGIN
Query Match 100.0%; Score 5; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.8e+06;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
 |||||
 Db 1 GTATG 5

RESULT 15

AR098909

LOCUS

Sequence 45 from patent US 6077685. 10 bp. DNA linear PAT 14-FEB-2001

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Unclasse

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

source

1. 10

/organism="unknown"

BASE COUNT

ORIGIN

2 a

2 c

3 g

3 t

Query Match

Best Local Similarity

Matches

5; Conservative

0; Mismatches

0; Indels

0; Gaps

0;

QY 1 GTATG 5

Db 1 GTATG 5

Search completed: June 2, 2003, 19:09:37
 Job time : 177.707 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 17:32:40 ; Search time 83.5366 Seconds
(without alignments)
134.791 Million cell updates/sec

Title: US-09-540-843-4

Perfect score: 5
Sequence: 1 gtag 5

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 2063506

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

N.Geneseq 101002:*

- 1: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT.*
- 2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT.*
- 3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT.*
- 4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT.*
- 5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT.*
- 6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT.*
- 7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT.*
- 8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT.*
- 9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT.*
- 10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT.*
- 11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT.*
- 12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT.*
- 13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT.*
- 14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT.*
- 15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT.*
- 16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT.*
- 17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT.*
- 18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT.*
- 19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT.*
- 20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT.*
- 21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT.*
- 22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT.*
- 23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT.*
- 24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	ID	Description
1	5	100.0	5 20 AA210695	Oligonucleotide se
2	5	100.0	5 20 AA210696	Oligonucleotide se
3	5	100.0	5 23 AA214908	Melanogenesis asso
4	5	100.0	5 23 AA214910	Melanogenesis asso
5	5	100.0	7 20 AA210694	Oligonucleotide se
6	5	100.0	7 23 AA214907	Melanogenesis asso
7	5	100.0	7 23 AA214911	Melanogenesis asso
8	5	100.0	8 22 AAD02250	Direct repeat sequ
9	5	100.0	9 19 AAV22350	A promoter regulat

10	5	100.0	9 19 AAV22283	GAS complement gen
11	5	100.0	9 19 AAV15899	Cyclin D transcrip
12	5	100.0	9 20 AA210692	Oligonucleotide se
13	5	100.0	9 23 AA214905	Melanogenesis asso
14	5	100.0	9 24 AB071504	zinc finger protei
15	5	100.0	9 24 AB071932	zinc finger protei
16	5	100.0	9 24 AB071958	zinc finger protei
17	5	100.0	10 14 AA043164	Donor oligomer vlt
18	5	100.0	10 15 AA071104	Merlin exon 14 spl
19	5	100.0	10 16 AA097224	Oligonucleotide Ec
20	5	100.0	10 16 AA097224	Anticancer duplex
21	5	100.0	10 17 AAT35734	Primer E19 for V.d
22	5	100.0	10 18 AAT66073	(dc-d)n (dc-d)n
23	5	100.0	10 19 AAV50271	Yeast tag for addi
24	5	100.0	10 19 AAV50250	Yeast tag for addi
25	5	100.0	10 19 AAV50184	Yeast tag for addi
26	5	100.0	10 19 AAV50127	Yeast tag for addi
27	5	100.0	10 19 AAV35934	Primer used in RAP
28	5	100.0	10 19 AAV35910	p53 serial analysi
29	5	100.0	10 20 AAX18629	Chromophore contai
30	5	100.0	10 20 AAX73806	Human dendritic ce
31	5	100.0	10 21 AAC73931	Human monocyte and
32	5	100.0	10 21 AAC74120	Human monocyte and
33	5	100.0	10 21 AAC74154	Oligonucleotide us
34	5	100.0	10 21 AAA93858	Oligonucleotide us
35	5	100.0	10 21 AAA93865	Mouse DNA adapter
36	5	100.0	10 21 AAA53110	Primer MR15 for mo
37	5	100.0	10 21 AAA15244	Human monocyte gen
38	5	100.0	10 21 AAA56166	Human monocyte gen
39	5	100.0	10 21 AAA56218	Human macrophage g
40	5	100.0	10 21 AAA56224	Human macrophage g
41	5	100.0	10 21 AAA56294	Human macrophage g
42	5	100.0	10 21 AAA56321	Human macrophage g
43	5	100.0	10 21 AAA56331	Human macrophage g
44	5	100.0	10 21 AAA56407	Human macrophage g
45	5	100.0	10 21 AAA56440	Human macrophage g

ALIGNMENTS.

RESULT 1	AAZ10695	AAZ10695 standard; DNA; 5 BP.
XX	XX	XX
AC	AAZ10695;	
XX	XX	XX
DT	23-NOV-1999	(first entry)
XX	XX	XX
DE	Oligonucleotide sequence that increases p53 activity in a cell.	
XX	XX	XX
KW	p53 activity; UV mutagenic; UV-irradiation; UV-induced dermatosis;	
KW	UV-induced hyperproliferative disease; psoriasis; vitiligo;	
KW	atopic dermatitis; allergic rhinitis; conjunctivitis; photodagng;	
KW	skin cancer; ss.	
XX	XX	XX
OS	Synthetic.	
XX	XX	XX
PN	GB2336157-A.	
XX	XX	XX
PD	13-OCT-1999.	
XX	XX	XX
PF	24-MAR-1999;	99GB-0006758.
XX	XX	XX
PR	26-MAR-1998;	98US-0048927.
XX	XX	XX
PA	(UYBO-) UNITV BOSTON.	
XX	XX	XX
PI	Gilchrest BA, Yaar M, Eller M;	
XX	XX	XX
DR	WPI, 1999-543520/46.	
XX	XX	XX
PT	DNA fragments useful for increasing p53 activity in a cell and reducing	

PT susceptibility to UV-induced hyperproliferative diseases -

XX Claim 11; Page 30; 44pp; English.

PS

XX AA210692-97 represent DNA fragments that are used for increasing p53

CC activity in a cell. The oligonucleotides are UV mimetics and

CC protect cells against subsequent exposure to UV-irradiation or

CC chemicals. The oligonucleotides are useful for increasing p53 activity

CC in a cell, reducing the susceptibility to UV-induced hyperproliferative

CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic

CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging

CC and reducing susceptibility to skin cancer.

XX

XX Sequence 5 BP; 1 A; 0 C; 2 G; 2 T; 0 other;

SO

Query Match 100.0%; Score 5; DB 20; Length 5;

Best Local Similarity 100.0%; Pred. No. 4.3e+08;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5

DB 1 GTATG 5

RESULT 2

AA210696/C

ID AA210696 standard; DNA; 5 BP.

XX

XX AA210696;

XX

XX 23-NOV-1999 (first entry)

XX

DE Oligonucleotide sequence that increases p53 activity in a cell.

XX

XX p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;

KW UV-induced hyperproliferative disease; psoriasis; vitiligo;

KW atopic dermatitis; allergic rhinitis; conjunctivitis; photoaging;

KW skin cancer; ss.

XX

OS Synthetic.

XX

XX GB2336157-A.

PN

XX 13-OCT-1999.

XX

XX 24-MAR-1999; 99GB-0006758.

PF

XX 26-MAR-1998; 98US-0048927.

PR

XX (UYBO-) UNIV BOSTON.

PA

XX Gilchrist BA, Yaar M, Eller M;

PI

XX WPI; 1999-543520/46.

DR

XX

XX DNA fragments useful for increasing p53 activity in a cell and reducing

PT susceptibility to UV-induced hyperproliferative diseases -

XX

XX Claim 11; Page 30; 44pp; English.

PS

XX AA210692-97 represent DNA fragments that are used for increasing p53

CC activity in a cell. The oligonucleotides are UV mimetics and

CC protect cells against subsequent exposure to UV-irradiation or

CC chemicals. The oligonucleotides are useful for increasing p53 activity

CC in a cell, reducing the susceptibility to UV-induced hyperproliferative

CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic

CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging

CC and reducing susceptibility to skin cancer.

XX

XX Sequence 5 BP; 2 A; 2 C; 0 G; 1 T; 0 other;

SO

Query Match 100.0%; Score 5; DB 20; Length 5;

Best Local Similarity 100.0%; Pred. No. 4.3e+08;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5

DB 5 GTATG 1

RESULT 3

AA214908

ID AA214908 standard; DNA; 5 BP.

XX

XX AA214908;

XX

XX 14-FEB-2002 (first entry)

XX

DE Melanogenesis associated oligonucleotide #4.

XX

XX Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;

KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;

KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;

KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;

KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;

KW conjunctivitis; allergic rhinitis; vitiligo; ss.

XX

OS Synthetic.

XX

XX WO200174342-A2.

PN

XX 11-OCT-2001.

XX

XX 30-MAR-2001; 2001WO-US10162.

PF

XX 31-MAR-2000; 2000US-0540843.

PR

XX (UYBO-) UNIV BOSTON.

PA

XX Gilchrist BA, Yaar M, Eller M;

PI

XX WPI; 2001-626338/72.

DR

XX

XX Inhibiting proliferation of epithelial cells, useful e.g. for treating

PT carcinoma, using specific oligonucleotides that mimic the effects of

PT ultra-violet light

XX

XX Claim 1; Page 36; 74pp; English.

PS

XX The invention describes inhibition of mammalian epithelial cell

CC proliferation by treating cells with at least one oligonucleotide, or

CC its fragment. The compounds, which have cytostatic, anti-allergic,

CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and

CC immunosuppressive activities, function as 'ultra-violet mimics' to induce

CC DNA repair processes (or a protective response to later exposure to

CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer

CC or a tumour necrosis factor inhibitor. Probably they mimic products of

CC DNA damage, or processed DNA-damage intermediates, by inducing the p53

CC pathway, resulting in transient arrest of cell growth, allowing more time

CC for DNA repair to occur before cell division takes place. The method is

CC especially used to treat carcinoma but may also be used to: treat other

CC hyperproliferative states (e.g. psoriasis or precancerous conditions);

CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat

CC allergically mediated inflammation (atopic or contact dermatitis);

CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in

CC cells caused by radiation or chemicals; increase melanin production

CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to

CC promote apoptosis in epithelial cells that contain damaged DNA. Also

CC oligonucleotides that contain non-hydrolyzable backbones are used to

CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This

CC sequence is melanogenesis associated oligonucleotide #4, a truncated

CC version of the oligonucleotide shown in AA214908, one of the

CC oligonucleotides used to inhibit mammalian epithelial cell

CC proliferation, described in the method of the invention.

XX

XX Sequence 5 BP; 1 A; 0 C; 2 G; 2 T; 0 other;

SO

Query Match 100.0%; Score 5; DB 23; Length 5;
 Best Local Similarity 100.0%; Pred. No. 4.3e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
 |||||
 Db 1 GTATG 5

RESULT 4
 AAS14910/c
 ID AAS14910 standard; DNA; 5 BP.
 XX
 AC AAS14910;
 XX
 DT 14-FEB-2002 (first entry)
 XX
 DE Melanogenesis associated oligonucleotide #6.

XX Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;
 KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KW conjunctivitis; allergic rhinitis; vitiligo; ss.

OS Synthetic.
 XX
 PN WO200174342-A2.
 XX
 PD 11-OCT-2001.

XX 30-MAR-2001; 2001WO-US10162.

XX 31-MAR-2000; 2000US-0540843.

XX (UYBO-) UNIV BOSTON.

XX Gilchrist BA, Yaar M, Eller M;
 XX
 DR WPI; 2001-626338/72.

XX Inhibiting proliferation of epithelial cells, useful e.g. for treating
 PT carcinoma, using specific oligonucleotides that mimic the effects of
 PT ultra-violet light
 XX
 XX

PS Claim 1; Page 36; 74pp; English.

CC The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic,
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferative response to later exposure to
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergically mediated inflammation (atopic or contact dermatitis; treat
 CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #6, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell proliferation,
 CC described in the method of the invention.

XX
 SQ Sequence 5 BP; 2 A; 2 C; 0 G; 1 T; 0 other;

Query Match 100.0%; Score 5; DB 23; Length 5;
 Best Local Similarity 100.0%; Pred. No. 4.3e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
 |||||
 Db 5 GTATG 1

RESULT 5
 AAZ10694
 ID AAZ10694 standard; DNA; 7 BP.
 XX
 AC AAZ10694;
 XX
 DT 23-NOV-1999 (first entry)
 XX
 DE Oligonucleotide sequence that increases p53 activity in a cell.

XX p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;
 KW UV-induced hyperproliferative disease; psoriasis; vitiligo;
 KW atopic dermatitis; allergic rhinitis; conjunctivitis; photoaging;
 KW skin cancer; ss.

OS Synthetic.

XX
 PN GB2336157-A.
 XX
 PD 13-OCT-1999.

XX 24-MAR-1999; 99GB-0006758.

XX 26-MAR-1998; 98US-0048927.

XX (UYBO-) UNIV BOSTON.

XX Gilchrist BA, Yaar M, Eller M;
 XX
 DR WPI; 1999-543520/46.

XX DNA fragments useful for increasing p53 activity in a cell and reducing
 PT susceptibility to UV-induced hyperproliferative diseases -
 PT
 XX
 XX

PS Claim 11; Page 30; 44pp; English.

CC AAZ10692-97 represent DNA fragments that are used for increasing p53
 CC activity in a cell. The oligonucleotides are UV mimetics and
 CC protect cells against subsequent exposure to UV-irradiation or
 CC chemicals. The oligonucleotides are useful for increasing p53 activity
 CC in a cell, reducing the susceptibility to UV-induced hyperproliferative
 CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic
 CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging
 CC and reducing susceptibility to skin cancer.

XX Sequence 7 BP; 3 A; 0 C; 2 G; 2 T; 0 other;

Query Match 100.0%; Score 5; DB 20; Length 7;
 Best Local Similarity 100.0%; Pred. No. 3.1e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
 |||||
 Db 2 GTATG 6

RESULT 6
 AAS14907
 ID AAS14907 standard; DNA; 7 BP.
 XX
 AC AAS14907;

XX 14-FEB-2002 (first entry)
 DT Melanogenesis associated oligonucleotide #3.
 DE
 XX Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;
 KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KW conjunctivitis; allergic rhinitis; vitiligo; ss.
 XX Synthetic.
 XX OS
 XX WO200174342-A2.
 XX PD 11-OCT-2001.
 XX PF 30-MAR-2001; 2001WO-US10162.
 XX PR 31-MAR-2000; 2000US-0540843.
 XX PA (UYBO-) UNIV BOSTON.
 XX PI Gilchrist BA, Yaar M, Eller M;
 XX WPI; 2001-626338/72.
 XX DR Inhibiting proliferation of epithelial cells, useful e.g. for treating
 XX PT carcinoma, using specific oligonucleotides that mimic the effects of
 XX PT ultra-violet light -
 XX PS
 XX PS Claim 1; Page 36; 74pp; English.
 XX The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergically mediated inflammation (atopic or contact dermatitis);
 CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #3, a truncated
 CC version of the oligonucleotide shown in AAS14906, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell
 CC proliferation, described in the method of the invention.
 CC
 XX Sequence 7 BP; 3 A; 0 C; 2 G; 2 T; 0 other;
 SO
 Query Match 100.0%; Score 5; DB 23; Length 7;
 Best local Similarity 100.0%; Pred. No. 3.1e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

ID AAS14911 standard; DNA; 7 BP.
 XX AAS14911;
 AC
 XX 14-FEB-2002 (first entry)
 DT Melanogenesis associated oligonucleotide #7.
 DE
 XX Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;
 KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KW conjunctivitis; allergic rhinitis; vitiligo; ss.
 XX Synthetic.
 XX OS
 XX WO200174342-A2.
 XX PD 11-OCT-2001.
 XX PF 30-MAR-2001; 2001WO-US10162.
 XX PR 31-MAR-2000; 2000US-0540843.
 XX PA (UYBO-) UNIV BOSTON.
 XX PI Gilchrist BA, Yaar M, Eller M;
 XX WPI; 2001-626338/72.
 XX DR Inhibiting proliferation of epithelial cells, useful e.g. for treating
 XX PT carcinoma, using specific oligonucleotides that mimic the effects of
 XX PT ultra-violet light -
 XX PS
 XX PS Claim 1; Page 38; 74pp; English.
 XX The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergically mediated inflammation (atopic or contact dermatitis);
 CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #7, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell
 CC proliferation, described in the method of the invention.
 CC
 XX Sequence 7 BP; 3 A; 0 C; 2 G; 2 T; 0 other;
 SO
 Query Match 100.0%; Score 5; DB 23; Length 7;
 Best local Similarity 100.0%; Pred. No. 3.1e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 2 GTATG 6

RESULT 8
AAD02250/c
ID AAD02250 standard; DNA; 8 BP.
XX
AC AAD02250;
XX
DT 28-MAR-2001 (first entry)
XX
DE Direct repeat sequence that binds to SB protein.
XX
DE Sleeping Beauty; SB; AdSB10; adenovirus; transposase;
KW non-integrating viral vector; cytosolic; anti-diabetic; cardiant;
KW neuroprotective; genetic disease; gene therapy; therapy; cancer;
KW cystic fibrosis; diabetes; cardiovascular disease; brain malfunction;
KW genome analysis; chemotherapy; transgenic host cell; direct repeat; ds.
XX
OS Unidentified.
XX
PN WO200068399-A2.
XX
PD 16-NOV-2000.
XX
PF 11-MAY-2000; 2000MO-US12827.
XX
PR 11-MAY-1999; 99US-0133569.
XX
XX (MING) UNIV MINNESOTA.
PA (BAYU) BAYLOR COLLEGE MEDICINE.
PA (MCIV) MCIVOR R S.
PA (HACK) HACKETT P B.
PA (AGUI) AGUILAR-CORDOVA E.
XX
PI McIvor RS, Hackett PB, Aguilar-Cordova E;
XX
DR WPI; 2001-024870/03.
XX
PT Non-integrating (adenovirus-based) viral vectors useful in gene
PT therapy, especially for treating patients suffering from a genetic
PT disease, e.g. cystic fibrosis, diabetes, cardiovascular disease, cancer
PT or brain malfunction -
XX
PS
XX

Disclosure; Page 14; 62pp; English.

CC The patent discloses non-integrating viral vectors comprising a
CC polynucleotide flanked by inverted repeats that bind a transposase, a
CC transposase-encoding polynucleotide operably linked to a regulatory
CC sequence comprising an operator, that alters expression of the
CC transposase-encoding polynucleotide. Transposon sequences can integrate
CC into genomic DNA whether or not the cell is dividing. AdSB10 is a SB
CC (Sleeping Beauty) transposase-transducing adenoviral non-integrating
CC vector. The non-integrating viral vectors are useful for treating
CC genetic disease characterized by subnormal production of a polypeptide or
CC RNA, e.g. for replacement of a defective gene, delivery of a polypeptide
CC drug or supplementation of a metabolic activity. These genetic diseases
CC include cystic fibrosis, diabetes, cardiovascular disease, cancer or
CC brain malfunction. The non-integrating viral vectors are useful as
CC nucleic acid delivery systems, e.g. for genome analysis or gene therapy
CC and can also be used for applications that involve long-term production
CC of a polypeptide. The non-integrating viral vectors are also useful for
CC creating transgenic host cells that provide normal cells with protection
CC against toxic side effects of chemotherapy.
CC The sequence of the present invention is a direct repeat sequence that
CC binds to SB protein.
XX
XX

SQ Sequence 8 BP; 4 A; 3 C; 0 G; 1 T; 0 other;

Query Match 100.0%; Score 5; DB 22; Length 8;

Best Local Similarity 100.0%; Pred. No. 2.7e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
Db 6 GTATG 2

RESULT 9
AAV22350
ID AAV22350 standard; RNA; 9 BP.
XX
AC AAV22350;
XX
DT 29-JUN-1998 (first entry)
XX
DE A promoter regulatory motif found in the utrons of the invention.
XX
XX 3' untranslated region; UTR; inhibition; gene expression; ICAM-7;
KW interferon-gamma; IFN-gamma; major histocompatibility complex; MHC;
KW antigen expression; gene promoter; utron; B7-1; B7-2; Fc gamma R;
KW HIV gene expression; transplant rejection; treatment;
KW autoimmune disease; inflammatory disease; ss.
XX
OS Unidentified.
XX
PN WO9744450-A1.
XX
PD 27-NOV-1997.
XX
PF 21-MAY-1997; 97MO-US09459.
XX
PR 21-MAY-1996; 96US-0646789.
XX
XX (UYA) UNIV YALE.
XX
PI Peyman JA;
XX
DR WPI; 1998-018505/02.
XX
PT Utrons, RNA molecules containing promoter regulatory motifs -
PT useful to suppress express expression from promoter of interest,
PT specifically TSD nucleic acid suppression of MHC Class I and II gene
PT expression
XX
PS
XX

Claim 20; Page 20; 200pp; English.

CC The present sequence represents a promoter regulatory element,
CC found in the utrons of the invention. Utrons are from, or are
CC homologous to, the 3' untranslated region (UTR), of an mRNA that
CC stimulates or inhibits a cellular response by sequence specific
CC interactions. The utron is able to suppress constitutive and
CC interferon-gamma (IFN-gamma) induced major histocompatibility complex
CC (MHC) class I and class II antigen expression and expression of other
CC antigens; the gene promoters of which contain related sequence motifs
CC that are stimulated by the same factors which stimulate MHC class I and
CC class II antigen expression. Such utrons can be used to regulate
CC gene expression in a subject, e.g. a human or a cell in vitro,
CC specifically inhibiting MHC Class I or II, ICAM-7, B7-1, B7-2,
CC Fc gamma R, IL-2 or HIV gene expression. They can be used to inhibit
CC transplant rejection, or treat an autoimmune or inflammatory disease or
CC disorder.
XX
XX

SQ Sequence 9 BP; 3 A; 0 C; 3 G; 3 U; 0 other;

Query Match 100.0%; Score 5; DB 19; Length 9;
Best Local Similarity 60.0%; Pred. No. 2.4e+08;
Matches 3; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|:|:|
Db 1 GUAUG 5

```

RESULT 10
AAV22283
ID AAV22283 standard; DNA: 9 BP.
XX
AC AAV22283;
XX
DT 29-JUN-1998 (first entry)
XX
DE GAS complement gene promoter motif found in a trophoblast STAR utron.
XX
KW Trophoblast STAR utron; TSU; 3' untranslated region; UTR; inhibition;
XX Interferon-gamma; IFN-gamma; major histocompatibility complex; MHC;
XX antigen expression; gene promoter; class II; IFN signalling;
XX GAS; ISRE; Interleukin-4 response element; gene expression; ICAM-7;
XX B7-1; B7-2; Fc gamma R; HIV gene expression; transplant rejection;
XX treatment; autoimmune disease; inflammatory disease; ss.
XX
OS Undeidentified.
XX
PN WO9744450-A1.
XX
PD 27-NOV-1997.
XX
PF 21-MAY-1997; 97WO-US09459.
XX
PR 21-MAY-1996; 96US-0646789.
XX
PA (UYVA ) UNITV YALE.
XX
PI Peyman JA;
XX
DR MPI; 1998-018505/02.
XX
PT Utrons, RNA molecules containing promoter regulatory motifs -
XX useful to suppress express expression from promoter of interest.
XX PT specifically TSU nucleic acid suppression of MHC Class I and II gene
XX expression
XX
PS Claim 22; Page 90; 200pp; English.
XX
CC The present sequence represents a GAS complement gene promoter motif
XX found in a trophoblast STAR utron (TSU). TSUs be isolated from a CDNA
XX library prepared from mRNA isolated from trophoblast cells. Utrons are
XX from, or are homologous to, the 3' untranslated region (UTR), of an mRNA
XX that stimulates or inhibits a cellular response by sequence specific
XX interactions. The TSU is able to suppress constitutive and
XX interferon-gamma (IFN-gamma) induced major histocompatibility complex
XX (MHC) Class I and class II antigen expression and expression of other
XX antigens, the gene promoters of which contain related sequence motifs
XX that are stimulated by the same factors which stimulate MHC class I and
XX class II antigen expression. The TSU sequence contains motifs related to
XX IFN signalling (GAS, ISRE and interleukin-4 response elements). The
XX nucleic acid can be used to regulate gene expression in a subject, e.g. a
XX human or a cell in vitro, specifically inhibiting MHC Class I or II,
XX ICAM-7, B7-1, B7-2, Fc gamma R, IL-2 or HIV gene expression. It can be
XX used to inhibit transplant rejection, or treat an autoimmune or
XX inflammatory disease or disorder. It can also be used to inhibit the
XX action of STAI-6, or a cytokine.
XX
SQ Sequence 9 BP; 3 A; 0 C; 3 G; 3 T; 0 other;
XX
Query Match 100.0%; Score 5; DB 19; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.4e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
DB 1 GTATG 5

```

```

ID AAV15899 standard; DNA: 9 BP.
XX
AC AAV15899;
XX
DT 26-MAY-1998 (first entry)
XX
DE Cyclin D transcription factor DMP1 nonamer consensus sequence.
XX
KW Cyclin D transcription factor; binding affinity; D-type cyclin; probe;
XX cell cycle inhibitor; tumour; detection; cancer; DMP1; competitor;
XX nonamer consensus sequence; ss.
XX
OS Mus musculus.
XX Homo sapiens.
XX
PN WO9743415-A1.
XX
PD 20-NOV-1997.
XX
PF 16-MAY-1997; 97MO-US08480.
XX
PR 15-MAY-1997; 97US-0017815.
XX 16-MAY-1996; 96US-0017815.
PR 16-MAY-1996; 96US-0648837.
XX
PA (SUUD-) ST JUDE CHILDREN'S RES HOSPITAL.
XX
PI Hirai H, Inoue K, Sherr CJ;
XX
DR MPI; 1998-008884/01.
XX
PT Cyclin D transcription factor and related DNA - can be used to
XX develop products for treatment of, e.g. cancer
XX
PS Claim 3; Page 99; 120pp; English.
XX
CC This is a nonamer consensus sequence of a cyclin D transcription factor
XX DMP1. DMP1 is an amino acid polymer which has binding affinity for a
XX D-type cyclin, in vitro, and for a specific DNA nucleotide sequence and
XX is a transcription factor involved in the activation of genes that
XX prevent cell proliferation. The DMP1 nucleic acid is operatively linked
XX to an expression control sequence in an expression vector. The expression
XX vector has a transcription control sequence comprising this nonamer
XX sequence operably associated with a recombinant gene or a cassette
XX insertion site for a recombinant gene. The vector is homologously
XX recombined in a chromosome of a transgenic animal. A probe or a
XX competitor in DMP1 transactivation assays is designed based on this
XX nonamer sequence. The presence of activity of DMP1 can be determined by
XX detecting binding of DMP1 and a probe by contacting a biological sample
XX from a mammal with the probe under conditions that allow binding of the
XX probe to DMP1, where the probe contains the core sequence GTR, and where
XX the presence or activity of DMP1 is suspected in the sample. DMP1 can
XX function as a cell cycle inhibitor when expressed in a tumour cell.
XX Modulating the expression of DMP1 can be used to treat tumours and other
XX cancers. DMP1 can also be used for controlling expression of heterologous
XX proteins. Antisense sequences and ribozymes can be used to inhibit
XX expression of the transcription factor. Detecting the level and activity
XX of DMP1 in cells is useful for detection of cancer cells or
XX dysproliferative cells.
XX
SQ Sequence 9 BP; 1 A; 3 C; 2 G; 3 T; 0 other;
XX
Query Match 100.0%; Score 5; DB 19; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.4e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
DB 4 GTATG 8

```

RESULT 11
AAV15899

RESULT 12
AAZ10692

ID AA210692 standard; DNA; 9 BP.
 XX
 AC AA210692;
 XX
 DT 23-NOV-1999 (first entry)
 XX
 DE Oligonucleotide sequence that increases p53 activity in a cell.
 XX
 KM p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;
 KM UV-induced hyperproliferative disease; psoriasis; vitiligo;
 KM atopic dermatitis; allergic rhinitis; conjunctivitis; photoaging;
 KM skin cancer; ss.
 XX
 OS Synthetic.
 XX
 PN GB2336157-A.
 XX
 PD 13-OCT-1999.
 XX
 PF 24-MAR-1999; 99GB-0006758.
 XX
 PR 26-MAR-1998; 98US-0048927.
 XX
 PA (UYBO-) UNIV BOSTON.
 XX
 PI Gilchrist BA, Yaar M, Eller M;
 PT WPI; 1999-543520/46.
 XX
 DR DNA fragments useful for increasing p53 activity in a cell and reducing
 XX susceptibility to UV-induced hyperproliferative diseases -
 PT
 PS Claim 11; Page 29; 44pp; English.
 XX
 CC AA210692-97 represent DNA fragments that are used for increasing p53
 CC activity in a cell. The oligonucleotides are are UV mimetics and
 CC protect cells against subsequent exposure to UV-irradiation or
 CC chemicals. The oligonucleotides are useful for increasing p53 activity
 CC in a cell, reducing the susceptibility to UV-induced hyperproliferative
 CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic
 CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging
 CC and reducing susceptibility to skin cancer.
 CC
 SO Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;
 Query Match 100.0%; Score 5; DB 20; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GTATG 5
 |||||
 DB 3 GTATG 7
 RESULT 13
 AAS14905
 ID AAS14905 standard; DNA; 9 BP.
 XX
 AC AAS14905;
 XX
 DT 14-FEB-2002 (first entry)
 XX
 DE Melanogenesis associated oligonucleotide #1.
 XX
 KM Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;
 KM anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;
 KM immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;
 KM tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;
 KM carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;
 KM conjunctivitis; allergic rhinitis; vitiligo; ss.
 XX
 OS Synthetic.
 XX

FH Key Location/Qualifiers
 FT modified_base 1
 FT /*tag= a
 FT /mod_base= g
 FT /note= "Optionally phosphorylated"
 XX
 XX WO200174342-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-US10162.
 XX
 PR 31-MAR-2000; 2000US-0540843.
 XX
 PA (UYBO-) UNIV BOSTON.
 XX
 PI Gilchrist BA, Yaar M, Eller M;
 PT WPI; 2001-626338/72.
 XX
 DR Inhibiting proliferation of epithelial cells, useful e.g. for treating
 XX carcinoma, using specific oligonucleotides that mimic the effects of
 PT ultra-violet light -
 PT
 PS Claim 1; Page 36; 74pp; English.
 XX
 CC The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergically mediated inflammation (atopic or contact dermatitis,
 CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #1, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell
 CC proliferation, described in the method of the invention.
 CC
 SO Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;
 Query Match 100.0%; Score 5; DB 23; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GTATG 5
 |||||
 DB 3 GTATG 7
 RESULT 14
 ABQ71504/c
 ID ABQ71504 standard; DNA; 9 BP.
 XX
 AC ABQ71504;
 XX
 DT 28-AUG-2002 (first entry)
 XX
 DE Zinc finger protein related oligonucleotide target SEQ ID NO:623.
 XX
 KM Zinc finger protein; ZFP; DNA binding protein; zinc finger; ss.
 XX

XX OS Homo sapiens.
 OS Synthetic.
 XX PN WO200242459-A2.
 XX PD 30-MAY-2002.
 XX PF 20-NOV-2001; 2001WO-US43438.
 XX PR 20-NOV-2000; 2000US-0716637.
 XX PA (SANG-) SANGAMO BIOSCIENCES INC.
 XX PI Liu Q;
 XX P1 WPI: 2002-500284/53.
 DR New zinc finger protein that binds to target site, useful in studying
 PT gene function and for human therapeutics and plant engineering,
 PT comprises first, second and third zinc fingers, ordered from N- to
 PT C-terminus -
 PS Example 1; Page 45; 81pp; English.
 XX CC The present invention describes a zinc finger protein (I) that binds to
 CC a target site, comprising a first (F1), a second (F2), and a third (F3)
 CC zinc finger, ordered F1, F2, F3 from N-terminus to C-terminus, where the
 CC target site comprises, in 3'-5' direction, a first (S1), a second (S2),
 CC and a third (S3) target subsite. Also described are: (1) a polypeptide
 CC (II) comprising (I); (2) a polynucleotide (III) encoding (I) or (II); and
 CC (3) designing (M) (I) involves selecting the F1 zinc finger such that
 CC it binds to the S1 target subsite, selecting the F2 zinc finger such
 CC that it binds to the S2 target subsite, and selecting the F3 zinc
 CC finger such that it binds to the S3 target subsite, thus designing (I)
 CC that binds to a target site. (I) is useful for recognition of triplet
 CC target subsites having the nucleotide G in the 5'-most position of the
 CC subsite. (I) is useful in studying gene function, and for human
 CC therapeutics and plant engineering. (I), (II) or (III) is useful in
 CC therapeutic methods to modulate the expression of a target region within
 CC a subject, in diagnostic methods for sequence specific detection of
 CC target nucleic acid in a sample, and in assays to determine the
 CC phenotype and function of gene expression. (I) has improved affinity
 CC and specificity for their target sequences, as well as enhanced
 CC biological activity. ABQ71213 to ABQ72214 and ABP48191 to ABP51230
 CC represent DNA target sequences and zinc finger peptides which are given
 CC in the exemplification of the present invention.
 XX CC
 SQ Sequence 9 BP; 2 A; 2 C; 3 G; 2 T; 0 other;
 Query Match 100.0%; Score 5; DB 24; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GRATG 5
 DB 6 GRATG 2
 RESULT 15
 ABQ71922
 ID ABQ71922 standard; DNA: 9 BP.
 XX AC ABQ71922;
 XX DT 28-AUG-2002 (first entry)
 XX DE Zinc finger protein related oligonucleotide target SEQ ID NO:2220.
 XX KW Zinc finger protein; ZFP; DNA binding protein; zinc finger; ss.
 XX OS Homo sapiens.
 OS Synthetic.

XX PN WO200242459-A2.
 XX PD 30-MAY-2002.
 XX PF 20-NOV-2001; 2001WO-US43438.
 XX PR 20-NOV-2000; 2000US-0716637.
 XX PA (SANG-) SANGAMO BIOSCIENCES INC.
 XX PI Liu Q;
 XX P1 WPI: 2002-500284/53.
 DR New zinc finger protein that binds to target site, useful in studying
 PT gene function and for human therapeutics and plant engineering,
 PT comprises first, second and third zinc fingers, ordered from N- to
 PT C-terminus -
 PS Example 1; Page 58; 81pp; English.
 XX CC The present invention describes a zinc finger protein (I) that binds to
 CC a target site, comprising a first (F1), a second (F2), and a third (F3)
 CC zinc finger, ordered F1, F2, F3 from N-terminus to C-terminus, where the
 CC target site comprises, in 3'-5' direction, a first (S1), a second (S2),
 CC and a third (S3) target subsite. Also described are: (1) a polypeptide
 CC (II) comprising (I); (2) a polynucleotide (III) encoding (I) or (II); and
 CC (3) designing (M) (I) involves selecting the F1 zinc finger such that
 CC it binds to the S1 target subsite, selecting the F2 zinc finger such
 CC that it binds to the S2 target subsite, and selecting the F3 zinc
 CC finger such that it binds to the S3 target subsite, thus designing (I)
 CC that binds to a target site. (I) is useful for recognition of triplet
 CC target subsites having the nucleotide G in the 5'-most position of the
 CC subsite. (I) is useful in studying gene function, and for human
 CC therapeutics and plant engineering. (I), (II) or (III) is useful in
 CC therapeutic methods to modulate the expression of a target region within
 CC a subject, in diagnostic methods for sequence specific detection of
 CC target nucleic acid in a sample, and in assays to determine the
 CC phenotype and function of gene expression. (I) has improved affinity
 CC and specificity for their target sequences, as well as enhanced
 CC biological activity. ABQ71213 to ABQ72214 and ABP48191 to ABP51230
 CC represent DNA target sequences and zinc finger peptides which are given
 CC in the exemplification of the present invention.
 XX CC
 SQ Sequence 9 BP; 2 A; 0 C; 4 G; 3 T; 0 other;
 Query Match 100.0%; Score 5; DB 24; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1 GRATG 5
 DB 4 GRATG 8
 Search completed: June 2, 2003, 18:45:12
 Job time : 84.7366 secs

FEATURES	source
LOCUS	BM398220
DEFINITION	5009.0-42-D11.t.1 Chilcoat/Turkewitz cDNA (large fraction)
ACCESSION	Tetrahymena thermophila cDNA, mRNA sequence.
VERSION	BM398220
KEYWORDS	BM398220.1 GI:18198273
SOURCE	EST.
ORGANISM	Tetrahymena thermophila.
REFERENCE	Tetrahymena thermophila.
AUTHORS	Enayati, A.; Alveolata; Cilophora; Oligohymenophorea; Eumetazoa; Tetrahymena; Tetrahymena.
JOURNAL	1 (bases 1 to 14)
COMMENT	Turkewitz, A.P., Karrer, K.M., Jahn, C., Ortas, E., Kirk, K.E., Frankel, J. and Klobutcher, L.
	EST from Tetrahymena thermophila, strain CU428.1, growing cells
	Unpublished (2002)
	Contact: Turkewitz AP
	Molecular Genetics and Cell Biology
	University of Chicago
	920 E. 58th Street, Chicago, IL 60637, USA
	Tel: 773 702 4374
	Fax: 773 702 3172
	Email: apturkew@midway.uchicago.edu
	Seq primer: T3.
	Location/Qualifiers
	1..14
	/organism="Tetrahymena thermophila"
	/strain="CU428.1"

```

/db_xref="taxon:5911"
/clone.lib="Chlicoat/Turkewitz cDNA (large fraction)"
/Note="Vector: Bluescript SK+; Details on library
preparation can be found in Chlicoat and Turkewitz (2001)
Proc. Natl. Acad. Sci USA, 98: 8709-8713."

BASE COUNT      4 a      5 c      0 g      5 t

ORIGIN
Query Match      100.0%; Score 5; DB 13; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.1e+06;
Matches          5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTATG 5
        |||||
Db      5 GTATG 1

RESULT 2
A1424037/c      16 bp      mRNA      linear      EST 09-MAR-1999
LOCUS          tf51h06.x1 NCI_CGAP_Brn23 Homo sapiens cDNA clone IMAGE:2102843 3'
DEFINITION     similar to TR:Q69566 Q69566 ; mRNA sequence.
ACCESSION      A1424037
VERSION        A1424037.1 GI:4269968
KEYWORDS       EST.
SOURCE         human.
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE      1 (bases 1 to 16)
AUTHORS        NCI/NINDS-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE          National Cancer Institute / National Institute of Neurological
Disorders and Stroke, Brain Tumor Genome Anatomy Project
(CCAP/BTCAP), Tumor Gene Index
Unpublished (1998)
JOURNAL        Contact: Robert Strausberg, Ph.D.
COMMENT        Email: cgapbs-r@mail.nih.gov
                Tissue Procurement: David N. Louis, M.D., Myrna R. Rosenfeld M.D.,
                Ph.D.
                cDNA Library Preparation: M. Bento Soares, Ph.D., M. Fatima
                Bonaldi, Ph.D.
                cDNA Library Arrayed by: Greg Lennon, Ph.D.
                DNA Sequencing by: Washington University Genome Sequencing Center
                Clone distribution: NCI-CGAP clone distribution information can be
                found through the I.M.A.G.E. Consortium/LLNL at:
                www.bio.llnl.gov/dbp/image/image.html

FEATURES
source
    1..16
    /organism="Homo sapiens"
    /db_xref="taxon:9606"
    /clone_image="IMAGE:2102843"
    /clone.lib="NCI_CGAP_Brn23"
    /tissue_type="glioblastoma (pooled)"
    /lab_host="DH10B"
    /note="Organ: brain; Vector: pT7T3D-Pac (Pharmacia) with a
    modified polylinker; Site:1: Not I; Site:2: Eco RI; 1st
    strand cDNA was primed with a Not I - oligo(dT) primer [5'
    TGTTCACATCTGAGTGGAGCGCGCCATATCTTTTCTTTTCTTTTCTTTT
    T 3']; double-stranded cDNA was ligated to Eco RI
    adaptors (Pharmacia), digested with Not I and cloned into
    the Not I and Eco RI sites of the modified pT7T3 vector.
    Library is normalized, and was constructed by Bento
    Soares and M.Fatima Bonaldi."

BASE COUNT      8 a      6 c      1 g      1 t

ORIGIN
Query Match      100.0%; Score 5; DB 9; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches          5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1 GTATG 5
        |||||
Db      6 GTATG 2

RESULT 3
A1685758/c      16 bp      mRNA      linear      EST 27-MAY-1999
LOCUS          tu37g09.x1 NCI_CGAP_Pr28 Homo sapiens cDNA clone IMAGE:2253280 3'
DEFINITION     similar to TR:Q02393 Q02393 HUMAN PAPILLOMAVIRUS 18 E5 CENTRAL
SEQUENCE MOTIF PROTEIN 1; contains element LTR4 repetitive element
; mRNA sequence.
ACCESSION      A1685758
VERSION        A1685758.1 GI:4897052
KEYWORDS       EST.
SOURCE         human.
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE      1 (bases 1 to 16)
AUTHORS        NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE          National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
JOURNAL        Contact: Robert Strausberg, Ph.D.
COMMENT        Email: cgapbs-r@mail.nih.gov
                Tissue Procurement: Michael J. Brownstein, M.D., Ph.D., Michael R.
                Emmert-Buck, M.D., Ph.D.
                cDNA Library Preparation: M. Bento Soares, Ph.D.
                cDNA Library Arrayed by: Greg Lennon, Ph.D.
                DNA Sequencing by: Washington University Genome Sequencing Center
                Clone distribution: NCI-CGAP clone distribution information can be
                found through the I.M.A.G.E. Consortium/LLNL at:
                www.bio.llnl.gov/dbp/image/image.html

FEATURES
source
    1..16
    /organism="Homo sapiens"
    /db_xref="taxon:9606"
    /clone_image="IMAGE:2253280"
    /clone.lib="NCI_CGAP_Pr28"
    /sex="male"
    /dev_stage="adult"
    /lab_host="DH10B"
    /note="Organ: prostate; Vector: pT7T3D-Pac (Pharmacia)
    with a modified polylinker; Plasmid DNA from the
    normalized library NCI-CGAP_Pr22 was prepared, and ss
    circles were made in vitro. Following HAP purification,
    this DNA was used as tracer in a subtractive hybridization
    reaction. The driver was PCR-amplified cDNAs from a pool
    of 5,000 clones made from the same library (clonids
    985608-986759, 1101192-1101959, and 1217928-1220615)."
    Subtraction by Bento Soares and M. Fatima Bonaldi."

BASE COUNT      7 a      7 c      1 g      1 t

ORIGIN
Query Match      100.0%; Score 5; DB 9; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches          5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTATG 5
        |||||
Db      9 GTATG 5

RESULT 4
A1721735/c      16 bp      mRNA      linear      EST 07-JUN-2001
LOCUS          fc31g08.x1 zebrafish washu MPING EST Danio rerio cDNA clone
DEFINITION

```


JOURNAL
MEDLINE
COMMENT

osteoarthritic cartilage cDNA libraries
Osteoarthr. Cartil. 9 (7), 641-653 (2001)
21482651
Contact: Sanjay Kumar
DW2109
GlasgowSmithKline
709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406, USA
Tel: 610-270-7245
Fax: 610-270-5598
Email: sanjay.kumar-1@gsk.com
Seq primer: T7
Location/Qualifiers

FEATURES
source

1. 17
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="HNC (Human Normal Cartilage)"
/tissue_type="cartilage"
/lab_host="E.coli DH10 B"
/note="Vector: pSPORT I; Site_1: SalI; Site_2: NotI;
Directional"

BASE COUNT
ORIGIN

Query Match 100.0%; Score 5; DB 13; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
DB 10 GTATG 6

RESULT 7
C21103 17 bp mRNA linear EST 23-OCT-1996
LOCUS HMG50002626 Human adult (K.Okubo) Homo sapiens cDNA 3', mRNA
DEFINITION sequence.

ACCESSION C21103
VERSION C21103.1 GI:1622213
KEYWORDS EST.

SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 17)
Okubo, K.
BodyMap: human gene expression database
Unpublished (1995)
Contact: Okubo, K.
Institute for Molecular and Cellular Biol
Osaka University
1-3 Yamada-oka, Suita, Osaka Pref. 565, Japan
Tel: 06-877-5111 (ex. 3315)
Email: kousaku@imb.osaka-u.ac.jp
Human Gene Signature, 3'-directed cDNA sequence. We are not
submitting the same cDNA sequence redundantly to DDBJ since 1993.
For the abundance information of clones with this sequence in this
library and as well as in other 3'-directed libraries, see
http://www.imb.osaka-u.ac.jp/bodymap/. The sequences of the clones
represented by this GS sequence is also found there.

FEATURES
source

1. 17
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="Human adult (K.Okubo)"
/dev_stage="adult"

/note="Organ: Blood; Vector: 1-9t-11; Site_1: Eco-RI;
Monocytes were prepared from blood by ficoll-hypaque,
percoll and T cell rosetting purification steps (purity:
96 %). mRNA was prepared from activated monocytes from a
patient with rheumatoid arthritis. mRNA was reverse
transcribed with MuLV. Using Eco-RI linkers cDNA was
cloned into 1-9t-11 vector arms. The cDNA library was

screened by differential hybridization using radioactively
marked ss-cDNA from activated and non-activated
monocytes.

BASE COUNT
ORIGIN

Query Match 100.0%; Score 5; DB 14; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
DB 13 GTATG 9

RESULT 8
BM397954 18 bp mRNA linear EST 17-JAN-2002
LOCUS BM397954/c 5009-0-39-G08.t.1 Chilcoat/Turkewitz cDNA (large fraction)
DEFINITION Tetrahymena thermophila cDNA, mRNA sequence.

ACCESSION BM397954
VERSION BM397954.1 GI:18198022
KEYWORDS EST.
SOURCE Tetrahymena thermophila.
ORGANISM Tetrahymena thermophila
Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
Hydrozoa; Tetrahymenida; Tetrahymena.

REFERENCE
AUTHORS Turkewitz, A.P., Karrer, K.M., Jahn, C., Ortas, E., Kirk, K.E., Frankel
J. and Klobutcher, L.
EST from Tetrahymena thermophila, strain CU428.1, growing cells
Unpublished (2002)
CONTACT: Turkewitz AP
Molecular Genetics and Cell Biology
University of Chicago
920 E. 58th Street, Chicago, IL 60637, USA
Tel: 773 702 4374
Fax: 773 702 3172
Email: apturkew@midway.uchicago.edu
Seq primer: T3.

FEATURES
source

1. 18
/organism="Tetrahymena thermophila"
/strain="CU428.1"
/db_xref="taxon:5911"
/clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
/note="Vector: Bluescript SK+; Details on library
preparation can be found in Chilcoat and Turkewitz (2001)
Proc. Natl. Acad. Sci USA, 98: 8709-8713."

BASE COUNT
ORIGIN

Query Match 100.0%; Score 5; DB 13; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
DB 5 GTATG 1

RESULT 9
AA977115 19 bp mRNA linear EST 26-MAY-1998
LOCUS AA977115 oq24c08.s1 NCI_CGAP_GC4 Homo sapiens cDNA clone IMAGE:1587278 3'
DEFINITION similar to TR:Q69566 Q69566; mRNA sequence.

ACCESSION AA977115
VERSION AA977115.1 GI:3154561
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 19)
 AUTHORS NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 JOURNAL Tumor Gene Index
 COMMENT Unpublished (1997)
 Contact: Robert Strausberg, Ph.D.
 Email: cgaps-ri@mail.nih.gov
 Tissue Procurement: Christopher A. Moskaluk, M.D., Ph.D., Michael
 Emmert-Buck, M.D., Ph.D.
 CDNA Library Preparation: M. Bento Soares, Ph.D.
 CDNA Library Arrayed by: Greg Lennon, Ph.D.
 DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/LNL at:
www.bio.linn.gov/bdrip/image/image.html

FEATURES
 SOURCE
 Trace considered overall poor quality
 Seq primer: -40ml3 fwd. ET from Amersham
 High quality sequence stop: 1.
 Location/Qualifiers
 1..19
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:1587278"
 /clone_lib="NCI CGAP GC4"
 /tissue_type="pooled germ cell tumors"
 /lab_host="DH10B"
 /note="Vector: pT7T3D-Pac (Pharmacia) with a modified
 polylinker; 1st strand cDNA was prepared from 3 pooled
 germ cell tumors, and was then primed with a Not I -
 oligo(dT) primer. Double-stranded cDNA was ligated to Eco
 RI adaptors (Pharmacia), digested with Not I and cloned
 into the Not I and Eco RI sites of the modified pT7T3
 vector. Library is normalized. Library was constructed by
 Bento Soares and M. Fatima Bonaldo."

BASE COUNT 2 a 0 c 7 g 10 t

ORIGIN

Query Match 100.0%; Score 5; DB 9; Length 19;
 Best local Similarity 100.0%; Pred. No. 1.2e+06;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
 |||||
 DB 3 GTATG 7

RESULT 10
 A1120725/c 19 bp mRNA linear EST 02-SEP-1998
 DEFINITION ub72b11.r1 Soares mammary gland NMLMG Mus musculus CDNA clone
 IMAGE:1383261 5' similar to TR:Q15009 Q15009 ORF, COMPLETE CDS. ;,
 mRNA sequence.
 ACCESSION A1120725
 VERSION A1120725.1 GI:3521049
 KEYWORDS EST.
 SOURCE house mouse.
 ORGANISM Mus musculus.
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 19)
 Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
 Giesel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
 Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
 Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and
 Waterston,R.
 The WashU-HMI Mouse EST Project
 Unpublished (1996)
 CONTACT: Marra M/Mouse EST Project
 WashU-HMI Mouse EST Project
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800

TITLE
 JOURNAL
 COMMENT

Fax: 314 286 1810
 Email: mouseest@watson.wustl.edu
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.linn.gov) for further information.
 MGI:905729

FEATURES
 SOURCE
 Trace considered overall poor quality
 Possible reversed clone: similarity on wrong strand
 Seq primer: -28ml3 rev2 ET from Amersham
 High quality sequence stop: 1.
 Location/Qualifiers
 1..19
 /organism="Mus musculus"
 /db_xref="taxon:10090"
 /clone="IMAGE:1383261"
 /clone_lib="Soares mammary_gland_NMLMG"
 /sex="Female (lactating)"
 /tissue_type="mammary gland"
 /lab_host="DH10B"
 /note="Vector: pT7T3D-Pac (Pharmacia) with a modified
 polylinker; 1st strand cDNA was prepared from mammary
 gland tissue from a lactating female, and was then primed
 with a Not I - oligo(dT) primer. Double-stranded cDNA was
 ligated to Eco RI adaptors (Pharmacia), digested with Not
 I and cloned into the Not I and Eco RI sites of the
 modified pT7T3 vector. Library is normalized. Library
 was constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 9 a 3 c 4 g 3 t

ORIGIN

Query Match 100.0%; Score 5; DB 9; Length 19;
 Best local Similarity 100.0%; Pred. No. 1.2e+06;
 Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
 |||||
 DB 11 GTATG 7

RESULT 11
 A1747751 19 bp mRNA linear EST 22-JUN-1999
 LOCUS u121h05.x1 Sugano mouse embryo mewa Mus musculus CDNA clone
 DEFINITION IMAGE:2088249 3' similar to TR:P79101 P79101 CLEAVAGE AND
 POLYADENYLATION SPECIFICITY FACTOR PROTEIN. ;, mRNA sequence.
 A1747751
 ACCESSION A1747751.1 GI:5126015
 VERSION EST.
 KEYWORDS house mouse.
 SOURCE house mouse.
 ORGANISM Mus musculus.
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 19)
 Marra,M., Hillier,L., Kucaba,T., Martin,J., Beck,C., Wylie,T.,
 Underwood,K., Steptoe,M., Theising,B., Allen,M., Bowers,Y., Person
 ,B., Swaller,T., Gibbons,M., Pape,D., Harvey,N., Schurk,R., Ritter
 ,E., Kohn,S., Shin,T., Jackson,Y., Cardenas,M., McCann,R.,
 Waterston,R. and Wilson,R.
 The WashU-NCI Mouse EST Project 1999
 Unpublished (1999)
 CONTACT: Marra M/WashU-NCI Mouse EST Project 1999
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: mouseest@watson.wustl.edu
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.linn.gov) for further information.
 MGI:995933

FEATURES
 SOURCE
 Trace considered overall poor quality
 Possible reversed clone: similarity on wrong strand
 Seq primer: custom primer used
 High quality sequence stop: 1.
 Location/Qualifiers

```

source
1. .19
/organism="Mus musculus"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:2088249"
/clone_lib="Sugano mouse embryo mewa"
/dev_stage="embryo, 14 dpc"
/lab_host="DH10B"
/notes="Vector: pME18S-FL3; site_1: DraIII (CACTGCTGTC);
site_2: DraIII (CACCATGTC); 1st strand cDNA was primed
with an oligo(dT) primer [ATGTCCTCTTTTCTTTTCTTTT];
double-stranded cDNA was ligated to a DraIII adaptor
[TTTGGCTACTGG], digested and cloned into distinct DraIII
sites of the pME18S-FL3 vector (5' site CACTGCTGTC, 3' site
CACCATGTC). XhoI should be used to isolate the cDNA
insert. Size selection was performed to exclude fragments
<1.5kb. Library constructed by Dr. Sumio Sugano
(University of Tokyo Institute of Medical Science).
Custom primers for sequencing: 5' end primer
CTTCTGCTCTAAAGCTGCG and 3' end primer
CGACTGCTGCTGAGCACA."

BASE COUNT      6 a      2 c      8 g      3 t

Query Match      100.0%; Score 5; DB 9; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1 GRATG 5
        |||||
Db      13 GRATG 17

RESULT 12
LOCUS      C00646      19 bp      mRNA      linear      EST 23-JUL-1996
DEFINITION      HMM50008192 Human adult (K.Okubo) Homo sapiens cDNA, mRNA
sequence.
ACCESSION      C00646
VERSION      C00646.1 GI:1432876
KEYWORDS      EST.
SOURCE      human.
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 19)
Okubo, K.
BodyMap: human gene expression database
Unpublished (1995)
Contact: Okubo, K.
Institute for Molecular and Cellular Biol
Osaka University
1-3, Yamada-oka, Suita, Osaka Pref. 565, Japan
Tel: 06-877-5111(ex 3315)
Email: kousaku@imcb.osaka-u.ac.jp
Human Gene Signature, 3'-directed cDNA sequence. We are not
submitting the same cDNA sequence redundantly to DDBJ since 1993.
For the abundance information of clones with this sequence in this
library and as well as in other 3'-directed libraries, see
http://www.imcb.osaka-u.ac.jp/bodymap/. The sequences of the clones
represented by this GS sequence is also found there.

FEATURES
source
1. .19
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="Human adult (K.Okubo)"
/dev_stage="adult"
/notes="Organ: blood; Vector: 1-gt-11; Site_1: Eco-RI;
Monocytes were prepared from blood by ficoll-hypaque,
percoll and T cell rosetting purification steps (purity:
96 %). mRNA was prepared from activated monocytes from a
patient with rheumatoid arthritis. mRNA was reverse
transcribed with M-MLV. Using Eco-RI linkers cDNA was

```

```

BASE COUNT      4 a      1 c      8 g      6 t

Query Match      100.0%; Score 5; DB 14; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1 GRATG 5
        |||||
Db      14 GRATG 18

RESULT 13
LOCUS      A2341880      19 bp      DNA      linear      GSS 29-SEP-2000
DEFINITION      IM0074004R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0074004 R, DNA sequence.
ACCESSION      A2341880
VERSION      A2341880
KEYWORDS      A2341880.1 GI:10418570
GSS.
SOURCE      house mouse.
ORGANISM      Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 19)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Rellily,
M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A.
and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., STC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: dunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0074 row: 0 column: 04
Seq primer: CACACAGCAACACGCTATGACC
Class: plasmid ends
High quality sequence stop: 19.

FEATURES
source
1. .19
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0074004"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/notes="Vector: pMD42nv: Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD42 (g114732114|g114732072.1), a copy-number
inducible derivative of plasmid RI. The vector was ligated
with adaptors complementary to the insert adaptors and

```

purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN
4 a 4 c 6 g 5 t

Query Match
Best Local Similarity 100.0%; Score 5; DB 17; Length 19;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
11111
DB 8 GRATG 12

RESULT 14

AZ345849/c 19 bp DNA linear GSS 29-SEP-2000
LOCUS 1M0080D16R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0080D16 R, DNA sequence.

ACCESSION AZ345849
VERSION AZ345849.1 GI:10425086
KEYWORDS GSS.

SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 19)
AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, J.M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausern, A. and Wright, D., Weiss, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)

COMMENT

Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0080 row: D column: 16
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 19.
Location/Qualifiers

FEATURES
SOURCE

1. 19
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0080D16"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g114732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and

BASE COUNT
ORIGIN
9 a 4 c 0 g 6 t

Query Match
Best Local Similarity 100.0%; Score 5; DB 17; Length 19;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GRATG 5
11111
DB 13 GRATG 9

RESULT 15

AZ355195/c 19 bp DNA linear GSS 02-OCT-2000
LOCUS 1M0094G22R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC1M0094G22 R, DNA sequence.

ACCESSION AZ355195
VERSION AZ355195.1 GI:10467355
KEYWORDS GSS.

SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 19)
AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, J.M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausern, A. and Wright, D., Weiss, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)

COMMENT

Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0094 row: G column: 22
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 19.
Location/Qualifiers

FEATURES
SOURCE

1. 19
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0094G22"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g114732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and

purified. The sheared, adaptored mouse DNA was annealed to
adaptored vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

BASE COUNT 7 a 7 c 3 g 2 t
ORIGIN

Query Match 100.0%; Score 5; DB 17; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 GTATG 5
|||||
Db 12 GTATG 8

Search completed: June 2, 2003, 20:35:43
Job time : 630.439 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Comphen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:31:20 ; Search time 20.4878 Seconds

(without alignments)
74.844 Million cell updates/sec

Title: US-09-540-843-4

Perfect score: 5

Sequence: 1 gtag 5

Scoring table: IDENTITY_NDC

Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 558892

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents, NA.*
1: /cgn2_6/ptodata/1/ina/5A.COMB.seq:*
2: /cgn2_6/ptodata/1/ina/5B.COMB.seq:*
3: /cgn2_6/ptodata/1/ina/6A.COMB.seq:*
4: /cgn2_6/ptodata/1/ina/6B.COMB.seq:*
5: /cgn2_6/ptodata/1/ina/PCrus.COMB.seq:*
6: /cgn2_6/ptodata/1/ina/Backfile1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	5	100.0	5	US-08-855-372B-20	Sequence 20, Appl
2	5	100.0	5	US-09-048-927-4	Sequence 4, Appl
3	5	100.0	5	US-09-498-851-20	Sequence 20, Appl
4	5	100.0	7	US-08-615-170-10	Sequence 10, Appl
5	5	100.0	7	US-08-615-170-12	Sequence 12, Appl
6	5	100.0	9	US-09-048-927-3	Sequence 3, Appl
7	5	100.0	9	US-08-583-276-1	Sequence 8, Appl
8	5	100.0	9	US-08-646-789A-8	Sequence 8, Appl
9	5	100.0	9	US-08-646-789A-80	Sequence 8, Appl
10	5	100.0	9	US-09-048-927-1	Sequence 8, Appl
11	5	100.0	9	US-09-319-648-68	Sequence 68, Appl
12	5	100.0	10	US-08-335-565A-27	Sequence 27, Appl
13	5	100.0	10	US-08-250-951-1	Sequence 1, Appl
14	5	100.0	10	US-08-232-233-1	Sequence 1, Appl
15	5	100.0	10	US-08-232-233-1	Sequence 1, Appl
16	5	100.0	10	US-08-232-177A-422	Sequence 422, App
17	5	100.0	10	US-08-351-748-23	Sequence 23, Appl
18	5	100.0	10	US-08-351-748-25	Sequence 25, Appl
19	5	100.0	10	US-08-202-927-25	Sequence 25, Appl
20	5	100.0	10	US-08-430-536A-23	Sequence 23, Appl
21	5	100.0	10	US-08-430-536A-25	Sequence 25, Appl
22	5	100.0	10	US-08-171-718-45	Sequence 45, Appl
23	5	100.0	10	US-08-703-601-1	Sequence 1, Appl
24	5	100.0	10	US-08-684-547-23	Sequence 23, Appl
25	5	100.0	10	US-08-684-547-25	Sequence 25, Appl
26	5	100.0	10	US-08-469-318-174	Sequence 174, App
27	5	100.0	10	US-08-468-609A-174	Sequence 174, App
				US-08-478-087-45	Sequence 45, Appl

C 28	5	100.0	10	3	US-09-063-450-24	Sequence 24, Appl
C 29	5	100.0	10	3	US-09-063-450-33	Sequence 33, Appl
C 30	5	100.0	10	4	US-09-123-638-1	Sequence 1, Appl
C 31	5	100.0	10	4	US-08-646-695-30	Sequence 30, Appl
C 32	5	100.0	10	4	US-08-875-533-31	Sequence 31, Appl
C 33	5	100.0	10	4	US-08-446-872A-174	Sequence 174, App
C 34	5	100.0	10	4	US-09-724-753-1	Sequence 1, Appl
C 35	5	100.0	10	4	US-08-762-227A-174	Sequence 174, App
C 36	5	100.0	10	5	PCT-US92-09827-1	Sequence 1, Appl
C 37	5	100.0	10	5	PCT-US95-01185-174	Sequence 15, Appl
C 38	5	100.0	10	5	PCT-US95-02419-25	Sequence 25, Appl
C 39	5	100.0	10	5	PCT-US96-06053-30	Sequence 30, Appl
C 40	5	100.0	10	6	5198343-3	Patent No. 5198343
C 41	5	100.0	11	1	US-08-401-512-19	Sequence 19, Appl
C 42	5	100.0	11	1	US-08-147-696E-4	Sequence 4, Appl
C 43	5	100.0	11	1	US-08-696-139-6	Sequence 6, Appl
C 44	5	100.0	11	1	US-08-484-334-4	Sequence 4, Appl
C 45	5	100.0	11	2	US-08-441-887A-82	Sequence 82, Appl

ALIGNMENTS

RESULT 1
US-08-855-372B-20
Sequence 20, Application US/08855372B

Patent No. 6090549

GENERAL INFORMATION:

APPLICANT: Mirzabekov, Andrei D

APPLICANT: Parinov, Sergei V

APPLICANT: Barsky, Victor E

APPLICANT: Kirillov, Eugene V

APPLICANT: Dubiley, Svetlana A

TITLE OF INVENTION: Use of Continuous/Contiguous Stacking Hybridization as a Di

NUMBER OF SEQUENCES: 88

CORRESPONDENCE ADDRESS:

ADDRESSEE: CHERSKOV & FLAYNIK

STREET: 20 N. Wacker Drive

CITY: Chicago

STATE: Illinois

COUNTRY: United States

ZIP: 60606

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.50 inch, 1.4 MB storage

COMPUTER: PC

OPERATING SYSTEM: Microsoft Windows 98

SOFTWARE: Wordperfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/855,372B

FILING DATE: 13-MAY-97

PRIOR APPLICATION DATA:

APPLICATION NUMBER: U.S. 08/587,332

FILING DATE: 16-JAN-96

ATTORNEY/AGENT INFORMATION:

NAME: Cherskov, Michael J.

REGISTRATION NUMBER: 33,664

REFERENCE/DOCKET NUMBER: ANL-IN-95-027

TELECOMMUNICATION INFORMATION:

TELEPHONE: (312) 621-1330

TELEFAX: (312) 621-0088

INFORMATION FOR SEQ ID NO: 20:

SEQUENCE CHARACTERISTICS:

LENGTH: 5 bases

TYPE: nucleic acid

STRANDEDNESS: No. 6090549 Applicable

TOPOLOGY: linear

MOLECULE TYPE: Genomic DNA

HYPOTHETICAL: yes

Query Match 100.0%; Score 5; DB 3; Length 5;
Best local Similarity 100.0%; Pred. No. 5.8e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
Db 1 GTATG 5

RESULT 2
US-09-048-927-4
; Sequence 4, Application US/09048927
; Patent No. 6147056
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Yaar, Mina
; APPLICANT: Eller, Mark
; TITLE OF INVENTION: Use of Locally Applied DNA Fragments
; FILE REFERENCE: BU94-68A2
; CURRENT APPLICATION NUMBER: US/09/048,927
; CURRENT FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 08/952,697
; EARLIER FILING DATE: 1996-06-03
; EARLIER APPLICATION NUMBER: 08/467,012
; EARLIER FILING DATE: 1995-06-06
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 5
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA Fragment
US-09-048-927-4

Query Match 100.0%; Score 5; DB 3; Length 5;
Best Local Similarity 100.0%; Pred. No. 5.8e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
Db 1 GTATG 5

RESULT 3
US-09-498-851-20
; Sequence 20, Application US/09498851
; Patent No. 6440671
; GENERAL INFORMATION:
; APPLICANT: Mirzabekov, Andrei D
; APPLICANT: Parinov, Sergei V
; APPLICANT: Barsky, Victor E
; APPLICANT: Kirillov, Eugene V
; APPLICANT: Dubiley, Svetlana A
; TITLE OF INVENTION: Use of Continuous/Contiguous
; TITLE OF INVENTION: Stacking Hybridization as a Diagnostic Tool.
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CHERSKOV & FLAYNIK
; STREET: 20 N. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.50 inch, 1.4 MB storage
; COMPUTER: PC
; OPERATING SYSTEM: Microsoft Windows 98
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/498,851
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/855,372
; FILING DATE: 13-MAY-97
; APPLICATION NUMBER: U.S. 08/587,332

FILING DATE: 16-JAN-96
; ATTORNEY/AGENT INFORMATION:
; NAME: Cherskov, Michael J.
; REGISTRATION NUMBER: 33,664
; REFERENCE/DOCKET NUMBER: ANL-IN-95-027
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 621-1330
; TELEFAX: (312) 621-0088
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 5 bases
; TYPE: nucleic acid
; STRANDEDNESS: No. 6440671 Applicable
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; HYPOTHETICAL: yes
US-09-498-851-20

Query Match 100.0%; Score 5; DB 4; Length 5;
Best Local Similarity 100.0%; Pred. No. 5.8e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
Db 1 GTATG 5

RESULT 4
US-08-615-170-10/c
; Sequence 10, Application US/08615170
; Patent No. 5776776
; GENERAL INFORMATION:
; APPLICANT: ORDAHL, Charles P.
; APPLICANT: AZAKIE, Anthony
; APPLICANT: MAR, Janet H.
; APPLICANT: FARRANCE, Iain K.G.
; APPLICANT: HALL, Deborah E.
; APPLICANT: STEWART, Alexandre F.R.
; TITLE OF INVENTION: LARKIN, Sarah B.
; TITLE OF INVENTION: DTEF-1 ISOFORMS AND USES THEREOF
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourile and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US
; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/615,170
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/01526
; FILING DATE: 06-FEB-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/191,493
; FILING DATE: 04-FEB-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Heslin, James M.
; REGISTRATION NUMBER: 29,541
; REFERENCE/DOCKET NUMBER: 2307U-053120
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 326-2400
; TELEFAX: (415) 326-2422
; INFORMATION FOR SEQ ID NO: 10:

```

;
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..7
; OTHER INFORMATION: /standard_name="Sph-II binding
; OTHER INFORMATION: site in SV40"
US-08-615-170-10

Query Match
Best Local Similarity 100.0%; Score 5; DB 1; Length 7;
Pred. No. 4.1e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
DB 5 GTATG 1

RESULT 5
US-08-615-170-12/c
; Sequence 12, Application US/08615170
; Patent No. 5776776
; GENERAL INFORMATION:
; APPLICANT: ORDAHL, Charles P.
; APPLICANT: AZAKIE, Anthony
; APPLICANT: MAR, Janet H.
; APPLICANT: FARRANCE, Iain K.G.
; APPLICANT: HALL, Deborah E.
; APPLICANT: STEWART, Alexandre F.R.
; APPLICANT: LARKIN, Sarah B.
; TITLE OF INVENTION: DTFE-1 ISOFORMS AND USES THEREOF
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Hourie and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US
; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/615,170
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/01526
; FILING DATE: 06-FEB-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/191,493
; FILING DATE: 04-FEB-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Heslin, James M.
; REGISTRATION NUMBER: 29,541
; REFERENCE/DOCKET NUMBER: 2307U-053120
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 326-2400
; TELEFAX: (415) 326-2422
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 7 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

```

;
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..7
; OTHER INFORMATION: /standard_name="Rat beta-Myosin
; OTHER INFORMATION: Heavy Chain M-CAR binding element"
US-08-615-170-12

Query Match
Best Local Similarity 100.0%; Score 5; DB 1; Length 7;
Pred. No. 4.1e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
DB 5 GTATG 1

RESULT 6
US-09-048-927-3
; Sequence 3, Application US/09048927
; Patent No. 6147056
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Yaar, Mina
; APPLICANT: Eller, Mark
; TITLE OF INVENTION: Use of Locally Applied DNA Fragments
; FILE REFERENCE: BU94-68A2
; CURRENT APPLICATION NUMBER: US/09/048,927
; CURRENT FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 08/952,697
; EARLIER FILING DATE: 1996-06-03
; EARLIER APPLICATION NUMBER: 08/467,012
; EARLIER FILING DATE: 1995-06-06
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA Fragment
US-09-048-927-3

Query Match
Best Local Similarity 100.0%; Score 5; DB 3; Length 7;
Pred. No. 4.1e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
DB 2 GTATG 6

RESULT 7
US-08-583-276-1
; Sequence 1, Application US/08583276
; Patent No. 5837536
; GENERAL INFORMATION:
; APPLICANT: McDonagh, Kevin T.
; APPLICANT: Mienhuis, Arthur
; APPLICANT: Tolstoshev, Paul
; TITLE OF INVENTION: IMPROVED EXPRESSION OF HUMAN
; TITLE OF INVENTION: MULTIDRUG RESISTANCE GENES AND IMPROVED
; TITLE OF INVENTION: SELECTION OF CELLS TRANSDUCED WITH SUCH GENES
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
; ADDRESS: Cecchi & Stewart
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07068
; COMPUTER READABLE FORM:
```

MEDIUM TYPE: 3.5 Inch diskette
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: DM4.V2
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/583,276
FILING DATE: 05-JAN-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/332,444
FILING DATE: 31-OCT-1994
APPLICATION NUMBER: 07/887,712
FILING DATE: 22-MAY-1992
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 bases
TYPE: nucleic acid
STRANDEDNESS: singular
TOPOLOGY: linear
MOLECULE TYPE:
DESCRIPTION: Genomic DNA
US-08-583-276-1

Query Match 100.0%; Score 5; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
|||||
DB 4 GTATG 8

RESULT 8
US-08-646-789A-8
Sequence 8, Application US/08646789A
Patent No. 6022863
GENERAL INFORMATION:
APPLICANT: Peyman, John A.
TITLE OF INVENTION: REGULATION OF GENE EXPRESSION
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: PENNIE & EDMONDS
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/646,789A
FILING DATE: May 21, 1996
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: Mistrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 6523-006
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-9741/8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-646-789A-8

Query Match 100.0%; Score 5; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
|||||
DB 1 GTATG 5

RESULT 9
US-08-646-789A-80
Sequence 80, Application US/08646789A
Patent No. 6022863
GENERAL INFORMATION:
APPLICANT: Peyman, John A.
TITLE OF INVENTION: REGULATION OF GENE EXPRESSION
NUMBER OF SEQUENCES: 101
CORRESPONDENCE ADDRESS:
ADDRESSEE: PENNIE & EDMONDS
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/646,789A
FILING DATE: May 21, 1996
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: Mistrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 6523-006
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-9741/8864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 80:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA
US-08-646-789A-80

Query Match 100.0%; Score 5; DB 3; Length 9;
Best Local Similarity 60.0%; Pred. No. 3.2e+07;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTATG 5
|:|:|
DB 1 GUAUG 5

RESULT 10
US-09-048-927-1
Sequence 1, Application US/09048927
Patent No. 6147056
GENERAL INFORMATION:
APPLICANT: Glitchest, Barbara A.
APPLICANT: Yaar, Mina
TITLE OF INVENTION: Use of Locally Applied DNA Fragments
FILE REFERENCE: BU94-68A2
CURRENT APPLICATION NUMBER: US/09/048,927
CURRENT FILING DATE: 1998-03-26
EARLIER APPLICATION NUMBER: 08/952,697
EARLIER FILING DATE: 1996-06-03

```

; EARLIER APPLICATION NUMBER: 08/467,012
; EARLIER FILING DATE: 1995-06-06
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA Fragment
US-09-048-927-1

Query Match
Best Local Similarity 100.0%; Score 5; DB 3; Length 9;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GRATG 5
DB 3 GRATG 7

RESULT 11
US-09-319-648-68/c
; Sequence 68, Application US/09319648
; Patent No. 6451350
; GENERAL INFORMATION:
; APPLICANT: Hawkins, Mary
; TITLE OF INVENTION: Fluorescent Nucleotide Analog Halpin
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/319,648
; FILING DATE: 30-Jul-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/032,844
; FILING DATE: 13-DEC-1996
; APPLICATION NUMBER: WO PCT/US97/22448
; FILING DATE: 10-DEC-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Pang, Carol
; REGISTRATION NUMBER: 48,631
; REFERENCE/DOCKET NUMBER: 015280-288100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 68:
US-09-319-648-68

Query Match
Best Local Similarity 100.0%; Score 5; DB 4; Length 9;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GRATG 5
DB 3 GRATG 7
```

```

DB 7 GRATG 3

RESULT 12
US-08-335-565A-27
; Sequence 27, Application US/08335565A
; Patent No. 3527671
; GENERAL INFORMATION:
; APPLICANT: Li, Kenng
; APPLICANT: Rouse, Douglas I.
; APPLICANT: German, Thomas L.
; TITLE OF INVENTION: ASSAY FOR VERTICILLIUM DAHLIAE
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Quarles and Brady
; STREET: 1 South Pinckney St., PO BOX 2113
; CITY: Madison
; STATE: WI
; COUNTRY: USA
; ZIP: 53701-2113
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/335,565A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Seay, Nicholas J
; REGISTRATION NUMBER: 27,386
; REFERENCE/DOCKET NUMBER: 960296.93065
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 608-251-5000
; TELEFAX: 608-251-9166
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-335-565A-27

Query Match
Best Local Similarity 100.0%; Score 5; DB 1; Length 10;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GRATG 5
DB 6 GRATG 10

RESULT 13
US-08-250-951-1/c
; Sequence 1, Application US/08250951
; Patent No. 5532128
; GENERAL INFORMATION:
; APPLICANT: Heller, Michael J
; TITLE OF INVENTION: SELF-ORGANIZING MOLECULAR PHOTONIC
; STRUCTURES BASED ON CHROMOPHORE- AND FLUOROPHORE-CONTAINING
; POLYNUCLEOTIDES AND METHODS OF THEIR USE
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bingham & Fitting
; STREET: 12526 High Bluff Drive, Suite 300
; CITY: San Diego
; STATE: California
; COUNTRY: USA
; ZIP: 92130
; COMPUTER READABLE FORM:
```

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/250,951
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/790,262
FILING DATE: 07-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: Fitting, Thomas
REGISTRATION NUMBER: 34,163
REFERENCE/DOCKET NUMBER: HEL0002P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-792-3680
TELEFAX: 619-792-8477
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
FEATURE:
NAME/KEY: misc_feature
LOCATION: 10
OTHER INFORMATION: /note="Donor chromophore at the 3'
US-08-250-951-1

Query Match 100.0%; Score 5; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.1e+04;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GRATG 5
|||||
DB 8 GRATG 4

RESULT 14
US-08-232-233-1/C
Sequence 1, Application US/08232233
Patent No. 5565332
GENERAL INFORMATION:
APPLICANT: Michael J. Heller
TITLE OF INVENTION: SELF-ORGANIZING MOLECULAR PHOTONIC
STRUCTURES BASED ON CHROMOPHORE- AND FLUOROPHORE-
CONTAINING POLYNUCLEOTIDES AND METHODS OF THEIR USE
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 611 West Sixth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/232,233
FILING DATE: May 4, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/790,262
FILING DATE: No. 5565322ember 7, 1992
ATTORNEY/AGENT INFORMATION:

NAME: Murphy, David B.
REGISTRATION NUMBER: 31,125
REFERENCE/DOCKET NUMBER: 207/170
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
FEATURE:
NAME/KEY: misc_feature
LOCATION: 10
OTHER INFORMATION: /note="Donor chromophore at the 3' T nucleotide"
US-08-232-233-1

Query Match 100.0%; Score 5; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.1e+04;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GRATG 5
|||||
DB 8 GRATG 4

RESULT 15
US-08-222-177A-422/C
Sequence 422, Application US/08222177A
Patent No. 5582979
GENERAL INFORMATION:
APPLICANT: Weber, James L.
TITLE OF INVENTION: LENGTH POLYMORPHISMS IN
(dc-da)n, (dg-dt)n SEQUENCES AND METHODS OF USING SAME
NUMBER OF SEQUENCES: 460
CORRESPONDENCE ADDRESS:
ADDRESSEE: Demilt Ross & Stevens, S.C.
STREET: 8000 Excelsior Drive, Suite 401
CITY: Madison
STATE: Wisconsin
COUNTRY: USA
ZIP: 53717-1914
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/222,177A
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/341,562
FILING DATE: 21-APR-1989
ATTORNEY/AGENT INFORMATION:
NAME: Sara, Charles S.
REGISTRATION NUMBER: 30,492
REFERENCE/DOCKET NUMBER: 09865.601
TELECOMMUNICATION INFORMATION:
TELEPHONE: (608) 831-2100
TELEFAX: (608) 831-2106
TELEX:
INFORMATION FOR SEQ ID NO: 422:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear

; MOLECULE TYPE: DNA (genomic)
US-08-222-177A-422

Query Match 100.0%; Score 5; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6.1e+04;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
DB 8 GTATG 4

Search completed: June 2, 2003, 20:38:34
Job time : 21.4878 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 19:09:45 ; Search time 35.4878 Seconds
(without alignments)
189.976 Million cell updates/sec

Title: US-09-540-843-4

Perfect score: 5
Sequence: 1 gtagg 5

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 845702 seqs, 674182571 residues

Total number of hits satisfying chosen parameters: 477662

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published_Applications_NA:*

1: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
2: /cgn2_6/ptodata/2/pubpna/PCT_NEW_PUB.seq:*
3: /cgn2_6/ptodata/2/pubpna/US06_NEW_PUB.seq:*
4: /cgn2_6/ptodata/2/pubpna/US06_PUBCOMB.seq:*
5: /cgn2_6/ptodata/2/pubpna/US07_NEW_PUB.seq:*
6: /cgn2_6/ptodata/2/pubpna/PCTUS_PUBCOMB.seq:*
7: /cgn2_6/ptodata/2/pubpna/US08_NEW_PUB.seq:*
8: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
9: /cgn2_6/ptodata/2/pubpna/US09_NEW_PUB.seq:*
10: /cgn2_6/ptodata/2/pubpna/US09_PUBCOMB.seq:*
11: /cgn2_6/ptodata/2/pubpna/US10_NEW_PUB.seq:*
12: /cgn2_6/ptodata/2/pubpna/US10_PUBCOMB.seq:*
13: /cgn2_6/ptodata/2/pubpna/US60_NEW_PUB.seq:*
14: /cgn2_6/ptodata/2/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	5	100.0	5	9	US-10-122-630-4
2	5	100.0	5	9	US-10-122-630-6
3	5	100.0	5	9	US-10-122-633-4
4	5	100.0	5	9	US-10-122-633-6
5	5	100.0	7	9	US-10-122-630-3
6	5	100.0	7	9	US-10-122-630-7
7	5	100.0	7	9	US-10-122-633-3
8	5	100.0	7	9	US-10-122-633-7
9	5	100.0	8	10	US-09-142-593-11
10	5	100.0	8	10	US-09-142-593-17
11	5	100.0	8	10	US-09-927-886-17
12	5	100.0	9	9	US-10-122-630-1
13	5	100.0	9	9	US-10-122-633-1
14	5	100.0	9	9	US-10-096-596-32
15	5	100.0	9	9	US-09-990-186-623
16	5	100.0	9	9	US-09-990-186-623
17	5	100.0	9	9	US-09-990-186-2220
18	5	100.0	9	10	US-09-989-789-623
19	5	100.0	9	10	US-09-989-789-2220

20	5	100.0	9	10	US-09-989-789-2256	Sequence 2256, Ap
21	5	100.0	10	9	US-10-006-542B-5	Sequence 5, Appl1
22	5	100.0	10	9	US-09-962-602-7	Sequence 7, Appl1
23	5	100.0	10	9	US-09-962-602-8	Sequence 8, Appl1
24	5	100.0	10	9	US-09-990-186-622	Sequence 622, App
25	5	100.0	10	9	US-09-990-186-636	Sequence 636, App
26	5	100.0	10	9	US-09-990-186-1338	Sequence 1338, Ap
27	5	100.0	10	9	US-09-990-186-1341	Sequence 1341, Ap
28	5	100.0	10	9	US-09-990-186-1342	Sequence 1342, Ap
29	5	100.0	10	9	US-09-990-186-1343	Sequence 1343, Ap
30	5	100.0	10	10	US-09-898-789-1343	Sequence 1343, Ap
31	5	100.0	10	10	US-09-898-789-31	Sequence 31, Appl1
32	5	100.0	10	10	US-09-989-789-622	Sequence 622, App
33	5	100.0	10	10	US-09-989-789-636	Sequence 636, App
34	5	100.0	10	10	US-09-989-789-1338	Sequence 1338, Ap
35	5	100.0	10	10	US-09-989-789-1341	Sequence 1341, Ap
36	5	100.0	10	10	US-09-989-789-1342	Sequence 1342, Ap
37	5	100.0	10	10	US-09-989-789-1343	Sequence 1343, Ap
38	5	100.0	10	10	US-09-898-789-31	Sequence 31, Appl1
39	5	100.0	10	12	US-10-033-145-2	Sequence 2, Appl1
40	5	100.0	10	12	US-10-033-145-313	Sequence 313, App
41	5	100.0	10	12	US-10-033-145-549	Sequence 549, App
42	5	100.0	10	12	US-10-033-145-723	Sequence 723, App
43	5	100.0	10	12	US-10-033-145-766	Sequence 766, App
44	5	100.0	10	12	US-10-033-145-824	Sequence 824, App
45	5	100.0	10	12	US-10-033-145-979	Sequence 979, App

ALIGNMENTS

RESULT 1
US-10-122-630-4
; Sequence 4, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Glitchest, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to inhibit Cell Growth using
; FILE REFERENCE: 0054.1088-018
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 5
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-4

Query Match 100.0%; Score 5; DB 9; Length 5;
Best Local Similarity 100.0%; Pred. No. 2.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGG 5
DB 1 GTAGG 5

```
RESULT 2
US-10-122-630-6/c
; Sequence 6, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to inhibit cell growth using
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 5
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-6
```

```
Query Match          100.0%; Score 5; DB 9; Length 5;
Best Local Similarity 100.0%; Pred. No. 2.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1 GTATG 5
    |||||
Db 5 GTATG 1
```

```
RESULT 3
US-10-122-633-4
; Sequence 4, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to inhibit cell growth using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 5
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-4
```

```
Query Match          100.0%; Score 5; DB 9; Length 5;
Best Local Similarity 100.0%; Pred. No. 2.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1 GTATG 5
    |||||
Db 1 GTATG 5
```

```
RESULT 4
US-10-122-633-6/c
; Sequence 6, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to inhibit cell growth using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 5
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-6
```

```
Query Match          100.0%; Score 5; DB 9; Length 5;
Best Local Similarity 100.0%; Pred. No. 2.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1 GTATG 5
    |||||
Db 5 GTATG 1
```

```
RESULT 5
US-10-122-630-3
; Sequence 3, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to inhibit cell growth using
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-3
```

Query Match 100.0%; Score 5; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
DB 2 GTATG 6

RESULT 6
US-10-122-630-7
; Sequence 7, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Glitchrest, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-7

Query Match 100.0%; Score 5; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
DB 2 GTATG 6

RESULT 7
US-10-122-633-3
; Sequence 3, Application US/10122633
; Publication No. US2003003611A1
; GENERAL INFORMATION:
; APPLICANT: Glitchrest, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 7

TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-3

Query Match 100.0%; Score 5; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
DB 2 GTATG 6

RESULT 8
US-10-122-633-7
; Sequence 7, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Glitchrest, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-7

Query Match 100.0%; Score 5; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
|||||
DB 2 GTATG 6

RESULT 9
US-09-142-593-11/C
; Sequence 11, Application US/09142593
; Patent No. US20020016975A1
; GENERAL INFORMATION:
; APPLICANT: HACKETT ET AL.
; TITLE OF INVENTION: DNA-BASED TRANSPOSON SYSTEM FOR THE
; NUMBER OF SEQUENCES: 63
; CORRESPONDENCE ADDRESS:
; ADDRESS: MUEITING, RAASCH & GEBHARDT, P.A.
; STREET: 119 NORTH FOURTH STREET, SUITE 203
; CITY: MINNEAPOLIS
; STATE: MINNESOTA
; COUNTRY: USA
; ZIP: 55402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/142,593
FILING DATE: 10-SEP-1998
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/040,664
FILING DATE: 11-MAR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/053,868
FILING DATE: 28-JUL-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/065,303
FILING DATE: 13-NOV-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US98/04687
FILING DATE: 11-MAR-1998
ATTORNEY/AGENT INFORMATION:
NAME: SANDBERG, VICTORIA A.
REGISTRATION NUMBER: 41,287
REFERENCE/DOCKET NUMBER: 110.00450101
TELEPHONE: 612-305-1226
TELEFAX: 612-305-1228
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 8 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-142-593-11

Query Match 100.0%; Score 5; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
DB 6 GTATG 2

RESULT 10
US-09-927-886-17/c
Sequence 17, Application US/09927886
Patent No. US20020103152A1
GENERAL INFORMATION:
APPLICANT: Kay, Mark A.
APPLICANT: Yant, Stephen
TITLE OF INVENTION: Methods of In Vivo Gene Transfer Using a
FILE REFERENCE: STAN-160CIP
CURRENT APPLICATION NUMBER: US/09/927,886
CURRENT FILING DATE: 2001-08-10
PRIOR FILING DATE: 1999-10-28
PRIOR APPLICATION NUMBER: 60/162,279
PRIOR FILING DATE: 1999-11-17
PRIOR APPLICATION NUMBER: 09/440,301
NUMBER OF SEQ ID NOS: 19
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 17
LENGTH: 8
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: transposon repeat sequence
US-09-927-886-17

Query Match 100.0%; Score 5; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
DB 6 GTATG 2

RESULT 11
US-09-861-014-6/c
Sequence 6, Application US/09861014
Patent No. US20020115216A1
GENERAL INFORMATION:
APPLICANT: Steer, Clifford
APPLICANT: Kren, Betsy
APPLICANT: Linehan-Stileers, Cheryl
APPLICANT: McIvor, R.
TITLE OF INVENTION: Composition for Delivery of Compounds to Cells
FILE REFERENCE: 110.0130101
CURRENT APPLICATION NUMBER: US/09/861,014
CURRENT FILING DATE: 2001-05-19
PRIOR FILING DATE: 2000-05-19
PRIOR APPLICATION NUMBER: US 60/206,002
PRIOR FILING DATE: 2001-04-20
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn version 3.0
SEQ ID NO 6
LENGTH: 8
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Direct repeat sequence
US-09-861-014-6

Query Match 100.0%; Score 5; DB 10; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.6e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTATG 5
|||||
DB 6 GTATG 2

RESULT 12
US-10-122-630-1
Sequence 1, Application US/10122630
Publication No. US20030032610A1
GENERAL INFORMATION:
APPLICANT: Gilchrist, Barbara A.
APPLICANT: Eller, Mark S.
TITLE OF INVENTION: Method to Inhibit Cell Growth Using
FILE REFERENCE: 0054.1088-018
CURRENT APPLICATION NUMBER: US/10/122,630
CURRENT FILING DATE: 2002-04-12
PRIOR APPLICATION NUMBER: US 08/467,012
PRIOR FILING DATE: 1995-06-06
PRIOR APPLICATION NUMBER: PCT/US96/08386
PRIOR FILING DATE: 1996-06-03
PRIOR APPLICATION NUMBER: US 09/048,927
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: US 09/540,843
PRIOR FILING DATE: 2000-03-31
PRIOR APPLICATION NUMBER: PCT/US01/10162
PRIOR FILING DATE: 2001-03-30
NUMBER OF SEQ ID NOS: 15
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 1
LENGTH: 9
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-1

Query Match 100.0%; Score 5; DB 9; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
 |||||
Db 3 GTATG 7

RESULT 13

US-10-122-633-1
; Sequence 1, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054,1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-1

Query Match 100.0%; Score 5; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
 |||||
Db 3 GTATG 7

RESULT 14

US-10-096-596-32/c
; Sequence 32, Application US/10096596
; Publication No. US20030049653A1
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth W
; APPLICANT: Vogelstein, Bert
; APPLICANT: Velculescu, Victor
; APPLICANT: Zhang, Lin
; TITLE OF INVENTION: METHOD FOR SERIAL ANALYSIS OF GENE EXPRESSION
; FILE REFERENCE: 001107,00242
; CURRENT APPLICATION NUMBER: US/10/096,596
; PRIOR FILING DATE: 2002-03-14
; PRIOR APPLICATION NUMBER: US 08/527,154
; PRIOR FILING DATE: 1995-09-12
; PRIOR APPLICATION NUMBER: US 08/544,861
; PRIOR FILING DATE: 1995-10-18
; PRIOR APPLICATION NUMBER: US 09/107,228
; PRIOR FILING DATE: 1998-06-30
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 32
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-096-596-32

Query Match 100.0%; Score 5; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
 |||||
Db 7 GTATG 3

RESULT 15

US-09-990-186-623/c
; Sequence 623, Application US/09990186
; Publication No. US20030068675A1
; GENERAL INFORMATION:
; APPLICANT: Liu, Qiang
; TITLE OF INVENTION: POSITION DEPENDENT RECOGNITION OF GNN NUCLEOTIDE
; FILE REFERENCE: 8325-0011.21 / S11-US3
; CURRENT APPLICATION NUMBER: US/09/990,186
; PRIOR FILING DATE: 2001-11-20
; NUMBER OF SEQ ID NOS: 4085
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 623
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: example target
US-09-990-186-623

Query Match 100.0%; Score 5; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTATG 5
 |||||
Db 6 GTATG 2

Search completed: June 2, 2003, 23:43:13
Job time : 35.4878 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:06:10 ; Search time 318.073 Seconds

(without alignments)
823.475 Million cell updates/sec

Title: US-09-540-843-2

Perfect score: 9

Sequence: 1 tagagagat 9

Scoring table:

IDENTITY-NUC
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 774614

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl:*
1: gb_da:*
2: gb_hcg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vl:*
15: em_da:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_ph:*
24: em_pl:*
25: em_ro:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vl:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htg_mus:*
34: em_htg_pln:*
35: em_htg_rod:*
36: em_htg_mam:*
37: em_htg_vrt:*
38: em_sy:*
39: em_htgo_hum:*
40: em_htgo_mus:*
41: em_htgo_other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	9	100.0	9	6	AX268754
2	9	100.0	16	6	AX419832
3	9	100.0	20	6	A39511
4	9	100.0	20	6	AR166936
5	9	100.0	20	6	AX298850
6	9	100.0	20	6	AX327004
7	9	100.0	20	12	AB069488
8	9	100.0	22	6	E55148
9	9	100.0	23	6	E36547
10	9	100.0	23	6	E40169
11	9	100.0	23	11	DOC00506A
12	9	100.0	24	6	AR135197
13	9	100.0	24	6	AR146693
14	9	100.0	24	6	AR152264
15	9	100.0	24	6	AR157802
16	9	100.0	26	6	AX477111
17	9	100.0	27	6	A94623
18	9	100.0	27	6	AX017661
19	9	100.0	28	6	AR143009
20	9	100.0	29	6	I55932
21	9	100.0	30	6	AX286793
22	9	100.0	36	6	AX044051
23	9	100.0	36	6	AX044105
24	9	100.0	36	6	AX044153
25	9	100.0	37	6	A08117
26	9	100.0	39	6	E36735
27	9	100.0	40	6	AX147669
28	8	88.9	12	6	AR105116
29	8	88.9	15	6	AR033402
30	8	88.9	15	6	AR033403
31	8	88.9	15	6	AR108949
32	8	88.9	15	6	AR113224
33	8	88.9	15	6	AR113225
34	8	88.9	15	6	BD005791
35	8	88.9	15	6	I57631
36	8	88.9	15	6	I57632
37	8	88.9	16	6	A03756
38	8	88.9	16	6	A15048
39	8	88.9	16	6	A22501
40	8	88.9	16	6	A30883
41	8	88.9	16	6	A89421
42	8	88.9	16	6	AR035160
43	8	88.9	16	6	AX419833
44	8	88.9	16	6	AX419834
45	8	88.9	16	6	AX419835

ALIGNMENTS

RESULT 1
AX268754 LOCUS AX268754 9 bp DNA
DEFINITION Sequence 2 from Patent WO0174342. linear PAT 29-OCT-2001
ACCESSION AX268754
VERSION AX268754.1 GI:16541826
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Gilchrist, B.A., Yaar, M. and Eller, M.
TITLE Use of locally applied dna fragments
JOURNAL Patent: WO 0174342-A 2 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)

synthetic construct.
synthetic construct.
artificial sequences.

```

FEATURES
  source
    location/Qualifiers
      1..9
        /organism="synthetic construct"
        /db_xref="taxon:32630"
        /note="Synthetic DNA Fragment"
BASE COUNT
  3 a      0 c      4 g      2 t
ORIGIN

Query Match
  100.0%: Score 9; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 3,2e+09; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0;

QY
  1 TAGGAGCAT 9
  |||||
  1 TAGGAGCAT 9
Db
  1 TAGGAGCAT 9

RESULT 2
AX419832/c
LOCUS
  AX419832
DEFINITION
  Sequence 169 from Patent WO0198537.
ACCESSION
  AX419832
VERSION
  AX419832.1 GI:21524159
KEYWORDS
  synthetic construct.
  synthetic construct.
  artificial sequences.
REFERENCE
  1
  Lyamlichev,V., Allawi,H., Dong,F., Nerl,B.P. and Vener,I.T.
  Nucleic acid accessible hybridization sites
  Patent: WO 0198537-A 169 27-DEC-2001;
  THRD WAVE TECHNOLOGIES, INC. (US)
  Location/Qualifiers
    1..16
      /organism="synthetic construct"
      /db_xref="taxon:32630"
FEATURES
  source
    location/Qualifiers
      1..16
        /organism="synthetic construct"
        /db_xref="taxon:32630"
BASE COUNT
  5 a      7 c      0 g      4 t
ORIGIN

Query Match
  100.0%: Score 9; DB 6; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.3e+05; Indels 0; Gaps 0;
Matches 9; Conservative 0; Mismatches 0;

QY
  1 TAGGAGCAT 9
  .|||
  12 TAGGAGCAT 4
Db
  12 TAGGAGCAT 4

RESULT 3
A39511
LOCUS
  A39511
DEFINITION
  Sequence 6 from Patent EP0614980.
ACCESSION
  A39511
VERSION
  A39511.1 GI:2295829
KEYWORDS
  unidentified.
  unidentified.
  unclassified.
  1 (bases 1 to 20)
  Mehtali,M. and Sorg,T.
  TAT transdominant variants from human Immunodeficiency virus
  Patent: EP 0614980-A 6 14-SEP-1994;
  TRANSGENE SA (FR)
  other publication CA 2112652 940705
  other publication JP 6234791 940823
  other publication AU 5280393 940714
  other publication AU 668441 960502
  other publication FR 2700169 940708.
  Location/Qualifiers
    1..20
      /organism="unidentified"
      /db_xref="taxon:32644"
FEATURES
  source
    location/Qualifiers
      1..20
        /organism="unidentified"
        /db_xref="taxon:32644"
BASE COUNT
  6 a      4 c      7 g      3 t

```

ORIGIN	Query Match	100.0%;	Score 9;	DB 6;	Length 20;
	Best Local Similarity	100.0%;	Pred. No. 1.2e+05;		
	Matches	9;	Conservative 0;	Mismatches 0;	Indels 0;
QY	1 TAGGAGCAT 9				
DB	5 TAGAGGAT 13				
RESULT 4	ARI166936	20 bp	DNA	linear	PAT 17-OCT-2001
LOCUS	Sequence 6 from patent US 6284252.				
DEFINITION	ARI166936				
ACCESSION	ARI166936.1	GI:16243331			
VERSION					
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 20)				
TITLE	Meltail,M. and Sorg,T.				
JOURNAL	Transdominant rat variants of the human immunodeficiency virus				
FEATURES	Patent: US 6284252-A 6 04-SEP-2001;				
source	Location/Qualifiers				
	1..20				
BASE COUNT	/organism="unknown"				
ORIGIN	6 a 4 c 7 g 3 t				
Query Match	100.0%;	Score 9;	DB 6;	Length 20;	
Best Local Similarity	100.0%;	Pred. No. 1.2e+05;			
Matches	9;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1 TAGGAGCAT 9				
DB	5 TAGAGGAT 13				
RESULT 5	AX298850/c	20 bp	DNA	linear	PAT 26-NOV-2001
LOCUS	AX298850				
DEFINITION	Sequence 484 from Patent WO0183749.				
ACCESSION	AX298850				
VERSION	AX298850.1	GI:17128840			
KEYWORDS					
SOURCE	Mus sp.				
ORGANISM	Mus sp.				
REFERENCE	Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;				
AUTHORS	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.				
TITLE	1				
JOURNAL	Bachmanov,A.A., Beauchamp,G.K., Chatterjee,A., de Jong,P.J., Li,S.,				
	Li,X., Ohmen,J.D., Reed,D.R., Ross,p. and Tordoff,M.G.				
	Gene and sequence variation associated with sensing carbohydrate				
	compounds and other sweeteners				
	Patent: WO 0183749-A 484 08-NOV-2001;				
	WARNER-LAMBERT COMPANY (US) ; The Monell Chemical Senses Center				
	(US)				
FEATURES	Location/Qualifiers				
source	1..20				
	/organism="Mus sp."				
	/db_xref="taxon:10095"				
BASE COUNT	3 a 7 c 4 g 6 t				
ORIGIN					
Query Match	100.0%;	Score 9;	DB 6;	Length 20;	
Best Local Similarity	100.0%;	Pred. No. 1.2e+05;			
Matches	9;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1 TAGGAGCAT 9				
DB	17 TAGGAGCAT 9				


```

RESULT 6
LOCUS AX327004/c 20 bp DNA linear PAT 07-JAN-2002
DEFINITION Sequence 200 from Patent WO/18894.
ACCESSION AX327004
VERSION AX327004.1 GI:18097715
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1
AUTHORS Keith,T.
TITLE Novel human gene relating to respiratory diseases, obesity, and
JOURNAL Inflammatory bowel disease
Genome Therapeutics Corp. (US)
Patent: WO 0178894-A 200 25-OCT-2001;
Location/Qualifiers
FEATURES
source 1..20
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Primer"
BASE COUNT 2 a 8 c 4 g 6 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 19 TAGGAGGAT 11

RESULT 7
LOCUS AB069488/c 20 bp DNA linear SYN 08-AUG-2001
DEFINITION Synthetic construct DNA, forward primer for human STS sts-W47099 at
ACCESSION AB069488
VERSION AB069488
KEYWORDS
SOURCE synthetic construct DNA.
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K.,
Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H.,
Morohashi,A., Ohlra,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A.
and Soeda,E.
A BAC-based STS-content map spanning a 35-Mb region of human
chromosome 1p35-p36
Genomics 74 (1), 55-70 (2001)
JOURNAL 2 (bases 1 to 20)
MEDLINE 21269192
REFERENCE Horii,A.
AUTHORS Direct Submission
JOURNAL Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
Miyagi 980-8575, Japan (E-mail:horii@mail.cc.tohoku.ac.jp,
Tel:81-22-717-8042, Fax:81-22-717-8047)
FEATURES
source 1..20
Location/Qualifiers
misc.feature /organism="synthetic construct"
/db_xref="taxon:32630"
1..20
/note="forward primer for human STS sts-W47099 at 1p36
sts-W47099 obtained from clones B61b17, B66A23, B26b112,
B316h11, B26p17, B179a2, B16612, Human BAC library
RPci-11"
BASE COUNT 3 a 9 c 2 g 6 t
ORIGIN

Query Match 100.0%; Score 9; DB 12; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 20 TAGGAGGAT 12

RESULT 8
LOCUS E55148/c 22 bp DNA linear PAT 31-JAN-2002
DEFINITION Method for determining the presence of apoptosis regulatory
ACCESSION E55148
VERSION E55148.1 GI:18629759
KEYWORDS JP 2000217598-A/6.
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1
AUTHORS Kamata,S., Tsujimoto,Y., Otsubo,T. and Murakami,Y.
TITLE Method for determining the presence of apoptosis regulatory
JOURNAL Patent: JP 2000217598-A 6 08-AUG-2000;
SUMITOMO CHEM CO LTD
OS Artificial Sequence
PN JP 2000217598-A/6
PD 08-AUG-2000
PE 29-JAN-1999 JP 199022356
PR
PI SHINGJI KAMATA,YOSHIHIDE TSUJIMOTO,TSUGUTERU OTSUBO, PI YUKO
MURAKAMI
PC C1201/37,A61K31/00,A61K31/00,A61K31/00,A61K31/00,A61K38/00, PC
A61K45/00,
PC A61K48/00,C12N15/09,G01N33/15,G01N33/50,G01N33/50, PC
G01N33/68/C07K14/47,
PC A61K37/02,C12N15/00
CC
FH
FT Key Location/Qualifiers
FT source 1..22
/organism="Artificial Sequence".
FEATURES
source 1..22
Location/Qualifiers
BASE COUNT 5 a 6 c 4 g 7 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
Db 14 TAGGAGGAT 6

RESULT 9
LOCUS E36547 23 bp DNA linear PAT 31-JAN-2002
DEFINITION Method of gene diagnosis of bovine Chediak-Higashi syndrome.
ACCESSION E36547
VERSION E36547.1 GI:18626484
KEYWORDS JP 2000189165-A/34.
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1
AUTHORS Yamaguchi,H., Kashigawa,A., Sugimoto,Y. and Tahara,N.
TITLE Method of gene diagnosis of bovine Chediak-Higashi syndrome

```

JOURNAL Patent: JP 2000189165-A 34 11-JUL-2000;
KAGOSHIMA PREF, LIVESTOCK TECHNOLOGY ASSOCIATION
COMMENT OS Artificial Sequence
PN JP 2000189165-A/34
PD 11-JUL-2000
PF 25-DEC-1998 JP 1998368649

PI HIROSHI YAMAGUCHI, AGABA KASHIGUMA, YOSHINORI SUGIMOTO, PI
NORIO TAHARA
PC C12N15/09, C12Q1/68, C12N15/09, C12R1.91, C12N15/00, C12N15/00,
PC C12R1.91)
CC
FH Key
FT source
FT Location/Qualifiers
1.23
Location/Qualifiers
/organism="synthetic construct"
/db_xref="taxon:32630"

BASE COUNT 8 a 1 c 8 g 6 t

ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
|||||
Db 15 TAGGAGGAT 23

RESULT 10
E40169 23 bp DNA linear PAT 31-JAN-2002
LOCUS E40169
DEFINITION Genetic diagnosis method of bovine Chediak-Higashi syndrome.
ACCESSION E40169
VERSION E40169.1 GI:18627243
KEYWORDS JP 2000189176-A/34.
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1 (bases 1 to 23)
AUTHORS Yamaguchi, H., Kashiguma, A., Sugimoto, Y. and Tahara, N.
TITLE Genetic diagnosis method of bovine Chediak-Higashi syndrome
JOURNAL Patent: JP 2000189176-A 34 11-JUL-2000;
KAGOSHIMA PREF, LIVESTOCK TECHNOLOGY ASSOCIATION
COMMENT OS Artificial Sequence
PN JP 2000189176-A/34
PD 11-JUL-2000
PF 15-OCT-1999 JP 1999294619
PR
PI HIROSHI YAMAGUCHI, AGABA KASHIGUMA, YOSHINORI SUGIMOTO, PI
NORIO TAHARA
PC C12N15/09, C12Q1/68, C12N15/00
CC
FH Key
FT source
FT Location/Qualifiers
1.23
Location/Qualifiers
/organism="synthetic construct"
/db_xref="taxon:32630"

BASE COUNT 8 a 1 c 8 g 6 t

ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
|||||
Db 15 TAGGAGGAT 23

RESULT 11
LOCUS DOGC00506A/c 23 bp DNA linear STS 11-APR-1996
DEFINITION Canis familiaris STS microsatellite marker (repeat motif in reference clone (GI)2A(GT)9) DNA, sequence tagged site.
ACCESSION L77541.1 GI:1261665
VERSION L77541.1
KEYWORDS STS; PCR identification; microsatellite; sequence tagged site.
SOURCE Canis familiaris female adult peripheral blood DNA.
ORGANISM Canis familiaris
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE 1 (bases 1 to 23)
Yuzbasizyan-Gurkan, V., Cao, Y., Gurkan, M., Yuxun, W., Venta, P.J., Brewer, G.J. and Blanton, S.H.
Microsatellite markers for the canine genome
Unpublished (1996)
Hotstart, touchdown PCR. Starting at 60 C, decreasing by one degree for 10 cycles, 25 further cycles at 52. Motif and size of product as found in the reference dog.
FEATURES
source
1.23
Location/Qualifiers
/organism="Canis familiaris"
/db_xref="taxon:9615"
/sex="female"
/cell_type="white blood cells"
/tissue_type="peripheral blood"
/dev_stage="adult"
1.23
/note="product size 173"
SFS
BASE COUNT 6 a 9 c 0 g 8 t
ORIGIN

Query Match 100.0%; Score 9; DB 11; Length 23;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
|||||
Db 16 TAGGAGGAT 8

RESULT 12
LOCUS ARI35197/c 24 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 15 from patent US 6194559.
ACCESSION ARI35197
VERSION ARI35197.1 GI:14124102
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Kim, S. Young.
TITLE Abscisic acid responsive element-binding transcription factors
JOURNAL Patent: US 6194559-A 15 27-FEB-2001;
FEATURES
source
1.24
Location/Qualifiers
/organism="unknown"
BASE COUNT 5 a 6 c 5 g 8 t
ORIGIN

Query Match 100.0%; Score 9; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAGGAGGAT 9
|||||
Db 17 TAGGAGGAT 9

RESULT 13

```

ARI46693/c  ARI46693  24 bp  DNA  linear  PAT 08-AUG-2001
LOCUS       ARI46693
DEFINITION  Sequence 15 from patent US 6218527.
ACCESSION   ARI46693
VERSION     ARI46693.1  GI:15109882
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 24)
AUTHORS     Kim,S.Young
TITLE       Nucleic acid molecule encoding abscisic acid responsive
            element-binding factor 3
JOURNAL     Patent: US 6218527-A 15 17-APR-2001;
FEATURES
  source     1..24
            /organism="unknown"
BASE COUNT  5 a 6 c 5 g 8 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
   |||||||
Db 17 TAGGAGGAT 9

RESULT 14
ARI52264/c  ARI52264  24 bp  DNA  linear  PAT 08-AUG-2001
LOCUS       ARI52264
DEFINITION  Sequence 15 from patent US 6232461.
ACCESSION   ARI52264
VERSION     ARI52264.1  GI:15118314
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 24)
AUTHORS     Kim,S.Young.
TITLE       Nucleic acid molecule encoding abscisic acid responsive
            element-binding factor 4
JOURNAL     Patent: US 6232461-A 15 15-MAY-2001;
FEATURES
  source     1..24
            /organism="unknown"
BASE COUNT  5 a 6 c 5 g 8 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
   |||||||
Db 17 TAGGAGGAT 9

RESULT 15
ARI57802/c  ARI57802  24 bp  DNA  linear  PAT 17-OCT-2001
LOCUS       ARI57802
DEFINITION  Sequence 15 from patent US 6245905.
ACCESSION   ARI57802
VERSION     ARI57802.1  GI:16218814
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 24)
AUTHORS     Kim,S.Young
TITLE       Nucleic acid molecule encoding abscisic acid responsive
            element-binding factor 2

```

```

JOURNAL     Patent: US 6245905-A 15 12-JUN-2001;
FEATURES
  source     1..24
            /organism="unknown"
BASE COUNT  5 a 6 c 5 g 8 t
ORIGIN
Query Match 100.0%; Score 9; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.2e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAGGAGGAT 9
   |||||||
Db 17 TAGGAGGAT 9

Search completed: June 2, 2003, 19:09:34
Job time : 320.073 secs

```


GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:06:10 ; Search time 388.756 Seconds

(without alignments)
823.475 Million cell updates/sec

Title: US-09-540-843-5

Perfect score: 11
Sequence: 1 gtaagggttag 11

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 774614

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl.*
1: gb_da.*
2: gb_hcg.*
3: gb_in.*
4: gb_om.*
5: gb_ov.*
6: gb_pat.*
7: gb_ph.*
8: gb_pl.*
9: gb_pr.*
10: gb_ro.*
11: gb_sts.*
12: gb_sy.*
13: gb_un.*
14: gb_vt.*
15: em_da.*
16: em_fun.*
17: em_hum.*
18: em_in.*
19: em_mu.*
20: em_om.*
21: em_or.*
22: em_ov.*
23: em_pat.*
24: em_ph.*
25: em_pl.*
26: em_ro.*
27: em_sts.*
28: em_un.*
29: em_vt.*
30: em_hcg_hum.*
31: em_hcg_inv.*
32: em_hcg_other.*
33: em_hcg_mus.*
34: em_hcg_pin.*
35: em_hcg_rtd.*
36: em_hcg_man.*
37: em_hcg_vtl.*
38: em_sy.*
39: em_higo_hum.*
40: em_higo_mus.*
41: em_higo_other.*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	11	100.0	11	AR016034	AR016034 Sequence
2	11	100.0	11	AR026486	AR026486 Sequence
3	11	100.0	11	AR026487	AR026487 Sequence
4	11	100.0	11	AR059195	AR059195 Sequence
5	11	100.0	11	AR075506	AR075506 Sequence
6	11	100.0	11	AR161904	AR161904 Sequence
7	11	100.0	11	AR033373	AR033373 Sequence
8	11	100.0	11	AX268757	AX268757 Sequence
9	11	100.0	11	AX268761	AX268761 Sequence
10	11	100.0	11	AX283296	AX283296 Sequence
11	11	100.0	11	I31749	I31749 Sequence 2
12	11	100.0	15	AR026479	AR026479 Sequence
13	11	100.0	16	AR050942	AR050942 Sequence
14	11	100.0	16	AR204610	AR204610 Sequence
15	11	100.0	16	I51743	I51743 Sequence 11
16	11	100.0	17	A84605	A84605 Sequence 15
17	11	100.0	17	AR026488	AR026488 Sequence
18	11	100.0	17	AR145675	AR145675 Sequence
19	11	100.0	17	AR145676	AR145676 Sequence
20	11	100.0	18	A79654	A79654 Sequence 3
21	11	100.0	18	A79665	A79665 Sequence 14
22	11	100.0	18	A84598	A84598 Sequence 8
23	11	100.0	18	A84599	A84599 Sequence 9
24	11	100.0	18	AR016059	AR016059 Sequence
25	11	100.0	18	AR026482	AR026482 Sequence
26	11	100.0	18	AR026483	AR026483 Sequence
27	11	100.0	18	AR026484	AR026484 Sequence
28	11	100.0	18	AR037860	AR037860 Sequence
29	11	100.0	18	AR037861	AR037861 Sequence
30	11	100.0	18	AR037862	AR037862 Sequence
31	11	100.0	18	AR050936	AR050936 Sequence
32	11	100.0	18	AR050962	AR050962 Sequence
33	11	100.0	18	AR053263	AR053263 Sequence
34	11	100.0	18	AR054739	AR054739 Sequence
35	11	100.0	18	AR054740	AR054740 Sequence
36	11	100.0	18	AR054741	AR054741 Sequence
37	11	100.0	18	AR059509	AR059509 Sequence
38	11	100.0	18	AR059546	AR059546 Sequence
39	11	100.0	18	AR059547	AR059547 Sequence
40	11	100.0	18	AR069393	AR069393 Sequence
41	11	100.0	18	AR069394	AR069394 Sequence
42	11	100.0	18	AR069395	AR069395 Sequence
43	11	100.0	18	AR075504	AR075504 Sequence
44	11	100.0	18	AR079895	AR079895 Sequence
45	11	100.0	18	AR079896	AR079896 Sequence

ALIGNMENTS

RESULT 1
AR016034/c AR016034 11 bp DNA linear PAT 05-DEC-1998
LOCUS Sequence 2 from patent US 5776679.
DEFINITION AR016034
ACCESSION AR016034
VERSION AR016034.1 GI:3972311
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 11)
AUTHORS Villeponteau,B., Feng,J., Funk,W. and Andrews,W.H.
TITLE Assays for the DNA component of human telomerase
JOURNAL Patent: US 5776679-A 2 07-JUL-1998;
FEATURES Location/Qualifiers

```

source
1. .11
/organism="unknown"
BASE COUNT      4 a      5 c      0 g      2 t
ORIGIN
Query Match      100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTTAGGCTTAG 11
      11 GTTAGGCTTAG 1
DB

RESULT 2
AR026486
LOCUS      AR026486      11 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 11 from patent US 5856096.
ACCESSION  AR026486
VERSION     AR026486.1 GI:5937326
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 11)
AUTHORS     Windle,B.E., Qiu,M., Chen,S.-F., Fletcher,T.M. and Maine,I.
TITLE       Rapid and sensitive assays for detecting and distinguishing between
            processive and non-processive telomerase activities
JOURNAL     Patent: US 5856096-A 11 05-JAN-1999;
            Location/Qualifiers
FEATURES
source      1. .11
            /organism="unknown"
BASE COUNT      2 a      0 c      5 g      4 t
ORIGIN
Query Match      100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTTAGGCTTAG 11
      1 GTTAGGCTTAG 11
DB

RESULT 3
AR026487/c
LOCUS      AR026487      11 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 12 from patent US 5856096.
ACCESSION  AR026487
VERSION     AR026487.1 GI:5937327
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 11)
AUTHORS     Windle,B.E., Qiu,M., Chen,S.-F., Fletcher,T.M. and Maine,I.
TITLE       Rapid and sensitive assays for detecting and distinguishing between
            processive and non-processive telomerase activities
JOURNAL     Patent: US 5856096-A 12 05-JAN-1999;
            Location/Qualifiers
FEATURES
source      1. .11
            /organism="unknown"
BASE COUNT      4 a      5 c      0 g      2 t
ORIGIN
Query Match      100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTTAGGCTTAG 11
      1 GTTAGGCTTAG 11
DB

```

```

RESULT 4
AR059195/c
LOCUS      AR059195      11 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 2 from patent US 5837857.
ACCESSION  AR059195
VERSION     AR059195.1 GI:5984772
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 11)
AUTHORS     Villeponteau,B., Feng,J., Funk,W. and Andrews,W.H.
TITLE       Mammalian telomerase
JOURNAL     Patent: US 5837857-A 2 17-NOV-1998;
            Location/Qualifiers
FEATURES
source      1. .11
            /organism="unknown"
BASE COUNT      4 a      5 c      0 g      2 t
ORIGIN
Query Match      100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTTAGGCTTAG 11
      11 GTTAGGCTTAG 1
DB

RESULT 5
AR075506/c
LOCUS      AR075506      11 bp      DNA      linear      PAT 30-AUG-2000
DEFINITION Sequence 3 from patent US 5958680.
ACCESSION  AR075506
VERSION     AR075506.1 GI:10002256
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 11)
AUTHORS     Villeponteau,B., Feng,J., Funk,W. and Andrews,W.H.
TITLE       Mammalian telomerase
JOURNAL     Patent: US 5958680-A 3 28-SEP-1999;
            Location/Qualifiers
FEATURES
source      1. .11
            /organism="unknown"
BASE COUNT      4 a      5 c      0 g      2 t
ORIGIN
Query Match      100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 GTTAGGCTTAG 11
      11 GTTAGGCTTAG 1
DB

RESULT 6
AR161904/c
LOCUS      AR161904      11 bp      DNA      linear      PAT 17-OCT-2001
DEFINITION Sequence 2 from patent US 6258535.
ACCESSION  AR161904
VERSION     AR161904.1 GI:16228913
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 11)
AUTHORS     Villeponteau,B., Feng,J., Funk,W. and Andrews,W.H.
TITLE       Mammalian telomerase
JOURNAL     Patent: US 6258535-A 2 10-JUL-2001;

```

FEATURES
source 1.11 Location/Qualifiers
BASE COUNT 4 a 5 c 0 g 2 t
ORIGIN

Query Match 100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||

Db 11 GTTAGGGTTAG 1

RESULT 7
AX033373/c 11 bp mRNA linear PAT 21-SEP-2000
LOCUS
DEFINITION Sequence 5 from Patent WO0046601.
ACCESSION AX033373
VERSION AX033373.1 GI:10280147
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 11)
AUTHORS Larsen,F. and Skaanseng,M.
TITLE Detecting telomerase activity
JOURNAL Patent: WO 0046601-A 5 10-AUG-2000;
LARSEN FRANK (NO) ; SKAANSENG MARIANNE (NO)
FEATURES
source 1.11 Location/Qualifiers
BASE COUNT 4 a 5 c 0 g 2 t
ORIGIN

Query Match 100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||

Db 11 GTTAGGGTTAG 1

RESULT 8
AX268757 11 bp DNA linear PAT 29-OCT-2001
LOCUS
DEFINITION Sequence 5 from Patent WO0174342.
ACCESSION AX268757
VERSION AX268757.1 GI:16541829
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Gilchrist,B.A., Yaar,M. and Eller,M.
TITLE Use of locally applied dna fragments
JOURNAL Patent: WO 0174342-A 5 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)
FEATURES
source 1.11 Location/Qualifiers
BASE COUNT 2 a 0 c 5 g 4 t
ORIGIN

Query Match 100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||

Db 1 GTTAGGGTTAG 11

RESULT 9
AX268761/c 11 bp DNA linear PAT 29-OCT-2001
LOCUS
DEFINITION Sequence 9 from Patent WO0174342.
ACCESSION AX268761
VERSION AX268761.1 GI:16541833
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Gilchrist,B.A., Yaar,M. and Eller,M.
TITLE Use of locally applied dna fragments
JOURNAL Patent: WO 0174342-A 9 11-OCT-2001;
TRUSTEES OF BOSTON UNIVERSITY (US)
FEATURES
source 1.11 Location/Qualifiers
BASE COUNT 4 a 5 c 0 g 2 t
ORIGIN

Query Match 100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||

Db 11 GTTAGGGTTAG 1

RESULT 10
AX283296 11 bp DNA linear PAT 20-NOV-2001
LOCUS
DEFINITION Sequence 60 from Patent WO0179249.
ACCESSION AX283296
VERSION AX283296.1 GI:17044177
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Uhlmann,E., Breipohl,G. and Will,D.W.
TITLE Polyamide nucleic acid derivatives, agents and methods for
JOURNAL producing the same
Patent: WO 0179249-A 60 25-OCT-2001;
Aventis Pharma Deutschland GmbH (DE)
FEATURES
source 1.11 Location/Qualifiers
BASE COUNT 2 a 0 c 5 g 4 t
ORIGIN

Query Match 100.0%; Score 11; DB 6; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.5e+04;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTTAGGGTTAG 11
|||||

Db 1 GTTAGGGTTAG 11

RESULT 11

I31749/c
 LOCUS I31749 11 bp DNA linear PAT 06-FEB-1997
 DEFINITION Sequence 2 from patent US 5583016.
 ACCESSION I31749
 VERSION I31749.1 GI:1822540
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 11)
 AUTHORS Vallefonteu, B., Feng, J., Funk, W. and Andrews, W.H.
 TITLE Mammalian telomerase
 JOURNAL Patent: US 5583016-A 2 10-DEC-1996.
 FEATURES
 source
 1..11
 Location/Qualifiers
 BASE COUNT 4 a 5 c 0 g 2 t
 ORIGIN
 Query Match 100.0%; Score 11; DB 6; Length 11;
 Best Local Similarity 100.0%; Pred. No. 2.5e+04;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 GTTAGGCTTAG 11
 Db 11 GTTAGGCTTAG 1

RESULT 12
 LOCUS AR026479/c 15 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 4 from patent US 5856096.
 ACCESSION AR026479
 VERSION AR026479.1 GI:5937319
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Windle, B.E., Qiu, M., Chen, S.-F., Fletcher, T.M. and Maine, I.
 TITLE Rapid and sensitive assays for detecting and distinguishing between
 processive and non-processive telomerase activities
 JOURNAL Patent: US 5856096-A 4 05-JAN-1999;
 FEATURES
 source
 1..15
 Location/Qualifiers
 BASE COUNT 4 a 9 c 0 g 2 t
 ORIGIN
 Query Match 100.0%; Score 11; DB 6; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.3e+04;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 GTTAGGCTTAG 11
 Db 13 GTTAGGCTTAG 3

RESULT 13
 LOCUS AR050942/c 16 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 11 from patent US 5830644.
 ACCESSION AR050942
 VERSION AR050942.1 GI:5974306
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 16)
 AUTHORS West, M.D., Shay, J. and Wright, W.E.
 TITLE Method for screening for agents which increase telomerase activity
 in a cell
 JOURNAL Patent: US 5830644-A 11 03-NOV-1998;

FEATURES
 source Location/Qualifiers
 1..16
 /organism="unknown"
 BASE COUNT 4 a 9 c 0 g 3 t
 ORIGIN
 Query Match 100.0%; Score 11; DB 6; Length 16;
 Best Local Similarity 100.0%; Pred. No. 2.3e+04;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 GTTAGGCTTAG 11
 Db 13 GTTAGGCTTAG 3

RESULT 14
 LOCUS AR204610/c 16 bp DNA linear PAT 20-JUN-2002
 DEFINITION Sequence 60 from patent US 6368789.
 ACCESSION AR204610
 VERSION AR204610.1 GI:21501980
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 16)
 AUTHORS West, M.D., Shay, J., Wright, W. and Blackburn, E.H.
 TITLE Screening methods to identify inhibitors of telomerase activity
 JOURNAL Patent: US 6368789-A 60 09-APR-2002;
 FEATURES
 source
 1..16
 Location/Qualifiers
 BASE COUNT 4 a 9 c 0 g 3 t
 ORIGIN
 Query Match 100.0%; Score 11; DB 6; Length 16;
 Best Local Similarity 100.0%; Pred. No. 2.3e+04;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 GTTAGGCTTAG 11
 Db 13 GTTAGGCTTAG 3

RESULT 15
 LOCUS I51743 16 bp DNA linear PAT 07-OCT-1997
 DEFINITION Sequence 11 from patent US 5645986.
 ACCESSION I51743
 VERSION I51743.1 GI:2472944
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 16)
 AUTHORS West, M.D., Harley, C.B., Strahl, C.M., McEachern, M.J., Shay, J.,
 Wright, W.E., Blackburn, E.H. and Vaziri, H.
 TITLE Therapy and diagnosis of conditions related to telomere length
 and/or telomerase activity
 JOURNAL Patent: US 5645986-A 11 08-JUL-1997;
 FEATURES
 source
 1..16
 Location/Qualifiers
 BASE COUNT 4 a 9 c 0 g 3 t
 ORIGIN
 Query Match 100.0%; Score 11; DB 6; Length 16;
 Best Local Similarity 100.0%; Pred. No. 2.3e+04;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 GTTAGGCTTAG 11
 Db 13 GTTAGGCTTAG 3

Wed Jun 4 11:08:19 2003

Search completed: June 2, 2003, 19:09:39
job time : 390.756 secs

us-09-540-843-5.szlm40.rge

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 19:09:45 ; Search time 49.6829 Seconds
(without alignments)
189.976 Million cell updates/sec

Title: US-09-540-843-3

Perfect score: 7

Sequence: 1 agtatga 7

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 845702 seqs, 674182571 residues

Total number of hits satisfying chosen parameters: 477662

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_NA:*
1: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
2: /cgn2_6/ptodata/2/pubpna/PCT_NEW_PUB.seq:*
3: /cgn2_6/ptodata/2/pubpna/US06_NEW_PUB.seq:*
4: /cgn2_6/ptodata/2/pubpna/US06_PUBCOMB.seq:*
5: /cgn2_6/ptodata/2/pubpna/US07_NEW_PUB.seq:*
6: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
7: /cgn2_6/ptodata/2/pubpna/US08_NEW_PUB.seq:*
8: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
9: /cgn2_6/ptodata/2/pubpna/US09_NEW_PUB.seq:*
10: /cgn2_6/ptodata/2/pubpna/US09_PUBCOMB.seq:*
11: /cgn2_6/ptodata/2/pubpna/US10_NEW_PUB.seq:*
12: /cgn2_6/ptodata/2/pubpna/US10_PUBCOMB.seq:*
13: /cgn2_6/ptodata/2/pubpna/US60_NEW_PUB.seq:*
14: /cgn2_6/ptodata/2/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	7	100.0	7	9	US-10-122-630-3
2	7	100.0	7	9	US-10-122-630-7
3	7	100.0	7	9	US-10-122-633-3
4	7	100.0	7	9	US-10-122-633-7
5	7	100.0	9	9	US-10-122-630-1
6	7	100.0	9	9	US-10-122-633-1
7	7	100.0	10	10	US-09-398-399-31
8	7	100.0	10	10	US-09-899-381-31
9	7	100.0	10	12	US-10-033-145-1423
10	7	100.0	14	9	US-09-875-440-22
11	7	100.0	15	10	US-09-504-231A-527
12	7	100.0	15	10	US-09-504-231A-528
13	7	100.0	15	10	US-09-504-231A-529
14	7	100.0	15	10	US-09-504-231A-1527
15	7	100.0	15	10	US-09-504-231A-1569
16	7	100.0	15	10	US-09-504-231A-1570
17	7	100.0	15	10	US-09-398-399-30
18	7	100.0	15	10	US-09-899-381-30
19	7	100.0	15	10	US-09-274-553D-527

20	7	100.0	15	10	US-09-274-553D-528	Sequence 528, App
21	7	100.0	15	10	US-09-274-553D-529	Sequence 529, App
22	7	100.0	15	10	US-09-274-553D-1527	Sequence 1527, Ap
23	7	100.0	15	10	US-09-274-553D-1569	Sequence 1569, Ap
24	7	100.0	15	10	US-09-274-553D-1570	Sequence 1570, Ap
25	7	100.0	15	10	US-09-272-343-1	Sequence 1, Appl1
26	7	100.0	15	10	US-09-272-343-2	Sequence 2, Appl1
27	7	100.0	17	9	US-10-060-830-716	Sequence 716, App
28	7	100.0	17	9	US-10-060-830-717	Sequence 717, App
29	7	100.0	17	9	US-10-060-830-718	Sequence 718, App
30	7	100.0	17	9	US-10-060-830-719	Sequence 719, App
31	7	100.0	17	9	US-10-060-830-720	Sequence 720, App
32	7	100.0	17	9	US-10-060-830-721	Sequence 721, App
33	7	100.0	17	9	US-10-060-830-722	Sequence 722, App
34	7	100.0	17	9	US-10-060-830-723	Sequence 723, App
35	7	100.0	17	9	US-10-060-830-724	Sequence 724, App
36	7	100.0	17	9	US-10-060-830-725	Sequence 725, App
37	7	100.0	17	9	US-10-060-830-726	Sequence 726, App
38	7	100.0	17	9	US-09-818-875-639	Sequence 726, App
39	7	100.0	17	9	US-09-818-875-640	Sequence 726, App
40	7	100.0	17	9	US-09-848-754A-443	Sequence 640, App
41	7	100.0	17	9	US-09-848-754A-444	Sequence 443, App
42	7	100.0	17	9	US-09-848-754A-444	Sequence 444, App
43	7	100.0	17	9	US-09-848-754A-2583	Sequence 2583, Ap
44	7	100.0	17	9	US-09-848-754A-2584	Sequence 2584, Ap
45	7	100.0	17	9	US-09-848-754A-2971	Sequence 2971, Ap
					US-09-848-754A-3616	Sequence 3616, Ap

ALIGNMENTS

RESULT 1
US-10-122-630-3
Sequence 3, Application US/10122630
Publication No. US20030032610A1
GENERAL INFORMATION:
APPLICANT: Glitchest, Barbara A.
APPLICANT: Eiler, Mark S.
APPLICANT: Yaer, Mina
TITLE OF INVENTION: Method to Inhibit Cell Growth Using
FILE REFERENCE: 0054,1088-018
CURRENT APPLICATION NUMBER: US/10/122,630
CURRENT FILING DATE: 2002-04-12
PRIOR APPLICATION NUMBER: US 08/467,012
PRIOR FILING DATE: 1995-06-06
PRIOR APPLICATION NUMBER: PCT/US96/08386
PRIOR FILING DATE: 1996-06-03
PRIOR APPLICATION NUMBER: US 09/048,927
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: US 09/540,843
PRIOR FILING DATE: 2000-03-31
PRIOR APPLICATION NUMBER: PCT/US01/10162
PRIOR FILING DATE: 2001-03-30
NUMBER OF SEQ ID NOS: 15
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 3
LENGTH: 7
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-3

Query Match 100.0%; Score 7; DB 9; Length 7;
Best Local Similarity 100.0%; Pred. No. 1.9e+08;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
DB 1 AGTATGA 7

```
RESULT 2
US-10-122-630-7
; Sequence 7, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 7
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-7

Query Match
Best Local Similarity 100.0%; Score 7; DB 9; Length 7;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
Db 1 AGTATGA 7

RESULT 3
US-10-122-633-3
; Sequence 3, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 3
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-3

Query Match
Best Local Similarity 100.0%; Score 7; DB 9; Length 7;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
Db 1 AGTATGA 7
```

```
RESULT 4
US-10-122-633-7
; Sequence 7, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 7
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-7

Query Match
Best Local Similarity 100.0%; Score 7; DB 9; Length 7;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
Db 1 AGTATGA 7

RESULT 5
US-10-122-630-1
; Sequence 1, Application US/10122630
; Publication No. US20030032610A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-018
; CURRENT APPLICATION NUMBER: US/10/122,630
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 08/467,012
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: PCT/US96/08386
; PRIOR FILING DATE: 1996-06-03
; PRIOR APPLICATION NUMBER: US 09/048,927
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 1
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-630-1

Query Match
Best Local Similarity 100.0%; Score 7; DB 9; Length 7;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
Db 1 AGTATGA 7
```

Query Match 100.0%; Score 7; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 7; Conservative 0; Mismatches 0; Indels 0;

QY 1 AGTATGA 7
|||||||
Db 2 AGTATGA 8

RESULT 6

US-10-122-633-1
; Sequence 1, Application US/10122633
; Publication No. US20030032611A1
; GENERAL INFORMATION:
; APPLICANT: Gilchrist, Barbara A.
; APPLICANT: Eller, Mark S.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Method to Inhibit Cell Growth Using
; FILE REFERENCE: 0054.1088-019
; CURRENT APPLICATION NUMBER: US/10/122,633
; CURRENT FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 09/540,843
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: PCT/US01/10162
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA Fragment
US-10-122-633-1

Query Match 100.0%; Score 7; DB 9; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.5e+08;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 2 AGTATGA 8

RESULT 7

US-09-398-399-31
; Sequence 31, Application US/09398399
; Patent No. US20020051973A1
; GENERAL INFORMATION:
; APPLICANT: DELENSTARR, GLENDA C.
; APPLICANT: LEFKOWITZ, STEVEN M.
; APPLICANT: LUEBEKE, KEVIN J.
; APPLICANT: OVERMAN, LESLIE B.
; APPLICANT: SAMPSON, NICHOLAS M.
; APPLICANT: SAMPSON, JEFFREY R.
; APPLICANT: WOLBER, PAUL K.
; TITLE OF INVENTION: TECHNIQUES FOR ASSESSING NONSPECIFIC BINDING OF NUCLEIC
; FILE REFERENCE: 10981620-1
; CURRENT APPLICATION NUMBER: US/09/398,399
; CURRENT FILING DATE: 1999-09-17
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 31
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-398-399-31

Query Match 100.0%; Score 7; DB 10; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.9e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0;

QY 1 AGTATGA 7
|||||||
Db 1 AGTATGA 7

RESULT 8

US-09-899-381-31
; Sequence 31, Application US/09899381
; Patent No. US20020068293A1
; GENERAL INFORMATION:
; APPLICANT: Delenstarr, Glend C.
; APPLICANT: Wolber, Pual K.
; APPLICANT: Sana, Theodore R.
; TITLE OF INVENTION: Arrays Having Background Features and
; FILE REFERENCE: 10010760-1
; CURRENT APPLICATION NUMBER: US/09/899,381
; CURRENT FILING DATE: 2001-07-05
; PRIOR APPLICATION NUMBER: 09/398,399
; PRIOR FILING DATE: 1999-09-17
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic probe
US-09-899-381-31

Query Match 100.0%; Score 7; DB 10; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.9e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 1 AGTATGA 7

RESULT 9

US-10-033-145-1423/C
; Sequence 1423, Application US/10033145
; Patent No. US20020151515A1
; GENERAL INFORMATION:
; APPLICANT: GENZYME CORPORATION
; APPLICANT: ROBERTS, BRUCE
; APPLICANT: SHANKARA, SRINIVAS
; TITLE OF INVENTION: PREPARATION AND USE OF SUPERIOR VACCINES
; FILE REFERENCE: GAO201C
; CURRENT APPLICATION NUMBER: US/10/033,145
; CURRENT FILING DATE: 2001-11-05
; PRIOR APPLICATION NUMBER: PCT/US99/13800
; PRIOR FILING DATE: 1999-06-18
; NUMBER OF SEQ ID NOS: 2137
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1423
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-033-145-1423

Query Match 100.0%; Score 7; DB 12; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.9e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 7 AGTATGA 1

RESULT 10
US-09-875-440-22/c

; Sequence 22, Application US/09875440
; Patent No. US2002015035A1

; GENERAL INFORMATION:

; APPLICANT: Reinhard, Christoph
; APPLICANT: Jefferson, Anne B.

; APPLICANT: Winter, Jill A.

; APPLICANT: Randazzo, Filippo

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING

; TITLE OF INVENTION: NEOPLASTIC DISEASE USING NET-4 MODULATORS

; FILE REFERENCE: PP-01701.002/200130.522

; CURRENT APPLICATION NUMBER: US/09/875,440

; CURRENT FILING DATE: 2001-06-05

; NUMBER OF SEQ ID NOS: 22

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 22

; LENGTH: 14

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Oligonucleotide NET-4 oligo 868 used for in-situ

; OTHER INFORMATION: hybridization

US-09-875-440-22

Query Match 100.0%; Score 7; DB 9; Length 14;

Best Local Similarity 100.0%; Pred. No. 4.9e+04;

Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7

Db 13 AGTATGA 7

RESULT 11

US-09-504-231A-527

; Sequence 527, Application US/09504231A

; Patent No. US20020013458A1

; GENERAL INFORMATION:

; APPLICANT: Blatt, Lawrence

; APPLICANT: McSwiggen, James

; APPLICANT: Roberts, Beth

; APPLICANT: Pavco, Pamela

; APPLICANT: Macejak, Dennis

; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE

; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION

; FILE REFERENCE: TPI 247/282

; CURRENT FILING DATE: 2000-02-15

; PRIOR APPLICATION NUMBER: US/09/504,231A

; PRIOR FILING DATE: 1999-03-23

; PRIOR APPLICATION NUMBER: 09/274,553

; PRIOR FILING DATE: 1999-02-24

; PRIOR APPLICATION NUMBER: 60/100,842

; PRIOR FILING DATE: 1998-09-18

; PRIOR APPLICATION NUMBER: 60/083,217

; PRIOR FILING DATE: 1998-04-27

; NUMBER OF SEQ ID NOS: 3242

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 527

; LENGTH: 15

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target

US-09-504-231A-527

Query Match 100.0%; Score 7; DB 10; Length 15;

Best Local Similarity 71.4%; Pred. No. 4.9e+04;

Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7

Db 9 AGUATGA 15

RESULT 12

US-09-504-231A-528

; Sequence 528, Application US/09504231A

; Patent No. US20020013458A1

; GENERAL INFORMATION:

; APPLICANT: Blatt, Lawrence

; APPLICANT: McSwiggen, James

; APPLICANT: Roberts, Beth

; APPLICANT: Pavco, Pamela

; APPLICANT: Macejak, Dennis

; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS REL

; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION

; FILE REFERENCE: TPI 247/282

; CURRENT APPLICATION NUMBER: US/09/504,231A

; CURRENT FILING DATE: 2000-02-15

; PRIOR APPLICATION NUMBER: 09/274,553

; PRIOR FILING DATE: 1999-03-23

; PRIOR APPLICATION NUMBER: 09/257,608

; PRIOR FILING DATE: 1999-02-24

; PRIOR APPLICATION NUMBER: 60/100,842

; PRIOR FILING DATE: 1998-09-18

; PRIOR APPLICATION NUMBER: 60/083,217

; PRIOR FILING DATE: 1998-04-27

; NUMBER OF SEQ ID NOS: 3242

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 528

; LENGTH: 15

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target

US-09-504-231A-528

Query Match 100.0%; Score 7; DB 10; Length 15;

Best Local Similarity 71.4%; Pred. No. 4.9e+04;

Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7

Db 8 AGUATGA 14

RESULT 13

US-09-504-231A-529

; Sequence 529, Application US/09504231A

; Patent No. US20020013458A1

; GENERAL INFORMATION:

; APPLICANT: Blatt, Lawrence

; APPLICANT: McSwiggen, James

; APPLICANT: Roberts, Beth

; APPLICANT: Pavco, Pamela

; APPLICANT: Macejak, Dennis

; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS REL

; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION

; FILE REFERENCE: TPI 247/282

; CURRENT APPLICATION NUMBER: US/09/504,231A

; CURRENT FILING DATE: 2000-02-15

; PRIOR APPLICATION NUMBER: 09/274,553

; PRIOR FILING DATE: 1999-03-23

; PRIOR APPLICATION NUMBER: 09/257,608

; PRIOR FILING DATE: 1999-02-24

; PRIOR APPLICATION NUMBER: 60/100,842

; PRIOR FILING DATE: 1998-09-18

; PRIOR APPLICATION NUMBER: 60/083,217

; PRIOR FILING DATE: 1998-04-27

; NUMBER OF SEQ ID NOS: 3242

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 529

; LENGTH: 15

```

; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-559

Query Match
Best Local Similarity 100.0%; Score 7; DB 10; Length 15;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
   |||:|:|
Db 5 AGTATGA 11

RESULT 14
US-09-504-231A-1527/c
; Sequence 1527, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Payco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; FILE REFERENCE: IPI 247/282
; CURRENT APPLICATION NUMBER: US/09/504,231A
; PRIOR FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274,553
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1527
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-1527

Query Match
Best Local Similarity 100.0%; Score 7; DB 10; Length 15;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
   |||:|:|
Db 13 AGTATGA 7

RESULT 15
US-09-504-231A-1569/c
; Sequence 1569, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Payco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; FILE REFERENCE: IPI 247/282
; CURRENT APPLICATION NUMBER: US/09/504,231A
; PRIOR FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274,553
```

```

; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1569
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-1569

Query Match
Best Local Similarity 100.0%; Score 7; DB 10; Length 15;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
   |||:|:|
Db 12 AGTATGA 6

Search completed: June 2, 2003, 23:43:13
Job time : 50.6829 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:31:20 ; Search time 28.6829 Seconds
(without alignments)
74.844 Million cell updates/sec

Title: US-09-540-843-3

Perfect score: 7

Sequence: 1 agataga 7

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 441362 seqs, 15338381 residues

Total number of hits satisfying chosen parameters: 558892

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

Issued Patents.NA.*
1: /cgn2_6/ptodata/1/ina/5A.COMB.seq.*
2: /cgn2_6/ptodata/1/ina/5B.COMB.seq.*
3: /cgn2_6/ptodata/1/ina/6A.COMB.seq.*
4: /cgn2_6/ptodata/1/ina/6B.COMB.seq.*
5: /cgn2_6/ptodata/1/ina/PCrus.COMB.seq.*
6: /cgn2_6/ptodata/1/ina/backfile1.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	7	100.0	7	US-09-048-927-3	Sequence 3, Appl1
2	7	100.0	9	US-09-048-927-1	Sequence 1, Appl1
3	7	100.0	14	US-08-485-133-27	Sequence 2, Appl1
4	7	100.0	14	US-08-744-905A-4	Sequence 4, Appl1
5	7	100.0	15	US-08-334-847-24	Sequence 24, Appl1
6	7	100.0	15	US-08-334-847-327	Sequence 327, Appl1
7	7	100.0	15	US-08-671-071B-2	Sequence 2, Appl1
8	7	100.0	15	US-08-747-121-4	Sequence 4, Appl1
9	7	100.0	15	US-08-585-684B-130	Sequence 130, App
10	7	100.0	15	US-08-585-684B-1315	Sequence 1315, Ap
11	7	100.0	15	US-08-485-133-28	Sequence 28, Appl1
12	7	100.0	15	US-09-094-714A-33	Sequence 33, Appl1
13	7	100.0	15	US-09-094-714A-34	Sequence 34, Appl1
14	7	100.0	15	US-09-049-190-6	Sequence 6, Appl1
15	7	100.0	15	US-09-049-190-7	Sequence 7, Appl1
16	7	100.0	15	US-09-038-073-130	Sequence 130, App
17	7	100.0	15	US-09-038-073-1315	Sequence 1315, Ap
18	7	100.0	15	US-08-932-140C-6	Sequence 6, Appl1
19	7	100.0	15	US-08-932-140C-7	Sequence 7, Appl1
20	7	100.0	15	US-09-253-977-2	Sequence 2, Appl1
21	7	100.0	16	US-07-977-284A-59	Sequence 59, Appl1
22	7	100.0	16	US-08-719-593-24	Sequence 24, Appl1
23	7	100.0	16	US-08-256-426B-59	Sequence 59, Appl1
24	7	100.0	16	US-08-458-814-1	Sequence 1, Appl1
25	7	100.0	17	US-08-390-850-461	Sequence 461, App
26	7	100.0	17	US-08-435-634-461	Sequence 461, App
27	7	100.0	17	US-08-758-306-365	Sequence 365, App

C 28	7	100.0	17	1	US-08-758-306-367	Sequence 367, App
C 29	7	100.0	17	1	US-08-758-306-369	Sequence 369, App
C 30	7	100.0	17	1	US-08-758-306-371	Sequence 371, App
C 31	7	100.0	17	1	US-08-758-306-813	Sequence 813, App
C 32	7	100.0	17	1	US-08-758-306-815	Sequence 815, App
C 33	7	100.0	17	2	US-08-671-320-6	Sequence 6, Appl1
C 34	7	100.0	17	2	US-08-868-577-6	Sequence 6, Appl1
C 35	7	100.0	17	2	US-08-485-133-2	Sequence 2, Appl1
C 36	7	100.0	17	3	US-08-985-162-443	Sequence 443, App
C 37	7	100.0	17	3	US-08-985-162-444	Sequence 444, App
C 38	7	100.0	18	1	US-07-688-352C-8	Sequence 8, Appl1
C 39	7	100.0	18	1	US-08-363-585-55	Sequence 55, Appl1
C 40	7	100.0	18	1	US-08-358-995-10	Sequence 10, Appl1
C 41	7	100.0	18	2	US-08-928-692-48	Sequence 48, Appl1
C 42	7	100.0	18	2	US-08-474-379C-8	Sequence 8, Appl1
C 43	7	100.0	18	2	US-09-200-141-19	Sequence 19, Appl1
C 44	7	100.0	18	2	US-09-213-768-24	Sequence 24, Appl1
C 45	7	100.0	18	2	US-09-213-768-25	Sequence 25, Appl1

ALIGNMENTS

```
RESULT 1
US-09-048-927-3
; Sequence 3, Application US/09048927
; Patent No. 6147056
; GENERAL INFORMATION:
; APPLICANT: Glitchest, Barbara A.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Use of Locally Applied DNA Fragments
; FILE REFERENCE: BU94-68A2
; CURRENT APPLICATION NUMBER: US/09/048,927
; EARLIER FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 08/952,697
; EARLIER FILING DATE: 1996-06-03
; EARLIER APPLICATION NUMBER: 08/467,012
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 7
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA Fragment
US-09-048-927-3
; Sequence 1, Application US/09048927
; Patent No. 6147056
; GENERAL INFORMATION:
; APPLICANT: Glitchest, Barbara A.
; APPLICANT: Yaar, Mina
; TITLE OF INVENTION: Use of Locally Applied DNA Fragments
; FILE REFERENCE: BU94-68A2
; CURRENT APPLICATION NUMBER: US/09/048,927
; EARLIER FILING DATE: 1998-03-26
; EARLIER APPLICATION NUMBER: 08/952,697
; EARLIER FILING DATE: 1996-06-03
; EARLIER APPLICATION NUMBER: 08/467,012
```

Query Match 100.0%; Score 7; DB 3; Length 7;
Best Local Similarity 100.0%; Pred. No. 4.1e+07;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGATAGA 7
Db 1 AGATAGA 7

;; EARLIER FILING DATE: 1995-06-06
;; NUMBER OF SEQ ID NOS: 4
;; SOFTWARE: FastSeq for Windows Version 3.0
;; SEQ ID NO 1
;; LENGTH: 9
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: DNA Fragment
US-09-048-927-1

Query Match 100.0%; Score 7; DB 3; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||
DB 2 AGTATGA 8

RESULT 3
US-08-485-133-27
; Sequence 27, Application US/08485133
; Patent No. 5976789
; GENERAL INFORMATION:
; APPLICANT: Allibert, Patrice A.
; APPLICANT: Cros, Philippe
; APPLICANT: Mach, Bernard F.
; APPLICANT: Mandrand, Bernard F.
; APPLICANT: Tiercy, Jean-Marie
; TITLE OF INVENTION: SYSTEM OF PROBES ENABLING HLA-DR TYPING
; TITLE OF INVENTION: TO BE PERFORMED, AND TYPING METHOD USING SAID PROBES
; NUMBER OF SEQUENCES: 81
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OLIVE & BERRIDGE
; STREET: P.O. Box 19928
; CITY: Alexandria
; STATE: Virginia
; ZIP: 22320
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,133
; FILING DATE: 7-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/030,143
; FILING DATE: 11-MAR-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Berridge, William P.
; REGISTRATION NUMBER: 30,024
; REFERENCE/DOCKET NUMBER: WPB 285964
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6400
; TELEFAX: 703-836-2787
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-485-133-27

Query Match 100.0%; Score 7; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||

DB 8 AGTATGA 14

RESULT 4
US-08-744-905A-4/C
; Sequence 4, Application US/08744905A
; Patent No. 5990294
; GENERAL INFORMATION:
; APPLICANT: Murphy, Gerald
; APPLICANT: Boynton, Alton
; APPLICANT: Sengul, Anil
; TITLE OF INVENTION: NUCLEOTIDE AND AMINO ACID
; TITLE OF INVENTION: SEQUENCES OF C4-2, A TUMOR SUPPRESSOR GENE,
; TITLE OF INVENTION: AND METHODS OF USE THEREOF
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/744,905A
; FILING DATE: 08-NOV-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Baldwin, Geraldine F.
; REGISTRATION NUMBER: 31,232
; REFERENCE/DOCKET NUMBER: 8511-009
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)7909090
; TELEFAX: (212)8698864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: Modified Base
; LOCATION: 1
; OTHER INFORMATION: where N is any nucleotide
US-08-744-905A-4

Query Match 100.0%; Score 7; DB 2; Length 14;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||
DB 14 AGTATGA 8

RESULT 5
US-08-334-847-24
; Sequence 24, Application US/08334847
; Patent No. 5693532
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Diaper, Kenneth
; APPLICANT: Pavco, Pam
; APPLICANT: Woolf, Tod
; TITLE OF INVENTION: METHOD AND REAGENT FOR

TITLE OF INVENTION: INHIBITING RESPIRATORY
TITLE OF INVENTION: SYNCYTIAL VIRUS
NUMBER OF SEQUENCES: 909
CORRESPONDENCE ADDRESS:-
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/334,847
FILING DATE: No. 5693532ember 4, 1994
PRIORITY APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/032
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-334-847-24

Query Match 100.0%; Score 7; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 6.1e+03;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
||:|:|
DB 5 AGUAGUA 11

RESULT 6
US-08-334-847-327
Sequence 327, Application US/08334847
Patent No. 5693532
GENERAL INFORMATION:
APPLICANT: McSwiggen, James
APPLICANT: Draper, Kenneth
APPLICANT: Pavco, Pam
APPLICANT: Woolf, Tod
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING RESPIRATORY
TITLE OF INVENTION: SYNCYTIAL VIRUS
NUMBER OF SEQUENCES: 909
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/334,847
FILING DATE: No. 5693532ember 4, 1994
PRIORITY APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/032
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 327:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-334-847-327

Query Match 100.0%; Score 7; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 6.1e+03;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
||:|:|
DB 5 AGUAGUA 11

RESULT 7
US-08-671-071B-2/c
Sequence 2, Application US/08671071B
Patent No. 5811270
GENERAL INFORMATION:
APPLICANT: Grandgenett, Duane
TITLE OF INVENTION: An in vitro method for concerted integration of
TITLE OF INVENTION: donor DNA molecules using retroviral integrase proteins.
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Grandgenett, Duane
STREET: 8610 Henrietta Ave
CITY: Brentwood
STATE: Missouri
COUNTRY: USA
ZIP: 63144
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch;
COMPUTER: Gateway 2000,4DX2-66E(Intel)
OPERATING SYSTEM: IBM clone
SOFTWARE: Microsoft Word
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/671,071B
FILING DATE: 06/27/96
CLASSIFICATION: 435
TELECOMMUNICATION INFORMATION:
TELEPHONE: (314) 962-0064
TELEFAX: (314) 577-8406
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE: Combination of avian or HIV-1 retrovirus
ORIGINAL SOURCE: DNA, plasmid and pGEM plasmid.
IMMEDIATE SOURCE: Same as in 2,v1.

FEATURE:
OTHER INFORMATION: The sequence is the bottom strand of
OTHER INFORMATION: M-2 U5 and the pGEM target of the top clone shown in
OTHER INFORMATION: Figure 14 of original application.
US-08-671-071B-2

Query Match 100.0%; Score 7; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
1111111
Db 9 AGTATGA 3

RESULT 8
US-08-747-121-4/c
Sequence 4, Application US/08747121
Patent No. 5874290
GENERAL INFORMATION:
APPLICANT: Murphy, Gerald
APPLICANT: Boynton, Alton
APPLICANT: Sehgal, Anil
TITLE OF INVENTION: NUCLEOTIDE AND AMINO ACID
TITLE OF INVENTION: SEQUENCES OF A D2-2 GENE ASSOCIATED WITH
TITLE OF INVENTION: BRAIN TUMORS AND METHODS BASED THEREON
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10036-2711
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/747,121
FILING DATE: 08-NOV-1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Baldwin, Geraldine F
REGISTRATION NUMBER: 31,232
REFERENCE/DOCKET NUMBER: 8511-008
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212)7909090
TELEFAX: (212)8698864
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified Base
LOCATION: 1
OTHER INFORMATION: Where N is any nucleotide
US-08-747-121-4

Query Match 100.0%; Score 7; DB 2; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
1111111
Db 15 AGTATGA 9

RESULT 9
US-08-585-684B-130
Sequence 130, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James

TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 130:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-130

Query Match 100.0%; Score 7; DB 2; Length 15;
Best Local Similarity 71.4%; Pred. No. 6.1e+03;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
1111111
Db 5 AGUATGA 11

RESULT 10
US-08-585-684B-1315
Sequence 1315, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1315:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-1315

Query Match
Best Local Similarity 100.0%; Score 7; DB 2; Length 15;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
||:|:|
DB 5 AGUAGUA 11

RESULT 11
US-08-485-133-28
Sequence 28, Application US/08485133
Patent No. 5976789
GENERAL INFORMATION:
APPLICANT: Allibert, Patrice A.
APPLICANT: Cros, Philippe
APPLICANT: Mach, Bernard F.
APPLICANT: Mandrand, Bernard F.
APPLICANT: Tiercy, Jean-Marie
TITLE OF INVENTION: SYSTEM OF PROBES ENABLING HLA-DR TYPING
TITLE OF INVENTION: TO BE PERFORMED, AND TYPING METHOD USING SAID PROBES
NUMBER OF SEQUENCES: 81
CORRESPONDENCE ADDRESS:
ADDRESSEE: OLIFF & BERRIDGE
STREET: P. O. Box 19928
CITY: Alexandria
STATE: Virginia
ZIP: 22320
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,133
FILING DATE: 7-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/030,143

FILING DATE: 11-MAR-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Berridge, William P.
REGISTRATION NUMBER: 30,024
REFERENCE/DOCKET NUMBER: WPB 28596A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-836-6400
TELEFAX: 703-836-2787
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-485-133-28

Query Match
Best Local Similarity 100.0%; Score 7; DB 2; Length 15;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
||:|:|
DB 9 AGTATGA 15

RESULT 12
US-09-094-714A-33/C
Sequence 33, Application US/09094714A
Patent No. 6117847
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett, Nicholas M. Dean
TITLE OF INVENTION: OLIGONUCLEOTIDES FOR ENHANCED MODULATION OF
NUMBER OF SEQUENCES: 69
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6117847rls, LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 8.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/094,714A
FILING DATE: June 15, 1998
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/601,269
FILING DATE: 14-FEB-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/478,178
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/089,996
FILING DATE: 09-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/852,852
FILING DATE: 16-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul K. Legard
REGISTRATION NUMBER: 38,534
REFERENCE/DOCKET NUMBER: ISIS-2943
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 15

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-094-714A-33

Query Match 100.0%; Score 7; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0;

QY 1 AGTATGA 7
|||||
DB 12 AGTATGA 6

RESULT 13
US-09-094-714A-34/C
Sequence 34, Application US/09094714A
Patent No. 6117847

GENERAL INFORMATION:
APPLICANT: C. Frank Bennett, Nicholas M. Dean
TITLE OF INVENTION: OLIGONUCLEOTIDES FOR ENHANCED MODULATION OF
PROTEIN KINASE C EXPRESSION
NUMBER OF SEQUENCES: 69
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6117847r1s, LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 8.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/094,714A
FILING DATE: June 15, 1998

CLASSIFICATION: 435
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 3
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone

REGISTRATION NUMBER: 38,534
REFERENCE/DOCKET NUMBER: ISIS-2943
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-094-714A-34

Query Match 100.0%; Score 7; DB 3; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0;

QY 1 AGTATGA 7
|||||
DB 14 AGTATGA 8

RESULT 14
US-09-049-190-6/C
Sequence 6, Application US/09049190
Patent No. 6190866

GENERAL INFORMATION:
APPLICANT: Nielsen et al.
TITLE OF INVENTION: Peptide Nucleic Acids Having
Antibacterial Activity
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 MB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/049,190
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION NUMBER:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-2560
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 3
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone

REGISTRATION NUMBER: 38,534
REFERENCE/DOCKET NUMBER: ISIS-2943
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 3
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone

FEATURE:
NAME/KEY: Modified-site
LOCATION: 7
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 8
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 9
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 10
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 11
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 12
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 13
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 14
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 15
OTHER INFORMATION: N-[acetyl(2-aminoethyl)]-C-lysine-glycine
OTHER INFORMATION: backbone
US-09-049-190-6
Query Match 100.0%; Score 7; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGTATGA 7
|||||||
Db 10 AGTATGA 4
RESULT 15
US-09-049-190-7/C
Sequence 7, Application US/09049190
Patent No. 6190866
GENERAL INFORMATION:
APPLICANT: Nielsen et al.
TITLE OF INVENTION: Peptide Nucleic Acids Having
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESS: Woodcock Washburn Kurtz Mackiewicz
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM: a No. 6190866r1s LLP

MEDIUM TYPE: 3.5 inch disk, 1.44 MB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/049,190
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-2560
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ. ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Modified-site
LOCATION: 1
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 2
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 3
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 4
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 5
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 6
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 7
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 8
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 9
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 10
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine

```
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 11
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 12
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 13
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 14
OTHER INFORMATION: N-acetyl(2-aminoethyl)glycine
OTHER INFORMATION: backbone
FEATURE:
NAME/KEY: Modified-site
LOCATION: 15
OTHER INFORMATION: N-[acetyl(2-aminoethyl)]-C-lysine-glycine
OTHER INFORMATION: backbone
US-09-049-190-7

Query Match 100.0%; Score 7; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 6.1e+03;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
   |||||
Db 13 AGTATGA 7
```

Search completed: June 2, 2003, 20:38:33
Job time : 29.6829 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 18:29:55 ; Search time 878.415 Seconds
(without alignments)
129.060 Million cell updates/sec

Title: US-09-540-843-3

Perfect score: 7

Sequence: 1 agatgca 7

Scoring table: GAPOP 10.0, Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 60474

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:*
1: em_estha:*
2: em_esthum:*
3: em_estlin:*
4: em_estlmu:*
5: em_estlov:*
6: em_estov:*
7: em_estro:*
8: em_estro:*
9: em_estro:*
10: em_estro:*
11: em_estro:*
12: em_estro:*
13: em_estro:*
14: em_estro:*
15: em_estro:*
16: em_estro:*
17: em_estro:*
18: em_gss_hum:*
19: em_gss_inv:*
20: em_gss_pln:*
21: em_gss_vrt:*
22: em_gss_vrt:*
23: em_gss_vrt:*
24: em_gss_vrt:*
25: em_gss_vrt:*
26: em_gss_vrt:*
27: em_gss_vrt:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	7	100.0	19	AZ817238	AZ817238 2M0086E01
2	7	100.0	19	AZ990856	AZ990856 2M0274E14
3	7	100.0	22	AZ623945	AZ623945 1M0462J10
4	7	100.0	22	AZ658158	AZ658158 1M0534H17
5	7	100.0	24	AW059679	AW059679 AHUTH.DBS
6	7	100.0	24	AZ423817	AZ423817 1M0203P19

C 7	7	100.0	24	AZ478673	AZ478673 1M0298J20
C 8	7	100.0	24	AZ816657	AZ816657 2M0085E05
C 9	7	100.0	25	H96935	H96935 YU01d01.r1
C 10	7	100.0	25	AZ605844	AZ605844 1M0427J22
C 11	7	100.0	25	AZ802490	AZ802490 2M0061I22
C 12	7	100.0	25	BH852860	BH852860 SALR_0756
C 13	7	100.0	25	BH852865	BH852865 SALR_0756
C 14	7	100.0	25	BH852866	BH852866 SALR_0756
C 15	7	100.0	26	AZ456685	AZ456685 1M0080C06
C 16	7	100.0	26	AZ473354	AZ473354 1M0289N08
C 17	7	100.0	27	D45824	D45824 HMG03044
C 18	7	100.0	27	TA187C01P	TA187C01P T. brucei
C 19	7	100.0	28	A1790546	A1790546 U102e08.x
C 20	7	100.0	28	AZ861130	AZ861130 2M0167M21
C 21	7	100.0	29	BH856420	BH856420 SALR_0797
C 22	7	100.0	29	TA230F03P	TA230F03P T. brucei
C 23	7	100.0	30	C21099	C21099 HMG000262
C 24	7	100.0	30	AL766985	AL766985 Arabidops
C 25	7	100.0	31	A1159285	A1159285 V285B12.T
C 26	7	100.0	31	A1198585	A1198585 q150c03.x
C 27	7	100.0	31	BH853749	BH853749 SALR_0782
C 28	7	100.0	32	AZ587241	AZ587241 1M0394D14
C 29	7	100.0	32	BH862820	BH862820 SALR_0906
C 30	7	100.0	32	AL769600	AL769600 Arabidops
C 31	7	100.0	33	AZ463054	AZ463054 1M0271H10
C 32	7	100.0	33	AZ481169	AZ481169 1M0303D13
C 33	7	100.0	33	AZ778279	AZ778279 2M0013N15
C 34	7	100.0	33	AZ826520	AZ826520 2M0102B04
C 35	7	100.0	33	TA307A09Q	TA307A09Q T. brucei
C 36	7	100.0	34	AU256929	AU256929 AU256929
C 37	7	100.0	34	AZ333219	AZ333219 1M0062C09
C 38	7	100.0	35	AZ476942	AZ476942 1M0296H11
C 39	7	100.0	35	AZ817309	AZ817309 2M0086N18
C 40	7	100.0	36	AU258145	AU258145 AU258145
C 41	7	100.0	36	AA624760	AA624760 VN91A08..r
C 42	7	100.0	36	AZ405651	AZ405651 1M0174C03
C 43	7	100.0	36	AZ621129	AZ621129 1M0454I08
C 44	7	100.0	36	AZ776722	AZ776722 2M0010A12
C 45	7	100.0	36	BH789482	BH789482 SALR_0297

ALIGNMENTS

RESULT 1	AZ817238	19 bp	DNA	linear	GSS 20-FEB-2001
DEFINITION	2M0086E01R Mouse 10kb plasmid UGCCIM library Mus musculus genomic				
LOCUS	AZ817238				
ACCESSION	AZ817238				
VERSION	AZ817238.1	GI:12987146			
KEYWORDS	GSS.				
SOURCE	house mouse.				
ORGANISM	Mus musculus.				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.				
AUTHORS	Dunn,D., Aoyagi,A., Barber,M., Beecorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tinney,A., von Niederhausern,A. and Wright,D., Weiss,R.				
TITLE	Mouse whole genome scaffolding with paired end reads from 10kb				
JOURNAL	Unpublished (2000)				
COMMENT	Contact: Robert B. Weiss University of Utah Genome Center University of Utah Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT 84112, USA Tel: 801 585 5606 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu Insert Length: 10000 Std Error: 0.00				

Plate: 0086 row: E column: 01
Seq primer: CACACGGAACACCTATGACC
Class: plasmid ends
High quality sequence stop: 19.
Location/Qualifiers

FEATURES
Source

```
1..19
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0086E01"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"/
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g14732114[gb]AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
```

BASE COUNT
ORIGIN

6 a 1 c 6 g 6 t

Query Match 100.0%; Score 7; DB 17; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
| | | | |
Db 10 AGTATGA 16

RESULT 2

AZ990856/c 19 bp DNA linear GSS 27-APR-2001
LOCUS
DEFINITION
clone UUGC2M0274F14 R, DNA sequence.

ACCESSION
AZ990856
VERSION
AZ990856.1 GI:13862083

KEYWORDS
SOURCE
ORGANISM

house mouse.
Mus musculus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 19)

REFERENCE
AUTHORS

Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A.
and Wright,D., Weis,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

TITLE

Unpublished (2000)
Contact: Robert B. Weiss

JOURNAL
COMMENT

University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

Plate: 0274 row: F column: 14
Seq primer: CACACGGAACACCTATGACC
Class: plasmid ends
High quality sequence stop: 19.
Location/Qualifiers

FEATURES
Source

```
1..19
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0274F14"
/clone_lib="Mouse 10kb plasmid UUGC2M library"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"/
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (g14732114[gb]AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
```

BASE COUNT
ORIGIN

8 a 5 c 0 g 6 t

Query Match 100.0%; Score 7; DB 17; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.5e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
| | | | |
Db 18 AGTATGA 12

RESULT 3

AZ623945/c 22 bp DNA linear GSS 13-DEC-2000
LOCUS
DEFINITION
clone UUGC1M0462J10 F, DNA sequence.

ACCESSION
AZ623945
VERSION
AZ623945.1 GI:11746135

KEYWORDS
SOURCE
ORGANISM

house mouse.
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 22)

REFERENCE
AUTHORS

Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A.
and Wright,D., Weis,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

TITLE

Unpublished (2000)
Contact: Robert B. Weiss

JOURNAL
COMMENT

University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

Plate: 0462 row: J column: 10
Seq primer: CCGTGTAAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 22.
Location/Qualifiers

FEATURES
source

1..22
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="U061M0462J10"
/clone.lib="Mouse 10kb plasmid U061M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g14732114[gb|AF129072.1]), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN

7 a 5 c 2 g 8 t

Query Match

Best Local Similarity 100.0%; Score 7; DB 17; Length 22;
Pred. No. 1.6e+05; Mismatches 0; Indels 0; Gaps 0;

Matches

QY 1 AGTATGA 7
|||||
DB 11 AGTATGA 5

RESULT 4
A2658158

LOCUS

22 bp DNA linear GSS 14-DEC-2000
1M0534H17R Mouse 10kb plasmid U061M library Mus musculus genomic

DEFINITION

A2658158
clone U061M0534H17 R, DNA sequence.

ACCESSION

A2658158.1 GI:11795304
GSS.

VERSION

KEYWORDS

SOURCE

ORGANISM

house mouse.

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

AUTHORS

TITLE

JOURNAL

Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunne@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

COMMENT

Plate: 0534 row: H column: 17
Seq primer: CACACAGCAACACGCTATGACC
Class: plasmid ends
High quality sequence stop: 22.
Location/Qualifiers

FEATURES
source

1..22
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="U061M0534H17"
/clone.lib="Mouse 10kb plasmid U061M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g14732114[gb|AF129072.1]), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN

6 a 0 c 9 g 7 t

Query Match

Best Local Similarity 100.0%; Score 7; DB 17; Length 22;
Pred. No. 1.6e+05; Mismatches 0; Indels 0; Gaps 0;

Matches

QY 1 AGTATGA 7
|||||
DB 4 AGTATGA 10

RESULT 5
AM059679/c

LOCUS

24 bp mRNA linear EST 23-AUG-2000
AHUTH.bset.dnc15.aa.A050g08 DNC15 Homo sapiens cDNA, mRNA sequence.

DEFINITION

AM059679
Proc. Acad. Sci. U.S.A. 97 (4), 1665-1670 (2000)

ACCESSION

KEYWORDS

EST.

SOURCE

human.

ORGANISM

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE

AUTHORS

TITLE

JOURNAL

in vitro cloning of complex mixtures of DNA on microbeads: Physical
separation of differentially expressed cDNAs
Proc. Natl. Acad. Sci. U.S.A. 97 (4), 1665-1670 (2000)

MEDLINE

COMMENT

contact: Burcham TS

LYNX Therapeutics, Inc.
25861 Industrial Blvd., Hayward, CA 94545, USA
Tel: 510 670 9338
Fax: 510 670 9302

Email: timb@lynxgen.com

Sequence obtained from LYNX Therapeutics Megasort technology.
Collected from the down-regulated gate.

High quality sequence stop: 24.

Location/Qualifiers

FEATURES

source
1. .24
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="DNC15"
/cell_type="monocytic leukemia"
/cell_line="THP-1 (TIB-202)"
/note="Vector: pCR2.1; Cloning of PCR products from micro-beads carrying 3' end of down-regulated cDNA. THP-1 cells non-induced (treated with DMSO only)."

BASE COUNT
ORIGIN
9 a 6 c 1 g 8 t

Query Match
Best Local Similarity 100.0%; Score 7; DB 10; Length 24;
Pred. No. 1.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 23 AGTATGA 17

RESULT 6
AZ423817/c 24 bp DNA linear GSS 03-OCT-2000
LOCUS
DEFINITION IM0203P19F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
ACCESSION AZ423817
VERSION AZ423817.1 GI:10547830
KEYWORDS
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Mus.
REFERENCE 1 (bases 1 to 24)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A. and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah
Blommedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0203 row: P column: 19
Seq primer: CGTTGTAACGACGCGCCAGT
Class: plasmid ends
High quality sequence stop: 24.
Location/Qualifiers
1. .24
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0203P19"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to

10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g14732114|db|AF129072.1), a copy-number inducible derivative of plasmid RL. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN
7 a 3 c 2 g 12 t

Query Match
Best Local Similarity 100.0%; Score 7; DB 17; Length 24;
Pred. No. 1.7e+05;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
|||||||
Db 17 AGTATGA 11

RESULT 7
AZ478673/c 24 bp DNA linear GSS 04-OCT-2000
LOCUS
DEFINITION IM0298U20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
ACCESSION AZ478673
VERSION AZ478673.1 GI:10637794
KEYWORDS
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 24)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A. and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah
Blommedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0298 row: J column: 20
Seq primer: CACACAGAAACACCTATGACC
Class: plasmid ends
High quality sequence stop: 24.
Location/Qualifiers
1. .24
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0298U20"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to

BASE COUNT 6 a 5 c 6 g 8 t
 ORIGIN

Query Match 100.0%; Score 7; DB 14; Length 25;
 Best Local Similarity 100.0%; Pred. No. 1.7e+05;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
 |||||
 Db 19 AGTATGA 13

RESULT 10
 AZ605844 25 bp DNA linear GSS 13-DEC-2000
 LOCUS
 DEFINITION 1M0427J22F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 clone UUGC1M0427J22 F, DNA sequence.
 ACCESSION AZ605844
 VERSION
 KEYWORDS
 ORGANISM
 SOURCE
 house mouse.
 Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
 1 (bases 1 to 25)
 Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
 Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Relilly,
 M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A.
 and Wright, D., Weiss, R.
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts

TITLE
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts

JOURNAL
 COMMENT
 Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0427 row: J column: 22
 Seq primer: CGTGTAAACGACGCCAGT
 Class: plasmid ends
 High quality sequence stop: 25.
 Location/Qualifiers

FEATURES
 source
 1..25
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0427J22"
 /clone_1lb="Mouse 10kb plasmid UUGC1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD42nv; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 ligated DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of PMD42 (g114732114|g1AF129072.1), a copy-number
 inducible derivative of plasmid R1. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells

BASE COUNT 7 a 6 c 5 g 7 t
 ORIGIN

Query Match 100.0%; Score 7; DB 17; Length 25;
 Best Local Similarity 100.0%; Pred. No. 1.7e+05;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTATGA 7
 |||||
 Db 17 AGTATGA 11

RESULT 11
 AZ802490 25 bp DNA linear GSS 16-FEB-2001
 LOCUS
 DEFINITION 2M0611122F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 clone UUGC2M061122 F, DNA sequence.
 ACCESSION AZ802490
 VERSION
 KEYWORDS
 ORGANISM
 SOURCE
 house mouse.
 Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
 1 (bases 1 to 25)
 Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
 Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Relilly,
 M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A.
 and Wright, D., Weiss, R.
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts

TITLE
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts

JOURNAL
 COMMENT
 Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0061 row: I column: 22
 Seq primer: CGTGTAAACGACGCCAGT
 Class: plasmid ends
 High quality sequence stop: 25.
 Location/Qualifiers

FEATURES
 source
 1..25
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC2M061122"
 /clone_1lb="Mouse 10kb plasmid UUGC1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD42nv; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 ligated DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of PMD42 (g114732114|g1AF129072.1), a copy-number
 inducible derivative of plasmid R1. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells

BASE COUNT 5 a and selected for ampicillin resistance.
 ORIGIN 5 a 6 c 5 g 9 t

Query Match 100.0%; Score 7; DB 17; Length 25;
 Best Local Similarity 100.0%; Pred. No. 1.7e+05;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
 |||||
 DB 22 AGTATGA 16

RESULT 12
 BH852860
 LOCUS
 DEFINITION BH852860 25 bp DNA linear GSS 13-JUN-2002
 SALK_075689.48.55.x Arabidopsis thaliana TDNA insertion lines

ACCESSION
 VERSION BH852860
 KEYWORDS
 SOURCE GSS.
 ORGANISM
 thale cress.
 Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
 1 (bases 1 to 25)
 Alonso,J.M., Leisbe,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrinab
 ,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P.
 , Zimmerman,J. and Ecker,J.R.
 A Sequence-Indexed Library of Insertion Mutations in the
 Arabidopsis Genome
 Unpublished (2001)
 Contact: Joseph R. Ecker
 Salk Institute Genomic Analysis Laboratory (SIGAL)
 The Salk Institute for Biological Studies
 10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
 Tel: 858 453 4100 x1752
 Fax: 858 558 6379
 Email: ecker@salk.edu
 This is single pass sequence recovered from the left border of
 TDNA. This sequence lies within an annotated exon of At3g41627.
 Class: TDNA tagged.

FEATURES
 source
 Location/Qualifiers
 1..25
 /organism="Arabidopsis thaliana"
 /strain="Columbia 0"
 /db_xref="taxon:3702"
 /clone="SALK_075689.48.55.x"
 /note="PCR was performed on Arabidopsis thaliana lines
 each of which contains one or more TDNA insertion
 elements. The resultant fragment for each line was
 directly sequenced to determine the genomic sequence at
 the site of insertion. Details of the protocols used can
 be found at http://signal.salk.edu/tdna_protocols.html"

BASE COUNT 9 a 2 c 6 g 8 t

ORIGIN

Query Match 100.0%; Score 7; DB 17; Length 25;
 Best Local Similarity 100.0%; Pred. No. 1.7e+05;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
 |||||
 DB 12 AGTATGA 18

RESULT 13
 BH852866
 LOCUS
 DEFINITION BH852866 25 bp DNA linear GSS 13-JUN-2002
 SALK_075697.38.25.x Arabidopsis thaliana TDNA insertion lines

Arabidopsis thaliana genomic clone SALK_075697.38.25.x. DNA
 sequence.
 BH852866
 BH852866.1 GI:21423737
 GSS.
 SOURCE
 ORGANISM
 Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
 1 (bases 1 to 25)
 Alonso,J.M., Leisbe,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrinab
 ,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P.
 , Zimmerman,J. and Ecker,J.R.
 A Sequence-Indexed Library of Insertion Mutations in the
 Arabidopsis Genome
 Unpublished (2001)
 Contact: Joseph R. Ecker
 Salk Institute Genomic Analysis Laboratory (SIGAL)
 The Salk Institute for Biological Studies
 10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
 Tel: 858 453 4100 x1752
 Fax: 858 558 6379
 Email: ecker@salk.edu
 This is single pass sequence recovered from the left border of
 TDNA. This sequence lies within an annotated exon of At3g41627.
 Class: TDNA tagged.

FEATURES
 source
 Location/Qualifiers
 1..25
 /organism="Arabidopsis thaliana"
 /strain="Columbia 0"
 /db_xref="taxon:3702"
 /clone="SALK_075697.38.25.x"
 /note="PCR was performed on Arabidopsis thaliana lines
 each of which contains one or more TDNA insertion
 elements. The resultant fragment for each line was
 directly sequenced to determine the genomic sequence at
 the site of insertion. Details of the protocols used can
 be found at http://signal.salk.edu/tdna_protocols.html"

BASE COUNT 9 a 2 c 6 g 8 t

ORIGIN

Query Match 100.0%; Score 7; DB 17; Length 25;
 Best Local Similarity 100.0%; Pred. No. 1.7e+05;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
 |||||
 DB 12 AGTATGA 18

RESULT 14
 BH857761
 LOCUS
 DEFINITION BH857761 25 bp DNA linear GSS 08-JUL-2002
 SALK_015664.41.95.x Arabidopsis thaliana TDNA insertion lines

ACCESSION
 VERSION BH857761
 KEYWORDS
 SOURCE GSS.
 ORGANISM
 Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
 1 (bases 1 to 25)
 Alonso,J.M., Leisbe,T.J., Barajas,P., Chen,H., Cheuk,R., Gadrinab
 ,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P.
 , Zimmerman,J. and Ecker,J.R.
 A Sequence-Indexed Library of Insertion Mutations in the
 Arabidopsis Genome
 Unpublished (2001)

COMMENT

Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGNAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: eckersalk.edu

This is single pass sequence recovered from the left border of
TDNA. This sequence lies within an annotated intron of At3g22930.
Class: TDNA tagged.

FEATURES

SOURCE

Location/Qualifiers
1..25
/organism="Arabidopsis thaliana"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="SALK_015664.41.95.x"
/note="11b-Arabidopsis thaliana TDNA insertion lines"
/note="PCR was performed on Arabidopsis thaliana lines
each of which contains one or more TDNA insertion
elements. The resultant fragment for each line was
directly sequenced to determine the genomic sequence at
the site of insertion. Details of the protocols used can
be found at http://signal.salk.edu/tdna_protocols.html"

BASE COUNT

9 a 5 c 0 g 11 t

ORIGIN

/clone="UUCG1M080C06"
/clone.lib="Mouse 10kb plasmid UUCG1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(<http://www.jax.org/resources/documents/dnares/>). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD42 (g114732114g1a129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

Query Match

100.0%; Score 7; DB 17; Length 25;

Best Local Similarity 100.0%; Pred. No. 1.7e+05; Mismatches 0; Indels 0; Gaps 0;

100.0%; Score 7; DB 17; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.7e+05; Mismatches 0; Indels 0; Gaps 0;

Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 AGTATGA 7
|||||||

1 AGTATGA 7
|||||||

8 AGTATGA 2

9 AGTATGA 3

RESULT 15 26 bp DNA linear GSS 29-SEP-2000
A2345685

LOCUS 1M080C06R Mouse 10kb plasmid UUCG1M library Mus musculus genomic
clone UUCG1M080C06 R, DNA sequence.

ACCESSION A2345685

VERSION A2345685.1 GI:10424922

KEYWORDS

GSS.

SOURCE

house mouse.

ORGANISM

Mus musculus

REFERENCE

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

AUTHORS

Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
and Wright,D., Weis,R.

TITLE

Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

JOURNAL

Unpublished (2000)

COMMENT

Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177

FEATURES

SOURCE

High quality sequence stop: 26.

Location/Qualifiers
1..26
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"

Search completed: June 2, 2003, 20:35:40
Job time : 881.415 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 2, 2003, 17:32:40 ; Search time 116.951 Seconds
(without alignments)
134.791 Million cell updates/sec

Title: US-09-540-843-3

Perfect score: 7

Sequence: 1 agtatga 7

Scoring table: IDENTITY NUC

Gapop 10.0, Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 2063506

Minimum DB seq length: 0
Maximum DB seq length: 40

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

N_Geneseq_101002.*
1: /SID52/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
2: /SID52/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
3: /SID52/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
4: /SID52/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
5: /SID52/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
6: /SID52/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
7: /SID52/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
8: /SID52/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
9: /SID52/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
10: /SID52/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
11: /SID52/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
12: /SID52/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
13: /SID52/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
14: /SID52/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
15: /SID52/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
16: /SID52/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
17: /SID52/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
18: /SID52/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
19: /SID52/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
20: /SID52/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
21: /SID52/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
22: /SID52/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.*
23: /SID52/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
24: /SID52/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	7	100.0	7	AAZ10694	Oligonucleotide se
2	7	100.0	7	AAZ14907	Melanogenesis asso
3	7	100.0	7	AAZ14911	Melanogenesis asso
4	7	100.0	9	AAZ10692	Oligonucleotide se
5	7	100.0	9	AAZ14905	Melanogenesis asso
6	7	100.0	10	AAZ78995	Human dendritic ce
7	7	100.0	10	AAZ86425	Metastatic breast
8	7	100.0	10	AAZ32760	LPS activated huma
9	7	100.0	10	AAZ38936	Yeast NORF gene SA

10	7	100.0	10	AAZ39793	Yeast NORF gene SA
11	7	100.0	10	AAZ40876	Yeast NORF gene SA
12	7	100.0	10	AAZ47394	Human PLA2GIB ASO
13	7	100.0	10	AAZ41859	Human GCNT1 allele
14	7	100.0	10	AAZ67680	Human IL-8 gene po
15	7	100.0	10	AAZ67681	Human IL-8 gene po
16	7	100.0	10	AAZ42801	Human maturation/a
17	7	100.0	11	AAZ68727	Human skin stress/
18	7	100.0	12	AAZ40922	Primer E2HMF-1726
19	7	100.0	12	AAZ19080	Oligonucleotide 1
20	7	100.0	12	ABH77740	Oligonucleotide pr
21	7	100.0	12	ABH68353	Oligonucleotide pr
22	7	100.0	12	ABH70774	Oligonucleotide pr
23	7	100.0	12	ABH71335	Oligonucleotide pr
24	7	100.0	12	ABH71445	Oligonucleotide pr
25	7	100.0	12	ABH71785	Oligonucleotide pr
26	7	100.0	12	ABH74658	Oligonucleotide pr
27	7	100.0	12	ABH74660	Oligonucleotide pr
28	7	100.0	12	ABH75445	Oligonucleotide pr
29	7	100.0	12	ABH78137	Oligonucleotide pr
30	7	100.0	12	ABH78185	Oligonucleotide pr
31	7	100.0	12	ABH79172	Oligonucleotide pr
32	7	100.0	12	ABH79256	Oligonucleotide pr
33	7	100.0	12	ABH79332	Oligonucleotide pr
34	7	100.0	12	ABH79629	Oligonucleotide pr
35	7	100.0	12	ABH80384	Oligonucleotide pr
36	7	100.0	12	ABH80608	Oligonucleotide pr
37	7	100.0	12	ABH80919	Oligonucleotide pr
38	7	100.0	12	ABH81994	Oligonucleotide pr
39	7	100.0	12	ABH82603	Oligonucleotide pr
40	7	100.0	12	ABH84469	Oligonucleotide pr
41	7	100.0	12	ABH84470	Oligonucleotide pr
42	7	100.0	12	ABH84926	Oligonucleotide pr
43	7	100.0	12	ABH86238	Oligonucleotide pr
44	7	100.0	12	ABH87108	Oligonucleotide pr
45	7	100.0	12	ABH87400	Oligonucleotide pr

ALIGNMENTS

RESULT 1
AAZ10694 standard; DNA; 7 BP.
AAZ10694:
23-NOV-1999 (first entry)
Oligonucleotide sequence that increases p53 activity in a cell.
p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;
UV-induced hyperproliferative disease; psoriasis; vitiligo;
atopic dermatitis; allergic rhinitis; conjunctivitis; photoaging;
skin cancer; ss.
Synthetic.
GB2336157-A.
13-OCT-1999.
24-MAR-1999; 99GB-0006758.
26-MAR-1999; 98US-0048927.
(UYBO-) UNITV BOSTON.
Gillchrest BA, Yaar M, Eller M;
WPI; 1999-543520/46.
DNA fragments useful for increasing p53 activity in a cell and reducing

PT susceptibility to UV-induced hyperproliferative diseases -

XX Claim 11; Page 30; 44pp; English.

XX AA210692-97 represent DNA fragments that are used for increasing p53

CC activity in a cell. The oligonucleotides are UV mimetics and

CC protect cells against subsequent exposure to UV-irradiation or

CC chemicals. The oligonucleotides are useful for increasing p53 activity

CC in a cell, reducing the susceptibility to UV-induced hyperproliferative

CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic

CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging

CC and reducing susceptibility to skin cancer.

XX

SO Sequence 7 BP; 3 A; 0 C; 2 G; 2 T; 0 other;

Query Match 100.0%; Score 7; DB 20; Length 7;

Best Local Similarity 100.0%; Pred. No. 3.1e+08;

Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7

1111111

Db 1 AGTATGA 7

RESULT 2

AA514907 standard; DNA; 7 BP.

AC AA514907;

XX 14-FEB-2002 (first entry)

XX

DE Melanogenesis associated oligonucleotide #3.

XX

KW Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;

KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;

KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;

KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;

KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;

XX conjunctivitis; allergic rhinitis; vitiligo; ss.

XX

OS Synthetic.

XX

PN WO200174342-A2.

XX

PD 11-OCT-2001.

XX

PF 30-MAR-2001; 2001WO-US10162.

XX

PR 31-MAR-2000; 2000US-0540843.

XX

PA (UYBO-) UNIV BOSTON.

XX

PI Gilchrist BA, Yaar M, Eller M;

XX

DR WPI; 2001-626338/72.

XX

PT Inhibiting proliferation of epithelial cells, useful e.g. for treating

PT carcinoma, using specific oligonucleotides that mimic the effects of

PT ultra-violet light -

XX

PS Claim 1; Page 36; 74pp; English.

XX

CC The invention describes inhibition of mammalian epithelial cell

CC proliferation by treating cells with at least one oligonucleotide, or

CC its fragment. The compounds, which have cytostatic, anti-allergic,

CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and

CC immunosuppressive activities, function as 'ultra-violet mimics' to induce

CC DNA repair processes (or a protective response to later exposure to

CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer

CC or a tumour necrosis factor inhibitor. Probably they mimic products of

CC DNA damage, or processed DNA-damage intermediates, by inducing the p53

CC pathway, resulting in transient arrest of cell growth, allowing more time

CC for DNA repair to occur before cell division takes place. The method is

CC especially used to treat carcinoma but may also be used to: treat other

CC hyperproliferative states (e.g. psoriasis or precancerous conditions);

CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat

CC allergic rhinitis and inflammation (atopic or contact dermatitis);

CC inhibit apoptosis, in response to DNA damage, in epithelial cells. This

CC sequence is melanogenesis associated oligonucleotide #3, a truncated

CC version of the oligonucleotide shown in AA514906, one of the

CC oligonucleotides used to inhibit mammalian epithelial cell

CC proliferation, described in the method of the invention.

XX

SO Sequence 7 BP; 3 A; 0 C; 2 G; 2 T; 0 other;

Query Match 100.0%; Score 7; DB 23; Length 7;

Best Local Similarity 100.0%; Pred. No. 3.1e+08;

Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7

1111111

Db 1 AGTATGA 7

RESULT 3

AA514911 standard; DNA; 7 BP.

AC AA514911;

XX 14-FEB-2002 (first entry)

XX

DE Melanogenesis associated oligonucleotide #7.

XX

KW Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;

KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;

KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;

KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;

KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;

XX conjunctivitis; allergic rhinitis; vitiligo; ss.

XX

OS Synthetic.

XX

PN WO200174342-A2.

XX

PD 11-OCT-2001.

XX

PF 30-MAR-2001; 2001WO-US10162.

XX

PR 31-MAR-2000; 2000US-0540843.

XX

PA (UYBO-) UNIV BOSTON.

XX

PI Gilchrist BA, Yaar M, Eller M;

XX

DR WPI; 2001-626338/72.

XX

PT Inhibiting proliferation of epithelial cells, useful e.g. for treating

PT carcinoma, using specific oligonucleotides that mimic the effects of

PT ultra-violet light -

XX

PS Claim 1; Page 38; 74pp; English.

XX

CC The invention describes inhibition of mammalian epithelial cell

CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time
 CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photoaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergically mediated inflammation (atopic or contact dermatitis;
 CC allergic rhinitis and conjunctivitis); prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #7, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell
 CC proliferation, described in the method of the invention.

SO Sequence 7 BP; 3 A; 0 C; 2 G; 2 T; 0 other;

Query Match 100.0%; Score 7; DB 23; Length 7;
 Best Local Similarity 100.0%; Pred. No. 3.1e+08;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
 |||||
 Db 1 AGTATGA 7

RESULT 4

AA210692
 AA210692 standard; DNA; 9 BP.

AC AA210692;

DT 23-NOV-1999 (first entry)

DE Oligonucleotide sequence that increases p53 activity in a cell.

KW p53 activity; UV mimetic; UV-irradiation; UV-induced dermatosis;

KW UV-induced hyperproliferative disease; psoriasis; vitiligo;

KW atopic dermatitis; allergic rhinitis; conjunctivitis; photoaging;

KW skin cancer; ss.

OS Synthetic.

PN GB2336157-A.

PD 13-OCT-1999.

PF 24-MAR-1999; 99GB-0006758.

PR 26-MAR-1998; 98US-0048927.

PA (UYBO-) UNIV BOSTON.

PI Gilchrist BA, Yaar M, Eller M;

DR WPI; 1999-543520/46.

CC DNA fragments useful for increasing p53 activity in a cell and reducing
 CC susceptibility to UV-induced hyperproliferative diseases -

PS Claim 1; Page 29; 44pp; English.

CC AA210692-97 represent DNA fragments that are used for increasing p53
 CC activity in a cell. The oligonucleotides are are UV mimetics and

CC protect cells against subsequent exposure to UV-irradiation or
 CC chemicals. The oligonucleotides are useful for increasing p53 activity
 CC in a cell, reducing the susceptibility to UV-induced hyperproliferative
 CC diseases, treating psoriasis, vitiligo, atopic dermatitis, allergic
 CC rhinitis, conjunctivitis, and UV-induced dermatoses, reducing photoaging
 CC and reducing susceptibility to skin cancer.

SO Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;

Query Match 100.0%; Score 7; DB 20; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
 |||||
 Db 2 AGTATGA 8

RESULT 5

AA214905
 AA214905 standard; DNA; 9 BP.

AC AA214905;

DT 14-FEB-2002 (first entry)

DE Melanogenesis associated oligonucleotide #1.

KW Melanin; melanogenic; oligomer; cytostatic; anti-allergic; p53;

KW anti-inflammatory; dermatological; ophthalmological; anti-psoriatic;

KW immunosuppressive; DNA repair; proliferation inhibitor; apoptosis;

KW tumour necrosis factor inhibitor; photoaging; hyperproliferative disease;

KW carcinoma; oxidative stress; skin cancer; allergy mediated inflammation;

KW conjunctivitis; allergic rhinitis; vitiligo; ss.

OS Synthetic.

PN Key Location/Qualifiers

FT modified_base 1

FT /**tag= a

FT /mod_base= g

FT /note= "optionally phosphorylated"

XX WO200174342-A2.

PD 11-OCT-2001.

PF 30-MAR-2001; 2001WO-US10162.

PR 31-MAR-2000; 2000US-0540843.

PA (UYBO-) UNIV BOSTON.

PI Gilchrist BA, Yaar M, Eller M;

DR WPI; 2001-626338/72.

CC Inhibiting proliferation of epithelial cells, useful e.g. for treating
 CC carcinoma, using specific oligonucleotides that mimic the effects of
 CC ultra-violet light -

PS Claim 1; Page 36; 74pp; English.

CC The invention describes inhibition of mammalian epithelial cell
 CC proliferation by treating cells with at least one oligonucleotide, or
 CC its fragment. The compounds, which have cytostatic, anti-allergic,
 CC anti-inflammatory, dermatological, ophthalmological, anti-psoriatic and
 CC immunosuppressive activities, function as 'ultra-violet mimics' to induce
 CC DNA repair processes (or a protective response to later exposure to
 CC radiation or chemicals), as a proliferation inhibitor, apoptosis inducer
 CC or a tumour necrosis factor inhibitor. Probably they mimic products of
 CC DNA damage, or processed DNA-damage intermediates, by inducing the p53
 CC pathway, resulting in transient arrest of cell growth, allowing more time

CC for DNA repair to occur before cell division takes place. The method is
 CC especially used to treat carcinoma but may also be used to: treat other
 CC hyperproliferative states (e.g. psoriasis or precancerous conditions);
 CC reduce photocaging, oxidative stress or damage; prevent skin cancer; treat
 CC allergic rhinitis and conjunctivitis; prevent or reduce dermatitis;
 CC allergic rhinitis and conjunctivitis; prevent or reduce DNA damage in
 CC cells caused by radiation or chemicals; increase melanin production
 CC (pigmentation) in epithelial cells (e.g. for treating vitiligo), and to
 CC promote apoptosis in epithelial cells that contain damaged DNA. Also
 CC oligonucleotides that contain non-hydrolyzable backbones are used to
 CC inhibit apoptosis, in response to DNA damage, in epithelial cell. This
 CC sequence is melanogenesis associated oligonucleotide #1, one of the
 CC oligonucleotides used to inhibit mammalian epithelial cell
 CC proliferation, described in the method of the invention.

XX Sequence 9 BP; 3 A; 0 C; 4 G; 2 T; 0 other;

Query Match 100.0%; Score 7; DB 23; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.4e+08;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
 |||||
 Db 2 AGTATGA 8

RESULT 6
 AAZ78995/c
 ID AAZ78995 standard; DNA; 10 BP.
 XX
 AC AAZ78995;
 XX
 DT 10-APR-2000 (first entry).

DE Human dendritic cell SAGE tag, SEQ ID NO:1423.

XX SAGE tag: serial analysis of gene expression; antigen-presenting cell;
 KW APC; monocyte-derived dendritic cell; differential gene expression;
 KW immunostimulatory cofactor; costimulatory factor; CTL;
 KW cytotoxic T-lymphocyte; tumour antigen; immunotherapy; anticancer; ss.

XX Homo sapiens.

XX WO965924-A2.

XX 23-DEC-1999.

PF 18-JUN-1999; 99WO-US13800.

XX 19-JUN-1998; 98US-0089833.
 PR 19-JUN-1998; 98US-0089844.
 PR 19-JUN-1998; 98US-0089853.
 PR 19-JUN-1998; 98US-0089878.
 PR 19-JUN-1998; 98US-0089991.
 PR 19-JUN-1998; 98US-0089992.
 PR 19-JUN-1998; 98US-0089993.
 PR 19-JUN-1998; 98US-0089994.
 PR 19-JUN-1998; 98US-0089997.
 PR 19-JUN-1998; 98US-0089999.
 PR 19-JUN-1998; 98US-0090000.
 PR 19-JUN-1998; 98US-0090035.
 PR 19-JUN-1998; 98US-0090036.
 PR 19-JUN-1998; 98US-0090039.
 PR 19-JUN-1998; 98US-0090040.
 PR 19-JUN-1998; 98US-0090041.
 PR 19-JUN-1998; 98US-0090042.
 PR 19-JUN-1998; 98US-0090043.
 PR 19-JUN-1998; 98US-0090044.
 PR 19-JUN-1998; 98US-0090045.
 PR 19-JUN-1998; 98US-0090047.
 PR 19-JUN-1998; 98US-0090048.
 PR 19-JUN-1998; 98US-0090076.
 PR 19-JUN-1998; 98US-0090076.

PR 19-JUN-1998; 98US-0090077.
 PR 19-JUN-1998; 98US-0090078.
 PR 19-JUN-1998; 98US-0090079.
 PR 19-JUN-1998; 98US-0090080.
 PR 08-DEC-1998; 98US-0111715.

XX (GENZ) GENZYME CORP.
 PA (ROBE/) ROBERTS B L.
 PA (SHAN/) SHANKARA S.
 XX
 PI Roberts BL, Shankara S;
 XX
 DR WPI; 2000-106077/09.

PT Isolated polynucleotides differentially expressed in antigen-presenting
 PT cells, useful in gene vaccines against cancer -
 XX
 PS Claim 1; Page 105; 130pp; English.

XX Sequences AAZ7573-279709 represent SAGE (serial analysis of gene
 CC expression) tags used to identify mRNA transcripts encoding
 CC immunostimulatory cofactor proteins which are preferentially or
 CC differentially expressed in monocyte-derived dendritic cells compared
 CC with monocytes. Some of the transcripts correspond to known genes or
 CC ESTs (expressed sequence tags) which were previously unknown to be
 CC preferentially or differentially expressed in dendritic cells, while
 CC other transcripts correspond to novel genes. Antigen-presenting cell
 CC (APC)-associated costimulatory factors play an important role in the
 CC activation of the cytotoxic immune response, particularly against tumour
 CC cells. Tumour antigen presentation via the MHC (major histocompatibility
 CC complex) and subsequent recognition by T-cell receptors is alone
 CC insufficient to activate a robust cytotoxic immune response that can
 CC lyse the tumour cells. Immunostimulatory cofactors also being required
 CC for efficient activation of cytotoxic T-lymphocytes (CTLs). Nucleic acid
 CC sequences identified using the SAGE tags have several potential uses.
 CC They may be used in vaccines to induce an immune response, particularly
 CC against a tumour antigen; to modulate the genotype of an APC; to screen
 CC for agents that modulate expression of differentially expressed genes in
 CC an APC; and as hybridisation probes/amplification primers for the
 CC diagnosis, prognosis and monitoring of diseases related to abnormal
 CC expression of these genes. Detection of the dendritic cell
 CC differentially expressed genes, or of their encoded proteins, can be used
 CC to identify cells as belonging to the monocyte lineage. Cells containing
 CC these genes can be used in active immunotherapy (or to stimulate
 CC production of a population of antigen-specific effector cells) and
 CC vectors containing them are used in gene therapy. Co-administration of
 CC tumour antigens and APC-associated costimulatory factors ensures adequate
 CC antigen presentation to endogenous APCs and upregulates the APCs for the
 CC presentation of co-stimulatory signals, migration to T cell-rich sites,
 CC secretion of T cell growth factors and secretion of chemokines for
 CC recruitment of immune effector cells.

XX Sequence 10 BP; 4 A; 2 C; 1 G; 3 T; 0 other;

Query Match 100.0%; Score 7; DB 21; Length 10;
 Best Local Similarity 100.0%; Pred. No. 4.7e+04;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
 |||||
 Db 7 AGTATGA 1

RESULT 7
 AAZ86425
 ID AAZ86425 standard; DNA; 10 BP.

XX AAZ86425;

DT 07-APR-2000 (first entry)

DE Metastatic breast tumour cell downregulated transcript tag #5659.

XX

KW Human; metastatic breast tumour tissue; breast cancer; tag; primer;
 KW non-metastatic breast tumour tissue; gene therapy; anticancer;
 KW antimetastatic; vaccine; diagnosis; ss.
 OS Homo sapiens.
 XX MO965928-A2.
 PN 23-DEC-1999.
 PD 18-JUN-1999; 99MO-US13647.
 PF 19-JUN-1998; 98US-0089853.
 PR 19-JUN-1998; 98US-0089997.
 PR 19-JUN-1998; 98US-0090039.
 PR 19-JUN-1998; 98US-0090040.
 PR 19-JUN-1998; 98US-0090041.
 XX (GENZ) GENZYME CORP.
 PA (ROBE/) ROBERTS B L.
 PA (SHAN/) SHANKARA S.
 PI Roberts BL, Shankara S;
 DR WPI; 2000-106079/09.
 XX Isolated polynucleotides differentially expressed between metastatic
 PT and non-metastatic breast cancer cells, useful for diagnosis,
 PT prevention and treatment of cancer -
 XX Claim 1; Page 208; 219pp; English.
 PS
 XX AA280767 to AA283941 represent tags corresponding to distinct
 CC transcripts that are preferentially transcribed in the metastatic breast
 CC tumour tissue (i.e. are upregulated in metastatic breast tumour cells).
 CC AA283942 to AA286677 represent tags corresponding to distinct transcripts
 CC that are preferentially transcribed in the primary or non-metastatic
 CC breast tumour tissue (i.e. are downregulated in metastatic breast tumour
 CC cells). These transcripts can be used for diagnosis, prognosis,
 CC monitoring and treatment of breast cancer, particularly where metastatic.
 CC Diagnosis is by standard immunoassays or hybridisation/amplification
 CC reactions. Compounds that modulate expression of the transcripts are
 CC potentially useful for treatment of (metastatic) breast cancer, while
 CC promoters from the transcripts are used to direct expression, in selected
 CC cell types, of e.g. therapeutic genes (also ribozymes or antisense
 CC sequences), particularly an antigen-encoding sequence for use in gene or
 CC cell-based vaccines. Polypeptides encoded by the transcripts are also
 CC useful in vaccines; for diagnosing breast cancer and for raising
 CC specific antibodies (Ab). Ab are used to detect the polypeptides or as
 CC therapeutic agents. Host cells that produce the polypeptides can be used
 CC to expand and isolate populations of educated, antigen-specific immune
 CC effector cells, e.g. cytotoxic T lymphocytes, and these used for
 CC adoptive immunotherapy.
 CC
 SQ Sequence 10 BP; 5 A; 0 C; 3 G; 2 T; 0 other;
 XX
 QY Query Match 100.0%; Score 7; DB 21; Length 10;
 DE Best Local Similarity 100.0%; Pred. No. 4.7e+04;
 DE Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX 1 AGTATGA 7
 XX |||||||
 DB 4 AGTATGA 10

DE LPS activated human monocyte expression gene cDNA tag SEQ:133.
 XX Human; LPS; lipopolysaccharide; monocyte expression gene; tag; EST;
 KW expressed sequence tag; diagnosis; human disease; treatment; ss.
 OS Homo sapiens.
 XX JP2001069993-A.
 PN 21-MAR-2001.
 PD 28-APR-2000; 2000JP-0131079.
 PF 08-JUL-1999; 99JP-0195103.
 PR (KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
 PR WPI; 2001-304369/32.
 DR LPS activated human monocyte expression gene group -
 XX Claim 10; Page 28; 52pp; Japanese.
 PS
 PT The present invention describes an lipopolysaccharide (LPS) activated
 CC human monocyte expression gene group consisting of the high-ranking 50
 CC genes of the highest expression among the genes expressed by human
 CC monocyte stimulated by LPS in which the cDNA of each gene has the base
 CC sequence of (AAH32628 to AAH32677) continuous to the base sequence
 CC 5'-CATG-3' nearest to the polyA region. The gene group is useful for the
 CC development of new means for the diagnosis and the treatment of various
 CC human diseases in which human monocyte plays an important role.
 CC AAH32628 to AAH32943 represent specifically claimed LPS activated human
 CC monocyte expression gene cDNA tags from the present invention. AAH32944
 CC represents an LPS activated human monocyte expression gene cDNA sequence
 CC encoding AAB96009, which are given in the exemplification of the present
 CC invention.
 CC
 SQ Sequence 10 BP; 4 A; 0 C; 4 G; 2 T; 0 other;
 XX
 QY Query Match 100.0%; Score 7; DB 22; Length 10;
 DE Best Local Similarity 100.0%; Pred. No. 4.7e+04;
 DE Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX 1 AGTATGA 7
 XX |||||||
 DB 1 AGTATGA 7

RESULT 9
 AAF38936
 ID AAF38936 standard; DNA; 10 BP.
 AC AAF38936;
 XX
 DT 23-MAR-2001 (first entry)
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:5675.
 XX
 KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW not previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX
 XX Saccharomyces cerevisiae.
 OS
 PN WO200077214-A2.
 PN 21-DEC-2000.
 PD 14-JUN-2000; 2000WO-US16223.
 PF 16-JUN-1999; 99US-0335032.
 PR

```

XX PA (UVJO ) UNITV JOHNS HOPKINS.
XX PI Velculescu V, Vogelstein B, Kinzler K;
XX DR WPI; 2001-061874/07.
XX PR Yeast gene coding sequences comprising NORF genes with serial analysis
XX PT of gene expression (SAGE) tags, useful for studying, monitoring and
XX PA affecting phases of the cell cycle -
XX PS Example; Page 202; 419pp; English.
XX CC The present invention describes an isolated DNA molecule comprising a
XX CC coding sequence of a yeast gene selected from a group of 745 NORF (not
XX CC previously assigned open reading frame; or nonannotated ORF) genes
XX CC comprising a SAGE (serial analysis of gene expression) tag. Also
XX CC described are: (1) a method (M1) of using NORF genes to affect the cell
XX CC cycle comprising administering a NORF gene whose expression varies by at
XX CC least 10% between any two phases of the cell cycle selected from log
XX CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
XX CC antifungal drugs comprising: (a) contacting a test substance with a
XX CC yeast cell; and (b) monitoring expression of a NORF gene whose
XX CC expression varies as in M1, where a test substance which modifies the
XX CC expression of the yeast gene is a candidate antifungal drug; (3) a method
XX CC (M3) for identifying human genes which are involved in cell cycle
XX CC progression comprising contacting human DNA with a probe which comprises
XX CC at least 10 contiguous nucleotides of a NORF gene whose expression varies
XX CC as in M1; and (4) a method (M4) for identifying a candidate drug as a
XX CC member of a class of drugs having a characteristic effect on gene
XX CC expression in a yeast cell comprising contacting a yeast cell with a
XX CC candidate drug and monitoring expression in the yeast cell of at least 1
XX CC NORF gene whose expression is affected by the class of drugs. The NORF
XX CC genes may be used to study, monitor and affect phases of the cell cycle,
XX CC the differentially expressed genes may be used as markers of phases of
XX CC the cell cycle. The methods may be used to identify candidate drugs which
XX CC affect the cell cycle and for identification of antifungal drugs.
XX CC AAF33268 to AAF4064 represent SAGE tags used in the exemplification of
XX CC the present invention. AAF33262 to AAF33267 represent linkers and PCR
XX CC primers used in the SAGE method, in the exemplification of the present
XX CC invention.
XX SQ Sequence 10 BP; 4 A; 1 C; 3 G; 2 T; 0 other;
OY Query Match 100.0%; Score 7; DB 22; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.7e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0.
DB 1 AGTATGA 7
1111111
2 AGTATGA 8
RESULT 10
AAAF39793
ID AAF39793 standard; DNA; 10 BP.
AC AAF39793;
XX DT 23-MAR-2001 (first entry)
XX DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:6532.
XX KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
KW serial analysis of gene expression; antifungal; tag; identification;
KW linker; PCR primer; ds.
XX OS Saccharomyces cerevisiae.
XX PN WO200077214-A2.
XX PD 21-DEC-2000.

```

```

XX 14-JUN-2000; 2000OWO-US162233.
XX
XX PR 16-JUN-1999; 990US-0335032.
XX
XX PA (UYJO ) UNIV JOHNS HOPKINS.
XX
XX PI Velculescu V, Vogelstein B, Kinzler K;
XX
XX DR WPI; 2001-061874/07.
XX
XX PT Yeast gene coding sequences comprising NORF genes with serial analysis
XX of gene expression (SAGE) tags, useful for studying, monitoring and
XX affecting phases of the cell cycle .
XX
XX Example; Page 233; 419pp; English.
XX
XX The present invention describes an isolated DNA molecule comprising a
XX coding sequence of a yeast gene selected from a group of 745 NORF (not
XX previously assigned open reading frame; or nonannotated ORF) genes
XX comprising a SAGE (serial analysis of gene expression) tag. Also
XX described are: (1) a method (M1) of using NORF genes to affect the cell
XX cycle comprising administering a NORF gene whose expression varies by at
XX least 10% between any two phases of the cell cycle selected from 109
XX phase, S phase and G2/M; (2) a method (M2) for screening candidate
XX antitumoral drugs comprising: (a) contacting a test substance with a
XX yeast cell; and (b) monitoring expression of a NORF gene whose
XX expression varies as in M1, where a test substance which modifies the
XX expression of the yeast gene is a candidate antitumoral drug; (3) a method
XX (M3) for identifying human genes which are involved in cell cycle
XX progression comprising contacting human DNA with a probe which comprises
XX at least 10 contiguous nucleotides of a NORF gene whose expression varies
XX as in M1; and (4) a method (M4) for identifying a candidate drug as a
XX member of a class of drugs having a characteristic effect on gene
XX expression in a yeast cell comprising contacting a yeast cell with a
XX candidate drug and monitoring expression. In the yeast cell of at least 1
XX NORF gene whose expression is affected by the class of drugs. The NORF
XX genes may be used to study, monitor and affect phases of the cell cycle,
XX the differentially expressed genes may be used as markers of phases of
XX the cell cycle. The methods may be used to identify candidate drugs which
XX affect the cell cycle and for identification of antitumoral drugs.
XX AAF33268 to AAF44004 represent SAGE tags used in the exemplification of
XX the present invention. AAF33262 to AAF33267 represent linkers and PCR
XX primers used in the SAGE method, in the exemplification of the present
XX invention.
XX
XX Sequence 10 BP; 4 A; 1 G; 2 G; 3 T; 0 other;
XX
XX Query Match 100.0%; Score 7; DB 22; Length 10;
XX Best Local Similarity 100.0%; Pred. No. 4; Tc+04;
XX Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0
XX
XX QY 1 AGTATGA 7
XX | | | | |
XX Db 1 AGTATGA 7
XX
XX RESULT 11
XX AAF40876
XX ID AAF40876 standard; DNA; 10 BP.
XX
XX AAF40876;
XX
XX 23-MAR-2001 (first entry)
XX
XX Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:7615.
XX
XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
XX not previously assigned open reading frame; nonannotated ORF; SAGE;
XX serial analysis of gene expression; antitumoral; tag; identification;
XX linker; PCR primer; ds.
XX
XX Saccharomyces cerevisiae.

```

PN WO200077214-A2.
 PD 21-DEC-2000.
 XX 14-JUN-2000; 2000WO-US16223.
 PF
 XX 16-JUN-1999; 99US-0335032.
 PR
 XX (UYO) UNIV JOHNS HOPKINS.
 PA
 PI Velulescu V, Vogelstein B, Kinzler K;
 XX WPI; 2001-061874/07.
 DR
 XX
 PT Yeast gene coding sequences comprising NORF genes with serial analysis
 of gene expression (SAGE) tags, useful for studying, monitoring and
 affecting phases of the cell cycle -
 XX
 PS Example; Page 272; 419pp; English.
 XX
 CC The present invention describes an isolated DNA molecule comprising a
 coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from 10g
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a
 CC yeast cell; and (b) monitoring expression of a NORF gene whose
 CC expression varies as in M1, where a test substance which modifies the
 CC expression of the yeast gene is a candidate antifungal drug; (3) a method
 CC (M3) for identifying human genes which are involved in cell cycle
 CC progression comprising contacting human DNA with a probe which comprises
 CC at least 10 contiguous nucleotides of a NORF gene whose expression varies
 CC as in M1; and (4) a method (M4) for identifying a candidate drug as a
 CC member of a class of drugs having a characteristic effect on gene
 CC expression in a yeast cell comprising contacting a yeast cell with a
 CC candidate drug and monitoring expression in the yeast cell of at least 1
 CC NORF gene whose expression is affected by the class of drugs. The NORF
 CC genes may be used to study, monitor and affect phases of the cell cycle,
 CC the differentially expressed genes may be used as markers of phases of
 CC the cell cycle. The methods may be used to identify candidate drugs which
 CC affect the cell cycle and for identification of antifungal drugs.
 CC AAF33268 to AAF44064 represent SAGE tags used in the exemplification of
 CC the present invention. AAF33262 to AAF33267 represent linkers and PCR
 CC primers used in the SAGE method, in the exemplification of the present
 CC invention.
 CC
 XX Sequence 10 BP; 3 A; 3 C; 2 G; 2 T; 0 other;
 SO
 Query Match 100.0%; Score 7; DB 22; Length 10;
 Best Local Similarity 100.0%; Pred. No. 4.7e+04;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AGTATGA 7
 | | | | | | |
 Db 3 AGTATGA 9
 | | | | | | |
 XX
 RESULT 12
 ABR47394/C
 ID ABR47394 standard; DNA; 10 BP.
 XX
 AC ABR47394;
 XX
 DT 18-JUN-2002 (first entry)
 XX
 DE Human PLA2G1B ASO primer extension primer 3' end #5.
 XX
 KW Human; ss; primer; SNP; single nucleotide polymorphism; pancreatitis;
 KW pancreatic cancer; phospholipase A2 group IB; PLA2G1B; gene therapy;
 KW haplotype; genotype; chromosome 12q23-q24.1; transgenic; drug screening;

KW ASO; allele specific oligonucleotide; primer extension.
 XX
 OS Homo sapiens.
 XX
 PN WO200212562-A2.
 XX
 PD 14-FEB-2002.
 PF
 XX 06-AUG-2001; 2001WO-US24663.
 XX
 PR 04-AUG-2000; 2000US-223179P.
 PA (GENA-) GENAISSANCE PHARM INC.
 PI Kazeml A, Kilem SE, Koshy B;
 XX WPI; 2002-303982/34.
 DR
 XX
 PT Novel isolated human phospholipase A2, Group IB pancreas
 PT polynucleotide, for therapeutic purposes, for studying expression and
 PT function of the polynucleotide and for expressing the phospholipase
 PT protein -
 XX
 PS Claim 19; Page 13; 51pp; English.
 XX
 CC The invention relates to an isolated human phospholipase A2, Group IB
 CC (pancreas) (PLA2G1B) polynucleotide comprising a sequence which is a
 CC polymorphic variant for a reference sequence for the PLA2G1B gene or
 CC its fragment, or a polymorphic variant of a reference sequence for a
 CC PLA2G1B cDNA or its fragment. Also included are haplotyping/genotyping
 CC the PLA2G1B gene of an individual, predicting the haplotype pair for the
 CC PLA2G1B gene of an individual, identifying an association between a trait
 CC and at least one haplotype or haplotype pair of the PLA2G1B gene, an
 CC isolated genotyping oligonucleotide for detecting a polymorphism in the
 CC PLA2G1B gene, a recombinant non-human organism transformed or transfected
 CC with the PLA2G1B sequence, where the organism expresses a PLA2G1B
 CC protein encoded by the first nucleotide sequence or by the polymorphic
 CC variant sequence, an isolated polypeptide comprising a sequence which is
 CC a polymorphic variant of a reference sequence for the PLA2G1B protein or
 CC its fragment, an anti-PLA2G1B monoclonal antibody, screening for drugs
 CC targeting PLA2G1B, a computer system for storing and analysing
 CC polymorphism data for the PLA2G1B gene and a genome anthology for PLA2G1B
 CC gene. The PLA2G1B variant is useful in studying the expression and
 CC function of PLA2G1B, and in expressing PLA2G1B protein for use in
 CC screening for candidate drugs to treat diseases related to PLA2G1B
 CC activity (e.g. pancreatitis and pancreatic cancer) and for
 CC therapeutic purposes. The transgenic organism is useful for studying
 CC expression of the PLA2G1B isogenes in vivo, for in vivo screening and
 CC testing of drugs targeted against PLA2G1B protein, and for testing the
 CC efficacy of therapeutic agents and compounds in a biological system.
 CC The antibody is useful for studying the effect of the variation on the
 CC biological activity of PLA2G1B as well as on the binding affinity of
 CC candidate drugs targeting PLA2G1B. The PLA2G1B gene is located on
 CC chromosome 12q23-q24.1. The present sequence is an allele specific
 CC oligonucleotide (ASO) primer extension primer 3' end used to detect the
 CC polymorphisms in PLA2G1B.
 CC
 XX Sequence 10 BP; 3 A; 3 C; 0 G; 4 T; 0 other;
 SO
 Query Match 100.0%; Score 7; DB 24; Length 10;
 Best Local Similarity 100.0%; Pred. No. 4.7e+04;
 Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 AGTATGA 7
 | | | | | | |
 Db 9 AGTATGA 3
 | | | | | | |
 XX
 RESULT 13
 AAL41859
 ID AAL41859 standard; DNA; 10 BP.
 XX
 AC AAL41859;

XX 25-APR-2002 (first entry)
XX
XX Human GCNT1 allele specific primer extension oligo SEQ ID NO: 44.
DE
XX
XX Human: glucosaminyl (N-acetyl) transferase 1, core 2; GCNT1; cancer;
KW gene therapy; haplocty; chromosome 9q13; SNP; primer; cytostatic;
XX single nucleotide polymorphism; ss.
XX
OS Homo sapiens.
XX
XX WO200204470-A2.
XX
XX 17-JAN-2002.
XX
XX 06-JUL-2001; 2001WO-US21451.
XX
XX 06-JUL-2000; 2000US-216281P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Duda A, Finkel K, Koshy B;
XX
XX WPI: 2002-171696/22.
XX
XX Genetic variants of glucosaminyl (N-acetyl) transferase 1, core 2 gene
PT useful in studying expression and function of the protein, and for
PT screening drugs to treat diseases e.g. cancer
XX
XX
XX Claim 18; Page 14; 72pp; English.
XX
XX The present invention provides the gene, protein and cDNA sequences of
CC the human glucosaminyl (N-acetyl) transferase 1, core 1 (GCNT1). Also
CC identified are single nucleotide polymorphisms (SNPs) located within the
CC sequences. The sequences can be used in the treatment of GCNT1 related
CC diseases, including cancer. The present sequence is an allele specific
CC primer extension oligonucleotide for the GCNT1 gene, which is located on
CC chromosome 9q13.
XX
XX
XX Sequence 10 BP; 3 A; 1 C; 2 G; 4 T; 0 other;
SO
Query Match 100.0%; Score 7; DB 24; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.7e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGTATGA 7
DB 1 AGTATGA 7
RESULT 14
AA167680
ID AA167680 standard; DNA; 10 BP.
XX
XX AA167680;
XX
XX 27-FEB-2002 (first entry)
XX
XX Human IL-8 gene polymorphism detecting primer.
DE
XX IL-8; Interleukin; single nucleotide polymorphism; haploctyping; primer;
KW genotyping; cancer; chronic obstructive pulmonary disease; human; ss.
XX
XX Homo sapiens.
XX
XX WO200183499-A2.
XX
XX
XX 08-NOV-2001.
XX
XX 30-APR-2001; 2001WO-US13957.
XX
XX 28-APR-2000; 2000US-200416P.
XX

PA (GENA-) GENAISSANCE PHARM INC.
XX
XX Bentivegna SC, Chew A, Choi JY, Denton RR, Nandabalan K;
PI
XX WPI: 2002-049333/06.
DR
XX Novel isolated human interleukin 8 polynucleotide, useful for
PT therapeutic purposes, comprises a sequence which is a polymorphic
PT variant of a reference sequence for interleukin 8 gene or its fragment
XX
XX
XX Claim 18; Page 13; 52pp; English.
XX
XX The invention relates to novel single nucleotide polymorphisms in the
CC human interleukin 8 (IL-8) gene. Methods for haploctyping and genotyping
CC the IL-8 gene are also provided. The methods are useful for improving the
CC efficacy and reliability of several steps in the discovery and
CC development of drugs for treating diseases associated with IL-8 activity,
CC e.g., cancer and chronic obstructive pulmonary disease, to validate IL-8
CC as a candidate agent; in the design of clinical trials of candidate
CC drugs; to screen for compounds targeting IL-8 to treat a specific
CC conditions or disease associated with IL8 activity. The IL-8 gene is
CC useful in studying the expression and function of IL8, and in expressing
CC IL-8 protein for use in screening for candidate drugs to treat diseases
CC related to IL-8 activity. Sequences AA167679-90 represent primers for
CC detecting IL-8 gene polymorphisms by primer extension.
XX
XX
XX Sequence 10 BP; 3 A; 1 C; 4 G; 2 T; 0 other;
SO
Query Match 100.0%; Score 7; DB 24; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.7e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGTATGA 7
DB 4 AGTATGA 10
RESULT 15
AA167681/C
ID AA167681 standard; DNA; 10 BP.
XX
XX AA167681;
XX
XX 27-FEB-2002 (first entry)
XX
XX Human IL-8 gene polymorphism detecting primer.
DE
XX IL-8; Interleukin; single nucleotide polymorphism; haploctyping; primer;
KW genotyping; cancer; chronic obstructive pulmonary disease; human; ss.
XX
XX Homo sapiens.
XX
XX WO200183499-A2.
XX
XX 08-NOV-2001.
XX
XX 30-APR-2001; 2001WO-US13957.
XX
XX 28-APR-2000; 2000US-200416P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Bentivegna SC, Chew A, Choi JY, Denton RR, Nandabalan K;
PI
XX WPI: 2002-049333/06.
XX
XX Novel isolated human interleukin 8 polynucleotide, useful for
PT therapeutic purposes, comprises a sequence which is a polymorphic
PT variant of a reference sequence for interleukin 8 gene or its fragment
XX
XX Claim 18; Page 13; 52pp; English.
XX

XX The invention relates to novel single nucleotide polymorphisms in the
CC human interleukin 8 (IL-8) gene. Methods for haplotyping and genotyping
CC the IL-8 gene are also provided. The methods are useful for improving the
CC efficacy and reliability of several steps in the discovery and
CC development of drugs for treating diseases associated with IL-8 activity,
CC e.g., cancer and chronic obstructive pulmonary disease, to validate IL-8
CC as a candidate agent; in the design of clinical trials of candidate
CC drugs; to screen for compounds targeting IL-8 to treat a specific
CC conditions or disease associated with IL8 activity. The IL-8 gene is
CC useful in studying the expression and function of IL8, and in expressing
CC IL-8 protein for use in screening for candidate drugs to treat diseases
CC related to IL-8 activity. Sequences AA167679-90 represent primers for
CC detecting IL-8 gene polymorphisms by primer extension.
XX

SQ Sequence 10 BP; 2 A; 3 C; 1 G; 4 T; 0 other;

Query Match 100.0%; Score 7; DB 24; Length 10;
Best Local Similarity 100.0%; Pred. No. 4.7e+04;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGTATGA 7
|||||||
Db 10 AGTATGA 4

Search completed: June 2, 2003, 18:45:11
Job time : 118.151 secs

